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3Abstract
Effective and durable HIV treatment and increased longevity of HIV-positive (HIV+) people [1-6]
has led to a growing burden of cancers in this population [7-9]. The aims of this thesis were to
describe the changing epidemiology of commonly occurring cancers in HIV+ people (with a focus
on Europe) and to explore and characterise plasma biomarkers of common cancers in HIV+
people.
Results showed that the incidence of infection unrelated cancers are not declining in HIV+
people, primarily driven by aging of the HIV+ population and higher prevalence of cancer risk
factors such as smoking. Smoking presents as one of the few modifiable cancer risk factors which
can be targeted to reduce burden. Although smoking cessation quickly reduces the incidence of
many smoking related cancers, the incidence of lung cancer remains at a similar level to current
smokers ≥5 years after cessation. Risk factors for non-Hodgkin (NHL) and Hodgkin lymphoma 
(HL) differ, with HL primarily driven by low CD4 cell counts, whereas NHL is driven by a
combination of immune deficiency and other HIV-mediated immune dysfunction. Furthermore,
markers of immune activation are elevated ≥2 years prior to lymphoma diagnosis and are 
correlated with high level of HIV viremia. Levels of prostate specific antigen (PSA) were raised
and increasing many years prior to prostate cancer diagnosis, however, use of the cut off of PSA
>4 ng/mL to identify men at high risk of prostate cancer may not be appropriate in HIV+ men
due to lower levels of circulating PSA.
In conclusion, the results of this thesis provide evidence to advise and improve the care of aging
HIV+ people at elevated risk for cancers through the identification and characterisation of risk
factors for common cancers, investigating possible mechanisms driving cancer genesis, and
assessing the usefulness of commonly used diagnostic practices.
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Overview
HIV is a retrovirus that causes immune dysfunction as HIV invades and destroys cells of the
immune system, including CD4+ T cells which are a crucial component of the human immune
system. HIV inhibits the body’s ability to replace CD4 cells, which become depleted after years
of viral replication, putting people at risk of opportunistic infections [10, 11]. Early in the HIV
epidemic, almost all people with HIV died of an acquired immune deficiency syndrome (AIDS)
related cause. However, wide spread availability of combined anti-retroviral therapy (cART)
since the 1990s has improved immune-function and reduced the incidence of AIDS defining
events [12]. As a result, survival has dramatically improved, with the median age at death
projected to reach as high as 75 years [1-6].
Cancers are a significant source of morbidity and mortality and are now the second most
common cause of death following AIDS related deaths in HIV-positive (HIV+) people [13]. HIV+
people are at increased risk of many cancers compared to the general population, particularly
those with an infection-related cause [8, 14-18]. However, the introduction of cART in 1996 led
to restored immune function and a corresponding reduced incidence of infection related
cancers (IRC) [19-21]. In contrast, increased overall survival and life expectancy has led to a
growing burden of cancers in the HIV+ population and cancers traditionally associated with older
age [7-9].
The emergence of cancers as a major source of morbidity and mortality will require changes to
ongoing HIV care, as patients who require concurrent services and treatment for oncogenic
conditions become more prevalent. As a result, understanding the changing epidemiology of
cancers in HIV+ people and the underlying mechanisms will be crucial for future healthcare
planning and resource allocation, as well as improving the longevity and quality of life of
patients.
Objectives
My PhD has two key objectives
1. To describe the changing epidemiology of commonly occurring cancers in HIV+ people,
particularly focusing on specific cancers or groups of cancers that are expected to
become a major source of morbidity and mortality as the population ages.
2. To explore and characterise plasma biomarkers of common cancers in HIV+ people in
order to better understand the mechanisms leading to cancer development.
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These objectives will be investigated through 5 projects each corresponding to a results chapter.
Chapter 3 describes the incidence of infection related (IRC) and infection unrelated cancers
(IURC) over time in the aging HIV+ population across Europe, using the EuroSIDA study.
Chapter 4 investigates the association between smoking cessation and cancer risk in HIV+
people, based on data from the D:A:D study.
Chapter 5 compares and contrasts the risk factors for non-Hodgkin (NHL) and Hodgkin
lymphoma (HL) development in HIV+ people, based on data from the D:A:D study.
Chapter 6 explores levels of and changes in markers of B-cell activation prior to the development
of NHL and HL, using the EuroSIDA study.
Chapter 7 investigates the kinetics of total and free prostate specific antigen (PSA) prior to
diagnosis with prostate cancer (PCa) and examines their diagnostic ability, using the EuroSIDA
study.
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1 Introduction
Human Immunodeficiency Virus (HIV)
The beginning of the HIV epidemic.
Acquired immune deficiency syndrome (AIDS) was discovered in 1981 when an outbreak of
Kaposi’s sarcoma (KS, a cancer caused by infection with human herpes virus-8 [HHV8]), and
pneumonia (caused by pneumocystis carinii), two rare conditions usually confined to severely
immunocompromised individuals, occurred in a group of 26 young and otherwise healthy
homosexual men in the USA [22, 23]. Initially AIDS was thought to be perpetuated by an
infectious agent linked to homosexual men, however it was not long before the disease was also
reported in haemophiliacs [24, 25], transfusion recipients [25, 26], injecting drug users [25], and
women [10, 25]. Although immune-deficiency related conditions were not unheard of, AIDS had
almost a 100% mortality rate, making it unique [10]. In the years since it was discovered, Human
Immunodeficiency Virus (HIV) has progressed from small clusters of infection to a worldwide
pandemic [10].
In 1983 the retrovirus responsible for AIDS was simultaneously discovered by two independent
institutes. Barre Sinoussi, at The Pasteur institute, France, isolated a novel retrovirus from a
lymph node of a patient displaying symptoms often preceding the diagnosis of AIDS and named
it lymphadenopathy-associated virus (LAV) [27, 28]. At the same time, Gallo and his team also
isolated a novel virus named Human T-lymphotropic retrovirus (HTLV-III) and provided evidence
that this virus was the primary cause of AIDS [29-34]. These viruses were determined to be
variants of the same virus by 1985 [35] and were renamed as Human Immunodeficiency Virus
(HIV) in 1986 [36], in accordance with common nomenclature for retroviruses: beginning with
the host species (human), containing a word that describes a characteristic feature
(immunodeficiency) and ending in virus [36]. In 1986 it was determined that two separate types
of HIV were circulating in the population: HIV-1 and HIV-2. HIV-1 and HIV-2 are only distantly
related and show more similarities to other primate specific retroviruses than to each other [10,
37]. HIV-2 tends to exhibit longer latency periods[38], slower disease progression [39], and lower
HIV viral load (HIV-VL) [40].
The origin of HIV
The mechanisms by which HIV emerged in humans are widely speculated. Both HIV-1 and HIV-
2 are closely related to a group of lentiviruses which circulate in various primate populations,
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mainly African apes or old world monkeys, called simian immunodeficiency viruses (SIV). HIV-2
is closely related to SIV which circulates in sooty magnabeys (SIVsm), and has been confirmed
as the origin of HIV-2 [10, 37, 41-46]. The origin of HIV-1 is not so clear. Although HIV-1 has long
been suspected to have originated from SIV in chimpanzees (SIVcpz), a lack of a reservoir in the
wild population shed doubt on this theory [37]. However, in 1999 a group of researchers found
a strain of SIVspz present in Pan troglodytes troglodytes which was phylogenetically similar to
HIV-1 [47, 48] and it is now generally accepted as the probable origin of HIV-1 [10, 37, 47-51].
It is believed HIV-1 and 2 arose from cross-species transmissions of SIV to the human population
on several occasions which account for the range of subgroups for both HIV-1 and HIV-2 [37, 42,
52]. Human infection with SIVcpz and SIVsm is thought to arise from exposure to infected blood
during the hunting and butchering of chimpanzees and sooty magnabeys for food, bites from
pet animals and possible contact with faeces and urine [53, 54]. A disproved [55, 56] alternate
theory suggested that HIV-1 was a consequence of an oral polio vaccine (OPV), called CHAT, that
was potentially contaminated with SIVcpz from chimpanzee tissue used in the preparation of
the vaccine [57-59].
HIV-1 is the primary cause of AIDS worldwide [60, 61]. In most countries it is concentrated within
certain risk groups, including men who have sex with men, injecting drug users, sex workers and
the sexual partners of these people [62]. Many countries of sub-Saharan Africa have self-
sustaining generalised epidemics, although high risk groups still exist [62].
It is estimated that HIV-1 was first introduced into the human population between around 1910
– 1930, most likely originating from central Africa [49, 63-65]. This coincides with urbanisation
and the emergence of the first towns in this region [60]. The first reported evidence of AIDS in
Africa was in the late 1950’s – early 1960’s [66, 67]. The earliest confirmed case of HIV was
identified from a blood sample of a man from the Democratic Republic of Congo in 1959 [68].
Studies have found that strains had diversified substantially from the original strain that crossed
over to humans, indicating that HIV had been circulating in the human population decades
previously [63]. HIV-1 was suspected in the a Manchester man in 1959 who died of an AIDS–like
illness [69, 70], but this was never confirmed [71].
HIV-1 was present in the USA from around 1967 – 69, more than a decade before the initial
identification of AIDS in 1981 [64, 72, 73]. The serological prevalence of HIV in men who have
sex with men was retrospectively estimated to be 4.5% in San Francisco [74] and 6.6% in New
York City in 1978, suggesting that thousands of people in the USA were already infected by this
35
time but not identified due to the long asymptomatic phase of HIV [72]. Haiti was proposed as
a possible source of the USA epidemic due to the high prevalence of HIV-1 among Haitian
immigrants [64, 75-77]. However, the alternative possibility that sex tourism and Haitians
returning from the USA introduced HIV-1 to Haiti could not be ruled out [78, 79]. One study
found that Haiti had the oldest and most genetically diverse known HIV-1 epidemic outside Sub-
Saharan Africa [72], with most of the pandemic clade of subtype B likely originating from a single
point migration of the virus out of Haiti between 1966 – 1972 [72].
HIV-1 spread quickly through the pre-established contact networks of high risk groups such as,
men who have sex with men and people who inject drugs in the USA and Europe during the early
1980’s [10, 72]. The epidemic in Europe emerged 2 to 3 years after the USA [73], and differed in
that a high proportion of cases were diagnosed in African immigrants in addition to men who
have sex with men [80, 81]. Furthermore, the European epidemic emerged in people who inject
drugs later than in men who have sex with men. The introduction of HIV-1 into Europe was
thought to be driven by homosexual contact with individuals from the USA, Africa or Haiti;
needle sharing in injecting drug users with individuals from the USA; sexual contact with
individuals from central Africa; and immigration from central Africa [80-84].
Although specific factors and events that led to the emergence of epidemic HIV in the late 20 th
century are generally unknown, various contributors have been proposed. The HIV-1
transmission rate prior to this time was slower for an extensive period, possibly circulating in
heterosexual populations [72]. The introduction of injectable medications in Africa between
1950 – 1970 acted as a dispersion agent of HIV in the modern era through wide spread unsterile
use of needles and syringes [85]. This, in combination with destabilization of social structures
[86], rapid growth of cities [63], and an increased prevalence of sexually transmitted diseases,
such as genital ulcers [87], has been proposed to have facilitated the adaption and spread of
both HIV-1 and HIV-2. The increasingly widespread use of air, land and sea transport networks
also enabled rapid dispersion of the virus [88-90].
The HIV virus
Retroviruses are a family of enveloped viruses characterised by the presence of two single
stranded RNA genomes and the enzyme reverse transcriptase [10, 91]. The genus lentiviridae
(from the Latin lentus meaning ‘slow’) is characterised by a long interval between initial infection
and the onset of serious symptoms (incubation period), a high rate of evolution and mutation,
and an ability to integrate into the genome of non-dividing cells [10, 92]. Lentiviruses cause
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chronic persistent infections in mammals, including bovines, horses, sheep, felines, and
primates [37]. HIV and SIV encompass the primate lentiviruses [37, 91]. SIV covers a diverse
group of over 40 different species-specific primate lentiviruses circulating among African non-
human primate species [37, 93]. HIV-1 and HIV-2 are the only two lentiviruses known to circulate
in human populations [93]. Although it can infect multiple cells in the body, the main target are
the CD4 lymphocytes (T-cells or CD4 cells), a crucial part of the immune system [10, 11]. Figure
1.1 gives a graphical illustration of the HIV lifecycle within living cells of the infected host and is
explained in detail in the following sections [88].
Figure 1.1 The life cycle of HIV [88].
The life cycle of HIV
Viral attachment
The HIV virus attaches itself to the CD4 cells. The pg120 protein on the outer surface of the virus
binds to the CD4+ receptor on the cell surface. This then further binds to one or more of a set
of coreceptors, notably the CC chemokine receptor CCR5 and CXC chemokine receptor CXCR4
[10, 94]. The specific receptor(s) that are utilised depends on the strain of HIV. T-tropic strains
use the CXCR4 receptor have a preference for T-cells and can infect continuous CD4+ T cell lines
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and primary CD4+ T cells [94], while M-tropic strains make use of the CCR5 receptor and can
infect primary macrophages and primary CD4+T cells[94]. Dual-tropic strains can use both CXCR4
and CCR5 [94]. The binding with the corecepter results in a conformational change in gp120,
allowing the gp41 protein to facilitate the fusion of the viral and host cell membranes.
Entry into the cell host.
The HIV virus releases its viral core (or capsid) into the host cell cytoplasm. The viral core is
opened, releasing two copies of virus single strand RNA and the essential replication enzymes
reverse transcriptase, protease and integrase.
Reverse transcription and integration
A double strand DNA copy, known as the provirus, is transcribed using the virus RNA by the HIV
reverse transcriptase enzyme [95]. HIV integrase prepares the HIV DNA for integration into the
host genome by cleaving a di-nucleotide from each 3’ end of the DNA. It then guides it into the
host nucleus and facilitates integration into the host DNA. The HIV DNA is now part of the host
cell DNA.
Transcription and replication
Activation of the host cell induces transcription of the HIV DNA into messenger RNA (mRNA)
using human enzymes, which contain complete copies of the HIV genetic material. These
migrate into the cytoplasm and are used to synthesis new HIV proteins in a process called
translation. The viral protease cleaves the long proteins produced by translation into shorter
core proteins. HIV replication occurs at a very high rate and mutates extremely rapidly, resulting
in immense adaptive potential and high viral genetic diversity within individual hosts, leading to
a type of accelerated evolution. This is the reason that HIV is able to develop resistance to
individual antiviral drugs within months [10].
Budding
Two new strands of HIV RNA and replication enzymes come together and core proteins assemble
around them, forming a new capsid. The capsid then buds (peels off the host cell) taking some
of the host membrane and creating a new HIV virus particle. The virus then matures and infects
other cells. A single cell can produce thousands of infectious HIV particles. The host CD4 cell dies
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shortly after the release of the new virus particles, which is a major reason for the destruction
of the immune system [96, 97].
The provirus can lie dormant within a reservoir of latently infected cells, predominantly memory
CD4+ T cells, for several years [98-100]. This guarantees lifetime persistence of HIV-1 in the
majority of patients, despite effective cART regimens and prevents the development of vaccines
for eradication of the virus [24, 101]. Other potential reservoirs include peripheral lymphoid
organs and the tissues, bone marrow, the central nervous system and genitourinary tract [100].
HIV progression and clinical staging
The natural history of HIV infection, in the absence of effective treatment, is shown in Figure 1.2
[102].
Figure 1.2 Increase in HIV virus (plasma viremia titer) and the deterioration of the human
immune system (CD4 cell count) over the course of an untreated infection [102, 103]
Primary infection with HIV
Primary infection (or acute infection) characterises the initial period soon after acquisition of
HIV infection [104]. During the first few weeks, viral replication occurs rapidly [102], producing
bursts of virus that infect many CD4 cells and involves all lymphatic tissue. This results in high
levels of viremia in the blood which can reach over 1 million copies per ml [92] and a subsequent
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short term sharp drop in the CD4 cell count occurs within the first 3 months, as shown in Figure
1.2 [92, 102, 104-107]. During this period, the person has a high HIV-VL and is highly infectious,
but will be HIV seronegative if tested [105]. During the first few weeks of infection, most people
experience seroconversion illness or retroviral syndrome, which represents a detectable
humoral and cellular immune response to the virus (within 1 week-3 months) [102, 104, 106,
107]. Symptoms include a glandular fever like illness, rash, headache, feeling generally unwell,
aches and pains, mouth ulcers, sore throat, night sweats, weight loss, tiredness, swollen glands,
and neurological symptoms like meningitis [104]. The period at which the immune system
responds to the virus and HIV antibodies are developed is known as seroconversion. This can
take between 8 days to 3 months [102], after which the HIV-VL levels decline significantly
(although reduced HIV replication continues in lymph nodes and other reservoirs) and the CD4
cell count is somewhat recovered [102, 104].
Chronic infection
Following primary infection, a prolonged period of clinical latency, also known as chronic HIV
infection occurs, often lasting 10 – 12 years or more [104, 107-109]. During this time, the patient
is usually asymptomatic; the rate of viral replication and HIV-VL levels remain low (although
microbially active) and CD4 cell counts gradually decline slowly and continuously, reducing
immune function [92, 102, 104, 110-114]. Once the CD4 cell count falls below 500 cells/mm 3,
half of the immunological reservoir is destroyed and the patient is at risk of minor infections
such as cold sores (herpes simplex), condyloma (warts) and fungal infections, thrush and vaginal
candidiasis [92]. It is estimated that CD4 cell counts decline at 5.6x106/L per month until 18
months before AIDS diagnosis [113]. A subset of people are long term non-progressors and are
those who have had the virus for >10 years, remain clinically healthy in the absence of
treatment, and display anti-HIV immune response [92].
Symptomatic HIV infection and clinical AIDS
In the absence of treatment, symptoms begin to manifest a median of 10 years after
seroconversion and clinically apparent disease develops. When the CD4 cell count reaches <200
cells/mm3 the patient becomes highly susceptible to an AIDS defining event, which is the end
stage of HIV disease and includes serious opportunistic infections and AIDS defining cancers
(ADC) (list of conditions that are considered an AIDS defining event in Table 1.1) [92]. The
average survival time after AIDS diagnosis has been estimated to be less than 24 months [102,
103, 113, 115, 116] and varies according to population and type of AIDS defining event [117-
119]. In the absence of treatment, time from seroconversion to death varies depending on,
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amongst other things, age at seroconversion [120]. Estimates of median survival range from 4
years in those aged 65 at time of seroconversion or over to 12.5 years in those aged 15-24 years
[120]. The onset of a second AIDS defining event leads to a 1.5 – 2-fold shorter survival time
[121]. Very low CD4 cell counts have been associated with the onset of AIDS and death [122-
129]. CD4 cell counts decline over the course of HIV infection and the rate of decline is predictive
of disease progression [112, 123, 126, 130, 131] and death [131, 132].
Table 1.1 AIDS-indicator conditions [133, 134].
Candidiasis of bronchi, trachea, or lungs Lymphoma, Burkitt's (or equivalent term)
Candidiasis, esophageal Lymphoma, immunoblastic (or equivalent term)
Cervical cancer, invasive, confirmed by
biopsy
Lymphoma, primary, of brain (CNS)
Coccidioidomycosis, disseminated or
extrapulmonary
Mycobacterium avium complex (MAC) or M.
kansasii, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary Mycobacterium tuberculosis, any site (pulmonary
* or extrapulmonary)
Cryptosporidiosis, chronic intestinal (greater than
1 month's duration)
Mycobacterium, other species or unidentified
species, disseminated or extrapulmonary
Cytomegalovirus disease (other than liver, spleen,
or nodes)
Pneumocystis iroveci (formally carinii)
pneumonia (PCP)
Cytomegalovirus retinitis (with loss of vision) Pneumonia, recurrent *
Encephalopathy, HIV-related Progressive multifocal leukoencephalopathy
(PML)
Herpes simplex: chronic ulcer(s) (greater than 1
month's duration); or bronchitis, pneumonitis, or
esophagitis
Salmonella septicemia, recurrent (nontyphoid)
Histoplasmosis, disseminated or extrapulmonary Toxoplasmosis of brain
Isosporiasis, chronic intestinal (greater than 1
month's duration)
Wasting syndrome due to HIV (involuntary weight
loss >10% of baseline body weight) associated
with either chronic diarrhoea (two or more loose
stools per day for ≥1 month) or chronic weakness 
and documented fever for ≥1 month) 
Kaposi's sarcoma
41
Staging of HIV disease
Staging and classification of HIV disease is useful for monitoring the epidemic and for providing
important information about HIV clinical care to physicians and patients. There are two main
classification systems in use, both of which are explained below.
U.S. Centers for Disease Control and Prevention (CDC) classification (1993)
The CDC classification system uses CD4 cell counts and the presence of HIV-specific conditions
to classify HIV disease severity (summarised in Table 1.2). The CDC definition of AIDS includes all
people with their lowest documented CD4 cell count (also referred to as the CD4 nadir) <200 (or
CD4% <14%) and also those previously diagnosed with HIV specific conditions. The classification
is based on historic disease, meaning that once categorised, the patient will remain in that
category even if they subsequently become asymptomatic. Although the CDC classification
system tends to be used more often in epidemiological research than in a clinical setting,
nevertheless a working understanding of clinical stages, particularly the AIDS definition, is
important [134].
Table 1.2 CDC classification system for HIV-infected adults and adolescents [133, 134].
CD4 cell count
categories
Clinical Categories
A
Asymptomatic, acute
HIV or persistent
generalised
lymphadenopathy
B1
Symptomatic
conditions,
not in A or C
C
AIDS-indicator
conditions
(see Table 1.1)
(1) 500 cells/L A1 B1 C1*
(2)200 - 499 cells/L A2 B2 C2*
(3) <200 cells//L A3* B3* C3*
1The Category B Symptomatic Conditions refer to symptomatic conditions which occur in an
HIV+ adolescent or adult which are either attributed to HIV infection or indicate a defect in cell-
mediated immunity or considered to have a clinical course or management that is complicated
by HIV infection [133, 134].* Considered to have AIDS.
World Health Organization (WHO) Clinical Staging and Disease Classification
system (2007)
The clinical staging and disease classification system developed by WHO, developed in 1990 and
revised in 2007, was designed for use in resource limited settings and does not incorporate CD4
cell counts or other laboratory markers which may not be readily available [134]. The clinical
staging is classified from stage 1 (early HIV infection) to 4 (advanced HIV infection) and is
intended for use on people aged 15 years or older. Clinical staging is classified according to
recognisable and treatable clinical symptoms (Table 1.3) and was previously widely used to
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determine when to start cART, before the results of the START (Strategic Timing of Antiretroviral
Therapy) trial changed treatment guidelines [134-142]. For more details on the START trial, see
section 1.1.8.7.1).
Table 1.3 WHO clinical staging and disease classification.
Primary HIV infection
Asymptomatic Acute retroviral syndrome
Clinical stage 1
Asymptomatic Persistent generalised lymphadenopathy
Clinical stage 2
Moderate unexplained weight loss (<10% of
presumed or measured body weight)
Angular cheilitis
Recurrent respiratory infections (sinusitis,
tonsillitis, otitis media, and pharyngitis)
Recurrent oral ulceration
Herpes zoster Papular pruritic eruptions
Fungal nail infections Seborrheic dermatitis
Clinical stage 3
Unexplained severe weight loss (>10% of
presumed or measured body weight)
Severe presumed bacterial infections (e.g.,
pneumonia, empyema, pyomyositis, bone
or joint infection, meningitis, bacteraemia)
Unexplained chronic diarrhoea for >1 month Acute necrotizing ulcerative stomatitis,
gingivitis, or periodontitis
Unexplained persistent fever for >1 month
(>37.6ºC, intermittent or constant)
Unexplained anaemia (haemoglobin <8 g/dL)
Persistent oral candidiasis (thrush) Neutropenia (neutrophils <500 cells/μL)
Oral hairy leukoplakia Chronic thrombocytopenia (platelets <50,000
cells/μL) 
Pulmonary tuberculosis (current)
Clinical stage 4
HIV wasting syndrome, as defined by the CDC
(see Table 1.1)
Disseminated nontuberculosis mycobacteria
infection
Pneumocystis pneumonia Progressive multifocal leukoencephalopathy
Recurrent severe bacterial pneumonia Candida of the trachea, bronchi, or lungs
Chronic herpes simplex infection (orolabial, Chronic cryptosporidiosis (with diarrhoea)
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genital, or anorectal site for >1 month or
visceral
herpes at any site)
Esophageal candidiasis (or candidiasis of
trachea,
bronchi, or lungs)
Chronic isosporiasis
Extrapulmonary tuberculosis Disseminated mycosis (e.g., histoplasmosis,
coccidioidomycosis, penicilliosis)
Kaposi sarcoma Recurrent nontyphoidal Salmonella
bacteraemia
Cytomegalovirus infection (retinitis or
infection
of other organs)
Lymphoma (cerebral or B-cell non-Hodgkin)
Central nervous system toxoplasmosis Invasive cervical carcinoma
HIV encephalopathy Atypical disseminated leishmaniasis
Cryptococcosis, extrapulmonary (including
meningitis)
Symptomatic HIV-associated nephropathy
Symptomatic HIV-associated
cardiomyopathy
Reactivation of American trypanosomiasis
(meningoencephalitis or myocarditis)
HIV and the immune system
CD4 cell count
The size and composition of the CD4 cell population is regulated by a balance of proliferation of
progenitor cells and death of mature progeny[11]. HIV infection disturbs this balance as HIV kills
CD4 cells and inhibits the body’s ability to replace them. The pool of CD4 cells then become
depleted after years of viral replication, putting people at risk of opportunistic infections [10,
11]. A healthy person would usually have a CD4 cell count of between 500 – 1600 CD4+ T
cells/mm3 [92, 143, 144], although it is highly variable [110, 125, 144, 145] and can fluctuate
according to time of day [114], recent or acute illness [143, 146], sleep quality [147],
psychological factors [146, 148], exercise [149], smoking [143], and drug/pharmaceutical use
[145, 146]. Furthermore, the natural daily fluctuation of CD4 cell counts within an individual is
large [125, 150].
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Women tend to have higher CD4 cell counts than men, which may be further influenced by
phase of menstrual cycle and use of the contraceptive pill [151]. However the rate of decline
during HIV-infection is similar between the groups [110, 152]. Children have higher CD4 cell
counts than adults and CD4 cell counts naturally decline with age [144, 153]. Although a large
proportion of the variation observed in CD4 cell count is biological, it is likely that some is due
to measurement error and researchers have indicated that short term variations observed over
a few days are unlikely to reflect disease progression or response to treatment [150]. Older age
at seroconversion is associated with lower CD4 cell count at seroconversion, a steeper CD4 cell
count decline [152], and faster rate of HIV progression (independently of CD4 cell count) [130,
152, 154]. Older patients are more likely to develop AIDS than younger people with the same
CD4 cell count [154], likely due to increased exposure to opportunistic pathogens that can
become reactivated during severe immunosuppression [154].
HIV viral load
Assays for quantifying HIV-VL emerged in the early 1990s. There are various techniques to
measure HIV-VL, the main ones are reverse transcriptase PCR (RT-PCR), nucleic acid sequence-
based amplification (NASBA) and branched DNA (bDNA)[155]. All assays produce fairly similar
results, although each technique has advantages and disadvantages, including variations in
sensitivity, reproducibility, ease of implementation and cost [155, 156]. Early assays had a lower
detection limit of 400-500 copies/ml. This has dramatically improved over time with most
current and routinely used assays having a detection limit of 40 – 50 copies/ml [155, 156]. Assays
with lower detection limits are important for monitoring of patients on treatment. Highly
sensitive assays have been developed with limits as low as 1 copy/ml, but are not routinely
available [157, 158].
CD4 cell count and HIV viral load as markers of disease progression
Many studies have indicated that both HIV-VL and CD4 are important surrogate markers of HIV-
1 disease progression [103, 159, 160]. Risk of disease progression correlates directly with HIV-
VL level and inversely with the CD4 cell count [159, 161]. In turn, HIV-VL is inversely correlated
with the CD4 cell count [128, 129, 162]. The predictive value of HIV-VL is thought to be higher in
the initial stages of infection [131, 163, 164], whereas immunodeficiency, measured by CD4 cell
count, becomes a stronger prognostic marker in later disease stages [131, 163-165]. HIV-VL is
considered a good long term marker of disease progression, in other words, HIV-VL is predictive
of disease progression 5 or 10 years in the future [159, 163, 164, 166-168]. Conversely, CD4 cell
counts are better predictors of disease progression in the short term [161, 164, 165, 167]. The
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prognosis of HIV+ people is more accurately defined by combined measurement of HIV-VL and
CD4 lymphocytes [131, 159].
High HIV-VL strongly predicts an increased rate of CD4 decline [130, 159, 160, 164, 167, 168],
and faster progression to AIDS [126-129, 160, 162, 168-171], and death [126, 128]. Furthermore,
some studies have shown these associations exist across CD4 cell counts and risk group [131,
159, 160, 166, 169, 172]. In addition, the rate of change in HIV-VL over time (i.e. slope) has been
linked to faster disease progression [162, 168]. People with long term asymptomatic disease
have low HIV-VL levels [173, 174], further supporting the theory that increasing levels of viremia
primarily drives HIV progression. The CD4 cell count is also an important prognostic marker
[132], and many therapeutic decisions are based on CD4 cell count in practice. However, it
should be kept in mind that people with higher HIV-VL levels can progress rapidly to AIDS and
death even when CD4 cell counts are high [103].
Transmission of HIV
The global burden of people living with HIV is increasing, with an estimated 36.7 (34.0–39.8)
million people living with HIV in 2015 [175]. This is partly driven by new infections, of which
there were 2.1 (1.8–2.4) million in 2015 [175, 176] and a reduced mortality rate due to effective
cART [12]. However, the number of new HIV infections is believed to have been declining since
2001 [175, 176].
HIV is a sexually transmitted infection (STI), and can also be transmitted through exposure to
bodily fluids [92, 177]. Transmission can occur both vertically from mother to child (through
pregnancy or breast feeding) [178] and horizontally through sexual contact (including vaginal,
anal, and oral intercourse [179]), reuse of needles and syringes with residue of HIV+ blood [178,
180, 181], and blood transfusions [182, 183]. The risk of HIV transmission per act by exposure
type is summarised in Table 1.4. HIV is most infectious in semen [184], blood and possibly
cervical secretions, but has also been detected in lymphocytes, cell-free plasma, cerebrospinal
fluid, tears, saliva, urine and breast milk in varying concentrations [177]. Risk of HIV infection
depends on both the amount of secretions transferred from the HIV+ person and the amount of
HIV present in those secretions [184, 185]. Furthermore, transmission risk increases with
repeated exposure to HIV [179, 180], and varies by type of sexual contact [179]. HIV has limited
survival outside the body. Therefore, HIV is not transmitted through casual or social contact,
mosquitoes, lice, bed bugs, swimming pools, sharing of cooking/eating utensils, toilets or
airspace with an infected individual[186].
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Table 1.4 Estimated Per-Act Probability of Acquiring HIV in untreated populations from an Infected Source, by
Exposure Act [187, 188].
Type of Exposure Risk per 10,000
Exposures
Parenteral3
Blood Transfusion 9,250 (8900 – 9610)
Needle-sharing during injection drug use 63 (41 – 92)
Percutaneous (needle-stick) 23 (0- 46)
Sexual3
Receptive anal intercourse 138 (102 – 186)
Insertive anal intercourse 11 (4 – 28)
Receptive penile-vaginal intercourse 8 (6-11)
Insertive penile-vaginal intercourse 4 (1-14)
Receptive oral intercourse low (0 – 4)
Insertive oral intercourse low (0 – 4)
Other
Biting negligible
Spitting negligible
Throwing body fluids (including semen or saliva) negligible
Sharing sex toys negligible
Vertical
Mother to child transmission 2260 (1700 – 2900)
Sexual transmission
Sexual intercourse (both anal and vaginal) is the most common route of transmission [186, 189].
During sexual contact, dendritic cells, a type of immune cell, come into contact with the virus on
the exterior, transport it across mucosal barriers of the vagina, vulva, penis, or rectum, and
release the virus directly into lymphatic tissues or lymph node [92]. The virus binds to a CD4 cell,
where it is carried to lymphatic tissues and begins the first cycle of infection [92]. The HIV
lifecycle is explained in more detail in section 1.1.3.
Although male to male sexual contact drives transmission in central and western Europe [189],
most HIV transmissions globally are attributable to heterosexual sex [190]. Risk of sexual
transmission is increased by rough sex, later HIV stage, or high HIV-VL of the HIV+ person, and
coinfection with other STIs [184, 185]. Condom use, serostatus of chosen sexual partner and sex
act performed also impact on risk of transmission [179]. Consistent and correct condom use
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reduces the risk of transmission 20-fold, particularly among serodiscordant heterosexual
couples [179]. The presence of other STIs can impact on risk by causing genital ulcers (i.e. herpes
simplex virus [HSV]), or releasing inflammatory cytokines which increase HIV replication [92].
The risk of transmission is significantly reduced by antiretroviral therapy use by HIV+ people
(through the consequent reduction in HIV-VL) and by preexposure prophylaxis in HIV-negative
people [179, 191, 192]. There are many other approaches to reducing HIV transmission, some
of which are demonstrated in Figure 1.3. Three randomised control trials (RCTs) in African
countries have shown male circumcision to reduce the risk of infection through heterosexual
sex in men by approximately 60% [92, 185, 193-195] and is recommended by WHO as an
intervention to reduce HIV transmission in this group [196]. The role of circumcision has not
been fully investigated among men who have sex with men [197]. However, a recent study has
shown that circumcision is associated with a reduction in HIV incidence among participants who
reported a preference for the insertive role in anal intercourse [198]. There is compelling
evidence that male circumcision reduces the risk of transmission for males, however it has no
impact on transmission for females and other preventative measures, such as condom use, are
still required [48].
Figure 1.3 Changes in risk of transmission based on choices of partner and condom use.
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Transmission via blood
Transmission of HIV via contact with HIV infected blood or blood products is a highly efficient
route of infection [199] and can occur through blood transfusion with infected blood [182, 183],
reusing and sharing needles with residue of infected blood [178, 180, 181], or occupational
exposure (contact with infected blood) [92, 178, 186, 199]. The most common source of
transmission via blood is through the reusing or sharing of syringes and needles among
intravenous drug users (IDUs) [181]. Transmission occurs due to residual infected blood which
remains on used syringes [178], and risk of transmission depends on a variety of factors including
depth of injury, volume of blood, visible blood, location of injury i.e. artery or vein, HIV stage,
and HIV-VL [200]. Recipients of blood transfusions with infected blood have the highest risk of
infection, with infectivity estimates ranging from 88-100% per transfusion [182, 183, 201]. Blood
products were not screened for HIV in the early years of the epidemic, and as a result a number
of people became infected through exposure to infected blood products [202]. Blood has been
routinely screened for HIV in Europe, USA and Canada, since 1985, and infection via this route
is now uncommon where screening is correctly implemented [92].
Vertical transmission
A pregnant HIV+ woman can transmit HIV to her baby during pregnancy, labour, delivery, or
through breastfeeding [92, 186, 203-206]. In the absence of treatment interventions, the risk of
transmission from mother to child ranges from 15-40% [207-210], and is largely related to
maternal HIV-VL [211]. In developed countries the rate of mother to child transmissions of HIV
has decreased to <2% due to the implementation of universal prenatal HIV testing and
counselling, antiretroviral treatment (ART) and combination prophylaxis, elective caesarean
delivery, and avoidance of breastfeeding [92, 203, 212]. Coverage of antiretroviral programs for
pregnant women increased from 57 in 2011 – 77% in 2015 globally [175].
A disparity in transmission rates exist between high and low-middle income countries, with 90%
of children who acquired HIV infection in 2011 living in sub-Saharan Africa [203, 213]. Although
this may improve with roll out of option B+ [214]. Rates of vertical transmission remain higher
in low-middle income countries [176, 213], however the number of children who acquire HIV
perinatally is now approaching the low HIV transmission rates in high-income countries due to
increased coverage of preventative ART programmes [176].
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HIV treatment
The introduction of combination antiretroviral treatment (cART) in 1996 revolutionised the lives
of HIV+ people, and caused a sustained reduction in AIDS defining events and mortality (Figure
1.4)[12]. The mortality rate has reduced from 43.5/100 PYFU in the pre-ART era (1994/5) to 1.15
/100 PYFU in treated populations [12, 215-218]. Studies have shown that with timely diagnosis,
access to a variety of drugs and good adherence, people with recently acquired infections can
expect to have a life expectancy which is approaching that of HIV-negative individuals [2, 219].
As a result it is expected that non-AIDS defining illnesses, such as cancers, renal and
cardiovascular disease, are to become increasing contributors to the burden of disease as the
population ages [220, 221].
Figure 1.4 Combined incidence of AIDS and death rates in the EuroSIDA cohort, 1994 - 2015.
During the early stages of the epidemic there were no recognised treatments available and
death rates were high [222]. In 1986 zidovudine, the first drug that effectively treated HIV, was
developed. Initially intended to treat cancer [223], a phase II RCT in HIV+ people found that
zidovudine significantly reduced mortality and opportunistic infections in people with AIDS and
was terminated after 6 months at which point patients in the control arm were offered
zidovudine [223, 224]. However, a very high rate of adverse events was reported in the
zidovudine arm [225]. In March 1987 zidovudine became the first licenced drug to treat HIV in
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the USA and zidovudine monotherapy (1 drug only) was standard care for HIV+ people [226].
However, HIV with resistance to zidovudine began to appear in patients after 6 months on
treatment and treatment only prolonged life by 6 – 18 months [227-230]. There was a clear need
for more effective and more tolerable treatments to increase survival [231].
The emergence of additional drugs from the nucleoside reverse transcriptase inhibitors (NRTI)
class in 1991 allowed the use of dual therapy (2 drugs in combination) [222, 232]. The
introduction of a second drug class (protease inhibitors [PIs]) in 1995 marked the beginning of
the cART era, which allowed the use of 3 or more drugs in combination from at least 2 different
drug classes (usually 2 NRTIs with one PI, non-nucleoside reverse transcriptase inhibitor [NNRTI]
or integrase inhibitor [INSTI]) [222, 232, 233]. The introduction of a third drug class in 1998
(NNRTIs) lead to further options for cART regimens [222, 227, 232]. Each drug class is designed
to interfere with different stages of the HIV life cycle (Figure 1.5, for an overview of the HIV
lifecycle see section 1.1.3). RCTs have demonstrated that cART use is well tolerated and more
effective at reducing HIV-VL and increasing CD4 cell count, as well as reducing the incidence of
AIDS and death than dual therapy, and both more effective than monotherapy with lower risk
of resistance [226, 234-242].
RCTs are a pivotal part of the process of approving new drugs for general use as well as to
identify the best way to use treatment. New HIV drugs are often licenced based on RCTs with a
primary endpoint of the proportion of people who achieve HIV-VL less than 50 copies/mL after
48 weeks of treatment rather than through RCTs comparing clinical end points [243] (see section
1.1.6.3 for a discussion of HIV surrogate markers). Before 1997, RCTs used clinical end points,
such as HIV disease progression and mortality, to assess drugs for approval [243]. However the
introduction of cART, subsequent decline in HIV-related illnesses, and wide spread use of HIV-
VL monitoring to assess treatment response, rendered this unfeasible. It was concluded that
HIV-VL was an appropriate surrogate end point as treatment-induced decreases in HIV-VL were
highly predictive of a clinical benefit within a reasonable time frame [243].
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Figure 1.5 Effect of ARVs at various points in the HIV lifecycle [244].
Long term cART
As there is currently no cure for HIV and treatment is a lifelong commitment, maximising
treatment durability is crucial for successful and sustained outcomes [222]. Current treatment
works by inhibiting HIV from integrating with host DNA and reproducing. However, viral
reservoirs exist within the body which are beyond the reach of cART, and HIV will resume
reproduction if treatment is stopped [100]. As a result, current treatment can only manage HIV,
not cure it, and treatment is ongoing [100, 245].
The three main causes of treatment failure are drug toxicity, poor adherence, and development
of drug resistance and these three factors are very closely connected [246]. High levels of
adherence to cART are required to achieve long term suppression of HIV-VL. Incomplete
adherence has been associated with virological rebound, immune decompensation, clinical
progression, and HIV drug resistance [247-251]. However, unplanned treatment interruptions
or changes may be necessary due to severe drug toxicity, treatment failure illness, surgery that
prevents oral administration of medicine, or unavailability of drugs [246, 252].
Drug toxicities are the most frequent reason for discontinuation of a first line regimen in Europe
[216, 246]. Toxicities to an individual drug or entire drug class can reduce quality of life of
patients, leading to poor adherence to regimens and increasing the risk of developing resistant
mutations. In extreme cases toxicities can be fatal, such as mitochondrial toxicity, hepatotoxicity
and hypersensitivity reaction [253]. The Division of AIDS (DAIDS) produced the DAIDS adverse
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events grading table, which is a shared tool for consistent assessment of the severity of AEs in
participants enrolled in RCTs. Toxicities are graded as mild, moderate, severe, or life-threatening
based on their severity (Table 1.5) [136, 254]. Clinicians are encouraged to discuss possible side
effects due to drugs with their patients prior to treatment initiation to facilitate recognition of
symptoms and signs of toxicities.
Table 1.5 Division of AIDS (DAIDS) adverse event grading table [254].
Grade of event Condition
1: Mild Mild symptoms causing no or minimal interference with usual social &
functional activities with intervention not indicated
2: Moderate Moderate symptoms causing greater than minimal interference
with usual social & functional activities with intervention indicated
3: Severe Severe symptoms causing inability to perform usual social &
functional activities with intervention or hospitalization indicated
4: potentially life
threatening and
death
Potentially life-threatening symptoms causing inability to perform basic
self-care functions with intervention indicated to prevent
permanent impairment, persistent disability, or death
HIV treatment has developed rapidly over the last 20 years and patient responses have improved
due to better adherence as a result of improved toxicity profiles, more convenient regimens (i.e.
single tablet, once daily pill regimens) and adherence support [255-258]. CART remains the
standard of care for HIV patients internationally. The history of HIV treatment is outlined in
Figure 1.6. Since HIV treatment is not the main focus of this thesis, only a brief overview of each
class is given here. Information on treatment guidelines and drug toxicity profiles can be found
at the British HIV association (BHIVA) [139], AIDSinfo [259], and European AIDS clinical society
(EACS) [140]. The current EACS treatment guidelines are outlined in section 1.1.8.7.2.
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Figure 1.6 HIV treatment timeline history of drugs licenced for use in Europe.
Greyed out drugs are no longer recommended for use. NRTI Zidovudine [225, 260], Didanosine (ddl) [261-265], Zalcitabine (ddc) [266-272], Stavudine D4T [273], Lamivudine 3TC [274-280], Abacavir
[281-283], Tenofovir [284, 285], Tenofovir-AF [286], Emtricitabine [287-289], PI Ritonavir [290], Indinavir [237, 238, 291-293], Saquinavir [234, 236, 294-296], Nelfinavir [297], Amprenavir [298, 299],
Lopinavir/r [300-302], Atazanavir [303-308], Fosamprenavir [309-312], Tipranavir [313, 314], Darunavir [315-322], NNRTI Delavirdine [323-326], Nevirapine [241, 242, 327, 328], Efavirenz [329, 330],
Etravirine [331, 332], Rilpivirine [333, 334], Fusion/Entry/INSTI Enfuvirtide [335-337], Maraviroc [338-341], Raltegravir [342-348], Elvitegravir [349-352], Dolutegravir [353-360]. PK: Cobicistat [361,
362].
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Nucleoside reverse transcriptase inhibitors
The NRTI class was the first antiretroviral drug class approved for the treatment of HIV. NRTIs
are “structural analogues” of nucleosides, which are converted into nucleotide analogues via
cellular kinases – the molecular building blocks necessary for HIV reproduction [232, 363]. The
nucleotide analogues interrupt the reverse transcription phase of the HIV lifecycle, in which the
HIV enzyme reverse transcriptase converts single strand HIV RNA into double strand DNA [244].
When an analogue is used during reverse transcription instead of a viral nucleoside, the reverse
transcriptase enzyme is prevented from creating the required chemical bonds to allow further
addition of natural nucleotides [363]. This terminates the growing of the viral DNA chain and
HIV replication within the cell is halted [364-366]. It should be noted that nucleotide analogue
reverse-transcriptase inhibitors (NtRTIs) follow the same function as NRTIs, however they are
analogues of nucleotide as opposed to nucleosides, which allows for the usual conversion of
nucleoside to nucleotide to be skipped [363]. NRTIs licenced in Europe are summarised in Figure
1.6.
As previously mentioned, zidovudine was the first licenced drug to treat HIV [226], shortly
followed by the emergence of didanosine and zalcitabine in 1991 and 1992 respectively [261,
262, 265]. Many other NRTIs have been developed over the years. The current EACS and BHIVA
guidelines recommend tenofovir/emtricitabine or tenofovir-AF/emtricitabine as first line with
abacavir/lamivudine as an alternate therapy, depending on third drug class used [139, 140]. Use
of other NRTIs in naïve patients is no longer recommended due to mitochondrial toxicities
associated with extended NRTI use including liver damage (manifesting as either lactic acidosis
along with hepatic steatosis), myopathy, cardiotoxicity and peripheral neuropathy [225, 367,
368]. Both abacavir and zidovudine have been linked with cardiotoxicities and tenofovir with
renal disease [367, 369-373]. Although zidovudine use is no longer recommended, it is still
administered in some situations, such as pregnancy [368]. Zalcitabine and stavudine use is
associated with significant mitochondrial and hepatic toxicities [368]. Zalcitabine was withdrawn
from the market for adverse event concerns at the end of 2006 and stavudine is not
recommended due to the long-term irreversible side effects [374]. In Europe, stavudine use has
been progressively reduced during the past decade although it has not been yet completely
phased out [375]. Newer NRTIs generally have fewer side effects and are more tolerable than
older NRTIs [367].
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Protease inhibitors
PIs disrupt the HIV lifecycle by binding to the protease enzyme and blocking the breakdown
(cleavage) of large viral polyproteins into smaller functional subunits used to make new HIV
particles [232, 364, 365, 376]. PIs do not stop HIV replication all together, however virions
produced in the presence of PIs are immature and are not capable of infecting new cells [364].
Various RCTs have demonstrated the effectiveness of PIs in HIV+ people [371]. PIs approved for
use in Europe are summarized in Figure 1.6.
First generation PIs had limited clinical utility due to high pill burden and low bioavailability,
which lead to poor adherence and antiretroviral efficacy [233]. The first PIs to be developed
were saquinavir [234-236] followed by indinavir, both licensed for use in Europe in 1996. Use of
saquinavir boosted with ritonavir is no longer recommended due to high pill burden and possible
association with QT interval prolongation [368, 377], and despite RCTs demonstrating
favourable efficacy of indinavir containing cART, adverse renal toxicity and strict dietary intake
recommendations had a negative impact on long term success [238, 291].
Ritonavir was found to be very potent against HIV, but was poorly tolerated due to toxicities and
severe gastrointestinal symptoms [233, 290, 378-382]. However, it was found to increase
concentrations of other PIs when coadministerd in low doses, a phenomenon known as boosting
[383]. Ritonavir inhibits the primary enzyme involved in the metabolism of most PIs (the CYP3A4
isozyme located in the intestinal track and liver) leading to higher and more consistent
concentration in the blood stream [383, 384]. Use of ritonavir as a booster for other PIs was
found to be safe, generally well tolerated, with less frequent dosing, and better antiretroviral
efficacy properties in the short term than a non-boosted PI regimen [294, 295, 301, 302, 383,
384]. An alternative drug used as a booster is cobicistat, which is classed as a pharmacokinetic
enhancer and is licenced for use with atazanavir and darunavir [361, 362].
Darunavir boosted with either ritonavir or cobicistat is the only PI which is a currently
recommended option for first-line cART, in combination with two NRTIs. Boosted atazanavir
with either ritonavir or cobicistat and lopinavir boosted with ritonavir are listed as suitable
alternate therapy options [139, 140]. PIs have been associated with gastrointestinal disorders,
dysfunctions of lipid and glucose metabolism, sexual dysfunction, hepatic toxicity and increased
risk of bleeding [385].
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Non-nucleosides reverse transcript inhibitors
The first drug from the NNRTI class, nevirapine, was introduced with in 1998 and lead to further
cART options [226, 227]. Like NRTIs, NNRTIs interrupt the HIV lifecycle by preventing conversion
of HIV-RNA to HIV-DNA during reverse transcriptase. The difference between NRTI and NNRTIs
is how the drugs interact with the reverse transcriptase enzyme [232, 363, 364]. Rather than
acting as faulty nucleotides, NNRTIs bind to a hydrophobic pocket near the polymerase active
site of the reverse transcriptase enzyme [232, 363, 364]. This changes the shape of the binding
site making it incompatible with HIV-RNA, and thus interrupting the conversion of HIV RNA to
DNA [232, 363, 364]. NNRTIs licensed for use in Europe are summarised in Figure 1.6. NNRTIs
are only effective against HIV-1 [386].
Several RCTs demonstrated the superior efficacy of NNRTI use in combination with two NRTIs
compared to dual or monotherapy [239-242]. NNRTI based regimens are generally well
tolerated, with common adverse events including rash which can be treated with steroids and
antihistamines. Efavirenz has been associated with central nervous system (CNS)-related side
effects, including insomnia and vivid dreams [387]. Current guidelines recommend rilpivirine for
first line treatment of antiretroviral naïve patients, with efavirenz as an alternative [139, 140].
Rilpivirine has less adverse events, a better lipid profile and similar rates of virological
suppression than efavirenz, but higher rates of virological failure and resistance [333, 334, 388].
Effectiveness of efavirenz has been demonstrated across multiple RCTs, however the associated
CNS-side effects make it less tolerable than other regimens [136, 368].
Integrase inhibitors
INSTIs are a recently developed drug class which target the HIV integrase enzyme in order to
prevent the integration of HIV-DNA into the hosts DNA and in doing so inhibit replication [232,
389]. Raltegravir was the first INSTI to be approved in Europe in 2009 and there are currently
three drugs from this class licenced for use in Europe: raltegravir, dolutegravir, and elvitegravir
(Figure 1.6) [232].
Regimens containing raltegravir, dolutegravir, or elvitegravir have been shown to be non-
inferior to other preferred antiretroviral regimens for antiretroviral naïve patients [351, 352,
358], and are well tolerated in both naïve and experienced patients [232, 390]. Elvitegravir
boosted with cobicistat, dolutegravir and raltegravir are all approved as components of
antiretroviral treatment options [136, 368]. Elvitegravir is a promising new drug, however,
studies indicate a potentially high degree of cross resistance with raltegravir [391].
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Raltegravir, dolutegravir, and elvitegravir are currently recommended to be included in first line
cART regimens in combination with two NRTIs [139, 140]. Common adverse events are
gastrointestinal effects, hyperbilirubinemia, and low eGFR. Dolutegravir has been associated
with systemic hypersensitivity syndrome in <1% of users [140].
Entry and fusion inhibitors
Entry inhibitors prevent HIV from entering CD4 cells, by interfering with the ability of HIV to fuse
with the cellular membrane of CD4 cells [392, 393]. The three stages of entry which are targeted
include attachment of the viral gp120 to the CD4 T-cell receptor, binding of the GP120 to CCR5
or CDCR4 co-receptors, and fusion of the viral and cellular membranes (see section 1.1.3 for a
detailed description of the HIV lifecycle) [392, 393]. There are currently only two drugs licenced
from this class, maraviroc and enfuvirtide (previously known as T-20). Enfuvirtide was the first
drug from this class to be licensed in Europe in 2003 [393]. It was developed for use in
antiretroviral experienced people, and it has been found to be effective in in this group and in
those with multidrug resistant HIV [337, 394, 395].
Maraviroc is the only licenced drug of the CCR5 receptor antagonist class and is used people
with R5 HIV infection [396]. Maraviroc prevents HIV from entering CD4 cells by binding with the
CCR5 receptor and as a result blocks gp120 interaction with the CCR5 receptor [397]. Maraviroc
is not licenced in Europe for initial ART use, but can be used as salvage therapy in antiretroviral
experienced people with multidrug resistant HIV [368].
Optimal treatment
1.1.8.7.1 Initiation of treatment
Several RCTs have investigated treatment strategy. The START study was a RCT which assessed
the benefits and risks of earlier antiretroviral treatment. Antiretroviral naïve patients with CD4
cell counts > 500 cell/mm3 were randomised to either initiate treatment immediately, or to
initiate after CD4 cell count dropped below 350 cells/mm3 (deferred treatment) [141, 142]. The
trial demonstrated that those who initiated treatment immediately had a 57% reduction in the
risk of serious AIDS defining event, serious non–AIDS defining event, or death from any cause
[141].
The WHO, EACS, and BHIVA guidelines changed to recommend that all HIV+ people initiate cART
regardless of CD4 cell count (from a previous cut-off of below 350 cells/mm 3) [135-140]. In
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addition, the EACS guidelines recommend assessing the person’s readiness to start and remain
on cART prior to initiation [140]. A number of physiological and psychosocial factors, such as
cognitive function, alcohol and drug use, high risk sex behaviours and depression also impact on
the use of available treatments and resources by affecting drug uptake and adherence [104,
136]. Genotypic resistance testing is recommended prior to initiation of treatment [136]. It is
recommended that the HIV-VL level and CD4 cell count should be measured before starting
treatment to obtain a baseline to assess subsequent treatment response [136].
1.1.8.7.2 Current treatment guidelines and optimal ART regimen
Advancements in HIV treatment have transformed HIV infection from a fatal condition to a
manageable chronic disease [245]. There are currently 29 antiretroviral drugs approved for use
in Europe, which allows for a vast array of treatment options and regimens. Success rates are
highest with initial therapy and diminish with subsequent regimens [398]. As a result, it is
important that optimal treatment regimens are identified so that people commencing
treatment can maximise the benefit and adherence to treatment regimes. Due to many different
reasons there is still some debate over which choice of first-line treatment is optimal, one of the
most important factors being long term durability. Use of fixed dose combinations, where two
or more drugs are combined in a single dose, are thought to improve compliance [399]. For
example, atripla is a fixed dose combination of efavirenz, emtricitabine, and tenofovir.
It is currently recommended that initial regimens use a combination of two NRTIs and third
active drug of either a ritonavir boosted PI, NNRTI or INSTI as outlined in Table 1.6 [139, 140]. A
drug from column A should be combined with the drugs from column B. Alternative treatment
regimens are given in the lower part of Table 1.6. The third active drug should be individualised
based on a variety patient factors including potential side effects, dosing requirements, dosing
convenience, individual preference, co-morbidities, drug interactions and cost [400].
Although cART use is highly cost effective, it remains a major contributing factor to the cost of
managing HIV [400]. Generic drugs are becoming available and stand to dramatically reduce the
cost of some regimens. Currently, the EACS guidelines recommend the use of generics to replace
the same non-generic drug, as long as they are available as part of a fixed dose combination
where applicable [140]. However, it is possible that antiretroviral use may shift towards more
inconvenient regimens, with higher pill burden and twice daily regimens, in place of more
expensive yet convenient regiments [400, 401].
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Table 1.6 EACS Initial recommended regimen for antiretroviral naïve HIV+ adults [140].
A B
INSTI NRTI backbone
Recommended regimens
DTG ABC/3TC or TDF/FTC
or
TAF/FTC
EVG/c TDF/FTC or
TAF/FTC
RAL TDF/FTC or
TAF/FTC
NNRTI NRTI backbone
RPV TDF/FTC or
TAF/FTC
Boosted PI NRTI backbone
DRV/r TDF/FTC or
TAF/FTC
DRV/c TDF/FTC or
TAF/FTC
Alternative regimens
INSTI NRTI backbone
RAL ABC/3TC
NNRTI NRTI backbone
EFV ABC/3TC or TDF/FTC
Boosted PI NRTI backbone
ATV/r ABC/3TC or TDF/FTC
or
TAF/FTC
ATV/c ABC/3TC or TDF/FTC
or
TAF/FTC
DRV/r ABC/3TC
DRV/c ABC/3TC
LPV/r TDF/FTC or
TAF/FTC
Dual combinations
3TC LPV/r
RAL DRV/c or
DRV/r
PI/r: boosted with ritonavir, PI/C: boosted with cobicistat
Testing for HIV
In December 2013, the UNAIDS programme set a goal to reach the following target by 2020:
90% of people living with HIV will know their HIV status, 90% of all people diagnosed with HIV
will receive sustained antiretroviral therapy, and 90% of all people receiving antiretroviral
therapy will have viral suppression [402]. This would result in 73% of HIV+ people worldwide to
be virally suppressed [402]. The HIV cascade of care in Europe in 2014 is shown in Figure 1.7. It
has been estimated that 76% of people who have HIV are tested and diagnosed, 78% of those
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diagnosed are on treatment, and 88% of those on treatment are virally suppressed [403].
Overall, 53% of all HIV+ people (diagnosed and undiagnosed) are virally suppressed [403]. Similar
estimates have been produced for the USA [203]. In addition, the CDC has estimated that in the
USA up to 31% of people who test positive for HIV do not return to collect their test results and
are therefore unaware of their status [404]. Optimising the availability of timely HIV testing
facilitates linkage to care and initiation of treatment, and thus reduces new transmissions.
Figure 1.7 Cross-country continuum for 16 countries of Europe and Central Asia EU and EEA countries in 2014.
EU and EEA countries included: Austria, Bulgaria, Denmark, France, Germany, Luxembourg, the
Netherlands, Romania, Spain, Sweden and the UK Non-EEA countries included: Armenia,
Azerbaijan, Georgia and Serbia [403]
The global epidemic
There were estimated to be 36.7 (34.0–39.8) million people living with HIV in 2015, two thirds
of which live in sub-Saharan Africa where women make up more than half of the HIV+ population
[175]. The rate of new HIV infections per 100,000 population has declined by 38% from 3.4 (3.1
– 3.7) million in 2001 to 2.1 (1.8 – 2.4) to in 2015 (Figure 1.8), with a simultaneous decline in
AIDS deaths from 2.3 (2.1 – 2.6) in 2005 to 1.1 (0.9 – 1.3) in 2015 [175, 405]. However, the
number of people living with HIV is increasing (Figure 1.9) as more people have access to
effective antiretroviral therapy which has had a dramatic improvement on the life expectancy
[1-3, 175]. There is substantial variation in the HIV epidemic by region (Figure 1.10 and Figure
1.11) [175]. Sub-Saharan Africa is the region most affected by the HIV epidemic, with nearly 1 in
every 20 adults (4.9%) living with HIV [175, 176, 213].
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Figure 1.8 Estimated total number of new infections globally by calendar time [175].
Figure 1.9 Estimated total people living with HIV [175].
Figure 1.10 Estimated number of new HIV infections by region in 2015 [406, 407].
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Figure 1.11 Estimated number of people living with HIV by region in 2015 [406, 407].
The European epidemic
The HIV epidemic in Europe remains a public health issue, and is heterogeneous across
countries. It is mainly concentrated in key populations (although these vary by country) such as
men who have sex with men, injecting drug users, migrants, and people originating from
countries with generalised epidemics, such as Sub-Sahara African counties [408].
There were 153,407 new diagnoses of HIV reported in 50/53 countries of the WHO European
region in 2015 (defined in the footnote of Table 1.7), corresponding to a diagnosis rate [IR] of
17.6 per 100,000 population [408]. Almost two thirds of new HIV diagnoses in the European
region in 2015 occurred in from Russia (98,177, 64%), corresponding to a rate of 67/100,000
population [408]. There were an additional 55,230 diagnoses in 2015 in the rest of the region,
of which 41% (22,911 cases) were in east, 49% (27,022 cases) in west, and 10% (5,297) in central
Europe. Countries with the highest rates of HIV diagnosis were Russia (67 per 100,000
population), Ukraine (30), Belarus (24), Estonia (20) and Moldova (20), Latvia (20), and Georgia
(17). The breakdown of new HIV diagnoses in 2015 by region and in key groups are shown in
Table 1.7 [408].
Despite significant investment and efforts to control and prevention of HIV infection, the overall
incidence continues to increase over the last decade, with a slight decline in recent years (Figure
1.12). Since 2006, the incidence of new HIV diagnoses per 100,000 population has increased by
59% from 11.1 in 2006 to 17.6 in 2015 per 100,000 population (including Russia), driven mainly
by increases in eastern Europe, which represents a 108% increase from 22.8 in 2006 to 47.5 in
63
2015 (Figure 1.13) [408]. An increase in incidence was observed in central Europe (133 %, from
1.1 to 2.8 from 2006 to 2015). In western Europe incidence declined by 20%, from 7.9 to 6.3 in
2006 and 20105 respectively (Figure 1.13) [408].
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Table 1.7 HIV diagnoses in the WHO European Region 2015 [408].
Russian data are included in the numbers in parentheses for the European Region and the East.
* No data received from Bosnia and Herzegovina, Russia, Turkmenistan, Uzbekistan. All data presented
were reported to ECDC/WHO through the European Surveillance System (TESSy), except for data for
Russia which were obtained through the Russian Federal Scientific and Methodological Center for
Prevention and Control of AIDS
** EU/EEA rate is adjusted for reporting delay, the corresponding estimated number of new diagnoses
adjusted for reporting delay is 32483.
The who region consists of: Western Europe : Andorra, Austria, Belgium, Denmark, Finland, France,
Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, the Netherlands, Norway,
Portugal, San Marino, Spain, Sweden, Switzerland and the United Kingdom; Central Europe: Albania,
Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, the Czech Republic, Hungary, Poland, Romania, Serbia
and Montenegro, Slovakia, Slovenia, The former Yugoslav Republic of Macedonia and Turkey; Central
Asian republics : Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan; Eastern Europe: Baltic
states (Estonia, Latvia and Lithuania), Belarus, the Caucasus republics (Armenia, Azerbaijan and Georgia),
the central Asian republics mentioned above, the Republic of Moldova, the Russian Federation and
Ukraine;
Figure 1.12 Rate of new HIV diagnoses in the WHO European Region and European Union and European economic
area (EU/EAA) 1986 – 2015 [408].
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Figure 1.13 Incidence of HIV diagnoses over time within the WHO European Region by geographical area 2006 -
2015 [408].
Eastern Europe
The Eastern European epidemic began in 1995 in Ukraine, and spread to Belarus, the Republic
of Moldova and the Russian Federation in 1996, Latvia in 1998, Estonia in 2000, Lithuania in 2002
and central Asia in 2003 [409, 410]. Eastern Europe is a major public health challenge due to the
rising incidence of new HIV diagnosis, high incidence of AIDS defining events, and AIDS related
mortality [408]. In 2015, almost three quarters of all AIDS diagnoses in Europe occurred in the
east and increased by 80% between 2006 and 2015, however this has slowed since 2011 [408].
The high rate of AIDS diagnoses likely reflects a delay in HIV testing and diagnosis, late diagnosis,
poor retention in care and barriers to accessing cART in this region [409, 410].
There are various barriers to the effective management of HIV in Eastern Europe, including
structural barriers, treatment barriers, and social stigma [411]. Transmission of HIV in this region
is primarily driven by IDU and needle sharing, however, heterosexual sex has also emerged as
major contributor [409]. Eastern Europe has one of the largest IDU epidemics in the world a high
prevalence of hepatitis C (HCV) coinfection [412]. HCV and HIV are interlinked with higher
incidence of tuberculosis (TB), multidrug resistant TB (MDR-TB), end stage liver disease, and
death [413-415]. Although needle substitution programs (NSP) and opioid substitution therapy
(OST) programs are available in many countries, coverage of NSP is generally low and OST
programs are very limited with only 1% of people who use injecting drugs receiving OST [416].
Lack of access to cART and low cART use in eastern Europe is driven by a lack of integration of
health care services (such as HIV, TB, and OST), an expectation that HIV treatment is dependent
on treated drug use (which is highly limited), and complex administrative procedures [417].
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Social stigma and discrimination play a key part in the ongoing transmission of HIV, fuelling fear
of testing positive, disclosing their HIV status to family and sexual partners, seeking out care,
support, and treatment [411]. Stigma surrounding HIV is compounded in already stigmatised
groups, such as such as people who inject drugs, Men who have sex with men, sex workers and
migrants [411].
Cancers in the context of HIV
The availability of effective cART (see section 1.1.8 for an overview of HIV treatment) and
improvements in the efficacy and tolerability of treatment regimens has led to increased
immune-function and reduced incidence of AIDS defining events in HIV+ people [12]. As a result,
survival has dramatically improved, with the median age at death projected to be as high as 75
years [1-6] and traditionally age associated conditions such as many cancers, cardiovascular
events, and liver disease, are becoming key components of HIV care [418, 419]. Cancers are a
significant source of morbidity and mortality and are now the second most common cause of
death in HIV+ people following AIDS defining deaths (Figure 1.14) [13, 220]. It is estimated that
30 – 40% of HIV+ people are likely to develop cancer during the duration of their HIV infection
[418]. Increased risk could be partially explained by high prevalence of traditional cancer risk
factors such as smoking [420, 421], alcohol use [422, 423], and high risk sexual behaviour
(associated with increased risk of some oncogenic viruses) [9, 424, 425] in the HIV+ population.
However, coinfection with other oncogenic viruses [426], immunodeficiency [15, 427], activated
inflammation and coagulation [428], direct pro-oncogenic effect of HIV [429] and cART toxicity
[18] may also contribute.
As it has only been 20 years since the introduction of cART and many carcinogenic processes
have long latency periods, evidence of an increased risk of cancers may emerge in the near
future in addition to than those discussed in this section.
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Figure 1.14 Most common causes of death in people with HIV [220].
AIDS-defining and non-AIDS defining cancers
Due to the historical classification of illnesses into AIDS (defined in section 1.1.4) and non-AIDS
defining events, it has become custom to also classify cancers in this way. AIDS defining cancers
(ADC) are Hodgkin lymphoma (HL), KS, and cervical cancer [133]. All other cancers are
considered non-AIDS defining cancers (NADC) [133].
Common cancers in HIV-positive people
In the late cART era (2002 – present), the most commonly occurring cancers in the HIV+
population include: Non-Hodgkin lymphoma (NHL) (IR: 8 – 25 /10,000 PYFU), KS (6 – 23 /10,000
PYFU), HL (3 – 6 /10,000 PYFU), anal cancers (3 – 13/10,000 PYFU), prostate cancers (6 –
10/10,000 PYFU), head and neck cancers (2/10,000 PYFU), colorectal cancers (3-4/10,000 PYFU)
and lung cancers (4 – 10/10,000 PYFU) [430-436]. Cervical cancers are also highly common in
women (5 - 13/ 10,000 PYFU) [433, 436].
Non-Hodgkin Lymphoma
NHL remains the most common ADC in HIV+ people [430, 437]. Effective cART has led to a
significant decline in the incidence of NHL [16, 20, 21, 438-442]. This decline has been observed
for all subtypes (although mixed results have been reported for Burkitt’s lymphomas) [440, 441,
443]. Despite this, NHL account for approximately half of all ADCs [444] and incidence currently
remains around 10-fold higher [445] in HIV+ compared to negative people, albeit a decline from
earlier estimates of 10 to 200-fold higher [15, 442, 446-448]. The lifetime risk of NHL has been
estimated as 1 in 25 in HIV+ people in recent years [449].
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NHL can be grouped into primary central nervous system (PBCNS) lymphoma, and the systemic
lymphomas: Burkitt’s, immunoblastic, diffuse large B cell and other subtypes [442, 450, 451].
The pathology and relationship between immunodeficiency and lymphoma development vary
by subtype in HIV+ people [452]. For example, PBCNS lymphoma generally occur at advanced
disease stages at very low CD4 cell counts [451], whereas systemic lymphomas can also occur in
people with higher CD4, with almost half occurring in people with current CD4 >200 cells/mm 3
(however an increased risk increases with lower CD4 is still observed) [450]. NHL is discussed in
more detail in chapters 5 and 6.
Kaposi’s sarcoma
KS is the second most common ADC in HIV+ people in the late cART era [436, 453]. KS is a
vascular tumour which commonly manifests as multiple lesions of the skin and mouth, but can
also affect the lungs, liver, stomach and intestines [454]. KS is a rare type of cancer in the general
population, however it occurs at an extremely high rate in immunocompromised populations,
with a 112 – 3640-fold higher incidence in HIV+ people than in the general population [8, 15, 16,
442]. The lifetime risk of KS in HIV+ people has been estimated to be approximately 1 in 25 in
recent years [449]. KS incidence highly elevated in those with very low CD4 cell counts (most
occur with CD4 cell count < 150 cells/mm3) [16, 455, 456], and multiple studies have
demonstrated a notable decline in risk after cART initiation [21, 216, 457-460].
Cervical cancer
Cervical cancers are considered an ADC [133] and almost all cervical cancers are caused by
Human papillomavirus (HPV) [461] the majority of which are caused by genotypes 16 (50%) and
18 (10-15%) and the remainder by other subtypes [461-463]. Risk of cervical cancer is elevated
in HIV+ women, with highly variable estimated incidences of between 4 - 10 fold higher in HIV+
relative to HIV-negative women [15, 21, 436, 438, 444, 464, 465]. Early studies showed no
decline in cervical cancers since the introduction of cART [20, 21, 438], however more recent
studies have shown a decline of 12% per year [430, 436, 464]. A less prominent decline in cervical
cancer incidence is also evident in the general population [7, 436, 464].
Hodgkin lymphoma
HL is characterised by the presence of Reed-Sternberg (RS) cells, the malignant cell population
of this cancer type, within the cancer tissue [466]. HL is one of the most common NADCs that
occur in HIV+ people. The incidence has remained stable [19] or even increased [21, 430, 467]
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in HIV+ people since the introduction of cART [15, 20, 21, 438, 444, 468], and is estimated to be
11-fold higher (with estimates ranging from 5 – 19) than in the general population [8, 14-16,
438, 469]. This may in part be linked to a higher HL incidence associated with NNRTI use [467]
or it may be more strongly linked to prior immunodeficiency duration.
The incidence of HL has been linked to lower CD4 cell count [427] where incidence highest at
low - moderate CD4 cell counts [427, 470, 471]. The lifetime risk of HL in HIV+ people has been
estimated as 1 in 125 in recent years [449]. HL is discussed in more detail in chapters 5 and 6.
Head and neck cancer
Some of the head and neck cancers are related to HPV infection [472-474]. HPV related head
and neck cancers are one of the more frequently occurring NADCs, however the incidence is
similar to that of the background population [14, 430, 437]. There is no evidence of a decline in
the incidence of head and neck cancers since the introduction of cART [7, 467, 475]. The lifetime
risk of oral cavity/pharyngeal cancers in HIV+ people has been estimated to be 1 in 100 in recent
years [449].
Anal cancer
Anal cancers are related to HPV infection [476, 477] not considered an ADC, although the
incidence is between 25 – over 100-fold higher in the HIV+ people (in both men and women, but
for men who have sex with men in particular) compared to the general population and have a
higher relative incidence than invasive cervical cancer, which is considered an ADC [14-16, 19,
430, 437, 438, 478-480]. Some studies have shown an association between anal cancers and
lower nadir CD4 cell count [438, 481] and duration of immune suppression [433, 482], however
no decline in incidence since the introduction of cART has been observed, and some studies have
reported an increase [14, 19, 430, 432, 437, 438, 467, 479-481]. The lifetime risk of anal cancers
in HIV+ people has been estimated to be 1 in 59 in recent years [449].
Liver cancer
The incidence of liver cancer is between 2 – 6-fold higher in HIV+ people compared to HIV-
negative people [7, 15, 16, 20, 430, 437, 483] and are almost exclusively caused by Hepatitis B
(HBV) and HCV [474, 484]. Coinfection with HCV and/or HBV and HIV is common due to shared
transmission pathways, with up to 9% of HIV+ people from developed countries coinfected with
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HBV [485]. The lifetime risk in of liver cancer in HIV+ people has been estimated to be 1 in 72 in
recent years [449].
Prostate cancer
Prostate cancer (PCa) is the most common solid neoplasm in the older European man [1]. The
incidence of PCa in HIV+ men has been estimated to be 27 (95% confidence interval [95%CI]: 43
– 8)% lower than HIV-negative men after adjusting for differences in PCa screening practices; a
result that is consistent in many studies in the cART era [15, 16, 21, 431, 438, 469, 486-488].
Prostate cancer is explored in more detail in chapter 7.
Lung cancer
Lung cancer incidence in HIV+ people has been estimated to be 2 – 4-fold higher than in HIV-
negative people [430, 433, 437], although the relative contribution of life-style related risk
factors, such as smoking, towards elevated cancer risk, is not clear. The prevalence of smoking
is high in HIV+ people with around 40 – 70% estimated to be current smokers, which is 2 – 3-
fold higher than the general population [20, 489-496]. The lifetime risk in of liver cancer in HIV+
people has been estimated to be 1 in 25 in recent years [449]. Lung cancer is investigated in
more detail in chapter 4.
Infection-related and unrelated cancers
In the general population it is estimated that between 15 – 20% of all incident cancers are
associated with a viral infection [442]. HIV+ people are known to have higher rates of cancers
with an infection-related cause (IRC) due to increased immune deficiency [8, 14-18, 427]. The
classification of cancers into ADC and NADC, as described in section 1.2.1, is arbitrary and less
relevant to clinical practice in the late cART era. A more natural classification is as IRC and
infection-unrelated cancers (IURC), which are the terms to be used throughout this thesis. The
three ADCs (NHL, KS, and cervical cancers) each have some degree of causal link with viruses
and are therefore considered IRC:
 Epstein-Barr virus (EBV) has been linked to 30-100% of all NHL in HIV+ people [71, 72]
 human herpesvirus 8 (HHV8) infection is required for KS in both HIV+ and HIV-negative
people [474, 497, 498]
 Almost all cervical cancers are caused by HPV [461].
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In addition, the following NADC also have some degree of causal link with viruses and are
therefore considered IRC:
 EBV causes 80-100% of Hodgkin’s lymphoma (HL) [474, 499, 500].
 Liver cancers are almost exclusively caused by HCV and HBV [474, 484].
 Helicobacter pylori (H.Pylori) is associated with stomach cancer [474, 501]. However a
small proportion of gastric cancers have also been linked with EBV (10%) [502].
 HPV causes some cancers of the head and neck, anus, penis, vulva and vagina[472-474]
Chapter 3 contains a more detailed discussion of IURC and IRC.
HIV and aging
The proportion of HIV+ adults aged over 50 years has increased in all regions of Europe since
2007, particularly in western and central Europe and North America (Figure 1.15) [503]. This is
primarily driven by increased survival of HIV+ people due to effective treatment and a decline in
incidence among younger adults (resulting in a lower prevalence of HIV in these age groups)
[405, 503]. In addition, people aged over 50 years continue to be sexually active and have similar
risk factors for HIV acquisition to younger people [405, 503]. This raises multiple issues with
regard to future HIV care for older HIV+ people, for instance the increased complexity due to co-
management and treatment of age-associated conditions, such as cardiovascular disease,
diabetes and cancers [504].
Figure 1.15 The percentage of all people living with HIV aged over 50 years between 1995 and
2012 by region [503].
In addition, it has been suggested that HIV+ people suffer from premature “aging” of the
immune system or immune aging (“inflamm-ageing”) [505-508]. This theory is primarily driven
by the following observations. First, HIV treatment does not fully restore health and HIV+ people
72
continue to have a shorter life expectancy than HIV-negative people despite long term
treatment [219, 509-513]. Second, HIV+ people also have increased risk of traditionally “age
related” complications, including heart disease, cancer, liver disease, kidney disease, bone
disease, neurocognitive decline, and cataracts [505, 506, 514, 515]. Finally, HIV-associated
inflammation and immunosenescence have been implicated as causally related to the
premature onset of cancers, and end stage organ diseases, which occur despite effective
treatment [505, 506, 516-520].
Known risk factors for common cancers
Cancers are a heterogeneous collection of disease, and risk factors vary significantly both within
and between different cancer types. Table 1.8 shows some commonly known risk factors for
various cancers in HIV+ people.
Table 1.8 Common risk factors for cancers in HIV-positive people.
Demographic factors
Age Older age has been linked to KS, NHL, cervical, lung and liver cancers [433].
Gender Males have higher risk NHL, HL, lung, anal and liver cancers [433].
HIV
Transmission
group
Men who have sex with men have higher risk of KS, NHL, and anal cancers
compared to other risk groups. Injecting drug users have higher risk of lung
and liver cancers, however the association with liver cancers is due to the
high prevalence of HCV in this group [433].
HIV-associated and other health factors
CD4 Lower CD4 cell count has been linked to many cancers, including NHL,
cervical cancers, KS, head and neck cancers, lung, colorectal, and liver
cancers [16, 17, 433]. Lower CD4 cell count has been linked with lower HL
risk, however risk is highest in people with CD4 49 – 99 cells/mm3 [17].
Longer duration of CD4 < 200 cells/mm3 has been linked with higher risk of
anal cancer [433, 482].
HIV-VL Higher current HIV-VL has been linked to higher risk of NHL, KS, cervical
and head and neck cancers [16, 433]. Duration of time with HIV-VL < 200
copies/mL has been linked to lower high risk of anal cancers [433, 482].
HIV treatment HIV treatment for 6 months or more is associated with lower risk of NHL,
KS, and cervical cancers [433, 482].
HCV and HBV
coinfection
HCV and HBV coinfection is strongly associated with liver cancers [433,
477, 482, 521].
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Oncogenic
viruses
High prevalence of oncogenic viruses in HIV+ people has led to higher
incidence of IRCs, as discussed in section 1.2.3 [521].
Chronic
inflammation
HIV-associated and otherwise [522].
Life style factors
Smoking A strong risk factor for lung cancers, as well as other cancers such as head
and neck cancers, cervical cancers, and leukaemia [433, 482, 521].
Alcohol use A strong risk factor for liver cancer [433], has also been implicated in head
and neck cancers, colorectal, breast cancer [482, 521].
High risk sexual
behaviours
Have been linked to a higher prevalence of HPV, and therefore HPV
associated cancers [433].
Obesity Absence of excess body fat reduces the risk of breast cancers, colon and
rectal, oesophagus, kidney, gastric, gallbladder, pancreas, ovary, thyroid,
multiple myeloma [521, 523].
Other
Cancer causing
substances
Includes work place and house hold exposures, such as asbestos and radon
with lung cancer [524].
Sunlight Sunlight has been linked to incidence of skin cancers [525].
Radiation Radiation has been conclusively linked to lung, bone, and liver cancer.
Some evidence of an association with leukaemia, and cancers of the
pancreas and prostate also exist [526].
Pollution Long term exposure to ambient fine particles is associated with elevated
lung cancer risk [527].
Hormones Such as breast cancer risk following combined hormone therapy
(oestrogen and progesterone) [528].
KS: Kaposi’s sarcoma, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, HIV-VL: HIV viral
load, HCV: hepatitis C, HBV: hepatitis B, IRC: infection related cancer, HPV: human
papillomavirus.
Treatment and prognosis in HIV-positive people with cancers
Clinical care of HIV+ people diagnosed with cancers is not straightforward and requires the co-
operation of oncologists, haematologists, and HIV physicians [529]. The topic of cancer
treatment in HIV+ people is broad and complex. Treatment strategies vary according to type and
stage of cancer, drug interaction and toxicities with HIV treatment, and existing HIV-associated
immune suppression [7, 530]. There is some evidence that HIV+ people present with more
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aggressive and advanced disease at diagnosis [7, 530]. Poorer outcomes in HIV+ people have
historically been reported [7, 531]. However, cancer survival has improved in recent years due
to advancements in HIV and cancer therapies and some studies have shown survival for specific
cancers to be similar to the general population [532, 533]. Five year relative survival for some
cancers in a cohort of HIV+ Italian people and for the Italian general population are summarised
in Table 1.9. 5 year survival is best for ADC and lowest for NADC [534]. One recent study showed
that cancer related mortality within 5 years of diagnosis was higher among HIV+ compared with
HIV-negative individuals for prostate and lung cancers, but not HL, anal cancer, or colorectal
cancer [535]. Decreased survival following cancer diagnosis has been associated with lower CD4
cell count and injecting drug use. Use of cART has been shown to improve short – medium term
survival of people with ADC [534, 536, 537]. Use of cART has been shown to improve survival for
HL [538], but not other NADCs [534].
Table 1.9 Five year relative survival following cancer diagnosis in people with HIV in an Italian cohort [534].
Note: the five-year relative survival (age and gender-standardized) in the Italian general
population for the cancers diagnosed between 2000 and 2004, and the 5-years relative survival
in the Master cohort for the cancers diagnosed in the period 1998-2012.
Treatment recommendations for HIV-associated cancers in HIV+ people are given by BHIVA
[139, 529], however a lack of RCT data means no gold standard exists for many cancers. Various
drug interactions and overlapping toxicities for cancer treatments and antiviral drugs have been
Observational-
Time
1998-2012 2000-2004
Cancer Type or
site (ICD-10)
5-years survival in the Master
Cohort of HIV+ people
(standardized for age and
gender)
5-years survival in the Italian
general population (AIRTUM)
(standardized for age and gender)
AIDS-defining cancer
Kaposi sarcoma 80 (73-85) 87 (83-90)
Non-Hodgkin
lymphoma
55 (48-62) 60 (59-60)
Cervical cancer 88 (70-95) 68 (66-69)
Non AIDS-defining cancer
Liver cancer 32(20-45) 15 (15-16)
Hodgkin
lymphoma
58(42-71) 83 (81-84)
Lung cancer 30 (15-47) 14(14-14)
Breast cancer 79 (55-91) 85(85-85)
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described, including interactions between cancer treatments metabolized by P450 Enzymes
with PIs (and ritonavir in particular) [529], and overlapping toxicities between zidovudine and
cytotoxic chemotherapy (both cause myelosuppression and anaemia) [529]. Raltegravir does
not use CYP pathway and is thought to be a potential cART option to reduce the risk of drug
interactions [539]. The guidelines state that potential interactions and overlapping toxicities
between cART, opportunistic infection prophylaxis, and cancer therapy should be considered
when making treatment decisions [529, 530].
It is recommended that all HIV+ people diagnosed with ADCs should start cART. Similarly, HIV+
people starting chemoradiotherapy for NADCs should also start cART, unless contraindicated
[529]. Furthermore, all HIV+ people diagnosed with cancer should be referred to centers that
have expertise in the management of both diseases and that handle large volume of patients
[529]. Several studies have shown that HIV+ people with cancer and /or HIV attending larger
specialist centers have better patient outcomes [540-545]. Current treatment for cancer in HIV+
people is the same as for HIV-negative people.
Justification and objectives
At the commencement of this thesis, cancer had emerged as a major area of research in HIV+
people and was gathering a lot of interest, however, there were several research gaps that
needed to be addressed. First, the majority of the research in cancer incidence and cancer
burden in HIV+ people was focused on insured people within the USA. The changing
epidemiology of cancers in the European population and the impact of aging on cancer incidence
HIV+ people needed to be better characterised. Second, despite the well characterised harms
of smoking in HIV+ people, the clinical benefits of smoking cessation on cancer risk had not been
addressed in a well controlled, adequately powered study. Third, although both NHL and HL are
common cancers in HIV+ people, research into the risk factors for NHL and HL within the same
population was limited [433] and no studies had attempted to directly compare the two. Fourth,
the mechanisms of the genesis of lymphomas in HIV+ people were not clear and whether B-cell
activation prior to lymphoma development was driven by HIV facilitated B cell activation and
proliferation (and also promoted EBV expansion) or other factors such as ongoing EBV
replication was unspecified. Fifth, PCa is a highly common cancer in HIV-negative men and PSA
testing is used to identify men at high risk for PCa in the general population to undergo further
testing. There was limited data available on variations in PSA testing practices in HIV+ men. Most
studies were USA-based, where PSA testing has been widely used since 1980, and may not be
generalizable to European settings [431, 546]. No studies had evaluated levels of PSA to prior to
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PCa diagnosis in HIV+ men or verified the use of PSA > 4 ng/mL to identify men at high risk for
PCas.
My PhD has two key objectives
1. To describe the changing epidemiology of commonly occurring cancers in HIV+ people,
particularly focusing on specific cancers or groups of cancers that are expected to
become a major source of morbidity and mortality as the population ages.
2. To explore and characterise plasma biomarkers of common cancers in HIV+ people in
order to better understand the mechanisms leading to cancer development.
These objectives will be investigated through 5 projects each corresponding to a results chapter.
Chapter 3 describes the changing incidence of infection-related and infection-unrelated cancers
that occur as the HIV+ population ages across Europe, using the EuroSIDA study.
Chapter 4 investigates the impact of smoking cessation on cancer risk in HIV+ people, based on
data from the D:A:D study.
Chapter 5 compares and contrasts the risk factors for non-Hodgkin (NHL) and Hodgkin
lymphoma (HL) development in HIV+ people, based on data from the D:A:D study.
Chapter 6 explores markers of B-cell dysfunction and activation prior to the development of NHL
and HL, using the EuroSIDA study.
Chapter 7 investigates the kinetics and diagnostic ability of total and free prostate specific
antigen (PSA) associated with prostate cancer (PCa) risk prior to diagnosis, using the EuroSIDA
study.
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2 Data and methodology
Data
EuroSIDA
Overview
The studies presented in chapters 3, 6, and 7 are based on data from the EuroSIDA cohort, which
is one of the largest prospective observational cohort studies of HIV-positive (HIV+) people in 35
European countries, as well as Israel and Argentina (Figure 2.1). EuroSIDA was established in
May 1994 as the successor of the retrospective AIDS in Europe cohort study [547] and currently
follows in excess of 22,000 people under care in a network of 115 hospitals. The main objective
of EuroSIDA is to assess the impact of antiretroviral drugs on the long term prognosis for the
general population of HIV+ people living in Europe and to follow the long term clinical prognosis
of these people. However future objectives also included looking at AIDS (ADC) and non-AIDS
(NADC) defining cancers, organ specific end stage diseases, long term and rare toxicities of
combination antiretroviral therapy (cART), the HIV epidemic in Eastern Europe, Hepatitis B (HBV)
and C (HCV) coinfection and HIV drug resistance.
Figure 2.1 The European countries involved in EuroSIDA (Israel and Argentina are non-European participants).
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EuroSIDA has enrolled over 22,000 HIV+ people over the 20 years the study has been running.
This makes it particularly useful for looking at the natural history of disease, effects of different
treatment strategies and long term side effects, and long term patient outcomes such as cancers
and other non-AIDS defining events associated with aging. Furthermore, EuroSIDA has been able
to track the course of the HIV epidemic across Europe, the effects of the introduction of cART,
the use of cART in different regions of Europe, and shifts in the epidemic over time.
EuroSIDA is involved in or initiated several international cohort collaborative studies, which
allow research questions which are not answerable in the individual cohorts to be addressed.
These include the ART-Cohort Collaboration (ART-CC) and the Data Collection on Adverse Events
(D:A:D) study, The Pursuing Later Treatment Options (PLATO) collaboration, and Collaboration
of Observational HIV Epidemiological Research Europe (COHERE) study. EuroSIDA has
contributed significantly to the understanding of the HIV epidemic, including the impact of cART
on the combined AIDS and death rate in HIV+ people, and has informed treatment guidelines
across Europe. Production of scientific papers is the primary objective of the study. As of April
2017 EuroSIDA has had over 259 publications and presents original research at most major HIV
related conferences. A summary of EuroSIDA publications over time is given in Figure 2.2 and
full details of publications and presentations can be found at http://www.chip.dk/Ongoing-
Studies/EuroSIDA/About.
Figure 2.2 Summary of EuroSIDA and collaborative publications as of 2013.
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Enrolment of people
People aged 16 years or older were enrolled over 10 periods of enrolment (each of which is
referred to as a cohort) from May 1994 with the most recent cohort (Cohort X) enrolled from
May 2014. Each cohort commenced and continued until a predefined number of people had
been enrolled. The target number of enrolments for each center is primarily determined by the
total number of people under followed-up at the center and the ability of the center to provide
follow-up data. However, maintenance of overall regional representativeness of the entire
cohort is also taken into account.
The first cohort to be enrolled (cohort I and initially referred to as EuroSIDA I) began in May 1994
and enrolled 3,115 people. The second, cohort II, began in November 1995 and recruited 1,363
people. The third, cohort III, from February 1997 and recruited 2837 people. Since then, a further
7 cohorts have been added (Table 2.1). Recruitment is ongoing to ensure people in EuroSIDA are
periodically updated to reflect the current HIV+ population, and also to replace people who have
died or are lost to follow-up.
Table 2.1 10 Enrolment within EuroSIDA by cohort.
Cohort N of people Enrolment date
I 3115 Spring 1994
II 1363 Winter 1995
III 2837 Spring 1997
IV 1225 Spring 1999
V 1223 Autumn 2001
VI 2119 Spring 2004
VII 2458 Winter 2005
VIII 2259 Summer 2008
IX 2469 Winter 2012
X 3985 Spring 2014
People who are under follow-up during each period of enrolment are recruited in such a way
that ensures a random selection of people currently under care in each clinic. People were
required to have a booked routine outpatient appointment to be eligible for recruitment. This
ensures people are already in routine care and provides as close to an unbiased and
representative selection of people as possible from each clinic. The eligibility criteria for
enrolment have changed over time. People were initially required to have a CD4 count below
500 cells/mm3 within 4 months prior to the date of enrolment for cohorts I – III. However, this
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restriction was relaxed for cohorts IV and later as CD4 cell counts improved due to the generally
widespread availability of cART across Europe [548]. From cohort V onwards, recruitment
included people from Eastern Europe as research in this region was a priority due to the severity
and variation in the driving factors of the HIV epidemic [549]. Cohort X was the first EuroSIDA
cohort composed entirely of HCV/HIV coinfected people. There has been increasing interest in
HCV/HIV coinfected people in recent years. An entirely HCV/HIV coinfected cohort will facilitate
the monitoring of these people over time and also follow the roll out and impact of second
generation HCV drugs.
Analysis on EuroSIDA is often divided into 4 – 6 demographic regions, depending on the research
question to be answered and the number of people available for analysis. The regions are
southern, west central, north, east and central eastern Europe, and Argentina and are shown in
Table 2.2. In analyses using Cohorts I - VI, the east and east central regions were combined due
to small numbers, however these have been increasingly been treated as separate regions from
cohort VII onwards due to increased recruitment of people from eastern Europe.
Table 2.2 EuroSIDA regions by country and center.
Region Countries Centers
Southern Europe Spain, Portugal, Italy, Greece,
Serbia, Montenegro, Israel,
and Argentina1
26
West central France, Belgium, South
Germany, Luxemburg,
Switzerland, Austria
26
North United Kingdom, Ireland,
Netherlands, North Germany,
Denmark, Finland, Sweden,
Norway, Iceland
24
East2 Belarus, Estonia, Latvia,
Lithuania, Russia, Georgia,
and Ukraine
20
East Central Europe2 Poland, Czech Republic,
Slovenia, Slovakia, Hungary,
Romania, Bulgaria, Croatia,
Bosnia & Herzegovina, and
Serbia.
18
Argentina Argentina 1
1If numbers are small, Argentina is combined with Southern Europe region.
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The EuroSIDA organization
The structure of the EuroSIDA organisation is shown in Figure 2.3. EuroSIDA is governed by a
steering committee made up of 14 European scientists and physicians and the current chair of
the steering committee is Professor Jürgen Rockstroh (Bonn, Germany), election to the steering
committee is for a period of 2 years and is renewed by election every 4-5 years. A list of the
steering committee members of the EuroSIDA study group are shown in Appendix I.
Approximately every two months, the steering committee hold teleconferences to discuss the
progress of current projects, approval of new project proposals, and the overall running of
EuroSIDA, funding and sponsorship. In addition, face to face meetings are held at most major
European HIV conferences (such as the International Drug Congress in HIV Infection and the
European AIDS clinical society conferences [EACS]). Separately to the steering committee, a core
group of clinicians and statisticians meet 3-4 times a year to discuss future projects, work
priorities, and provide general feedback. This active collaboration between clinicians,
statisticians, epidemiologists, and HIV virologists, hepatologists and pharmacologists is crucial
for the running and ongoing development of the study.
Every potential research project within EuroSIDA must first be approved by the steering
committee and goes through a rigorous review process. Briefly, the proposing researcher must
put together a study proposal which summarised the background, objectives, significance,
feasibility, possible limitations, study design, data, statistical analysis, timelines, potential
conferences and budget. The proposal is then reviewed by two members of the steering
committee and any amendments are incorporated. The proposal is introduced and discussed at
the next scheduled steering committee meeting. If there are no further comments or
recommendations the project is approved. The template for new study proposals can be found
at http://www.chip.dk/Ongoing-Studies/EuroSIDA/Study-documents.
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Figure 2.3 Structure of the EuroSIDA organisation.
The Center of Excellence for Health, Immunity and Infections (CHIP) is a research department,
headed by Professor Jens Lundgren. CHIP is responsible for the overall coordination of the
EuroSIDA study (among other research activities) and for the management of the EuroSIDA
database (http://www.chip.dk/Ongoing-Studies/EuroSIDA/About). The statistical support is
provided by the statistical center which is based at the university College London (UCL) medical
School, Royal Free Campus, and London, UK. There are 3 working groups which conduct focused
research in the areas of biomarkers, Hepatitis, and virology.
The epidemiology of resistance to antivirals group
The Epidemiology of resistance to antivirals group in EuroSIDA has historically led research
projects in the field of HIV drug resistance. The main objective is to evaluate associations
between genotypic resistance test results and virological, immunological and clinical outcomes.
EuroSIDA maintains an additional database on HIV resistance tests performed locally in clinics
which are reported to the central database. In addition, plasma samples are also prospectively
collected for patients enrolled in a subset of centres approximately every 6 months.
Retrospective testing of these samples is possible as long as funding is secured for specific
projects. The collection and shipping guidelines for these samples follows those outlined for the
plasma repository in the section 2.1.1.9. The group originally included two virological
laboratories: the ICVC international clinical virology center, based in London, UK and the
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IrsiCaixa Foundation, Badalona, Spain. The collaboration with ICVC ended in 2004, since then all
virological analyses of the samples are performed at the IrsiCaixa Foundation Centre.
The hepatitis group
Hepatitis coinfection is common in HIV+ people and has become an area of increasing interest.
The main objective of this group is to assess the natural history of chronic HBV and HCV in HIV+
people, how they impact on the tolerability and efficacy of HIV treatment, the roll out of
hepatitis treatments and associated patient outcomes, as well as regional differences in these
parameters. The EuroSIDA steering committee decided in 2014 to enrol an entirely HCV/HIV
coinfected cohort (cohort X) with a target of 4,000 people in order to increase the ability to focus
on the impact of the new oral direct-acting antiviral hepatitis C drugs as they are gradually
introduced across Europe. EuroSIDA contains a large number of HCV/HIV coinfected people,
with approximately 35% of all people in EuroSIDA being anti-HCV IgG positive. The EuroSIDA
hepatitis group is headed by Jürgen Rockstroh and Lars Peters.
Biomarkers group
The biomarkers group conducts research into the roles of circulating biomarkers in HIV+ people.
The main objective is to identify and evaluate the use of serum biomarkers for various
conditions, with a particular focus on cancers, in HIV+ people. The biomarkers group is
comprised of members from both the statistical and coordinating centers. Projects undertaken
by this group are varied and address a broad range of conditions. A group of disease specific
clinicians act as an advisory board to provide disease specific clinical advice throughout the
design, analysis and interpretation of each study. The studies presented in chapters 6 and 7
involve biomarkers.
Data collection
The EuroSIDA data has been collected using electronic forms through the REDCAP system since
the beginning of 2017. A standardized electronic data collection form is completed by the sites
at the time of enrolment and every 12 months thereafter. Historically, EuroSIDA data was
collected using standardized paper forms every 6 months from 1994 to 2015. A process of
switching from paper to electronic forms using the REDCAP system started in 2015 and in 2017
it was decided to move from a 6 monthly to a 12 monthly data collection. Some but not all sites
provide an electronic download of data in HICDEP format [550]. Basic demographic, clinical and
laboratory data are collected, including all CD4 cell counts and HIV viral loads (HIV-VL) measured
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since last follow-up, starting and stopping dates of all antiretroviral drugs, smoking status, dates
of AIDS defining diagnoses (using the 1993 CDC clinical definition[133], includes ADCs) and of
non-AIDS defining diagnoses (prospectively recorded and included in quality assurance since 1
January 2001, includes NADCs) [221]. The data collected in EuroSIDA are summarised in Table
2.3. Those interested in more detail regarding the electronic forms and the wide range of data
collected can contact the staff at the coordinating center to gain access to the REDCAP data
system for a test person.
EuroSIDA collects information on both ADCs and NADCs in section G1 of the follow up form. The
question ‘Any new AIDS defining malignancies?’ is used to identify whether any new ADCs have
been diagnosed since the last follow-up form was completed. If no, then the option “No” is
selected with an X. If “Yes” then they are prompted to complete the additional questions
detailing date of diagnosis, method of diagnosis (definitive, presumptive, autopsy), and location
(selected from a list of common cancers or as free text). Prior to 2001, NADCs were non-routinely
collected using a passive reporting system. Subsequently, the standardised forms were updated
to collect data on all new diagnoses of NADCs in 2001 in a similar fashion to ADCs [221].
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Table 2.3 Summary of data items collected in EuroSIDA.
Demographics Antiretroviral treatment
Cohort History of antiretrovirals taken:
Region of Europe Starting and stopping dates
Country If discontinued, reason for
Center ID discontinuation
Date of birth Adherence rating
Gender Hepatitis virology/serology results and
Origin dates*:
Mode of HIV infection HBV antibody
Race HBsAg
Basic clinical information HBV DNA
Dates of clinic visits HCV antibody
Height HCV RNA
Weight HCV genotype
Blood pressure Liver fibrosis parameters
Smoking Liver biopsy
Family history of MI Fibroscan® elastography
Pregnancy in women Hyaluronic acid
Active injecting drug use APRI (calculation)
Alcohol abuse FIB-4 (calculation)
Hospitalisations Treatment for HBV and HCV infection:
AIDS defining cancers (ADC) Start and stop dates
Dates and diagnosis (definitive, presumptive,
autopsy) Adherence rating
Non-AIDS defining cancers (NADC) Treatment against infections
Dates and diagnosis (definitive, presumptive,
autopsy) Drugs to prevent or treat opportunistic infection:
AIDS defining events Start and stop dates
Date of AIDS onset Treatment related to risk of cardiovascular disease
Other clinical events Medication related to risk of cardiovascular disease:
Diagnosed since last follow-up (with date of
diagnosis): Starting and stopping dates
Cardiovascular events Severe opportunistic infections
Diabetes Dates and diagnosis (definitive, presumptive, autopsy)
severe hepatic encephalopathy (stage III or IV) Other severe infections
Pancreatitis Dates and diagnosis (definitive, presumptive, autopsy)
Renal disease Influenza
Lactic acidosis Dates and diagnosis (definitive, presumptive, autopsy)
Avascular Necrosis of the femural head Treatment
Bone fractures Hospitalisations
Laboratory values (and dates of measurement) For people who died
Serum total and HDL cholesterol Date of death
Serum triglycerides Presumed cause
Plasma glucose CoDe case report form including autopsy report [551,552]
S-creatinine
Haemoglobin
Platelet count
ALT and AST
INR
Bilirubin
S-lactate (not LDH)
S-amylase
CD4 cell counts
HIV viral load
HIV subtyping
Resistance testing
Prostate specific antigen
parathyroid hormone
25 hydroxy-vitamin D
Toxoplasma antibody
CMV antibody
Proteinuria
Diastolic and systolic blood pressure
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Data quality
Staff from the EuroSIDA coordinating center periodically visit all sites participating in EuroSIDA
to ensure high data quality is maintained and to ensure correct person inclusion according to
the established criteria. All reported ADC and NADC (since 2001) have been source verified
against case notes at the sites by members of the coordinating office to ensure data accuracy,
as well as for all other major clinical events and a random sample of 10% of all other people. To
date, EuroSIDA has collected a relatively large number of NADCs (and other non-AIDS defining
events) due to the large size and long follow-up time. This allows for research questions
focussing on NADCs to be investigated which might not be viable in other cohorts. Occasionally,
monitoring is used to obtain extra information from case notes that were not included in the
original data submission.
Plasma sample repository
The plasma sample repository was established in 1997. The repository contains a large number
of prospectively collected plasma samples for approximately 13,563 EuroSIDA participants,
stored at six-month intervals. It currently holds approximately 105,747 unique samples (or
171,1023 samples including duplicates). For each sample, between 3-5 ml of EDTA blood is
collected, separated by centrifugation (e.g. 1.500 g, 15 min.), stored in 2 x 1 ml aliquots in 1,8
ml screw top cryovials (e.g. Nunc 377267 or similar). Sites are recommended to store samples
locally at a – 70° Celsius or liquid nitrogen within 4-6 hours of venesection. If - 70° Celsius or
liquid nitrogen is not available, site are advised to use - 20° Celsius freezer. If plasma have been
stored in freezers with temperatures above - 50° Celsius, or if more than 6 hours have passed
before plasma has been frozen, then the sample labelled accordingly. Samples are periodically
shipped in batches to the central repository located at the coordinating center. The coordinating
center maintains a list of people detailing which have had samples collected, the date of
collection, as well as whether sample has been used for a previous analysis. When required for
a specific analysis, the sample id’s can be requested, extracted from the freezers and analysed.
Since samples are collected prospectively and independently of clinical events, they make
EuroSIDA an ideal cohort to investigate potential biomarkers for various conditions within
nested case-control studies. The plasma samples have been used to identify genotypic
resistance mutations for projects on HIV resistance mutations [553], to extract HCV antibodies
and HCV RNA viral loads to classify the status of HCV infection for projects on HCV coinfected
individuals [554], and to measure lab values not reported in the main EuroSIDA database, such
as vitamin D level prior to event in HIV+ people [555, 556].
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Loss to follow-up
EuroSIDA has a low lost to follow up rate of 3.72 per 100 person years of follow-up (PYFU) and
has been consistent over time [557], ranging between 2 and 8 per 100 PYFU [557] (Figure 2.4).
The total number of loss to follow-up in each calendar year is shown in the data table under the
graph. Older patients, those with higher CD4 count, and those who have started cART had lower
incidence of loss to follow-up and loss to follow-up has been found to be higher in those from
East Europe.
Ethical approval and funding
Clinical centres participating in EuroSIDA are all required to obtain ethics approval from their
local authority in order to contribute to the study. Copies of the ethics approval form for each
center are kept at the coordinating centre, as required by the previous funders (1994-2015), the
European commission.
Figure 2.4 Loss to follow-up (LTFU) in EuroSIDA 1998 – 2013.
EuroSIDA was supported 2010-2015 by the European Union’s Seventh Framework Programme
for research, technological development and demonstration under EuroCoord grant agreement
n˚ 260694. Current support includes unrestricted grants by Bristol-Myers Squibb, Gilead, 
GlaxoSmithKline LLC, Janssen R&D, Merck and Co. Inc., Pfizer Inc. The participation of centres
from Switzerland was supported by The Swiss National Science Foundation (Grant 108787). The
study is also supported by a grant [grant number DNRF126] from the Danish National Research
Foundation.
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Summary of key characteristics
The key characteristics of people under follow-up in EuroSIDA and the D:A:D Study (to be
discussed in section 2.1.2) on the 1 January 2015 are given in Table 2.4. There were 11,266
people under follow-up, with a median of 9 (Inter quartile range (IQR]: 3-16) years of follow-up
per person. The median age was 49 (IQR: 41 – 56) years. Approximately two thirds the cohort
were from south, west-central and north Europe, and the remaining one third from east central,
east, and Argentina. Just under three quarters were male (72%). The main mode of HIV
transmission was sex between men (38%), followed by heterosexual contact (32%) and injecting
drug use (23%). Of those under follow-up, 28% had had an AIDS defining event, 10% a non-AIDS
defining event, 32% had HCV and 5% had HBV. 81% were on cART, 87% had a HIV-VL ≤ 500 
copies/ml. The median CD4 cell count was 590 (IQR: 418, 801) cells/mm3.
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Table 2.4 Key characteristics of the EuroSIDA cohort and the D:A:D Study for people under follow-up on the 1
January 2015.
EuroSIDA D:A:D
N(%) or median (IQR) N(%) or median (IQR)
Total 11,266 ( 100) 28,785 ( 100)
Age (years)
16 - 34 1,233 (10.9) 1,733 ( 6.0)
35 - 44 2,731 (24.2) 6,509 (22.6)
45 - 54 4,227 (37.5) 11,897 (41.3)
55 - 64 2,141 (19.0) 5,971 (20.7)
65+ 924 ( 8.2) 2,673 ( 9.3)
Missing 10 ( 0.1) 2 ( 0.0)
Median (IQR) 49.2 (41.1,55.7) 50.3 (44.0,56.6)
gender
Male 8,133 (72.2) 21,270 (73.9)
Female 3,129 (27.8) 7,514 (26.1)
Missing 4 ( 0.0) 1 ( 0.0)
Region of Europe
South 2,451 (21.8) -
West central 2,572 (22.8) -
North 2,509 (22.3) -
East central 1,737 (15.4) -
East 1,532 (13.6) -
Argentina 465 ( 4.1) -
HIV mode of transmission
Sex between men 4,297 (38.1) 13,750 (47.8)
IDU 2,531 (22.5) 3,128 (10.9)
Heterosexual 3,600 (32.0) 10,197 (35.4)
Other or Unknown 838 ( 7.4) 1,710 ( 5.9)
HBV1 551 ( 4.9) 919 ( 3.2)
HCV2 3,629 (32.2) 5,782 (20.1)
Previous AIDS defining event 3,187 (28.3) 8,741 (30.4)
Previous non-AIDS defining event 1,142 (10.1) -
On cART3 9,103 (80.8) 22,842 (79.4)
HIV-VL (copies/mL)
    ≤ 500 9,801 (87.0) 26,567 (92.3)
>500 694 ( 6.2) 2,204 ( 7.7)
Unknown 771 ( 6.8) 14 ( 0.0)
Median (IQR) 36.0 (<19,<40) 50.0 (50.0,50.0)
CD4 cell count (cells/mm3)
<200 453 ( 4.0) 1,310 ( 4.6)
200-350 1,094 ( 9.7) 2,050 ( 7.1)
351-500 1,806 (16.0) 4,424 (15.4)
>500 5,918 (52.5) 17,995 (62.5)
Missing 1,995 (17.7) 3,006 (10.4)
Median (IQR) 590 (418, 801) 634 (462, 835)
Median follow-up per person (years, IQR) 8.9 (2.8, 15.6) 12.3 (8.8, 15.2)
IQR: Interquartile range, HBV: Hepatitis B, HCV: Hepatitis C, cART: combination antiretroviral therapy, HIV-VL: HIV
viral load.
1 Positive HBV status was defined by a prior positive HBsAG surface antigen test or presence of detectable HBV DNA,
2 Positive HCV status was defined as having a prior positive HCV surface antibody test
3 currently on ≥ 3 antiretroviral drugs from any drug class 
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The Data collection on adverse events of Anti-HIV Drugs (D:A:D)
study
Overview
Chapters 4 and 5 utilise data from The D:A:D Study, which was a large, observational, and
multinational multi-cohort study of HIV+ people set up in 1999 as part of a European Medicines
Agency (EMA) regulatory initiative. The collaboration was founded to address clinical questions
which could not readily be answered within the individual participating cohorts, and the main
objective was to assess the potential associations between exposure to cART and cardiovascular
disease (CVD) in HIV+ people. Additionally, the D:A:D Study has investigated potential
associations between cART and other serious non-AIDS events, such as end stage liver and renal
disease, cancer and death as well as risk factors for these events. In 2017, the regulatory
requirements formally ended and the funding of the D:A:D Study was concluded.
Participating Cohorts
The D:A:D Study incorporated data from 11 individual cohorts of HIV+ people including follow-
up on more than 49,000 people from 212 clinics in 33 countries in Europe, USA and Australia
(Figure 2.5). The study had accrued 467,477 person years of follow-up as of 1 February 2016.
The study population consisted of both ART-naive and experienced people, enrolled during
three enrolment cohorts (I: 1999-2001, II: 2001-2004 III: 2004-2009). The original study
population of 23,441 people were enrolled December 1999 - April 2001, and was referred to as
D:A:D Cohort I. An additional 12,900 were enrolled in D:A:D Cohort II throughout the spring
2004, and more than 16,000 were enrolled in D:A:D Cohort III in 2010.
As shown in Figure 2.5, EuroSIDA was one of the largest cohorts that contributed data to the
D:A:D Study. As of December 2016, EuroSIDA had contributed 12,000 people and 110,032
person years of follow-up, accounting for 24.1% of all people and 23.5% of person years of
follow-up included the D:A:D Study.
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Figure 2.5 Individual cohorts contributing to the D:A:D study.
The D:A:D organizational structure
The D:A:D Study was headed by the D:A:D Steering Committee, consisting of the study chair,
Professor Jens Lundgren, principal investigators for each of the contributing cohorts, members
of the statistical department and representatives from the Highly Active Antiretroviral Therapy
Oversight Committee (HAART-OC) (see Appendix II). The HAART-OC was a collaborative
committee with representation from academic institutions, the EMA, The US Food and Drug
Administration, the patient community and all pharmaceutical companies with licensed
antiretroviral drugs in the European Union.
The D:A:D coordinating office was located at CHIP, Denmark. The coordinating office was
responsible for collecting data in real-time from the contributing cohorts, continuous data
queries and cleaning and an annual data merger process, data cleaning as well as event
adjudication, review of events with external experts, annual monitoring of the D:A:D Study sites,
organisation of meetings and development and maintenance of study reports and manuals. The
statistical center was located at the Royal Free Campus of UCL medical school, UK, and provided
statistical support and support for further cleaning of data.
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Data collection
Data is stored in a central database at the D:A:D coordinating office at CHIP and collected in in
two ways. First, each participating cohort gathers and computerises its own data which is
collected bi-annually electronically using the using the HICDEP data exchange protocol [550].
This data includes information on basic socio-demographics, use of ARVs, various HIV and
laboratory markers, opportunistic infections and CVD risk factors such as familiar dispositions,
diabetes, hypertension and smoking status. Second, clinical events are reported to D:A:D in real
time, using designated case report forms, as defined by the D:A:D Study Manual of Operations
(MOOP, for more details see http://www.chip.dk/Studies/DAD/Study-Documents).
The D:A:D Study data collection on centrally validated events included cardiovascular disease
(CVD), including Myocardial Infarctions (MIs) (primary endpoint), Strokes, Diabetes, Invasive
Coronary Procedures (ICPs) and causes of death from 1999. The D:A:D Study data collection was
expanded in 2004 to include NADC, End-Stage Liver Disease (ESLD), End-Stage Renal Disease
(ESRD) and causes of death according to CoDe (Coding causes of Death in HIV); and AIDS-
Defining Cancer (ADC) [133] from 2013 (collected electronically from 1999). Since the
participating cohorts had systematically collected NADCs from 2004 or earlier, prospectively
collected NADCs diagnosed after 1 January 2004 were obtained from each cohort, except for
the Swiss cohort where all events were collected prospectively from 2008. For NADCs, detailed
information included date of diagnosis, type/location of cancer, stage of disease and
histology/cytology report or other applied diagnostic methods (imaging, laboratory markers or
clinical evaluation) (for details see http://www.chip.dk/Studies/DAD/Study-Documents).
Data quality
One of the most important strengths of the D:A:D Study was that all reported clinical events
were centrally validated at the D:A:D coordinating center by a medical doctor and difficult
cases were additionally reviewed by an expert in the relevant field (cardiology, nephrology and
oncology). Events were also monitored at the D:A:D Study sites annually to ensure that data
were accurate. Additionally, continuous and rigorous data querying of study sites for extra
information by the D:A:D coordination centre throughout the year contributed to a high level
of data quality. The validation of NADCs and ADCs were conducted as follows: All reported
cancers were evaluated and classified as definite, probable or possible cancers. This
classification reflects the degree of certainty of the NADC diagnosis (degree of strength in
descending order): definite: based on supportive histology/cytology reports or a detailed
summary of histopathological findings/cancer diagnosis in a hospital discharge
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summary/consultation note; probable: strong suspicion of cancer supported by (i) evidence
from radiological or other imaging technique or (ii) biochemical assay; possible: strong
suspicion of cancer by visual inspection (e.g. skin metastasis, suspected malignant melanoma,
tissue growth resembling cancer visualized during endoscopy/anoscopy) not explained by
other known conditions. Events not reaching any of these categories of classification were
classified as null events and not included in analyses
Loss to follow-up
The annual loss to follow-up rates in the individual participating cohorts as well as overall in the
D:A:D Study was very low (<3%), and had been since the study was initiated.
Ethics approval and funding
The D:A:D Study had appropriate ethical committee approval from each participating country.
Support for the study was given by HAART-OC and a number of pharmaceutical companies
producing antiretroviral drugs contribute financially. The funding of the D:A:D Study was
provided by the HAART-OC and in addition each cohort received additional funding in a national
level (for details see Appendix II).
Summary of key characteristics
The key characteristics of people under follow-up in the D:A:D Study on the 1 January 2015 are
given in Table 2.4. There were 28,785 people under follow-up, with a median of 12 (IQR: 9 – 15)
years of follow-up per person. The median age was 50 (IQR: 44 – 57) years. Just under three
quarters were male (74%). The main HIV transmission mode was sex between men (48%),
followed by heterosexual contact (35%) and injecting drug use (11%). Of those under follow-up,
30% had had an AIDS defining event, 20% had HCV and 3% had HBV. 79% were on cART, 92%
had a HIV-VL ≤ 500 copies/ml. The median CD4 cell count was 634 (IQR: 462, 835) cells/mm3.
Statistical methods
This section provides a detailed description of the statistical methods used throughout this
thesis. A brief snap shot of the data source, version and items used for each analysis as well as
the statistical methods used is shown in Table 2.5. The methods section of each results chapter
also summarizes the data and methods used, however greater detail is given here.
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Table 2.5 Summary of data source and methods for each chapter.
Chapter Data Study Design N included Inclusion criterion Primary Endpoint Statistical analysis
3 EuroSIDA D36 Prospective cohort
study
15,648 All people with follow-up after 1 /1/2004 Diagnosis of infection related
or unrelated cancers
Poisson regression and
Linear exponential
smoothing models
4 D:A:D (Feb
2016 merger)
Collaboration of 11
prospective cohorts
35,442 All people with follow-up after 1 /1/2004
with no history of any cancer
Primary diagnosis of lung
cancer, other smoking related
cancer (excluding lung) and
smoking unrelated cancers
Poisson regression
5 D:A:D (Feb
2015 merger)
Collaboration of 11
prospective cohorts
41,420 All people with follow-up after 1 January
2004, with ≥1 CD4 cell count, and no 
history of NHL or HL
Primary diagnosis of NHL and
HL
Cox regression and
Marginal cox models
6 EuroSIDA D39 Matched 1-2 Nested
case-control study
Cases: 73
Controls: 143
Cases: Men with a primary NHL or HL
diagnosis after 1 /1/2001 with ≥1 plasma 
sample available prior to the diagnosis
date. Controls: Men with no history of
NHL or HL and ≥1 plasma sample available 
at the diagnosis date of each case
Primary diagnosis of NHL and
HL
Conditional logistic
regression and
random effects models
7 EuroSIDA D38 1.Prospective cohort
study
2.Matched 1-2 Nested
case-control study
4482
Cases: 21
controls:40
All men with follow-up after 1 January
2008 who attended clinics who performed
PSA tests on >5% of men annually.
Cases: Men with a primary PCa diagnosis
after 1 /1/2001 with ≥1 plasma sample 
available prior to the date of diagnosis.
Controls: Men with no history of PCa and
≥1 plasma sample available at the date of 
diagnosis of each case
PSA testing
Primary diagnosis of prostate
cancer
Poisson regression
Conditional logistic
regression,
random effects models,
Sensitivity, specificity and
ROC analysis
PCa: Prostate cancer, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma
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Summary statistics.
The first step when analysing data is to produce summary statistics. This serves several purposes:
 to provide a description of the characteristics of the population being studied
 to compare the study population with other populations i.e. for example other studies
in the literature
 identify possible data errors or inconsistencies
 provide insight into the quality of the data.
Cohort and case-control studies are observational studies, meaning that the investigator does
not intervene and rather simply “observes” and assesses the strength of the relationship
between an exposure and disease variable. Unlike randomised control trials (RCTs), patients are
not randomised, therefore there are likely to be differences between the exposure groups. For
example, in a cohort study looking at the association between body mass index (BMI) and cancer
risk, those with a higher BMI are also likely to be older than those with a lower BMI. Summary
statistics are required to identify any such unbalances between the exposure groups under
investigation. The types of summary statistics used throughout this thesis are outlined below.
Categorical data
Categorical variables were described using the frequency (N) and percentage (%) within each
group. Differences across group were compared using Pearson’s chi-squared tests when there
were ≥5 and Fisher exact tests when there were <5 people in any level. Chapters 6 and 7 in this 
thesis involve nested matched case-control studies, for which differences across groups were
compared using conditional logistic regression.
Numerical data
Continuous variables were described using the median and the IQR. The median is a valid
measure of central tendency when the data has a symmetrical or skewed distribution and is less
susceptible to outliers. Another common approach is to present the mean and standard
deviation (SD), which is valid for symmetrically distributed data but not skewed data, and is more
susceptible to outliers (see Figure 2.6). For this reason, Median and IQR were used throughout
this thesis.
96
To compare numerical variables across two groups of people, the Wilcoxon rank sum test was
used. This is a non-parametric test and is valid in both normally and non-normally distributed
data, as there is no underlying assumption about the data distribution. The kruskal-wallis test
(an extension of the Wilcoxon rank sum test) was used when comparing 3 or more groups. The
signed rank test was used to compare a change in a numerical variable across two groups of
people, when the change between two measurements on the same person was of interest.
Figure 2.6 Examples of normal and skewed distributions [558].
Other commonly used tests include parametric unpaired t-tests (used to compare 2 groups of
people and is the parametric equivalent of the Wilcoxon ranked sum test) and F-tests (used to
compare >2 groups of people and is the parametric equivalent of the kruskal-wallis test), and
paired t-tests (parametric equivalent of the signed rank test) when comparing values within the
same person. These tests are only appropriate when the data is normal (an underlying
assumption of these test).
All statistical tests presented in this thesis were two sided with a type I error rate of 5%, i.e. a P-
value <0.05 was considered statistically significant, meaning there was sufficient evidence to
reject the null hypothesis (usually no difference between the groups or independence) in favour
of the alternate (usually there is a difference between the groups or dependence). When
interpreting data, it is important to also consider the clinical importance of your results. For this
reason, importance was also given to the effect size and width of the confidence intervals (wider
indicates less certainty). All statistical analyses were performed using SAS 9.4 (Statistical Analysis
Software, Cary NC, USA).
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Statistical models
Statistical models are a class of mathematical models which represent a simplification of the
complex real world processes which gave rise to the data observed. Statistical models allow us
to quantify the relationship between a dependent variable (sometimes referred to as the
outcome or response) and a set of independent variables (referred to as predictors, explanatory
variables or covariates). For example: describing how the incidence of cancer increases with
older age. They also incorporate a random element to account for differences between the
predicted model and the observed data. Furthermore, they can also be used as a method to
adjust for known confounding variables.
Alternatively, they can be used to predict the chance of an outcome of interest based on a set
of observed variables. For example: what is the chance that a given person develops a non-
Hodgkin lymphoma based on their age, gender and CD4 cell count.
Confounding
A Confounder is a variable whose presence distorts the association between the variables being
studied so that the results do not reflect the actual relationship (Figure 2.7) [559]. Confounding
is a real effect, not a bias, that may lead to errors in the conclusion of a study. To be a
confounder, a variable must satisfy all of the following criteria (Figure 2.8) [559]:
 be associated with the exposure
 be an independent risk factor of the outcome
 and not lie on the causal pathway between exposure and outcome (mediator)
For example, older individuals are at higher risk for cancers, however, older individuals also tend
to earn more than younger individuals, who have spent less time in the work force. If age was
not adjusted for in the analysis then we may come to the conclusion that people with higher
incomes are more likely to develop cancers than people with lower incomes. In this scenario we
say that age is confounding the relationship between income and development of a cancer.
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Figure 2.7 Effect of confounding on the estimate of an effect.
Figure 2.8 Definition of a counfounder.
The effects of confounding can be excluded or controlled for by design by using RCTs or
matching; or during analysis using restriction, stratification, or statistical modelling (if the
confounding variables are known).
Confounding is removed in the design phase of RCTs, as people are randomly assigned to each
intervention arm. Randomisation means that characteristics of the people included are likely to
be balanced between them. However, confounding is a major issue in the analysis of
observational data as people are not randomised and there are often significant imbalances
between groups of interest in the study population. Multivariate models can be used to control
for confounding due to known confounders that have been collected.
Fitting a statistical model including only one predictor (the variable of interest) will produce an
“unadjusted” estimate of the association with the outcome of interest, which does not take into
account the possible effects of confounding. Statistical models including more than one
predictor are called multivariate models. By including potential confounders (as additional
predictors) in a multivariate model, we are able to produce “adjusted” estimates of the
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association, which accounts for the effects of confounding variables. These estimates effectively
show the association between the variable of interest and the outcome, while holding all other
variables in the model constant, therefore removing their effect.
The magnitude of the effect of confounding can be assessed by observing the difference
between the unadjusted and adjusted estimates of the association. However, it is impossible to
completely remove the effects of confounding when analysing observational studies.
Confounding due to unmeasured and unknown variables cannot be controlled for through
statistical modelling and the risk of residual confounding remains in any cohort study, however
well designed. Residual confounding can be due to insufficiently detailed information, improper
classification or over simplification of information, measurement error and miss-specified
relationships between variables and outcomes.
A related concept is effect modification (also known as interaction), which refers to when the
association between the variable of interest and the outcome varies across the levels of a third
factor. Effect modification is a genuine finding and should be explored and presented rather
than adjusted away. For example, smoking has been shown to increase the persistence of oral
HPV infection (independently of sexual behaviours). Furthermore, it has been suggested that
the persistence of oral HPV infection in women who smoke is significantly longer than men who
smoke (where the effect is only marginal). In this example there is an interaction between
smoking status and gender. Multivariate models can include interaction terms, however it is not
common to test for all possible interaction terms, as the large number of tests increases the risk
of a false positive result. Therefore, the inclusion of interaction terms are usually decided a
priori based on scientific interest or of biological importance.
Throughout this thesis, both explanatory and predictive models have been used. The models
used for explanatory purposes include logistic regression models, conditional logistic regression
models and Poisson regression models, generalised estimating equations (GEEs), and random
effects models. Linear exponential smoothing (LES) models, a very basic method of predictive
modelling, was used and is described in chapter 3.
Logistic regression
Logistic regression models are appropriate for when the outcome of interest is binary or
dichotomous, such as success and failure or presence or absence of a characteristic of interest.
For example, say we are interested in whether people do or do not have lung cancer, where the
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proportion of people who have the outcome of interest is p and the proportion of people who
do not is p-1. A very simple analysis would be to compare the proportion between the two
groups: the proportion of people who have lung cancer in males and females. If we wanted to
take into account several possible confounding variables, we need to fit a multivariate model.
The simplest model we could fit would be to fit the linear probability model, this is where the
proportion is assumed to be a linear function of the predictors ( ) (Equation 2.1).
Equation 2.1 Linear probability model.
Equation 2.2 Logistic regression model using logit link.
The problem with fitting this model is the proportion ( ) can range from 0 – 1, however the
linear function of predictors can take on any real value from to (as shown by the red line
in Figure 2.9). As a result, a transformation is applied to the proportion, which ensures that the
predicted values will lie within the valid range (as shown by the blue line in Figure 2.9) [560-
562]. To do this, the logarithm of the odds is modelled instead of the proportion, where the odds
is defined as the proportion of those who have the event divided by the proportion of those who
do not ( . This transformation is called the log odds or logit and is referred to as a
“link” function (Equation 2.2).
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Figure 2.9 Comparison of logistic vs linear probability model.
The output from the logistic regression model is straightforward to interpret. The logit function
is the log of the odds of an event, which is the number of successes divided by the number of
fails. Therefore, the back transformed (or exponentiated) estimates of the regression
coefficients (and 95% confidence intervals [95%CI]) represent the odds ratio (and 95%CI) for
the association between each predictor ( ) and the outcome [560-562]. Two examples of how
to interpret the back transformed coefficients are given below for the case where the outcome
is lung cancer
Categorical explanatory variable: Gender
The odds ratio tells us whether the odds of lung cancer was higher or lower for females
compared to males. An odds ratio of >1 indicates that the odds of lung cancer was higher in
females, whereas an odds ratio of <1 indicates that the odds was lower in females, relative to
males. Furthermore, if the 95%CI does not contain the value 1, this is analogous to a p-value of
<0.05 and a statistically significant result.
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Numerical explanatory variable: age
The odds ratio tells us whether the odds of lung cancer was higher or lower for a 1 year increase
in age. An odds ratio of >1 indicates that the odds of lung cancer was higher for a 1 year older
age, whereas an odds ratio of <1 indicates that the odds was lower for a 1 year older age.
Furthermore, if the 95%CI does not contain the value 1, this is analogous to a p-value of <0.05
and a statistically significant result.
Assumptions:
 The outcome has a binomial distribution
 The logit of the proportion is a linear function of the predictors
 Observations are independent
 Independent variables are not linear combinations of each other
 Equal follow-up time
Conditional Logistic regression
The studies presented in chapters 6 and 7 use the matched nested case-control study design to
answer the respective research questions [560]. Matching is sometimes used in studies with
binary outcomes where the people included are “matched” or “paired” in some way. Each case
(person with outcome of interest) is “matched” with one or more controls (person or people
without the outcome of interest) where they are chosen to be the same or similar for major
confounding variables. Each case and its respective matched controls are referred to as a
“matched set”. For example, controls might be selected to be a similar age (within 10 years).
Standard logistic regression can produce bias results in the presence of matching, and a variant
called “conditional logistic regression” should be used [560]. Parameter estimates are estimated
by considering possible combinations of exposures, conditional on the observed exposures
within each matched set. Results from the conditional logistic regression are interpreted in the
same way as classical logistic regression [560].
Time to event data
Poisson and Cox regression analysis are commonly used when dealing with time to an event
data. A great advantage of these methods is that they allow us to deal with “censored data”,
meaning that the “time to event” is unknown as the event of interest occurs outside of the
period of observation. There are three types of censoring that can occur:
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 right censored: the event of interest occurs after the period of observation
 left censored: the event of interest occurs before the period of observation
 interval censored: the event of interest is known to occur within a given time interval,
however the exact date is unknown [563].
This should not be confused with truncation:
 left truncation: occurs when the subjects have been at risk before entering the study.
 right truncation: occurs when the entire study population have already experienced
the event of interest before entering the study.
In most epidemiological studies, including many analyses in EuroSIDA and the D:A:D Study, the
most common issues are right censoring and left truncation. Often participants have historical
data available prior to recruitment, however, analyses are almost always left truncated at the
date of enrolment (or relevant date). Properly accounting for censoring is an important element
of time to event analysis as it allows us to include incomplete data. If only individuals with
complete data were included in analyses (i.e. those with a known baseline and last visit date),
then a large amount of information would be lost and we would potentially produce biased
results.
2.2.2.4.1 Poisson regression models
Poisson regression is used for the analysis of count data or rates. The structure of the Poisson
regression is similar to the logistic regression model, except that it is used when we have
observed events over time and the outcome of interest is the incidence rate of an event rather
than the odds of event. It is used to estimate incidence rate ratios between groups in the same
way that logistic regression is used to estimate odds ratios between groups. The incidence rate
of an event is defined in Equation 2.3.
Equation 2.3 Incidence rate.
The incidence rate can range from 0 to , however the linear function of predictors can take on
any real value from to . As done with the logistic regression model we use a logarithmic
transformation to map the range to to , referred to as the log link function.
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The form of the Poisson regression model is shown in Equation 2.4, where is the incidence
rate, are the estimated linear regression coefficients and are the predictors of interest.
Equation 2.4 Poisson regression model.
The output from the Poisson regression model is straightforward to interpret. The back
transformed estimates of the regression coefficients (and 95%CI) represent the incidence rate
ratio (and 95%CI) for the association between each predictor ( ) and the outcome [560-562].
Two examples of how to interpret the back transformed coefficients are given below for the
case where the outcome is lung cancer.
Categorical predictor: Gender
The incidence rate ratio tells us whether the incidence of lung cancer was higher or lower for
females compared to males. An incidence rate ratio of >1 indicates that the incidence of lung
cancer was higher in females, whereas an incidence rate ratio of <1 indicates that the incidence
was lower in females, relative to males. Furthermore, if the confidence interval does not contain
the value 1, this is analogous to a p-value of <0.05 and a statistically significant result.
Numerical predictor: age
The incidence rate ratio tells us whether the incidence rate of lung cancer was higher or lower
for a 1 year increase in age. An incidence rate ratio of >1 indicates that the incidence of lung
cancer was higher for a 1 year older age, whereas an incidence rate ratio of <1 indicates that the
incidence was lower for a 1 year older age. Furthermore, if the 95%CI does not contain the value
1, this is analogous to a p-value of <0.05 and a statistically significant result.
Assumptions:
 The outcome follows a Poisson distribution
 The log of the incidence rate is a linear function of the predictors
 Observations are independent
 Independent variables are not linear combinations of each other
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2.2.2.4.2 Proportional Cox regression
One of the most commonly used methods to analysis time to event data is Cox proportional
hazards regression. The form of the model (Equation 2.5) is very similar to that of logistic
regression and Poisson regression, except that the outcome is defined as the hazard function
[560, 561, 564]. The hazard function is shown in Equation 2.6 where is the density function
of survival times and is the survivor function [560, 561, 564]. The survivor function, shown
in Equation 2.7, is a summary measure of survival times, and displays the probability of survival
at time t. is the cumulative probability of failure at time t [560, 561, 564]. The terms are
the estimated linear regression coefficients and are the predictors. The term
represents the baseline hazard function.
Equation 2.5 The proportional cox model.
Equation 2.6 The hazard function.
Equation 2.7 The survivor function.
As suggested by the name, a key assumption of this model is that the ratio of the hazards
when comparing predictors is constant over time.
The back transformed estimates of the coefficients (and 95%CIs) are straight forward to
interpret, and represent the estimated hazard ratio (and 95%CI) for the association between
each predictor ( ) and the outcome. Two examples of how to interpret the back transformed
coefficients are given below for the case where the outcome is lung cancer.
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Categorical predictor: Gender
The hazard ratio tells us whether the risk of lung cancer was higher or lower for females
compared to males. A hazard ratio of >1 risk that the hazard rate of lung cancer was higher in
females, whereas a hazard ratio of <1 indicates that the hazard rate was lower in females,
relative to males. Furthermore, if the 95%CI does not contain the value 1, this is analogous to a
p-value of <0.05 and a statistically significant result.
Numerical predictor: age
The hazard ratio tells us whether the risk of lung cancer was higher or lower for a 1 year increase
in age. A hazard ratio of >1 indicates that the hazard rate of lung cancer was higher for a 1 year
older age, whereas a hazard ratio of <1 indicates that the hazard rate was lower for a 1 year
older age. Furthermore, if the 95%CI does not contain the value 1, this is analogous to a p-value
of <0.05 and a statistically significant result.
Assumptions
 Non-informative censoring: The mechanisms that give rise to censored individuals are
not related to the probability of an event occurring.
 Proportional hazards assumption: Ratio of the hazards comparing different predictors
is constant over time.
2.2.2.4.3 Comparison of Poisson regression and Cox proportional hazards models
Poisson regression and Cox proportional hazard models have many similarities and are often
used in similar circumstances, producing similar results. The key difference is that the outcome
for Poisson regression is a count or a rate over specific follow-up period, whereas for Cox
regression the outcome is time to event. Furthermore, the cox model also allows for censoring.
The Cox proportional hazard models are essentially extensions of Poisson regression models
where no assumptions are made about the baseline hazard rate.
2.2.2.4.4 Marginal Cox models
The Cox proportional hazards model described above allows for only one event per person,
however this can be extended to the situation where each subject can experience several
events, or multiple events data. Multiple events data can be analysed by a method proposed by
Wei, Lin, and Weissfeld based on the marginal Cox models [565]. This is sometimes referred to
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as the Wei, Lin and Weissfeld test, and allows for two or more dependent outcomes to be jointly
modelled and compared.
Generalised estimating equations (GEE)
Both logistic and Poisson regression assume observations are independent. This assumption is
violated if the data is clustered (i.e. if people within a cluster are more similar to each other than
those that are not). A special type of clustering is repeated measures in longitudinal data, which
is essentially clustering within individuals. Repeated measures within the same individual are
going to be more similar to each other than observations on different subjects.
For example, subjects within EuroSIDA develop several different types of cancers during their
follow-up, meaning each person may develop more than one cancer during follow-up. If
clustering is not dealt with during the analysis, the standard errors will be underestimated,
leading to overly narrow confidence intervals and small p-values and results may potentially be
biased.
GEEs are one method that can be used to take account of within individual variability when each
individual may contribute multiple endpoints [566]. They modify both parameter and standard
error estimates to take into account clustering.
Random effects models
Random effects models are another method of analysing data with repeated measurements
within individuals or clustering. They are also referred to as multi-level models because of the
hierarchical structure of the data: individuals are clustered within a higher level for example i.e.
observations clustered within people, people clustered within clinics, clinics clustered within
countries.
Random effect models explicitly model both between cluster and within cluster variation. The
simplest model incorporates a similar structure to that of a classical linear model (such as logistic
regression explained in the section 2.2.2.2) with the addition of a term that shifts the linear
predictor (the fixed effects) by an amount that randomly varies between individuals or clusters
(the random effect) (Equation 2.8). This is often referred to as a “random intercepts model”, as
the “intercept” term is shifted up or down depending on the cluster.
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Equation 2.8 Random intercepts model.
The green component represents the fixed linear predictor and the red component reflects the additional
random effect on the predicted value due to being in cluster i.
The random effects ( ) vary randomly between the clusters and are assumed to explain the
clustering within each individual, such that after allowing for random effects, observations
within the same cluster are now independent.
The full random effects model is shown in Equation 2.9. Where is a vector of observations for
each individual, is a vector of coefficients for fixed effects, is a vector of random effects, is
a vector of random error terms and and are matrices of fixed and random predictors.
Equation 2.9 Random effects model.
A fixed effect refers to a variable which is assumed to have the same effect across all individuals,
regardless of cluster [567]. For example, in longitudinal studies where observations are clustered
within people, age and gender are commonly considered to be fixed effects, as the effect of
these variables tend to be constant between people. The inclusion of random effects, which vary
for each individual, allows for the modelling of individual curves, or profiles, for each individual.
For example, if a random intercept term is included in the model it allows the intercept to vary
for each individual. Whereas additionally including a random slope variable allows completely
separate curves to be modelled for each individual, with different intercepts and slopes. The
model then combines these individual curves to estimate an overall effect for each variable
[567]. This is illustrated in Figure 2.10.
Fixed effects Random effects
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Figure 2.10 A comparison of a standard linear model, a random intercepts model and a random slopes model [568].
As previously mentioned, observations within individuals or clusters are more similar than those
between individuals. For example, if levels of a plasma biomarker, such as prostate specific
antigen, were measured multiple times on the same individual, then a high measurement would
be more likely to be followed by another high measurement. We can take this account by
specifying a covariance structure. Various correlation structures are shown in Table 2.6.
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Table 2.6 Covariance structures for multilevel modelling.
Unstructured UN The UN structure is the most flexible as no restrictions are placed on the covariance terms.
autoregressive
structure
AR(1) Assumes that observations which are taken close together are more similar than those taken further
apart. Assumes that all measurements are evenly spaced.
Compound
symmetry
CS Assumes there is a correlation between two separate measurements, but it is assumed that the
correlation is constant regardless of how far apart the measurements are
Spatial power SP(POW) This is the AR(1) structure generalised to the situation where the distance between measurements i
and j are not consistent. I.e. time is considered continuous.
111
Modelling strategy
Each chapter includes a brief methods section which gives a summary of the methods used to
analyse the data. A description of the predictors considered is provided. Most of the variables
investigated are well known in HIV and cancer research. However, detailed explanations are
provided were new or novel approaches are used.
For all analyses, both baseline and time updated variables were used. These are also detailed in
each chapter. However generally, baseline variables included non-varying variables such as
ethnicity, sex and HIV transmission mode. Time-updating variables included variables that are
routinely collected by EuroSIDA at regular intervals, such as CD4 cell counts and HIV-VL
measurements. Time-updating variables determine the short term association with an outcome
of interest.
The modelling approach used here involved univariate analysis followed by multivariate
analysis, which included variables which were statistically significant in univariate analyses at
the 10% level (p-value <0.1). However, in some analyses, variables included in analysis were
selected a priori, based on expert clinical knowledge and review of the current literature. Each
chapter will specify the model building process used.
Sensitivity analyses were performed to test the assumptions of the study design and definitions
used. Further details are given in each subsequent chapter in the methodology and discussion
sections.
Handling missing data
Incomplete and missing data were included in two ways.
1. Complete case-method: This approach restricts the analysis to people who had valid
values of key variables. This method was only used for key variables that were
considered to be crucial. This included date of birth, gender, and CD4 at first visit or
entry. This method has been showed to be unbiased when the missing data is not
missing as a function of either the outcome of interest or the model error term [569].
However, when many data are missing the complete-case method is highly inefficient
as it leads to a large number of cases being excluded.
2. Include a missing category: This methods was used when moderate amounts of data
were missing or incompletes. This approach is straight forward and retains maximal
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individuals in the analysis but is known to produce biased estimates in some
circumstances [569].
Summary
This chapter provides a brief overview of the two key data sources and statistical methods used
throughout this thesis. However, each chapter involved the use of specific methodology tailored
to the research question of interest. Although care has been taken to minimise the effect of
inherent bias, each analysis will have its own strengths and weaknesses which are addressed in
detail in each chapter. A detailed explanation of the methods for each chapter is included in the
methods section of each chapter. The relative strengths and weaknesses of each piece of work
are discussed in the discussion sections as well as chapter 8 of this thesis.
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3 Infection related and unrelated cancers, HIV, and the aging
population
Introduction
An increased risk of infection related cancers (IRCs), particularly Kaposi’s sarcoma (KS) and non-
Hodgkin lymphoma (NHL) has been observed since the beginning of the HIV epidemic [8, 14-18,
22, 23, 427, 570]. However, increased risk of some non-infection related cancers (IURCS), such
as lung cancers, has also been reported in recent years [14, 15]. The exact mechanisms for
increased cancer risk in HIV-positive (HIV+) people are complex, poorly understood, and involve
multiple processes [18]. The excess risk is, in part, explained by HIV associated immune
dysfunction [8, 14-18, 427, 571], and activated inflammation and coagulation pathways [572-
574]. Furthermore the wide spread availability of combination antiretroviral therapy (cART) has
improved survival of HIV+ people [1-6, 475, 575, 576]. This has led to an “aging” of the HIV+
population in high income countries and an increasing risk of traditionally age-associated
cancers. Increased survival has also increased the prevalence of prolonged exposure to cART
toxicities [18, 577-579] and exposure to the possible pro-oncogenic effects of HIV itself [580-
582], both of which have also been linked with increased cancer risk. Finally, HIV+ people have
a higher prevalence of many established risk factors, for example: smoking [420, 421], alcohol
use [422, 423] and sexual behaviours and oncogenic viruses (for example, a higher number of
sexual partners has been associated with HPV [human papillomavirus] infection) [9, 424, 425,
583]. Despite improvements in HIV treatment and patient outcomes, cancer continues to be a
major contributor to morbidity and mortality in HIV+ people [7, 584], and is the second most
common cause of death after AIDS defining deaths [220].
A broad overview of cancers in HIV+ people is given in chapter 1 section 1.2, including
justification of the classification of cancers into IRC and IURC, a brief epidemiological summary
of common cancers in HIV+ people, and a brief discussion on HIV and aging. Here, I summarise
the history of cancers in HIV+ people.
HIV, immune deficiency, and cancer
The immune system uses two processes to prevent cancer development including the clearance
and suppression of oncogenic viruses, and the process of “immune surveillance”, during which
the innate and adaptive immune systems work together to identify and destroy cancer cells [18,
475, 585]. HIV+ people are more susceptible to oncogenic viruses due to HIV associated immune
deficiency and dysfunction, and as a result, have a higher risk of associated IRCs than HIV-
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negative people [16, 17, 20, 427, 432, 441, 459, 465, 468, 470, 578, 586]. Before the availability
of effective cART, the incidence of many IRCs were extremely elevated in HIV+ people relative
to the HIV-negative population. This includes the AIDS defining cancers (ADCs): KS (Rates up of
around 1000-fold higher than the general population have been estimated), NHL (with rates
ranging from 10 to 200-fold higher), and invasive cervical cancer (3-12 fold higher) [15, 430, 438,
442, 446-448, 465, 469]. The elevated incidence of NHL and KS was strongly associated with to
the high prevalence of immune deficiency [475]. While there is some evidence of an association
between invasive cervical cancer and immune deficiency [475], this is also linked with increased
acquisition of HPV in HIV+ women compared to HIV-negative [587]. HIV+ women have increased
HPV cervical viral load and reduced HPV clearance than HIV-negative women, both of which are
associated with low CD4 cell count [587, 588]. Other IRCs are also at elevated risk in HIV+ people
included Hodgkin lymphoma (HL, SIR: 8 – 16 times higher than the general population), anal
cancers (SIR: 26 – 37), liver cancers (SIR: 2 – 7), head and neck cancers (SIR: 1.6 – 4.3), and
stomach cancers (SIR: 1.5 – 2) [430, 469, 589-591]. Interestingly, some IURCs have also been
linked with immune deficiency [16, 427, 433, 592, 593] which may reflect other the effect of HIV
on other components of immune function such as reduced immune surveillance.
The introduction of combination antiretroviral therapy and
cancer risk
The introduction of cART in 1996 had a major impact on the epidemiology of cancer in HIV+
people. Since the introduction of cART, a clear decline over time has been consistently reported
in KS and NHL [7, 17-19, 21, 437, 438, 441, 444, 451, 459, 465, 470, 483], likely due to restored
immune function from effective cART [20, 459, 594]. Early studies showed no decline in cervical
cancers since the introduction of cART [20, 21, 438], however more recent studies have shown
a decline of 12% per year [430, 436, 464]. No declines have been reported for HL [19, 21, 430,
467], anal cancers [14, 19, 430, 432, 436-438, 465, 467, 479-481], HPV associated head and neck
cancers [437], liver cancers [436, 464], or stomach cancers [437].
The impact of improved survival, reduced mortality, and age
associated cancers
Availability of effective cART and improvements in the efficacy and tolerability of cART regimens
has led to increased immune function and reduced incidence of AIDS defining events in HIV+
people [12]. As a result, survival has dramatically improved, with the median age at death
projected to be as high as 75 years in high income countries [1-6]. Briefly, it is estimated that
approximately one third of HIV+ people in high income countries are aged over 50 years, and
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this proportion is increasing [405, 503]. Not surprisingly, a tangible increase in the incidence of
IURCs has been observed in HIV+ people as a result of longer survival, and will increasingly
contribute to morbidity and mortality as the older population grows [419]. Several IURCs have
been identified as having excess risk in HIV+ people relative to the general population, including
lung cancer (SIR: 2.7, see Chapter 1 section 1.2.2.9), kidney cancer (SIR: 1.5-1.7), brain cancer
(SIR: 1.8 - 2.2), cancer of the testes (SIR: 1.3- 1.4), melanoma (SIR: 1.2), multiple myeloma (SIR:
2.6 - 2.7), and leukaemia (SIR: 2.6 - 3.2) [15, 475].
Future of HIV care
As the HIV+ population continues to grow and the proportion aged over 50 years continues to
rise, the burden from IURC, which are predominantly age associated cancers (including prostate
[PCa], breast and lung cancer [7, 587]), will continue to increase. This raises multiple issues in
regard to future HIV care for older HIV+ people, such as the increased complexity due to the
detection, diagnosis, comanagement and treatment of such cancers [504]. In addition, older
HIV+ people face a number of distinct clinical challenges, including slower immunologic recovery
when treated with cART than in younger people, and complicated treatment histories in those
with longer HIV duration due to exposure to toxic drugs earlier in the epidemic [504]. It has also
been suggested that people aged over 50 may be less likely to be tested for HIV and more likely
to be diagnosed later in the course of HIV infection [419, 504, 595]. This is a growing concern for
future healthcare planning and resource allocation as well as possible integration of healthcare
services. The changing epidemiology of cancers in Europe and the impact of aging on cancer
burden in HIV+ people needs to be better characterised.
Aims
There were two aims of this chapter
1. To describe the association between age and the incidence of IRC and IURC within
EuroSIDA, as well as to identify other risk factors that may vary over time
2. To estimate the change in incidence of IRC and IURC in HIV+ people in recent years and
to forecast the expected incidence for the next 5-10 years.
Methods
This study was performed within the EuroSIDA cohort, which is detailed in chapter 2 section
2.1.1, using the D36 release of the EuroSIDA cohort (included information on 18,791 people).
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Non-AIDS defining cancers (NADCs) have been routinely and prospectively collected and
included in quality assurance in the EuroSIDA study since 1 January 2001. Baseline was defined
as the later of either first visit or 1 January 2001. People were followed until the later of last visit
or death.
Inclusion criteria
Of the 18,791 people enrolled in the D36 release of EuroSIDA, I included all people with
prospective follow-up after 1 January 2001 and aged over 16 (N=15,648). The selection of
participants is detailed in Figure 3.1. I compared the characteristics of those excluded to those
included at their first visit date (which is not the same as the baseline date). At first visit, those
who were excluded were of a similar age (median age 36 in those excluded vs 37 years in those
included). Of those excluded, a lower proportion were female (18% vs 27%), were almost
exclusively from south, west central and northern Europe (99% vs 66%), and a higher proportion
acquired their HIV through sex between men (51% vs 39%). The median CD4 cell count in those
excluded was lower than those included at first visit (115 vs 350 cells/mm3). Use of cART in those
excluded was lower at first visit (16% vs 50%), and three quarters had no recorded HIV viral load
(HIV-VL) measurement (76% vs 23%).
Figure 3.1 Flow chart for inclusion of EuroSIDA participants in analysis.
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Outcomes
The primary outcomes for this study were the incidence of IRC and IURC diagnosis during follow-
up. All cancers diagnosed after 1 January 2001 were included. IRCs were defined as all cancers
with a probably infectious cause: KS (caused by human herpesvirus 8 [HHV8]), NHL and HL
(Epstein-Barr virus [EBV]), invasive cervical cancers, cancers of the head and neck, anus, penis,
vulva and vagina (HPV), liver cancer (Hepatitis B [HBV] and C [HCV]) and stomach cancer ( H.
Pylori]) [474], as detailed in Table 3.1. These groupings were derived from the published
literature [474] and reviewed by clinicians. All remaining cancers were defined as IURCs (Table
3.1).
Multiple diagnoses per person were allowed, however metastatic, secondary and repeated
diagnoses of the same cancer type, pre-cancers and non-melanoma skin cancers (not routinely
collected) were not included as outcomes. It was assumed that each cancer event within the
same person was unrelated to previous cancers (as metastatic, secondary and repeated cancers
were not counted). All cancers diagnosed during the follow-up period were included and
classified using the International Classification of Diseases and Related Health Problems, 10th
edition code classification system [596]. The ICD10 codes for each cancer type are shown in
Table 3.1. Furthermore, free text fields for cancer diagnoses were also used to identify additional
diagnoses and coded to the appropriate ICD10 code.
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Table 3.1 Definitions and classification of cancers according to infection related (IRC) and infection unrelated (IURC)
in EuroSIDA.
Cancer group Cancer type Icd10 codes
Total
Infection related cancers Total(IRC)
Epstein-Barr virus (EBV) HL C81
NHL C82,C83,C84,C85,C96
Hepatitis B or C (HBV/HCV) Liver C22
Human herpesvirus 8 (HHV8) KS C46
Human Papilloma virus (HPV) Anal C21
Cervix C53
Oral or Pharynx C01, C04, C09, C10, C11, C12,C13, C14
Penis C60
Vulva or Vagina C51, C52
Helicobacter Pylori (H.Pylori) Stomach C16
Infection unrelated cancers
Total
(IURC)
Accessory sinuses C31
Bladder C67
Bone and articular cartilage C41
Brain C71
Breast C50
Bronchus and lung C34
Colon and Rectal C18, C20
Connective and soft tissue
Corpus uteri C54
Endocrine glands and related
structures C75
Eye C69
Gallbladder C23
Kidney, except renal pelvis C64
Larynx C32
Leukaemia C95
Lymphoid leukaemia C91
Melanoma C43
Meninges C70
Mouth C06
Multiple myeloma and malignant
plasma cell neoplasms C90
Myeloid leukaemia C92
Nasal cavity and middle ear C30
Oesophagus C15
Other urinary organs C68
Other female genital organs C57
Ovarian C56
Pancreas C25
Parotid gland C07
Prostate C61
Retroperitoneum and peritoneum C48
Testis C62
Thyroid gland C73
Unknown site C80, C87
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Variables included in analyses
Both baseline and time updated variables from the EuroSIDA database were included in this
analysis, as detailed in Table 3.2. Current HIV-VL and CD4 cell count were Log 10 and log2
transformed respectively, due to the right skewed nature of the data, and also for interpretive
reasons i.e. a one unit increase in log10 Current HIV-VL is equivalent to a 10-fold increase, and a
one unit increase in log2 CD4 cell count is equivalent to a 2-fold increase.
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Table 3.2 Summary of baseline and time updated variables.
Variable Time
updated
Levels Definitions and comments
Age (years) Yes Continuous (per 10 years older) and
categorised into ≤35, 36 – 40, 41 – 
50, ≥ 51 years 
Calendar
year
Yes Continuous (per year) and
Categorised by year
Region of
Europe
East, east central, south, west
central, north Europe, and Argentina
See chapter 2 section 2.1.1.2
Ethnicity White, Non-white and other (includes
Asian, black and unknown race)
Gender
specific HIV
mode of
transmission
Sex between men, heterosexual
(male), heterosexual (female), IDU
(male), IDU (female), other or
unknown (male), other or
unknown(female)
Unknown gender was assumed
to be male
HIV mode of
transmission
(forecasts
only)
Sex between men, heterosexual, IDU,
other or unknown
BMI (kg/m2) Under weight (<18), normal weight
(18 – 25), Over weight (25 – 30),
obese( 30+)
Classified according to the WHO
standard [597]
Smoking
status
Yes Non-smokers, current smokers,
previous smokers, unknown
Current CD4
cell count
(cells/mm3)
Yes Continuous (per 2-fold higher) and
<200, 200 – 349, 350 – 499, ≥500 
cells/mm3, unknown
Within 6 months prior to date
of interest
Nadir CD4
cell count
(cells/ mm3)
Continuous. Was not included in
models due to correlation with
current CD4 cell count.
Lowest recorded CD4 cell count
measurement prior to date of
interest
Current HIV-
VL
(copies/mL)
Yes Continuous (per 10-fold higher) and
<400, ≥ 400 copies/mL, unknown 
Within 6 months prior to date
of interest
Prior ADC
diagnosis
Yes Yes , No Classified according to the 1993
CDC clinical definition [133]
Prior AIDS
defining
event
(excluding
ADC)
Yes Yes , No Classified according to the 1993
CDC clinical definition [133]
Prior NADC
diagnosis
Yes Yes , No
Prior non-
AIDS defining
event
(excluding
NADC)
Yes Yes , No Pancreatitis, grade 3 or 4
hepatic encephalopathy or liver-
related death, myocardial
infarction, stroke, coronary
artery bypass graft, coronary
angioplasty, carotid
endarterectomy, and end-stage
renal disease [221]
HBV
coinfection
Yes Positive, negative, or unknown Most recent positive HBsAG
surface antigen test or presence
of detectable HBV DNA
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HCV
coinfection
Yes Positive, negative, or unknown A prior positive HCV surface
antibody test
Antiretroviral
use
Yes Yes, no Ever received ≥ 1 antiretroviral 
drug
Protease
inhibitor (PI)
experienced
Yes Yes, no Ever received ≥ 1 PI 
Non-
nucleoside
reverse
transcriptase
inhibitor
(NNRTI)
experienced
Yes Yes, no Ever received ≥ 1 NNRTI 
BMI: Body mass index, IDU: through injecting drug use, HIV-VL: HIV viral load, ADC: AIDS defining cancer, NADC: non-
AIDS defining cancer, HBV: Hepatitis B, HCV; Hepatitis C, cART combination antiretroviral therapy.
Statistical methods
Characteristics at baseline and at time of first cancer diagnosis.
The characteristics at baseline of all people included in this analysis are presented using numbers
and percentages for categorical variables and medians with interquartile ranges (IQR) for
numeric variables. Those who developed an IRC and an IURC were compared at time of first
cancer diagnosis. All bivariate associations were tested using chi squared tests for categorical
variables and Kruskal-Wallis tests for numerical variables.
Crude incidence of infection related and infection unrelated cancer
The incidence of IRC and IURC was calculated per 1000 person years of follow-up (PYFU). Follow-
up began at the latter of first visit or 1 January 2001 and individuals were censored at last visit
or death. Incidence was stratified by time updated calendar year of follow-up, age group, and
current CD4 cell count category. Incidence rates were also calculated for cancers grouped by
oncogenic virus: EBV, HHV8, HPV, HCV and HBV, and H.Pylori and as well as selected IURC
cancers of interest where numbers allowed (It was decided a priori to use N≥20).  Sex specific 
rates were calculated for HPV associated cancers combined, as well as invasive cervical cancer,
prostate, and breast cancer.
Factors associated with infection related and infection unrelated
cancer incidence
Poisson regression with generalised estimating equations assuming auto-regressive (AR1)
correlation were used to estimate the association between age and other factors and IRC and
IURC incidence. The AR(1) correlation structure was selected in order to assume that correlation
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diminished with increasing calendar time between observations. Variables included in the model
were identified a priori based on expert clinical input, availability of data, and the published
literature.
Models were adjusted for various baseline and time updated variables (as listed in Table 3.2). It
was decided a priori to stratify associations between IRC and IURC with CD4 cell count and
smoking status by age (<50 and ≥50 years) due to the strong associations with both age and 
cancer risk. Interactions between age and all other variables were also investigated.
Adjusted population attributable fractions (PAF%)
Adjusted population attributable fractions (PAF%) of IRC and IURC were calculated for each
statistically significant modifiable risk factor as well as age in the adjusted models. The PAF%
indicates the proportion of excess cancers within the cohort attributable to each risk factor. In
order to calculate the PAF%, I used the case based approach detailed in Equation 3.1 [598, 599].
Where RRi represents the relative risk of those in category i relative to the reference category
and CFi represents the case fraction, or in other words, the proportion of people with a cancer
exposed to the risk factor out of all those who developed a cancer. There were two reasons why
I chose to use the case based formula (Equation 3.1) instead of the commonly used population
based approach (Equation 3.2, where PF i represents the proportion of people exposed in the
population). First, it can be used for exposures with three or more categories (the population
based approach in Equation 3.2 overestimates the PAF when used for non binary exposures).
Second, the case based approach in Equation 3.1 produces an internally valid estimate of the
PAF in the presence of confounding (use of the population based approach in Equation 3.2
produces spurious estimates) [598, 599].
Equation 3.1 formula for PAF using the case based approach as detailed in [599, 600]
Equation 3.2 formula for PAF using the case based approach as detailed in [599, 600]
For example, if 100 people included in my study developed an IRC of which 60 were current
smokers and the adjusted relative risk of IRC in current smoking relative to never smokers was
1.9. The PAF% based on Equation 3.1 would be
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Forecasting future incidence
Future crude IRC and IURC biannual incidence in people enrolled before 1 January 2001 was
forecast using linear exponential smoothing (LES) models. LES are simple models which smooth
time series data and extrapolate current trends into the short term future. They work on the
assumption that the time series is locally stationary and vary slowly over time. They break the
time series into two components: level and trend, and use these estimates to forecast into the
near future. LES models were used to project the current incidence forwards, using log incidence
as the outcome and time as the dependant variable. Forecasts were restricted to those enrolled
prior to 2001. This ensures a stable population over time (i.e. no new recruitments), however
people were allowed to leave the cohort i.e. death or loss to follow-up. No further adjustments
for covariates were made.
LES were fit to the data overall, and stratified by key characteristics, including baseline age group
(<50, ≥50 years), CD4 cell count (<350, ≥350 cells/mm3), HIV mode of transmission, and smoking
status. These variables were selected as they represented populations that may be at higher risk
of cancer that could be targeted for screening and prevention, i.e. older age, CD4 cell count <
350 cells/mm3, those who acquired their HIV through sex between men, those who acquired
their HIV through injecting drug use (IDU), and current smokers.
All statistical tests were two sided with a type I error rate of 5%. All statistical analyses were
performed using SAS 9.3 (Statistical Analysis Software, Cary NC, USA).
Results
15,648 persons contributed 95,033 PYFU with a median follow-up of 6.0 (Interquartile range
[IQR]:2.5-10.7) years per person. 610 people (3.9%) developed at least one cancer (accounting
for 643 cancer events), 374 people developed an IRC (N=388 IRC events) and 247 people
developed an IURC (N=255 IURC events). Please note, a small number of people developed both
an IRC and an IURC (N=11).
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Characteristics at the patient population at baseline
Baseline characteristics of the cohort are shown in Table 3.3. At baseline, 16.0% were aged 50
or older, 72.6% of the population were male, 88.3% were of white ethnicity and 38.7% attained
HIV through sex between men. Approximately one third of people were current smokers and
one third had never smoked. At baseline, less than 5% had had a prior ADC diagnosis and 24%
an AIDS defining event (other than ADC). Less than 2% had a prior NADC and less than 2% had a
prior non-AIDS defining event (other than NADC). Close to three quarters were cART
experienced. The median CD4 cell count at baseline was 410 (IQR: 265, 588) cells/mm 3 with
14.8% having  200 cells/mm3 and the median HIV-VL was 123 (IQR: ≤50, 5200) copies/mL with 
54.5% having HIV-VL 400 copies/mL. 23.0% and 5.6% were HCV coinfected and HBV coinfected
respectively.
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Table 3.3 Baseline1 characteristics of people included in analysis.
Characteristics N (%)/Median(IQR)
Overall 15,648 (100.0)
N (%)
Age (years)
≤35 5,419 (34.63)
36 – 40 3,337 (21.33)
41 – 50 4,390 (28.05)
51 + 2,502 (15.99)
Baseline year
2001 – 2005 9,583 (61.24)
2006 – 2009 4,004 (25.59)
2010 – 2012 2,061 (13.17)
Region
Argentina 597 ( 3.82)
East 2,733 (17.47)
East central 2,041 (13.04)
North 3,220 (20.58)
West central 3,332 (21.29)
South 3,725 (23.80)
Gender
Female 4,292 (27.43)
Male 11,356 (72.57)
White ethnicity 13,821 (88.32)
Gender specific HIV transmission group
Sex between men 6,051 (38.67)
IDU (Male) 2,290 (14.63)
IDU (Female) 1,091 (6.97)
Heterosexual (Male) 2,178 (13.92)
Heterosexual (Female) 2,830 (18.09)
Other (Male) 910 ( 5.82)
Other (Female) 298 ( 1.90)
BMI
Under weight 360 ( 2.30)
Normal weight 7,422 (47.43)
Over weight 2,326 (14.86)
Obese 483 ( 3.09)
Unknown 5,057 (32.32)
Smoking status
Current 5,393 (34.46)
Previous 61 ( 0.39)
Never 5,030 (32.14)
Unknown 5,164 (33.00)
Prior ADC diagnosis 734 ( 4.69)
Prior AIDS defining event (excluding ADC) 3,811 (24.35)
Prior NADC diagnosis 222 ( 1.42)
Prior non-AIDS defining event (excluding NADC) 297 ( 1.90)
HBV coinfection 868 ( 5.55)
HCV coinfection 3,607 (23.05)
History of HIV treatment
None 2,921 (18.67)
ART 781 ( 4.99)
cART 11,946 (76.34)
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Baseline CD4 cell count (cells/mm3)
Unknown 380 ( 2.43)
≤200 2,319 (14.82)
200 – 349 3,693 (23.60)
350 – 499 3,754 (23.99)
500 + 5,502 (35.16)
Baseline HIV-VL (copies/mL)
< 400 8,526 (54.49)
≥ 400 5,624 (35.94)
Unknown 1,498 (9.6%)
Median (IQR)
Age (years) 39 (33,46)
CD4 cell count (cells/mm3) 410 (265,588)
Nadir CD4 cell count (cells/mm3) 182 (76,303)
log10 HIV-VL (copies/ml) 123 (<50,5200)
calendar year of baseline 2003 (2001,2008)
IDU: injecting drug use, BMI: body mass index, ADC: AIDS defining cancer, NADC: non-AIDS
defining cancer, HBV: hepatitis B, HCV: Hepatitis C, ART: antiretroviral therapy, cART:
combination antiretroviral therapy, HIV-VL: HIV viral load.
1 Baseline was defined as the latest of first visit or 01 January 2001.
Characteristics at date of first cancer in those who developed IRC
compared to IURC at first cancer diagnosis
Characteristics at date of first cancer are shown in Table 3.4. At diagnosis, those who developed
IURCs relative to IRC were older (Median age: [IURC] 54 IQR: 46, 61 vs [IRC] 46 IQR: 39, 52 years),
had a higher CD4 cell count (446 IQR: 295, 608 vs 342 IQR: 182, 546 cells/mm3) and a higher
proportion had a suppressed HIV-VL (85.0 vs 59.4% with HIV-VL <400 copies/mL). A higher
proportion of those who developed NADC relative to ADCs were currently on or had previously
been on cART (87.0 vs 81.3%), a lower proportion were HCV coinfected (17.4 vs 21.9%) and the
proportion of HBV coinfected (8.9 vs 11.0%) was similar. Proportions of current smokers in IURCS
(45.8%) and IRCs (44.7%) were similar. At diagnosis of IURC, 7.7% had a prior ADC diagnosis,
28.7% had a prior AIDS defining event (other than ADC), 7.3% had a prior NADC diagnosis and
15.0% had a prior non-AIDS defining event. Of those who developed IRC, 9.1% had been
previously diagnosed with an ADC, 36.9% had a prior AIDS defining event (other than ADC), 4.0%
had a prior NADC diagnosis and 9.6% had a prior non AIDS defining event (other than NADC).
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Table 3.4 Characteristics of people at diagnosis of first infection related cancer (IRC) and first infection unrelated
cancer (IURC) during follow-up.
Total First IRCdiagnosis
First IURC
diagnosis
Overall 3742 (100.0) 2472 (100.0)
N (%)
Age (years)
≤35 53 (14.17) 4 ( 1.62)
36 – 40 50 (13.37) 13 ( 5.26)
41 – 50 150 (40.11) 73 (29.55)
≥51 121 (32.35) 157 (63.56)
Calendar year of diagnosis
2001 – 2005 161 (43.05) 84 (34.01)
2006 – 2009 142 (37.97) 105 (42.51)
2010 – 2012 71 (18.98) 58 (23.48)
Region
Argentina 13 ( 3.48) 6 ( 2.43)
East 14 ( 3.74) 6 ( 2.43)
East central 40 (10.70) 25 (10.12)
North 86 (22.99) 63 (25.51)
West central 97 (25.94) 71 (28.74)
South 124 (33.16) 76 (30.77)
Gender
Female 79 (21.12) 53 (21.46)
Male 295 (78.88) 194 (78.54)
White ethnicity 331 (88.50) 228 (92.31)
Gender specific HIV mode of transmission
Sex between men 191 (51.07) 123 (49.80)
IDU (Male) 49 (13.10) 24 ( 9.72)
IDU (Female) 32 ( 8.56) 10 ( 4.05)
Heterosexual (Male) 35 ( 9.36) 32 (12.96)
Heterosexual (Female) 43 (11.50) 36 (14.57)
Other (Male) 20 ( 5.35) 16 ( 6.48)
Other (Female) 4 ( 1.07) 6 ( 2.43)
BMI
Under weight 13 ( 3.48) 7 ( 2.83)
Normal weight 207 (55.35) 126 (51.01)
Over weight 50 (13.37) 43 (17.41)
Obese 6 ( 1.60) 6 ( 2.43)
Unknown 98 (26.20) 65 (26.32)
Smoking status
Current 167 (44.65) 113 (45.75)
Previous 24 ( 6.42) 27 (10.93)
Never 130 (34.76) 85 (34.41)
Unknown 53 (14.17) 22 ( 8.91)
Prior ADC diagnosis2 34 ( 9.09) 19 ( 7.69)
Prior AIDS defining events (excluding ADC)2 138 (36.90) 71 (28.74)
Prior NADC diagnosis 15 ( 4.01) 18 ( 7.29)
Prior non-AIDS defining events (excluding NADC)3 36 ( 9.63) 37 (14.98)
HBV coinfection 41 (10.96) 22 ( 8.91)
HCV coinfection 82 (21.93) 43 (17.41)
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HIV treatment
None 46 (12.30) 17 ( 6.88)
ART 24 ( 6.42) 15 ( 6.07)
cART 304 (81.28) 215 (87.04)
Current CD4 cell count
(cells/mm3)
Unknown 2 ( 0.53) 0 ( 0.00)
<200 99 (26.47) 31 (12.55)
200 – 349 89 (23.80) 49 (19.84)
350 – 499 75 (20.05) 63 (25.51)
≥500 109 (29.14) 104 (42.11)
HIV-VL (copies/mL)
< 400 222 (59.36) 210 (85.02)
≥ 400 152 (40.64) 37 (14.98)
Median (IQR)
Age (years) 46 (39,52) 54 (46,61)
CD4 cell count (cells/mm3) 342 (182,546) 446 (295,608)
Nadir CD4 cell count (cells/mm3) 124.5 (47,250) 160 (70,255)
log10 HIV-VL (copies/mL) 61 (<50,20002) <50 (<50,84)
Calendar year 2006(2003,2009) 2007 (2005,2009)
IRC: infection related cancer, IURC: infection unrelated cancer, IDU: injecting drug use, BMI:
body mass index, ADC: AIDS defining cancer, NADC: non-AIDS defining cancer, BMI: Body mass
index, HCV: hepatitis C, HBV: hepatitis B, ART: antiretroviral therapy, cART: combination
antiretroviral therapy, HIV-VL: HIV viral load.
1 Baseline was defined as the latest of first visit or 01 January 2001.
2 11 people developed both an IRC and an IURC during follow-up and are included in both
columns.
Description of cancers
Overall
610 people developed 643 cancers. Of the 643 cancers, 388 (60.3%) were IRC and the remaining
255 (39.7%) were IURC (Figure 3.2). Among all cancers, the most common were NHL (N=116),
anal (N=83), KS (N=62), and lung (N=55). The most common IRCs were NHL, anal, KS and HL
(N=43). Cancers of the lung, prostate (N=28), colorectal (N=23) and breast (N=26) were common
IURCs. Of the IRC, almost 90% were related to EBV, HPV or HHV8.
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Figure 3.2 Distribution of IRC and IURC. The labels for each cancer include the cancer site, frequency, and the
percent.
* Only the 5 highest frequency IURCs are displayed in the graph. A list of all cancers included are
listed in Table 3.1
IRC: infection related cancer, IURC: infection unrelated cancer, HPV: human papillomavirus, EBV:
Epstein-Barr virus, HCV: hepatitis C, HBV: hepatitis B, HHV8: human herpesvirus 8, KS: Kaposi’s
sarcoma, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma.
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Frequencies of cancers in different age groups
In those aged under 50 years (N=353 cancers), the most frequently occurring cancers were
exclusively IRC: NHL (N=79), anal cancers (N=53), KS (N=45), HL (N=32) and cervical cancers
(N=29) (Figure 3.3). In those aged over 50 years (N=290 cancer), the most frequently occurring
cancers were those of the lung (N=37), NHL (N=37), anal (N=30), prostate (N=27) and KS (N=17)
(Figure 3.4). The distribution of cancers in those aged over 50 was more heterogeneous than
those in younger people. The 5 most frequently occurring cancers in those aged < 50 years
accounted for 93% of all cancers, whereas the 5 most frequently occurring cancers accounted
for 58% of the all cancers observed and the remaining 42% explained by various other IURCs.
Figure 3.3 Distribution of cancers in HIV+ people aged < 50 years.
Figure 3.4 Distribution of cancers in HIV+ people aged ≥ 50 years. 
IURC: infection unrelated cancer, HPV: human papillomavirus, EBV: Epstein-Barr virus, HCV:
hepatitis C, HBV: hepatitis B, HHV8: human herpesvirus 8, KS: Kaposi’s sarcoma, NHL: non-
Hodgkin lymphoma, HL: Hodgkin lymphoma.
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Unadjusted incidence of infection related and infection unrelated
cancer
Overall
The incidences of IRC and IURC by calendar time are shown in Figure 3.5 and Figure 3.6
respectively. The unadjusted incidence of IRC declined by 4.9 (95%CI: 1.7, 7.9) % /year from 6.1
(95%CI: 4.4, 8.3)/1000 PYFU in 2001 to 3.6 (95%CI: 2.7, 4.9) in 2011/12. The unadjusted
incidence of IURC increased by 3.4 (95%CI: -0.4, 7.3) % /year from 1.8 (95%CI: 1.0, 3.2)/1000
PYFU in 2001 to 2.9 (95%CI: 2.0, 4.0) in 2011/12, although this increase was non-significant in
univariate analysis (P=0.08). The shift in distribution of cancers over time from IRC towards IURC
are summarised in Figure 3.7. The proportion of all cancers that were IURCs in 2001 almost
doubled from 22.4% in 2001 to 44.2% in 2011/12, driven by the decline in IRC incidence and
slight increase in IURC incidence per year.
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Figure 3.5 Crude incidence of IRC over time from 2001 to 2011/12.
The percentage change in the crude incidence is given in the insert.
Figure 3.6 Crude incidence of IURC over time from 2001 to 2011/12.
The percentage change in the crude incidence is given in the insert.
Figure 3.7 Percent of all cancers diagnosed that were IURC per calendar year.
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Incidence of individual cancers
The overall crude incidence as well as change in incidence over time of selected individual
cancers is shown in Table 3.5. The unadjusted incidence of both HL and NHL (both EBV related),
and KS declined over time by 10.6 (95%CI: 1.6, 18.8)%, 11.4 (95%CI: 6.0, 16.4)% and 8.8 (95%CI:
1.3, 15.8)% respectively. The only significantly increasing incidence observed was for liver
cancers, which was increasing by 16.5 (95%CI: 3.2, 31.6)% per year. There was no significant
change over time in other IRCs or individual IURCs.
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Table 3.5 Crude incidence of infection related (IRC) and infection unrelated (IURC) cancers and percentage change over time in crude incidence per year since 2001.
Cancers N Crude IR (95% CI)/1000 PYFU % change per year P-value
IRC Overall 388 4.08 ( 3.69, 4.52) -4.87 (-7.93,-1.72) <0.01
EBV Overall 159 1.67 ( 1.43, 1.95) -11.2 (-15.5,-6.64) <0.01
HL 43 0.45 ( 0.34, 0.61) -10.6 (-18.8,-1.63) 0.02
NHL 116 1.23 ( 1.02, 1.47) -11.4 (-16.4,-6.02) <0.01
HPV Male 81 1.16 ( 0.93, 1.44) 1.64 (-5.20, 8.96) 0.65
Female 42 1.68 ( 1.24, 2.28) -0.41 (-9.68, 9.81) 0.93
Invasive cervical cancer (females) 33 1.33 ( 0.94, 1.87) 0.48 (-10.0,12.23) 0.93
Anal cancer 83 0.88 ( 0.71, 1.09) 0.15 (-6.49, 7.27) 0.97
HHV8 Kaposi’s Sarcoma 62 0.65 ( 0.51, 0.84) -8.82 (-15.8,-1.30) 0.02
HBV/HCV Liver 33 0.35 ( 0.25, 0.49) 16.53 ( 3.22,31.57) 0.01
H.Pylori Stomach 11 0.12 ( 0.06, 0.21) -8.63 (-24.3,10.28) 0.35
IURC Overall 255 2.68 ( 2.37, 3.04) 3.36 (-0.41, 7.28) 0.08
Lung 55 0.58 ( 0.44, 0.75) 4.98 (-3.69,14.43) 0.27
Prostate (males) 28 0.40 ( 0.28, 0.58) 8.40 (-4.09,22.51) 0.20
Breast (females) 26 0.27 ( 0.19, 0.40) 8.55 (-4.50,23.39) 0.21
Colon and rectal 23 0.24 ( 0.16, 0.36) -7.67 (-18.9, 5.13) 0.23
Other (all cancers with <20 events, combined) 123 1.29 (1.08, 1.54) 3.28 (-2.33, 9.23) 0.26
IRC: infection related cancer, IURC: infection unrelated cancer, HPV: human papillomavirus, EBV: Epstein-Barr virus, HCV: hepatitis C, HBV: hepatitis B, HHV8: human
herpesvirus 8, KS: Kaposi’s sarcoma, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma.
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Risk factors for infection related and infection unrelated cancer
The unadjusted (IRR) and adjusted (aIRR) incidence rate ratios for IRC and IURC for various risk
factors are given in Table 3.6 and Table 3.7.
Adjusted results for infection related cancer
Age was associated with higher IRC incidence after adjustment (Table 3.6). Those aged older
than 50 years had a 1.62 (95%CI: 1.14, 2.31)-fold higher incidence of IRC cancer incidence than
those aged 36–40 years, equivalent to a 17% increase in incidence for a 10 year increase in age
(95%CI:1.05, 1.32). As expected, factors most strongly related to a higher incidence of IRC were
predominantly HIV associated. For example, IRC incidence increased with decreasing current
CD4 cell count category in a dose response like manner, where CD4 cell count < 200 cells/mm3
(compared to ≥500 cells/mm3) was associated with a more than 3-fold higher IRC incidence 
(aIRR: 3.77; 95%CI: 2.59, 5.51). Furthermore, higher IRC incidence was also associated with
current HIV-VL ≥ 400 copies/mL (aIRR: 1.84; 95%CI: 1.39, 2.43) and having had a previous ADC 
diagnosis (aIRR: 1.41; 95%CI: 1.02, 1.96). Higher IRC incidence was associated with HBV
coinfection (aIRR: 1.70; 95%CI: 1.24, 2.32) and incidence was approximately halved in both
males (aIRR: 0.54; 95%CI: 0.38, 0.78) and females (aIRR: 0.57; 95%CI: 0.40, 0.80) who acquired
their HIV through heterosexual sex (relative to through sex between men). IRC incidence was
lower in east compared to west central Europe (aIRR: 0.28; 95%CI: 0.14, 0.53).
Adjusted results for infection unrelated cancer
A dramatic rise in IURC incidence was observed with older age, with those aged 41–50 and 51
or older having 2.37 (95%CI: 1.31, 4.27) and 7.33 (95%CI: 4.07, 13.21)-fold higher incidence of
IURC than those aged 36 – 40 years, after adjustment for other factors (Table 3.7). This
corresponds to approximately a 2-fold increase in risk for a 10 year increase in age (aIRR: 2.07;
95%CI: 1.84, 2.32 P<0.01). IURC incidence was also elevated in those with a prior NADC diagnosis
(aIRR: 2.13; 95%CI: 1.42, 3.20), current smokers relative to non-smokers (aIRR: 1.56; 95%CI: 1.17,
2.08), and those with HBV coinfection (aIRR: 1.73; 95%CI: 1.17, 2.55). IURC incidence was
elevated in those with a current CD4 cell count < 200 relative to ≥500 cells/mm3 (aIRR: 1.99;
95%CI: 1.26, 3.17), but was similar across other CD4 cell count categories.
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Table 3.6 Unadjusted (IRR) and adjusted incidence rate ratios (aIRR) of infection unrelated cancers (IRC).
Univariate Multivariate
Variable IRR(95%CI) P aIRR(95%CI) P
Age (years)
≤35  1.04(0.71,1.54) 0.84 1.34(0.90,2.01) 0.15
36 – 40 ref ref
41 – 50 1.32(0.96,1.81) 0.09 1.34(0.97,1.85) 0.07
≥51  1.44(1.03,2.00) 0.03 1.62(1.14,2.31) <.01
Calendar year (per year) 0.95 (0.92, 0.98) <.01 1.01(0.97,1.05) 0.55
Gender specific HIV transmission group
Sex between men ref ref
IDU (males) 0.76(0.56,1.04) 0.09 0.83(0.57,1.20) 0.32
IDU (females) 1.04(0.71,1.51) 0.85 1.21(0.79,1.86) 0.39
Heterosexual sex (Males) 0.55(0.39,0.79) <.01 0.54(0.38,0.78) <.01
Heterosexual sex (females) 0.52(0.37,0.72) <.01 0.57(0.40,0.80) <.01
Other (Males) 0.82(0.51,1.31) 0.40 0.79(0.49,1.26) 0.31
Other (Females) 0.44(0.17,1.18) 0.10 0.55(0.21,1.48) 0.24
Region of Europe
South 1.17(0.90,1.53) 0.24 1.31(0.99,1.74) 0.06
North 0.90(0.67,1.21) 0.50 0.90(0.68,1.20) 0.48
West central ref ref
East central 0.80(0.55,1.16) 0.24 0.89(0.60,1.32) 0.56
East 0.34(0.20,0.60) <.01 0.28(0.14,0.53) <.01
Argentina 0.97(0.54,1.72) 0.90 1.02(0.57,1.83) 0.94
Current CD4 cell count (cells/mm3)
<200 4.70(3.60,6.14) <.01 3.77(2.59,5.51) <.01
200 – 349 2.03(1.53,2.69) <.01 1.83(1.35,2.48) <.01
350 – 499 1.31(0.98,1.76) 0.07 1.24(0.92,1.67) 0.16
≥500  ref ref
Current HIV-VL ≥400 (copies/mL) 2.27(1.84,2.78) <.01 1.84(1.39,2.43) <.01
Prior ADC diagnosis 1.76(1.28,2.41) <.01 1.41(1.02,1.96) 0.04
Prior AIDS defining event (excl. ADC) 1.51(1.22,1.86) <.01 1.25(1.00,1.57) 0.05
Prior NADC diagnosis N/A .
prior non-AIDS defining event (excl. NADC) N/A .
HBV coinfected 1.92(1.41,2.59) <.01 1.70(1.24,2.32) <.01
HCV coinfected 0.89(0.69,1.13) 0.33 0.77(0.56,1.06) 0.11
BMI
Under weight 1.34(0.77,2.33) 0.29 1.16(0.66,2.04) 0.61
Normal weight ref ref
Over weight 0.73(0.54,1.00) 0.05 0.73(0.54,1.00) 0.05
Obese 0.48(0.22,1.08) 0.08 0.55(0.25,1.22) 0.14
Unknown 0.93(0.73,1.19) 0.58 0.85(0.66,1.09) 0.2
Non-white Ethnicity 0.91(0.66,1.26) 0.58 0.98(0.71,1.37) 0.92
cART naïve 1.02(0.73,1.43) 0.92 1.36(0.80,2.29) 0.25
PI experienced 1.36(1.05,1.76) 0.02 1.14(0.79,1.64) 0.48
NNRTI experienced 1.00(0.81,1.24) 0.98 0.90(0.70,1.16) 0.4
Smoking status
Never ref ref
Previous 0.79(0.52,1.19) 0.26 0.78(0.51,1.19) 0.25
Current 1.20(0.95,1.51) 0.12 1.15(0.91,1.46) 0.24
Unknown 1.14(0.83,1.58) 0.41 0.98(0.69,1.39) 0.9
IRR: incidence rate ratio, aIRR: adjusted incidence rate ratio, IDU: injecting drug use, HIV-VL: HIV
viral load, ADC: AIDS defining cancer, NADC: non-AIDS defining cancer, HCV: hepatitis C, HBV:
hepatitis B, BMI: body mass index, cART: combination antiretroviral therapy, PI: protease
inhibitor, NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor.
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Table 3.7 Unadjusted (IRR) and adjusted incidence rate ratios (aIRR) of infection unrelated cancers (IURC).
Univariate Multivariate
Variable IRR(95%CI) P aIRR(95%CI) P
Age (years)
≤35  0.30(0.10,0.93) 0.04 0.33(0.12,0.96) 0.04
36 – 40 ref ref
41 – 50 2.39(1.32,4.30) <.01 2.37(1.31,4.27) <.01
≥51  7.43(4.22,13.08) <.01 7.33(4.07,13.21) <.01
Calendar year (per year) 1.03(1.00,1.07) 0.08 1.00(0.96,1.04) 0.95
Gender specific HIV transmission group
Sex between men ref ref
IDU (males) 0.59(0.38,0.92) 0.02 0.97(0.57,1.64) 0.91
IDU (females) 0.48(0.25,0.90) 0.02 0.91(0.46,1.80) 0.78
Heterosexual sex (Males) 0.84(0.57,1.24) 0.38 0.91(0.61,1.36) 0.64
Heterosexual sex (females) 0.68(0.47,0.99) 0.04 1.25(0.86,1.83) 0.24
Other (Males) 0.93(0.55,1.56) 0.78 0.93(0.55,1.57) 0.79
Other (Females) 1.04(0.46,2.33) 0.93 1.59(0.71,3.54) 0.26
Region of Europe
South 1.05(0.76,1.45) 0.78 1.34(0.97,1.86) 0.07
North 0.95(0.67,1.33) 0.76 1.06(0.75,1.51) 0.74
West central ref ref
East central 0.72(0.46,1.13) 0.15 1.16(0.73,1.85) 0.54
East 0.21(0.09,0.48) <.01 0.61(0.27,1.37) 0.23
Argentina 0.64(0.28,1.46) 0.29 0.91(0.39,2.08) 0.82
Current CD4 cell count (cells/mm3)
<200 1.46(0.98,2.16) 0.06 1.99(1.26,3.17) <.01
200 – 349 1.14(0.81,1.61) 0.44 1.30(0.89,1.88) 0.17
350 – 499 1.19(0.88,1.62) 0.26 1.29(0.95,1.75) 0.11
≥500  ref ref
Current HIV-VL ≥400 (copies/mL) 0.56(0.40,0.79) <.01 0.91(0.62,1.35) 0.66
Prior ADC diagnosis 1.26(0.79,2.03) 0.33 0.92(0.57,1.49) 0.74
Prior AIDS defining event (excl. ADC) 1.01(0.77,1.34) 0.93 0.85(0.64,1.14) 0.29
Prior NADC diagnosis 3.66(2.47,5.44) <.01 2.13(1.42,3.20) <.01
prior non-AIDS defining event (excl. NADC) 2.50(1.63,3.85) <.01 1.36(0.87,2.10) 0.17
HBV coinfected 1.73(1.16,2.57) 0.01 1.73(1.17,2.55) <.01
HCV coinfected 0.66(0.47,0.92) 0.01 0.90(0.60,1.37) 0.62
Body mass index
Under weight 1.19(0.56,2.53) 0.65 1.24(0.59,2.61) 0.56
Normal weight ref ref
Overweight weight 1.04(0.74,1.47) 0.82 0.91(0.64,1.29) 0.6
Obese 0.80(0.35,1.79) 0.58 0.65(0.29,1.47) 0.3
Unknown 1.01(0.75,1.37) 0.94 1.01(0.75,1.36) 0.96
Non-white ethnicity 0.55(0.34,0.87) 0.01 0.62(0.38,1.01) 0.06
cART naïve 0.97(0.58,1.65) 0.69 1.07(0.51,2.29) 0.85
PI experienced 1.73(1.21,2.47) <.01 1.05(0.69,1.60) 0.81
NNRTI experienced 1.45(1.10,1.92) 0.01 1.13(0.84,1.52) 0.43
Smoking status
Never ref ref
Previous 1.27(0.82,1.96) 0.29 1.24(0.80,1.91) 0.34
Current 1.19(0.90,1.58) 0.23 1.56(1.17,2.08) <.01
Unknown 0.70(0.44,1.11) 0.13 0.87(0.53,1.42) 0.57
IRR: incidence rate ratio, aIRR: adjusted incidence rate ratio, IDU: injecting drug use, HIV-VL: HIV
viral load, ADC: AIDS defining cancer, NADC: non-AIDS defining cancer, HCV: hepatitis C, HBV:
hepatitis B, BMI: body mass index, cART: combination antiretroviral therapy, PI: protease
inhibitor, NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor.
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Population attributable fractions (PAF%)
The PAF% was calculated for variables that were significant modifiable risk factors for IRC and
IURC as well as age in multivariate analyses (section 3.4.5) and are summarised in Table 3.8. For
IRC, the highest proportion of excess IRCs was associated with HIV associated factors, such as a
current CD4 cell count <200 cells/mm3 and HIV-VL > 400 copies/mL, which accounted for 20.5%
and 19.3% of excess IRCs respectively. Just over 12% of excess IRCs were attributed to being
aged over 50 years (relative to 36 – 40 years). Although HBV coinfection was associated with a
significantly higher IRC incidence, this accounted for only 5.3% of excess IRCs overall.
The highest proportion of excess IURCs was attributable to being aged over 50 years (relative to
36 – 40 years), with 55.9% of excess IURCs attributed to this group. The second largest
contributor was smoking status, 16.4 of all excess IURCs attributed to this behaviour. Having a
CD4 cell count <200 cells/mm3 also contributed to excess risk, however the percent attributed
was low at 6.3%. Prior HBV coinfection was also associated with higher risk of IURC, however
again only 5% of excess risk was attributed to this group.
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Table 3.8 Population attributable fractions (PAF%) for factors associated with the incidence of infection related
cancer (IRC) and infection unrelated cancer (IURC).
IRC IURC
Variable PAF% (%)
P<0.05 in
multivariate
analysis
(Table 3.6)
PAF% (%)
P<0.05 in
multivariate
analysis
(Table 3.7)
Age (years)
≤35  3.6(-1.6,7.0) -3.1(-11.9,-0.1)
36 –40 Ref Ref
41 – 50 10.4(-1.2,18.7) 16.5(6.9,21.9)
≥51 12.3(3.9,18.2) * 55.9(48.8,59.8) *
Current CD4 cell count (cells/mm3)
<200 20.5(17.1,22.8) * 6.3(2.6,8.6) *
200 – 349 10.6(6.1,14.0) * 4.4(-2.3,9.0)
350 – 499 3.8(-1.7,7.9) 5.8(-1.5,11.1)
≥500  Ref Ref
Current HIV-VL ≥400 copies/mL 19.3(11.8,24.9) * -1.4(-9.5,4.0)
HBV coinfection 5.3(2.5,7.3) * 5.0(1.7,7.2) *
HCV coinfection -6.5(-17.2,1.2) -1.9(-11.7,4.6)
cART naïve 2.5(-2.3,5.4) 0.3(-3.8,2.2)
Smoking status
Never Ref Ref
Previous -1.9(-6.3,1.1) 2.1(-2.8,5.2)
Smoker 6.0(-4.6,14.3) * 16.4(6.8,23.7) *
Unknown -0.3(-6.3,3.9) -1.3(-7.8,2.6)
* P<0.05 for aIRR in multivariate model. Where the PAF% is blue and bolded are statistically significant.
PAF%: Population attributable fraction, IUC: infection related cancer, IURC: infection unrelated cancer, HIV-VL: HIV
viral load, HBV: hepatitis B, HCV: hepatitis C, cART: combination antiretroviral therapy.
Models were adjusted for the following baseline variables: age, calendar year, ethnicity, region, gender specific mode
of HIV transmission, body mass index, smoking status, current HIV viral load, CD4 cell count, current hepatitis B and
C coinfection, prior ADC diagnosis, prior AIDS-defining event diagnoses (excluding ADCs), prior NADCs, prior non-AIDS-
defining events, cART naïve, and regimen.
Interaction between immune deficiency, age, and smoking status
The association between current CD4 cell count and smoking status and IRC and IURC incidence
stratified by those aged <50 and ≥50 years is shown in Figure 3.8 - Figure 3.11. As mentioned in
the methods, it was decided to investigate this a priori.
Figure 3.8 shows the association between CD4 cell count and IRC incidence in those aged <50
years (left) and in those aged ≥50 years (right). The incidence of IRC significantly increased with 
decreasing CD4 cell count at a similar rate in those aged under <50 and ≥50 years (P-value for 
interaction = 0.82). There was no association between smoking status and IRC incidence in
multivariate analysis, however for consistency and comparison with IURC, I have provided the
stratified analysis. As expected, there was no difference in the association between smoking
status and IRC incidence in those aged <50 or ≥50 years (P- for interaction = 0.31, Figure 3.9).  
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Figure 3.10 shows the association between CD4 cell count and IURC incidence in those aged <50
years (left) in those aged ≥50 years (right). It is clear that the incidence of IURC was highest in 
those with CD4 cell count < 200 cells/mm3 in those aged <50 years (aIRR 2.52; 95% CI 1.40, 4.54;
P=0.01, left), but there was no association between IURC incidence and CD4 cell count in those
aged ≥50 (right), although, the P-value of the interaction term did not reach statistical 
significance (P=0.09). Figure 3.11 shows the association between smoking status and IURC
incidence in those aged <50 years (left) in those aged ≥50 years (right). In those aged ≥50 there 
was a higher incidence of IURC in current smokers (aIRR: 1.75; 95%CI: 1.23, 4.49; P<0.01; right),
however there was no significant association between smoking status and IURC incidence in
those aged <50 (aIRR: 1.12; 95%CI 0.71, 1.77; P=0.51, left), although the test for interaction was
non-significant (P-value for interaction = 0.32). All other interactions with age were non-
significant for both outcomes.
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Figure 3.8 Adjusted incidence rate ratios (aIRR) of infection related cancer (IRC)
for current CD4 cell count in those aged <50 and ≥50 years. 
Figure 3.9 Adjusted incidence rate ratios (aIRR) of infection related
cancer (IRC) for smoking status in those aged <50 and ≥50 years. 
Figure 3.10 Adjusted incidence rate ratios (aIRR) of infection unrelated cancer
(IURC) for current CD4 cell count in those aged <50 and ≥50 years. 
Figure 3.11 Adjusted incidence rate ratios (aIRR) of infection unrelated
cancer (IURC for smoking status in those aged <50 and ≥50 years. 
Models were adjusted for the following baseline variables: age, calendar year, ethnicity, region, gender specific mode of HIV transmission, body mass index, smoking status, current
HIV viral load, current CD4 cell count, current hepatitis B and C coinfection, prior AIDS defining cancer (ADC), diagnosis, prior AIDS-defining event diagnoses (excluding ADCs), prior
non-AIDS defining cancer (NADCs), prior non-AIDS-defining events (excluding NADCs), cART naive and regimen.
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Association between calendar year and age, HIV related factors,
and demographic variables on cancer
Table 3.9 shows the change in aIRR estimates controlling for calendar year and age (model A),
then adding HIV related factors (model B) and finally adding demographic and lifestyle variables
(Model C). This stepwise building of models shows the extent to which, for example, the
association between age and calendar year and IRC is further modified by the addition of other
variables. The incidence for IRC was estimated to be 16% higher for a 10 year increase in age
and decline by almost half for a 10 year increase in calendar time (model A). This decrease over
time was no longer significant after adjustment for HIV-specific variables, which indicates that
changes in these variables over time explain some of the decrease in IRC over time that was
observed. For IURC, the incidence was 2-fold higher for a 10 year increase in age and only a 10%
increase per 10 additional years of follow-up (although not significant). Neither of these
estimates changed after adjustment for HIV related factors (B) and demographic and lifestyle
factors (C).
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Table 3.9 Change in adjusted incidence rate ratios (aIRR) for infection related cancer (IRC) and infection unrelated cancer (IURC) when sequentially adjusting for variables.
aIRR (95%CI) of IRC aIRR (95%CI) of IURC
Model A Model B Model C Model A Model B Model C
Age (10 years older) 1.16(1.05,1.27)* 1.25(1.14,1.38)* 1.24(1.09,1.42)* 2.05(1.87,2.25)* 2.05(1.86,2.26)* 1.96(1.7,2.26)*
Calendar year (10 years longer) 0.52(0.36,0.76)* 1.43(0.91,2.26) 1.43(0.9,2.25) 1.09(0.73,1.63) 0.99(0.56,1.75) 0.87(0.48,1.58)
Log 2 CD4 cell count 0.77(0.7,0.84)* 0.79(0.71,0.88)* 0.81(0.7,0.93)* 0.88(0.73,1.06)
Log 10 HIV-VL 1.27(1.14,1.4)* 1.32(1.18,1.48)* 0.99(0.84,1.16) 1.04(0.87,1.24)
Prior ADC 1.62(1.17,2.24)* 1.68(1.15,2.45)* 0.95(0.58,1.54) 1.13(0.66,1.91)
Prior AIDS event (excl. ADC) 1.12(0.89,1.41) 1.47(1.14,1.9)* 0.89(0.66,1.2) 0.83(0.59,1.17)
Prior NADC - 2.2(1.38,3.5)*
Prior non-AIDS event (excl. NADC) - 0.85(0.47,1.51)
Current smoker 1.3(0.98,1.72) 1.79(1.27,2.52)*
Previous smoker 1.04(0.65,1.64) 1.16(0.69,1.96)
Never smoker 1 1
* P< 0.05
IRC: infection related cancer, IURC: infection unrelated factors, ADC: AIDS defining cancers, NADC: non-AIDS defining cancer, HIV-VL: HIV viral load, HBV: hepatitis
B, HCV: hepatitis C, cART: combination antiretroviral therapy
Model A contains age and calendar year
Model B contains variables in model A, CD4 cell count, current HIV-VL, prior ADC and prior AIDS defining event (excluding ADCs)
Model C contains variables in A and B and ethnicity, region of Europe, gender specific mode of HIV transmission mode, BMI, smoking status, current HIV-VL, CD4 cell
count, current HBV/HCV coinfection, prior ADC diagnosis, prior AIDS-defining event diagnoses (excluding ADCs), prior NADCs, prior non-AIDS defining events
(excluding NADCs), cART naive and regimen.
144
The future burden of infection related and infection unrelated
cancer
Assuming current trends continue, the crude IRC incidence for those recruited to EuroSIDA
before 2001 was forecast to decline (Figure 3.12), from an incidence of 3.1 (95%CI:1.5,5.9)/1000
PYFU in Jul-Dec 2011 to 2.2 (95%CI: 0.9, 4.3) after 5 and 1.6 (95%CI: 0.6, 3.4) after 10 years.
Forecasted crude IURC incidence increased from 4.1 (95%CI: 2.2, 7.2) Jul-Dec 2011 to 5.9 (95%CI:
3.2, 10.2) and 7.8 (95%CI: 4.3, 13.5) after 5 and 10 years respectivley (Figure 3.13).
Figure 3.12 Semi-annual crude incidence rate of infection related cancer (IRC)/1000 PYFU for those recruited before
2001 with 5 and 10 year forecast.
Figure 3.13 Semi-annual crude incidence rate of infection unrelated cancer (IURC)/1000 PYFU for those recruited
before 2001 with 5 and 10 year forecast.
IRC: infection related cancer, IURC: infection unrelated cancer, PYFU: person years of follow-up,
IR: incidence rate, PYFU: person years of follow up.
Table 3.10 shows the forecasted incidence of IRC and IURC at 5 years, overall and within different
subgroups. IRC incidence was overall forecast to decline across all strata, with the exception of
people who aquired HIV through IDU, in which the incidence remained stable at 4.9 /1000 PYFU.
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The largest relative declines were seen in those who were aged ≥50 years with a decline of 61.1% 
from 1.8 in Jul-Dec 2011 to 0.7 /1000 PYFU after 5 years, and those who acquired HIV through
sex between men, with a decline of 48.4% from 3.1 in Jul-Dec 2011 to 1.6 /1000 PYFU after 5
years. The groups with the highest IRC incidence after 5 years were those who acquired HIV
through IDU (IR: 4.9/1000 PYFU), those who acquired HIV through heterosexual sex (3.3/1000
PYFU) and persons who had ever smoked (3.3/1000 PYFU).
Conversely, overall IURC incidence was predicted to increase in all strata, with the exception of
those who had never smoked for whom the IURC incidence was forecast to decrease from 1.7
/1000 PYFU in Jul-Dec 2011 to 0.84 /1000 PYFU after 5 years. The largest relative increase in
IURC incidence was for those who acquired HIV through IDU, which more than doubled from 3.4
in Jul-Dec 2011 to 7.0 /1000 PYFU after 5 years, and those who have ever smoked with a relative
increase of 76% from 4.5 in Jul-Dec 2011 to 7.95 /1000 PYFU after 5 years. The groups with the
highest IRC incidence after 5 years were those aged older than 50 years (IR: 15.3/1000 PYFU),
those had whoever smoked (7.95/1000 PYFU) and those who acquired HIV through IDU
(7.0/1000 PYFU), however numbers were small and estimates uncertain, as reflected by the
wide confidence intervals for these estimates.
Table 3.10 Forecasted 5 year incidence of crude IRC and IURC for those recruited to EuroSIDA before 2001 within
strata.
Subgroups
Incidence of IRC
/1000 PYFU
Incidence of IURC
/1000 PYFU
Jul – Dec
2011
Forecast at 5
years
Jul – Dec
2011
Forecast at 5
years
Overall 3.1 (1.5, 5.9) 2.2 (0.9, 4.3) 4.1 (2.2, 7.2) 5.9 (3.2, 10.2)
baseline age
< 50 years 3.3 (1.8, 5.83) 2.4 (1.1, 4.35) 2.8 (1.0, 6.0) 4.4 (1.9, 9.2)
≥50 years 1.8 (0, 11.6) 0.74 (0, 7.04) 
10.4 (3.4,
28.8) 15.3 (5.1, 42.7)
Baseline CD4
<350 cells/mm3 4.3 (1.5, 10.2) 2.9 (0.8, 7.4) 4.1 (0.6, 15.5) 5.6 (1.0, 20.5)
≥ 350 cells/mm3 2.7(1.0, 5.7) 2.0 (0.6, 4.6) 3.6 (1.0, 9.5) 5.2 (1.6, 13.5)
HIV transmission
mode
Sex between men 3.1 (1.0, 7.0) 1.6 (0.3, 4.2) 4.2(1.5, 9.9) 5.0 (1.8, 12.1)
Heterosexual 3.8 (0.6, 13.7) 3.3(0.2, 14.1) 2.6 (0.0, 11.7) 3.3 (0.2, 14.1)
IDU 4.9 (1.0, 16.9) 4.9 (0.9, 17.1) 3.4 (0.0, 22.1) 7.0 (0.5, 42.4)
Baseline smoking status
Ever smokers 4.2 (0.7, 14.8) 3.3 (0.39, 12.34) 4.5 (0.3, 21.5) 7.9 (1.1, 36.4)
Non- smokers 3.5 (0.65,11.4) 2.6 (0.3, 9.2) 1.7 (0.0, 10.6) 0.84 (0.0, 7.01)
IRC: infection related cancer, IURC: infection unrelated cancer
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Discussion
This study identifies that IRC and IURC have different risk factors. Older age was the largest
contributor to IURC incidence, whereas IRC was primarily driven by HIV related risk factors such
as higher HIV-VL and lower CD4 cell counts. Through this study, I was able to demonstrate an
expected decline in IRC incidence over time, likely due to control of HIV related factors through
effective cART. Simultaneously, IURC incidence was expected to rise, primarily due to aging of
the HIV+ population. The burden of cancers is expected to shift towards IURC due to the non-
declining IURC incidence, the increasing proportion of HIV+ people aged over 50 years, as well
as higher prevalence of known cancer risk factors, such as smoking, and low prevalence of
untreated HIV infection [405, 503]. The future of HIV care will need to address the increasingly
complexity of management of the older HIV+ patient. Integration of HIV and oncological services
for the detection, diagnosis, comanagement and treatment of complex comorbidities, such as
cancers, may be needed in order to optimise care [504]. At the time of this study, this was one
of the largest studies in Europe to investigate the changing incidence of IRCs and IURCs over
time and to investigate associated risk factors, including demographic, HIV and lifestyle factors,
in the late cART era. This study contained a comparably large number of prospectively collected
IRC and IURC events over a long follow-up time of up to 12 years. Several other studies had
performed similar analyses at the time of this study [16, 20, 432, 433, 592, 601, 602], however
most were performed within HIV+ people in the USA, where the patient demographics and
health care structure is considerably different to those in Europe (and may not be generalizable)
[16, 432, 601] or other non-EU populations [602]. Furthermore, many compared populations or
groups, for example: HIV+ vs HIV-negative or HIV+ over time, rather than investigating individual
level risk factors in HIV+ people [8, 20]. Ecological studies present associations between risk
factors and outcomes for populations overall rather than the individual, and therefore,
associations may not accurately reflect those at the individual level [603].
Change in incidence of infection related and infection unrelated
cancer over time
The crude incidence of IRC has declined since 2001, with a clear decrease between 2001 and
2003 and stabilized thereafter. The change in IRC over time was driven by the control of HIV
related factors, such as controlling HIV viremia leading to CD4 recovery, likely due to
improvements in treatment regimes, treatment uptake and adherence [594]. Furthermore, the
proportion of all cancers that were IURCs almost doubled from 22.4% in 2001 to 44.2% in
2011/12, driven by the decline in IRC incidence and slight increase in IURC incidence per year.
This demonstrates a shift in cancer burden towards IURCs in recent years.
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The decline in IRC incidence was driven by the decline in EBV and HHV8 associated cancers,
consistent with previous studies [7, 8, 16-21, 430, 438, 439, 441, 442, 444, 450, 451, 459, 465,
470, 478, 483, 604]. In this study, HL incidence was decreasing by 10% per year, which is not
consistent with most previous research [8, 19, 21, 430, 467]. A study from the Swiss HIV cohort
study showed increasing rates of HL between the pre and early HARRT periods, but were fairly
stable thereafter [430]. There are several potential explanations for this difference. First, my
study covers the period from 2001-2011/12, whereas many other studies cover a much earlier
period and include a large number of people with advanced HIV infection. Second, the potential
benefits of cART for reducing HL incidence through improved immune function and EBV control
may take a long time to be visible at the population level [605-608]. For more detail on the
pathogenesis and risk factors of NHL and HL, see chapters 5 and 6. The decline in IRC incidence
was not consistent across individual cancers. Invasive cervical and anal cancers were both stable
over time in this study. Non declining cervical and anal cancer rates have been commonly
reported in the literature [14, 19, 430, 432, 436-438, 465, 467, 479-481, 609], however, a decline
in cervical cancer has been observed in recent years [436, 464]. In my study, liver cancers were
increasing which is consistent with previous studies [436, 437, 609]. However, the increase
presented here of 16.5% per year was higher than expected, with an increase of 8.5% per year
in the USA and 11% per year in Europe reported previously [610]. The increase in liver cancers
in EuroSIDA may in part be described by changes in EuroSIDA recruitment patterns over time,
such as the increased focus on eastern Europe (which have a very high prevalence of IDU and
HCV coinfection [412] and alcohol use [611], as well as the intensification of case finding
processes.
Forecasts of infection related and infection unrelated incidence
The incidence of IRCs was forecast to continue to decline in the near future. This was consistent
in all strata except IDUs who may be less likely to start and adhere to treatment and have
generally poorer clinical outcomes [612]. The incidence of IURCs was forecast to increase in the
near future across all strata with exception of non-smokers, driven by lower lung cancer rates,
and supports the need for smoking prevention initiatives and smoking cessation programs. If the
declining IRC and non-declining IURC incidence continue in the coming years, the burden of
cancers is expected to shift towards IURC due to the growing HIV+ population and the increasing
proportion of aged over 50 years [175, 405, 503]. Such a shift has been demonstrated in HIV+
people with AIDS in the USA, where the number of NADCs has exceeding that of ADCs since 2003
and the total cancer burden has increased since the early 2000s (following a steep decline
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following the introduction of cART) due to the growth and aging HIV+ population (Figure 3.14)
[7].
Figure 3.14 Total number of cancer cases (i.e. cancer burden) among people with AIDS in the United States, 1990–
2005 [7].
Risk factors
HIV Associated factors: HIV viral load and CD4 cell count
The strongest predictors for IRC were low current CD4 cell count and high current HV-VL. This
was not surprising given the strong link between reduced immune function and loss of control
of oncogenic viruses, particularly EBV (explored further in chapters 5 and 6) and HHV8 [453, 606-
608]. Many previous studies have found a strong association between immune deficiency and
individual IRCs, including KS, NHL, HL, and liver cancer [17, 20, 475, 487]. Although a French
study demonstrated and protective association with higher log2 CD4 cell count [433], a clear link
between CD4 cell count and cervical cancers has not been established in most cohort studies
[17, 487]. However, low CD4 cell counts have been linked to higher prevalence of HPV infection
(the cause of cervical cancer), and lower rates of HPV clearance in HIV+ women [613-615]. A link
between anal cancers and duration of immune suppression [433], nadir CD4 [438, 481], and CD4
cell count [16, 479] has previously been reported. There is growing evidence that HIV-VL is
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associated with incidence of some IRCs (mainly NHL and KS) independently of CD4 cell count
[16, 429, 433, 616].
IURC incidence was modestly associated with current CD4 cell count, however this only
accounted for a small percentage (6.3%) of excess IURC cases. This association appeared to be
limited to those aged <50 years although the interaction between age and CD4 cell count was
non-significant, possibly due to limited power. In the START trial (summarised in chapter 1
section 1.1.8.7.1), those in the immediate cART had a 51 (21 – 115)% lower risk of IURC relative
to differed cART arm but did not reach statistical significance (P=0.1). However, high baseline
CD8 cell count was associated with increased risk, indicating that immune dysfunction may play
a role in IURC development [616].
Age
Elevated IRC incidence was (although less prominently than for IURC) associated with higher
age. This probably reflects longer exposure to oncogenic viruses, such as replicating EBV, due to
longer survival. The effects of aging on the immune system are thought to occur at an
accelerated rate in HIV+ people, and may also explain this result (for more detail on HIV and
aging see chapter 1 section 1.2.4) [3, 617]. A similar association between IRC and age was also
identified by the START study [616]. The proportion of excess IRCs that were attributable to
being aged 51 year or older (PAF%: 12.3%), HIV-VL>400 copies/mL (19.3%) and CD4 cell count
<200 cells/mm3 (20.5%) were comparable, despite the strongest predictors of IRC being current
CD4 cell counts and HIV-VL.
Higher IURC incidence was strongly associated with age, and linked with more than 50% of the
excess of IURC incidence in EuroSIDA. The 2-fold higher IURC incidence for a 10 year increase in
age is similar to findings of the SMART study [594], START study [616] and to data published
online by the European cancer observatory, which showed a 1.9-fold increase per 10 years older
in incidence of all cancers in the general population [618]. Similar results were found for the UK
(Figure 3.15).
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Figure 3.15 All cancers (C00-C97 Excl. C44) average number of new cases per year and age-specific incidence rates,
UK, 2011-2014 [619].
Current smoking status
No association between smoking and IRCs was identified. This was surprising given the
established link between HPV associated head and neck cancers and tobacco use [620, 621].
This may suggest an alternative pathophysiological mechanism in the setting of HIV infection,
however, this is more likely due to the small number of head and neck cancers, the high
proportion of people with unknown smoking status, and the lack of detailed smoking
information, such as duration and intensity, in EuroSIDA (see chapter 2 section 2.1.1.7 for a list
of data items collected in EuroSIDA).
Current smoking was strongly associated with IURC incidence, driven by the causal link between
lung cancer and tobacco use [594, 620-622], and accounted for 16.4% of excess cancers in this
group. When stratified by age, current smoking was associated with higher IURC incidence in
those aged over 50 years only. This is probably in part due to the correlation between age and
the two strongest risk factors for lung cancer in the general population: smoking duration and
age at smoking cessation [622]. The strong association between lung cancer and older age has
been repeatedly shown in both HIV+ [617, 623] and the general population [622, 623], however,
it is difficult to assess this association without detailed smoking information. In addition, some
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studies have shown a higher prevalence of smoking status in the older age groups in HIV+ people
which may also explain the result [421, 489]. I have explored the association between smoking
and cancer in Chapter 4.
Hepatitis C and Hepatitis B coinfection
HBV coinfection was associated with high IRC incidence, driven by liver cancer, as expected [474,
624, 625]. Surprisingly, HBV coinfection was also associated with higher overall IURC incidence,
although due to small numbers I could not identify if this was driven by one cancer type. Other
studies have found a link between HBV and non-liver related outcomes, such as an excess of
non-liver cancer deaths in two studies in Asia in those with chronic HBV [626, 627], and several
studies have found a link with elevated B cell NHL risk [464, 477]. Misclassification of metastatic
liver cancer as other primary cancers is also a possible explanation. Unfortunately, due to
insufficient data, I was unable to explore this further. Although the association between HBV
and both IRC and IURC incidence was relatively strong, HBV coinfection only accounted for
approximately 5% of excess IRC and IURC due to the small proportion of people with IRC that
were HBV coinfected. No association between IRC or IURC and HCV coinfection was identified,
despite the established link with liver cancers (although liver cancers made up a relatively small
proportion of the IRCs included) [474]. Liver cancers tend to develop several decades after initial
hepatitis infection [628, 629] and are likely to become a source of burden in the aging
HIV/hepatitis coinfected population.
Other factors
Incidence of IRC varied by region with lower incidence in eastern Europe, as well as by mode of
HIV transmission, with lower incidence in males and females who acquired HIV through
heterosexual sex. This could reflect a competing risk of death in these groups (i.e. they died
before they could develop an IRC), although, I did perform a competing risks analysis and the
results were unchanged. Alternatively, the results could be influenced by unmeasured
confounding across regions or mode of HIV transmission groups, such as differences in
treatment quality or availability, cancer screening and detection rates, or socio-demographic
differences.
IRC incidence was higher in those who had a prior ADC or AIDS defining event. This could indicate
additional immune dysfunction in advanced HIV infection that is not captured by low CD4 cell
counts alone and uncontrolled replication of oncogenic viruses (such as EBV) [607].
Furthermore, some studies have shown increased risk of NHL following diagnosis of KS, and vice
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versa [435, 630], thought to be due to shared risk factors and simultaneous infection with EBV
and HHV8 in HIV+ people [607]. Alternatively, it could just reflect increased monitoring of HIV+
people following an AIDS defining event. After adjustment, IRC incidence was not associated
with ethnicity, cART use, cART regimen, or BMI.
IURC incidence was associated with a prior NADC. Studies in the general population have
identified previous cancer as a risk factor for subsequent cancers [631]. For example, breast
cancer is 8-fold higher in HL survivors, particularly those who received radiotherapy rather than
chemotherapy[632], and 14% higher in melanoma survivors [633]. Colorectal cancer survivors
are also at higher risk of cancers of the digestive system [631]. The increase may also be
explained by shared risk factors, such as smoking, that facilitate the development of multiple
cancers simultaneously (See chapter 1 section 1.2.5 for a list of common cancer risk factors).
Furthermore, increased cancer surveillance and clinic visits in cancer survivors for the first 2 - 3
years following diagnosis may also contribute [634], although, doctor visits are higher for up to
10 years following diagnosis, which may increase the chance a cancer is detected [635].
Alternatively, my result could reflect misclassified of metastatic cancers or recurrence of primary
cancers as second primary cancers in EuroSIDA. IURC incidence was not associated with gender
specific HIV transmission mode category, region, ethnicity, previous ADC or AIDS-defining
diagnosis, previous non-AIDS defining event (excluding NADC), HCV coinfection, cART use, cART
regimen, or BMI.
Strengths of these analyses
EuroSIDA is a large heterogeneous cohort of HIV+ people with a relatively large number of
prospectively collected cancers. All reported diagnoses of cancers are validated and undergo a
rigorous quality assurance process. Furthermore, EuroSIDA collects a range of longitudinal
demographic, HIV related, laboratory and treatment variables on each patient, which allows for
rich patient level analyses to explore individual level variations. Many existing studies compare
populations of HIV+ individuals over time, or HIV+ and HIV-negative individuals to identify
differences in risk. These studies give an extremely important overview of changes in the HIV+
population overall, however they are limited in terms of identifying patient relevant factors to
improve patient outcomes. This study identifies a list of patient based risk factors for IRC and
IURC in HIV+ populations, and demonstrates the shift in the cancers occurring in HIV+ people
over time.
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Limitations of these analyses
The limitations of this study should be noted. EuroSIDA has a relatively large number of
prospectively collected cancers, but despite this, the frequencies of individual cancers were
small and could not be investigated individually. EuroSIDA is an observational study, and
although analyses were adjusted for various potential confounders, I cannot rule out the effects
of confounding that remains due to unmeasured or unknown factors. Furthermore, several
known risk factors for cancer are either not collected or collected in an over simplified manor.
For example: the lack of detailed life time smoking and alcohol use information, such as duration
or intensity. Although detailed information on CD4 cell count and HIV-VL is available, alternative
measures of immune dysfunction (such as CD8) were not available. Another significant
limitation is the lack of other medication or treatment used in people under follow-up in
EuroSIDA, such as cancer treatments. As a result, I was not able to investigate mortality and
survival following cancer diagnosis adequately.
Linear exponential smoothing models are a simple method of forecasting which assume the
continuation of previous population trends. These methods can depict how the incidence may
change over time on a broad level, but cannot formally identify the reasons i.e. due to continuing
changes in the underlying population such as aging or improved treatment uptake and efficacy.
However, I could speculate based on the risk factor analysis. A limited amount of historical data
was available for forecasting, contributing to large uncertainty around forecasts. HIV-specific
population projections were not available at the time of this analysis, which prevented the use
of more advanced methodologies, such as age-period-cohort models.
Conclusions
This chapter shows that the incidence of IURC is expected to increase due to aging of the HIV+
population. Conversely, IRC incidence is expected to decline as a result of the low prevalence of
advanced and untreated HIV infection and severe immunodeficiency. Reducing the incidence of
IURCs should therefore be a priority in the coming years as the proportion of HIV+ people aged
over 50 years continues to increase. Studies evaluating cost-benefit of screening in the HIV+
population and targeted preventive interventions, such as cessation programs for smoking and
alcohol use, and vaccinations for oncogenic viruses such as HBV and HPV should be considered
to reduce the burden of avoidable cancers.
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There is a need for research into the risk factors, diagnostic markers, and pathological
mechanisms of common cancers in HIV+ people. Smoking prevalence tends to be higher in HIV+
people and the burden of lung cancer is expected to increase as the population ages. The
benefits of smoking cessation on cancer risk is explored in chapter 4. Furthermore, EBV
associated cancers (NHL) and (HL) account for the highest number of cancer diagnoses in this
population, and although declining, incidence is still elevated in HIV+ people and contribute
significantly to cancer burden. Risk factors for NHL and HL are identified and compared in
chapter 5, and markers of B cell activation preceding lymphoma development are addressed in
chapter 6. Finally, prostate cancers (PCa) are the most common cancer in older European men
in the general population and are strongly associated with age. The burden of PCa is expected
to increase in HIV+ people as the population age. Prostate specific antigen (PSA) is a diagnostic
marker used in the general population and its use in HIV+ men is assessed in chapter 7.
Publications
This chapter was published in HIV Medicine in 2016 [636] and is included in Appendix III. This
chapter was presented at the European AIDS clinical society (EACS) conference in 2013 and the
slides are included in Appendix IV.
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4 Cessation of cigarette smoking and the impact on cancer
incidence in the D:A:D Study
Introduction
As outlined in chapter 3, in the context of available and effective HIV treatment, cancers are a
major source of morbidity and mortality in HIV-positive (HIV+) people, due to a combination of
longer life expectancy, reduced immune function, and life style related factors [220, 637].
However, the relative contribution of life style related risk factors, such as smoking, towards
elevated cancer risk, is not clear [638]. Smoking is a known risk factor for many cancers in the
general population, and therefore, smoking cessation presents as an important modifiable
factor to reduce cancer risk [639].
Smoking, cancer, and other morbidity in the general population
In the general population, tobacco smoking is an established risk factor for many cancers and
the leading causes of cancer worldwide [622, 640]. It is estimated that more than 1.1 billion
people worldwide were smokers in 2015 with a prevalence of 27.3% in Europe [641]. In addition,
lung cancers are now the most common cancers with an estimated 1.2 million new cases per
year and are one of the most common causes of death globally [642, 643]. Incidence of lung
cancer is highest in regions where the smoking epidemic is oldest such as the USA and Europe
[642]. Therefore, smoking is currently one of most important modifiable factors for cancer risk
prevention [622, 644, 645].
Incidence of smoking related cancer and mortality has declined in high income countries in
recent years due to a combination of increasing rates of smoking cessation as well as the
proportion of people who never start smoking [646]. However, smoking cessation remains
uncommon in low to middle income countries and the burden of smoking related morbidity and
mortality in these regions are expected to rise if smoking cessation rates do not increase [646].
The harms of smoking
Current smokers are on average 2-3 times more likely to die from any cause than those who
have never smoked mainly due to smoking related diseases in high income countries [647-649].
In addition, studies from the UK and USA have estimated that smokers loose approximately a
decade of life compared with non-smokers in the general population [647, 648, 650, 651].
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Unfortunately, it is difficult to properly measure the harms of smoking at a population level, as
the full impacts may not be evident for up to 50 years after smoking enters a population [647].
It was established that smoking causes lung cancer in the 1950’s [622, 647, 651-653], and it has
been estimated that half of the excess mortality in current smokers is due to lung cancer [647].
The strongest risk factor for lung cancer in the general population is longer smoking duration
[622, 654], followed by smoking intensity (i.e. the daily number of cigarettes smoked) [622, 647].
All histological types of cancer have been causally linked to cigarette smoking, however, stronger
associations for squamous cell and small cell carcinomas than for large cell carcinomas and
adenocarcinomas have been reported [655, 656]. Smoking has also been causally linked with
many other cancers, which are listed in Table 4.1 [622, 640]. Risk of many other conditions have
been linked to smoking, including cardiovascular disease (CVD), respiratory diseases (such as
chronic obstructive pulmonary disease [COPD], pneumonia, and tuberculosis), diabetes,
rheumatoid arthritis, adverse effects on infant and child health, reduced fertility, pregnancy
complications, still births and low birth weight [622, 657]. In addition, smoking also causes
systemic inflammation and impaired immune function [657].
The benefits of cessation
The benefits of smoking cessation in the general population are well established and include
reduced mortality (restored longevity) and reduced incidence of lung cancer relative to those
who continue smoking [654, 658, 659]. However, estimates of the benefit in the general
population are highly variable and there is uncertainty about the size and timing of these effects
and how they vary according to age at cessation, smoking history, histology of lung cancer, and
the presence of other smoking related diseases [654, 660]. Nonetheless, most epidemiological
studies show a greater benefit of cessation in those with shorter smoking duration, lower
intensity of smoking, and younger age at cessation [647, 651]. Although smoking cessation can
reverse much of the carcinogenic effects of smoking, the risk will never return to that of never
smokers due to residual genetic damage [654].
It has been estimated that the benefits of cessation on the incidence of lung cancer take
between 5 – 9 years to become apparent, and increase with longer time since cessation [654,
661-663]. Following smoking cessation, the time for the excess lung cancer risk due to smoking
to reduce by half (or the “half-life”) is estimated to be 10 years [661]. Similar to lung cancer
incidence, risk of lung cancer mortality is also reduced following cessation and declines with
increasing time since cessation [654]. Reductions in risks after cessation have also been
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observed for many other cancers (although less pronounced than for lung cancers) [654]
including cancers of the head and neck, oesophagus, stomach, bladder cancer, pancreatic, and
cervix [654, 663]. Although the incidence of liver cancer is lower in former smokers than current
smokers, there is insufficient data on time since cessation, and conflicting results also exist for
myeloid leukaemia [654]. There is substantial variation in estimates from epidemiological
studies published in the literature of the effect of cessation on cancer incidence partially due to
differences between studies in smoking duration, smoking intensity, age, age at cessation,
gender and other factors [654].
The introduction of E-cigarettes
E-cigarettes (EC) have had rapid uptake in the general population since their introduction in 2007
[664] and are thought to help with achieving successful smoking cessation or at least reduce
smoking intensity [665-667]. A Cochrane review showed that people who used ECs were more
than 2-fold more likely to cease smoking for at least 6 months relative to those who did not
[668]. Furthermore, ECs do not involve combustion and prevent exposure to associated harmful
chemicals such as tar and carbon monoxide [665]. This has numerous health benefits including
potentially reduced incidence and progression of many cancers [665, 669]. ECs are thought to
be safer for long term health than traditional cigarettes [670], however, it is important to
remember that ECs are not risk free [665, 671]. ECs involve their own mix of potentially harmful
chemicals, including nitrosamines, formaldehyde, and heavy metals, which are potential
carcinogens, and have not been available long enough to assess the long term health impacts
[665, 670, 672-677]. This is a concern for conditions with long latency periods, such as cancers,
which may take up to several decades for an elevated risk to emerge [665]. Furthermore, it is
difficult to tease out the health impact of ECs as many people use them in conjunction with
conventional cigarettes [665].
Smoking and cancer in HIV-positive people.
Prevalence of smoking in HIV-positive people
Studies of HIV+ people often find higher smoking prevalence (between 40 – 84%) than the
general population (European countries: 13 – 45%, USA: 17%) [20, 421, 489-496, 641, 678-683],
with prevalence estimated to be 2-3-fold higher in HIV+ populations [491, 493, 679, 682, 684],
however estimates are highly variable between countries [685]. One French study demonstrated
variation in prevalence estimates according to age, gender, HIV transmission group, country,
and ethnic origin, and ranged from 9% in women from sub-Saharan Africa to 81% in people who
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acquired HIV through injecting drug use (IDU) [492]. Demographic factors may contribute to
higher smoking prevalence among HIV+ people and previous studies have found the following
factors to be associated with a higher prevalence of smoking: older age, male gender, higher
body mass index (BMI), alcohol use, white ethnicity, living in a smoking environment, lower
income, less social support, illicit drug use (including IDU), and depressive symptoms [493, 678-
681, 686, 687]. Smoking in HIV+ people is also thought to be linked with elevated stress and
reduced quality of life due to living with a HIV+ diagnosis and associated treatment [492]. In
addition, HIV+ smokers are thought to have high nicotine dependence with an average of 16 –
23 cigarettes smoked per day [420, 491].
Harms of smoking in HIV-positive people
Similar to the general population, HIV+ people also suffer from adverse health outcomes due to
smoking, including increased mortality (reduced longevity), morbidity, cancer risk, and reduced
quality of life [20, 621, 682, 684, 688-690]. In those on combination antiretroviral therapy
(cART), HIV+ smokers lose more life years due to smoking rather than due to HIV infection [496,
691]. Furthermore, the risk of death from any cause in HIV+ smokers was found to be 2 – 4-fold
higher than never smokers in those on cART [496, 691].
Smoking increases the risks of various diseases that are of concern in HIV+ people. These include
a range of pulmonary complications such as lower respiratory tract infections (tuberculosis and
bacterial pneumonia), COPD, and lung and other cancers [433, 638, 682, 688, 690, 692-709].
Other comorbidities associated with smoking include CVD [682, 710, 711], perinatal mortality
[712], periodontal disease [713], accelerated bone loss, fractures [714-716], and a decreased
quality of life [688, 690].
It has been suggested that the lungs of HIV+ people may be especially susceptible to the harms
of smoking [689] and studies have been shown that HIV+ smokers have higher rates of morbidity
and mortality than HIV-negative smokers controlling for other demographic factors [688, 691].
Smoking is thought to have detrimental effects on immune function and to increase activation
and inflammation in the lung in the context of HIV [696, 717]. This may put HIV+ smokers at
higher risk of several pulmonary diseases (which are known risk factors for lung cancer) relative
to HIV+ people who have never smoked [696]. This is particularly worrying in the context of HIV
due to existing immune dysfunction in this population and elevated risk of many pulmonary
disorders in the absence of smoking [507, 718-721].
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4.1.2.2.1 Lung cancer
Lung cancers are one of the most common non-AIDS defining cancers (NADC) in HIV+ people
lung cancer related deaths are the leading cause of NADC related death in HIV+ people in high
income countries [7, 21, 444, 722, 723]. Many studies have shown an excess incidence of lung
cancer in HIV+ people relative to the general population [14, 15, 433, 638, 705-707, 724-728],
however, it is hard to disentangle how much of this excess is due to the effects of HIV infection
or the higher prevalence of smoking in HIV+ people [638]. One study from the USA showed that
the incidence of lung cancer was elevated in HIV+ relative to HIV-negative people largely due to
differences in smoking behaviour. However, lung cancer incidence was still 2.5-fold higher after
adjustment for differences in smoking behaviour [725] (a result that has been replicated in other
studies [706, 728]) and suggests that HIV plays either a direct or indirect role in the development
of lung cancers in HIV+ people. Another recent study demonstrated that HIV+ people were not
at excess risk of lung cancer relative to HIV-negative people after accounting for differences in
cancer risk factors and history of pneumonia [729]. It remains unclear whether smoking has a
greater impact on lung cancer incidence in HIV+ people and no evidence of a synergistic
relationship between smoking and HIV have been formally identified [728]. Some studies have
found that HIV+ people present with lung cancer at a younger age [535, 584, 623, 727, 730], a
later stage [727, 731], and after less exposure to smoking than HIV-negative people [730].
However, data from larger studies have found no evidence of a later stage of lung cancer at
diagnosis in HIV+ people relative to the background population [535, 706, 732],. This also
suggests that the higher lung cancer risk observed in HIV+ relative to HIV-negative people is not
due to differences in cancer surveillance by clinicians [706].
The prognosis of HIV+ people following a lung cancer diagnosis is poor compared to the HIV-
negative population in the cART era (5 year survival estimates in HIV+ and HIV-negative people
following diagnosis of 10% and 19% respectively) [531, 535, 707, 726-728]. The reason for this
disparity is largely attributed to differences in lung cancer treatment in HIV+ and HIV-negative
people [733, 734], however, lower treatment tolerance, interaction between cancer treatment
and cART, cART toxicities, or competing risk of death due to HIV related factors may also
contribute [707, 734]. However one recent study has shown that lung cancer outcomes have
converged in HIV+ and HIV-negative people in recent years [735].
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4.1.2.2.2 Other smoking related cancers
Evidence of elevated incidence of other smoking related cancers (as defined Table 4.1) in HIV+
people is mixed. Consistently higher standardised incidence ratios (SIR) of cervical cancers [15,
20, 436], some head and neck cancers [15, 20, 521], and liver cancers [14, 15, 436, 521] have
been demonstrated in HIV+ people. Conversely, some studies report higher incidence of colon
and rectal cancers [15, 19], while others demonstrate comparable incidence to the general
population [19, 436, 521]. Similar conflicting results for cancer of the oesophagus (elevated:
[15], similar: [521]), stomach (Elevated: [15], similar: [521]), leukaemia (Elevated: [15], similar:
[521]), and kidney (elevated: [14] similar: [521]) have been reported. There is no evidence of
elevated incidence of ovarian cancers [15] or pancreatic cancer [19, 521]. However, many
smoking related cancers are also associated with oncogenic viruses and, therefore, incidence is
often increased in the context of immune suppression [8, 14-18, 427], as outlined in chapter 1
section 1.2.3 and addressed in chapter 3. A Danish study found excess risk of infection related
cancers (IRCs) and smoking related cancers (including lung) in HIV+ people relative to controls,
but not other cancers [621]. Never smokers had increased risk for IRCs but not smoking related
cancers [621].
Smoking cessation
The incidence of most cancers, including lung, increase with older age [736, 737]. Therefore, as
the HIV+ population ages [405, 503] and the burden of these cancers increase [7, 449, 584],
smoking presents as a critically important evidence-based modifiable risk factor [639]. HIV+
people have regular contact with various healthcare facilities, and therefore, there are multiple
opportunities for smoking cessation interventions [738]. However, HIV+ people who smoke have
additional barriers to cessation that are less prominent in HIV-negative people. For example,
smoking, drug, and alcohol use are closely intertwined in the context of HIV [492, 686] and the
likelihood of smoking is higher when also using drugs or alcohol. Furthermore, multiple
substance use is a marker for smoking cessation failure [420, 421, 491, 739-741] and additional
psychological stress and depression in HIV+ people make cessation more difficult and reduce
readiness to quit [420, 491, 686, 739-741]. For example, it has been reported that HIV+ people
use smoking to cope with the stress of living with HIV and to relieve the side effects of HIV
treatment [420, 492]. Previous studies have reported that between 30 – 60% of HIV+ smokers
have attempted to quit since their HIV diagnosis [493, 686]. However, the motivation to quit in
HIV+ people is mixed [421, 493, 686], with studies reporting variable estimates of the proportion
of HIV+ people interested in quitting as well as readiness to quit [421, 493, 686, 742]. In addition,
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studies have shown that HIV+ people are less likely to quit than the general population [743,
744].
Aims and objectives
Despite the well characterised harms of smoking in HIV+ people, the clinical benefits of smoking
cessation on cancer risk have not, to my knowledge, been reported in large epidemiological
studies. The aim of this study was to estimate cancer rates after smoking cessation in HIV+
people from the D:A:D study.
Methods
Study design and participants
This study was conducted within the Data Collection on Adverse events of Anti-HIV Drugs Study
(D:A:D) collaboration using the 17th merger the D:A:D database (which included follow-up on
49,706 people). AIDS defining cancers (ADC), including Kaposi’s sarcoma (KS), invasive cervical
cancers, and non-Hodgkin lymphoma (NHL) have been collected in D:A:D as such since 1999.
NADCs, including lung, anal, and Hodgkin lymphoma (HL), have been routinely collected and
validated since 1 January 2004. The D:A:D study is described in detail in chapter 2 section 2.1.2.
Outcomes
Four main outcomes were assessed: 1. the first diagnosis of any cancer during prospective
follow-up (referred to as all cancers). Cancers were further divided into the categories: (2) lung
cancer, (3) any smoking related cancer (excluding lung), including cancers of the head and neck,
oesophagus, stomach, pancreas, liver, kidney and urinary, colon and rectal, cervical, ovary, acute
myeloid leukaemia and chronic myeloid leukaemia [477]. Finally, all remaining cancers not
included in (2) and (3) were considered to be smoking unrelated. The cancers considered to be
smoking related were selected based on the IARC Monographs on the Evaluation of Carcinogenic
Risks to Humans [477]. These cancers have been causally linked with smoking. A list of cancers
included in each group are listed in Table 4.1.
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Table 4.1 The classification of cancers into lung cancers, smoking related cancers (excluding lung), and smoking
unrelated cancers in D:A:D.
Lung cancer Smoking related cancers (excluding lung)1 Smoking unrelated cancers
lung acute myeloid leukaemia (AML) anal
chronic myeloid leukaemia (CML) bladder
cervical bone
colon and rectal breast
head and neck connective tissue
kidney and urinary gallbladder
liver Hodgkin lymphoma (HL)
oesophagus Kaposi's sarcoma (KS)
ovary acute lymphoid leukaemia
pancreas unspecified leukaemia
stomach lip
malignant melanoma
multiple myeloma
non-Hodgkin lymphoma (NHL)
penis
prostate
testicular
uterus
other, unspecified or unknown
1 Smoking related cancers were selected in accordance with the IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans
Inclusion criteria
Baseline was defined as the latest of date of study entry or 1 st January 2004, and people were
followed from baseline until the earliest of their first cancer diagnosis, last visit plus 6 months,
death, or 1st February 2016.
There were 42,334 D:A:D people with follow-up after the 1 January 2004. I excluded a total of
6,892 people, where 2,422 people had a prior cancer diagnosis (including 16 had a first diagnosis
of metastatic cancer), 4,463 had no smoking information during follow-up, and 7 had no
recorded gender. This resulted in 35,442 people available for analysis. Those excluded were
older, and a higher proportion were male compared to those included. A flow chart for the
inclusion criteria is shown in Figure 4.1.
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Figure 4.1 Flow chart for inclusion of D:A:D participants in analysis
Current smoking status and time since cessation
Smoking status was collected by the individual cohorts and reported to D:A:D study
electronically using the using the HICDEP data exchange protocol on a bi-annual basis [550] (as
mentioned in chapter 2 section 2.1.2.4). Smoking status was reported as current smoker
(yes/no) and ever smoker (yes/no) at each visit based on physician inquiry at each center. In this
chapter, smoking status was considered as a time updated variable. The categorisation of the
variable is shown in Figure 4.2 and was defined as: never smokers, current smokers, ex smokers
at baseline, and ex smokers who stopped smoking during prospective follow-up. The ex smokers
were split in this way as the date of stopping smoking was not available in those who stopped
prior to baseline, and therefore, time since cessation could not be determined. For those who
stopped smoking during follow-up, time since smoking cessation was further categorised into
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those who stopped <1 year, 1 – 1.9 years, 2 – 2.9 years, 3 – 3.9 years, 4 – 4.9 years, and ≥5 years 
prior. For example, at a specific point during follow-up, a person who quit smoking 1.5 years
prior but during prospective follow-up would be in the ex smokers: 1 – 1.9 years category. If they
restarted smoking, they would then move from the ex smokers category to the current smokers
category. If they ceased smoking again, they would move back to the ex smokers category and
their time since cessation would restart at zero i.e. the ex smokers: < 1 year category. Change in
smoking behaviour was attributed to the midpoint of respective visits. If smoking status was
missing at any visit, the most recently recorded previous smoking status was carried forward.
Duration of smoking in D:A:D was calculated as the cumulative number of years spent as a
current smoker during active D:A:D follow-up.
Figure 4.2 definition of current smoking status.
Baseline was defined as latest of date of study entry or 1st January 2004.
1 Smoking status represents current smoking behaviour and is time updated
2 Information on the date of stopping was not available and therefore time since stopping for
previous smokers at baseline could not be determined
Variables included in analyses
Both baseline and time updated variables from the D:A:D database were included in this
analysis, as detailed in Table 4.2. Person years of follow-up (PYFU) were calculated per month
of additional follow-up.
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Table 4.2 Summary of baseline and time updated variables.
Variable Time
updated
Levels Definitions and comments
Age (years) Yes Continuous (per 10 years
older) and
categorised into 16 – 39,
40 – 49, ≥ 50 years 
Calendar year of
baseline
Continuous (per year)
and categorised by year
(2004 – 2005, 2006 –
2007, 2008 – 2009, 2010
– 2011, 2012 – 2016)
Calendar year of
follow-up
Yes Continuous (per year)
Ethnicity white, black or other, or
unknown
For multivariate analyses the categories
“black or other”, and “unknown” were
combined into one category called “non-
white” due to low numbers.
Gender Male, female
HIV mode of
transmission
Sex between men,
heterosexual, IDU, other
or unknown
BMI (kg/m2) Yes Under weight (<18),
normal weight (18 – 25),
Over weight (25 – 30),
obese( 30+)
Classified according to the WHO standard
[597]
Smoking status Yes Never smokers, current
smokers, ex smokers at
baseline, ex smokers
during follow-up: < 1, 1 –
2 smokers, 2 – 3, 3 – 5, >
5 years since cessation
See Figure 4.2
Current CD4 cell
count
(cells/mm3)
Yes Continuous (per 2-fold
higher) and <200, 200 –
349, 350 – 499, ≥500 
cells/mm3, unknown
Nadir CD4 cell
count (cells/
mm3)
Yes Continuous and included
in baseline tables only
Lowest recorded CD4 cell count
measurement prior to date
Current HIV-VL
(copies/mL)
Yes Continuous (per 10-fold
higher) and <400, ≥ 400 
copies/mL, unknown
Prior AIDS
defining event
(excluding ADC)
Yes Yes , no Classified according to the 1993 CDC
clinical definition [133]
Prior
cardiovascular
disease (CVD)
Yes Yes , no Defined as whether the person ever had a
diagnosis since entry into D:A:D.
Hypertension Yes Yes, no Defined as ever having Systolic BP >140,
Diastolic BP >90 mm Hg or receiving any
antihypertensive drugs or ACE inhibitors
since entry into D:A:D
Diabetes Yes Yes, no Defined as a reported diabetes diagnosis
on a case-report form or use of anti-
diabetic medication since entry into D:A:D
Severe anaemia Yes Yes, no Haemoglobin < 8 g/dl since entry into
D:A:D
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HBV status Yes Positive, prior, negative,
or unknown
Positive HBV status was defined by a prior
positive HBsAG surface antigen test or
presence of detectable HBV DNA, Prior
HBV status was defined by a prior positive
HBsAG surface antigen test or presence of
detectable HBV DNA, with a negative
latest HBsAG surface antigen test and/or
undetectable HBV DNA.
HCV status Yes Positive, negative, or
unknown
Positive HCV status was defined as having
a prior positive HCV surface antibody test.
cART use Yes On cART, not on cART,
unknown
Defined as being on at least 1 protease
inhibitor [PI] or non-nucleoside reverse
transcriptase inhibitor [NNRTI].
Cumulative
smoking
duration
Yes Continuous (per year
longer)
Accumulated time as a current smoker
since entry into D:A:D.
IDU: injecting drug use, BMI: Body mass index, HIV-VL: HIV viral load, ADC: AIDS defining cancer, HBV: Hepatitis B,
HCV; Hepatitis C, cART combination antiretroviral therapy.
Statistical analysis
Characteristics at baseline
The characteristics of all people included in this analysis and those who experienced each of
the four cancer outcomes during follow-up were described using numbers and percentages for
categorical variables and median with interquartile range (IQR) for numerical variables at
baseline. All bivariate associations were tested using chi squared tests for categorical variables
and Kruskal-Wallis tests for numerical variables.
Incidence rates of cancer
Incidence rates per 1000 PYFU of each cancer outcome were calculated according to key
variables of interest. These included current calendar year of follow-up and smoking status.
The association between smoking status and cancer
Poisson regression models were used to explore the association between time-updated smoking
status and each outcome separately. The main exposure of interest was smoking status with a
focus on time since cessation. Models were adjusted for baseline and time varying factors listed
in Table 4.2. All variables included in the models were identified a priori based on expert clinical
input, availability of data, and the published literature. A priori, I was additionally interested in
interactions between smoking status and gender, HIV mode of transmission, age and CD4 cell
count. Sensitivity analyses were also performed omitting all periods of follow-up where smoking
status was missing or not updated for more than 2 years, excluding those with unknown or
167
unspecified cancer type, and adjusting for baseline calendar year instead of current calendar
year.
All statistical tests were two sided and a type I error rate of 5%. All statistical analyses were
performed using SAS 9.4 (Statistical Analysis Software, Cary NC, USA).
Results
There were 35,442 people included in the analysis who contributed 309,803 PYFU with a median
follow-up of 9.9 (IQR: 6.7, 12.0) years per person. Of the 35,442 people included, 2,183 people
developed a cancer during follow-up and the distribution of cancers are shown in Figure 4.3. Of
these, 271 (12%) were lung cancers, 577 (26%) were other smoking related cancers (excluding
lung), and 1,335 (61%) were smoking unrelated cancers. The most common smoking related
cancers (excluding lung) were head and neck cancers (N=139, 24%), liver cancer (N= 136, 24%),
cervical cancers (N= 57, 10%) and colon and rectal cancers (N= 47, 8%). The most common
smoking unrelated cancers were NHL (N=301, 23%), KS (N=276, 21%), anal cancers (N=158, 12%)
and Prostate cancers (N=131, 10%).
Figure 4.3 The distribution of lung cancers, smoking related cancers (excluding lung), and smoking unrelated
cancers in D:A:D.
1 Smoking related cancers were selected in accordance with the IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans
Baseline characteristics
Baseline characteristics of the study population, as well as those who developed cancer during
follow are shown in Table 4.3. Overall, 16.6% of people were aged ≥ 50 years at baseline with a 
median age of 40 (IQR 34, 46) years, 72.6% were of male gender, 53.2% were of white ethnicity
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(37.1% were missing ethnicity information), and 41.9% acquired their HIV through sex between
men. Just under three quarters had a baseline date in 2004 or 2005. Approximately two thirds
of people had a BMI within the healthy range: 18 – 26 and 1 in 5 people had a previous AIDS
defining event (excluding ADCs). 18.3% of people had ever had hepatitis B (HBV) and 21.0% had
ever had hepatitis C (HCV). A history of CVD, diabetes, hypertension, or severe anaemia was
reported in 2.1%, 2.5%, 14.4% and 19.3% of the study population, respectively. Just over half
were on cART (52.0%) at baseline, 40.6% had a HIV viral load (HIV-VL) of ≤ 50 copies/mL and a 
median CD4 cell count of 444 (294,632) cells/mm3.
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Table 4.3 Baseline1 characteristics of D:A:D participants included in the analysis
Factors All includedpersons
People who developed a cancer during follow-up
All cancers Lung cancer Other smoking related cancers(excluding lung)
Smoking unrelated
cancers
N (%) 35,442 ( 100) 2,183 ( 100) 271 ( 100) 577 ( 100) 1,335 ( 100)
Age (years)
<30 5,063 (14.3) 109 ( 5.0) 1 ( 0.4) 18 ( 3.1) 90 ( 6.7)
30 - 39 12,955 (36.6) 518 (23.7) 37 (13.7) 108 (18.7) 373 (27.9)
40 - 49 11,530 (32.5) 829 (38.0) 105 (38.7) 258 (44.7) 466 (34.9)
50 - 59 4,265 (12.0) 486 (22.3) 92 (33.9) 126 (21.8) 268 (20.1)
    ≥60 1,629 ( 4.6) 241 (11.0) 36 (13.3) 67 (11.6) 138 (10.3)
Male 25,717 (72.6) 1,723 (78.9) 217 (80.1) 410 (71.1) 1,096 (82.1)
HIV risk group
Homosexual 14,845 (41.9) 1,033 (47.3) 118 (43.5) 180 (31.2) 735 (55.1)
IDU 5,753 (16.2) 378 (17.3) 59 (21.8) 164 (28.4) 155 (11.6)
Heterosexual 12,796 (36.1) 632 (29.0) 77 (28.4) 194 (33.6) 361 (27.0)
Unknown 2,048 ( 5.8) 140 ( 6.4) 17 ( 6.3) 39 ( 6.8) 84 ( 6.3)
Ethnicity
White 18,872 (53.2) 1,071 (49.1) 135 (49.8) 291 (50.4) 645 (48.3)
Black, other 3,437 ( 9.7) 100 ( 4.6) 4 ( 1.5) 32 ( 5.5) 64 ( 4.8)
Unknown 13,133 (37.1) 1,012 (46.4) 132 (48.7) 254 (44.0) 626 (46.9)
BMI (kg/m2)
<18 1,210 ( 3.4) 100 ( 4.6) 22 ( 8.1) 32 ( 5.5) 46 ( 3.4)
18 - 26 24,150 (68.1) 1,541 (70.6) 195 (72.0) 406 (70.4) 940 (70.4)
27 - 30 4,630 (13.1) 268 (12.3) 22 ( 8.1) 74 (12.8) 172 (12.9)
>30 1,575 ( 4.4) 87 ( 4.0) 9 ( 3.3) 21 ( 3.6) 57 ( 4.3)
unknown 3,877 (10.9) 187 ( 8.6) 23 ( 8.5) 44 ( 7.6) 120 ( 9.0)
Baseline Year
2004 - 2005 25,790 (72.8) 1,766 (80.9) 232 (85.6) 509 (88.2) 1,025 (76.8)
2006 - 2007 4,980 (14.1) 255 (11.7) 24 ( 8.9) 46 ( 8.0) 185 (13.9)
2008 - 2009 4,453 (12.6) 158 ( 7.2) 14 ( 5.2) 21 ( 3.6) 123 ( 9.2)
2010 - 2011 111 ( 0.3) 1 ( 0.0) 0 ( 0.0) 0 ( 0.0) 1 ( 0.1)
2012 - 2015 108 ( 0.3) 3 ( 0.1) 1 ( 0.4) 1 ( 0.2) 1 ( 0.1)
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HIV-VL (copies/mL)
    ≤ 50 14,405 (40.6) 892 (40.9) 143 (52.8) 300 (52.0) 449 (33.6)
51 - 1,000 5,165 (14.6) 291 (13.3) 40 (14.8) 95 (16.5) 156 (11.7)
1,001 - 10,000 4,135 (11.7) 240 (11.0) 25 ( 9.2) 54 ( 9.4) 161 (12.1)
10,001 - 100,000 6,682 (18.9) 454 (20.8) 41 (15.1) 72 (12.5) 341 (25.5)
>100,001 2,627 ( 7.4) 212 ( 9.7) 13 ( 4.8) 41 ( 7.1) 158 (11.8)
Unknown 2,428 ( 6.9) 94 ( 4.3) 9 ( 3.3) 15 ( 2.6) 70 ( 5.2)
CD4 cell count (cells/mm3)
<100 1,551 ( 4.4) 148 ( 6.8) 12 ( 4.4) 41 ( 7.1) 95 ( 7.1)
100 - 199 2,666 ( 7.5) 216 ( 9.9) 33 (12.2) 58 (10.1) 125 ( 9.4)
200 - 299 4,420 (12.5) 298 (13.7) 43 (15.9) 80 (13.9) 175 (13.1)
300 - 399 5,699 (16.1) 323 (14.8) 35 (12.9) 77 (13.3) 211 (15.8)
400 - 499 5,387 (15.2) 299 (13.7) 38 (14.0) 79 (13.7) 182 (13.6)
    ≥ 500 14,117 (39.8) 823 (37.7) 106 (39.1) 227 (39.3) 490 (36.7)
Unknown 1,602 ( 4.5) 76 ( 3.5) 4 ( 1.5) 15 ( 2.6) 57 ( 4.3)
Previous AIDS defining event
(excluding ADC) 6,536 (18.4) 500 (22.9) 74 (27.3) 178 (30.8) 248 (18.6)
HBV
Negative 24,858 (70.1) 1,481 (67.8) 174 (64.2) 358 (62.0) 949 (71.1)
Positive 1,618 ( 4.6) 130 ( 6.0) 20 ( 7.4) 54 ( 9.4) 56 ( 4.2)
Prior 4,867 (13.7) 349 (16.0) 49 (18.1) 106 (18.4) 194 (14.5)
Unknown 4,099 (11.6) 223 (10.2) 28 (10.3) 59 (10.2) 136 (10.2)
HCV
Negative 23,139 (65.3) 1,430 (65.5) 171 (63.1) 315 (54.6) 944 (70.7)
Positive 7,434 (21.0) 493 (22.6) 74 (27.3) 204 (35.4) 215 (16.1)
Unknown 4,869 (13.7) 260 (11.9) 26 ( 9.6) 58 (10.1) 176 (13.2)
Prior CVD 740 ( 2.1) 83 ( 3.8) 17 ( 6.3) 21 ( 3.6) 45 ( 3.4)
Diabetes 874 ( 2.5) 92 ( 4.2) 12 ( 4.4) 25 ( 4.3) 55 ( 4.1)
Prior Hypertension 5,114 (14.4) 454 (20.8) 56 (20.7) 137 (23.7) 261 (19.6)
Severe anaemia 6,842 (19.3) 403 (18.5) 36 (13.3) 137 (23.7) 230 (17.2)
On cART
No 6,495 (18.3) 454 (20.8) 52 (19.2) 129 (22.4) 273 (20.4)
Yes 18,447 (52.0) 1,165 (53.4) 169 (62.4) 370 (64.1) 626 (46.9)
Unknown 10,500 (29.6) 564 (25.8) 50 (18.5) 78 (13.5) 436 (32.7)
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N Median(IQR) N Median(IQR) N Median(IQR) N Median(IQR) N Median(IQR)
Age (years) 35442 39.8 (33.8,46.2) 2183 44.7 (39.2,53.5) 271 49.6 (42.8,55.8) 577 45.4 (40.8,53.5) 1335 43.5 (37.9,52.6)
CD4 cell count (cells/mm3) 33840 444 (294,632) 2107 420 (255,616) 267 420 (250,672) 562 420 (250,620) 1278 420 (259,605)
Nadir CD4 cell count
(cells/mm3) 33840 247 (120,400) 2107 212 (90,359) 267 190 (86,309) 562 185 (70,313) 1278 234 (102,390)
HIV-VL (copies/mL) 33014 194 (<50,15685) 2089 224 (<50,23100) 262 <50 (<50,3000) 562 <50 (<50,3100) 1265 1870 (<50,39800)
BMI: body mass index, ADC: AIDS defining cancer, HBV: Hepatitis B, HCV: hepatitis C, cART: combination antiretroviral therapy, CVD: cardiovascular disease, HIV-VL:
HIV viral load, IQR: interquartile range.
1 Baseline defined as the latest of 1 January 2004 or entry into D:A:D
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The distribution of smoking status at baseline is shown Figure 4.4. Of the 35,442 people included
in the analysis, 49% were reported to be current smokers at baseline, 21% were previous
smokers and 30% were never smokers. A similar distribution in smoking behaviour is
demonstrated in those who went on to develop any cancer, smoking related cancers (excluding
lung) and smoking unrelated cancers during follow-up. However, those who went on to develop
lung cancer had a much higher proportion of people reported to be current smokers at baseline
(72%) and a much lower proportion were reported as never smokers (6%).
Figure 4.4 Smoking status at baseline1
1Baseline defined as the latest of 1 January 2004 or entry into D:A:D
Crude incidence of cancer
The overall crude incidence of all cancers combined was 7.05 (95%CI: 6.76, 7.35) events per 1000
PYFU. The crude incidence of lung cancers was 0.88 (95%CI: 0.78, 0.99) events per 1000 PYFU,
smoking related cancers (excluding lung) was 1.86 (95%CI: 1.72, 2.02) events per 1000 PYFU,
and smoking unrelated cancers was 4.31 (95%CI: 4.08, 4.55) events per 1000 PYFU.
Crude incidence of cancer by calendar year
The crude incidence by calendar year of all four cancer outcomes is shown in Figure 4.5. The
incidence of all cancers was stable over time (% change per year: -0.6%, 95%CI: -1.9, 0.6%,
unadjusted P for trend = 0.32). Crude incidence of lung cancer was also stable over time (%
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change per year: 0.0%, 95%CI: -3.7, 3.5%, unadjusted P for trend = 0.94). The crude incidence of
smoking related cancers (excluding lung) was increasing over time by 4.8% (95%CI: 2.2, 7.4%,
unadjusted P for trend <0.01) per year from 1.17 (0.79, 1.71) events per 1000 PYFU in 2004 to
1.86 (1.37, 2.54) events per 1000 PYFU in 2015/16. Conversely, the incidence of smoking
unrelated cancers declined by 3.0% (95%CI: 1.4, 4.5%, unadjusted P for trend <0.01) events per
1000 PYFU from 3.90 (95%CI: 3.16, 4.82) events per 1000 PYFU in 2004 to 2.38 (95%CI: 1.81,
3.13) events per 1000 PYFU in 2015/16.
Figure 4.5 Crude incidence rates of each cancer by calendar year
IR: incidence rate, PYFU: person years of follow-up.
The unadjusted percentage change per year (% change per year) incidence of each cancer outcome per
more recent calendar year is shown to the right of the graph.
Crude incidence of cancer by smoking status
The crude incidence of each outcome by current smoking status is shown in Figure 4.6 to Figure
4.9. It should be noted that the graphs are on different scales in order to clearly display the
associations. The corresponding frequencies and crude incidence rates for each cancer group
are shown in Table 4.4. The incidence of all cancers was highest within the first year of cessation
(Figure 4.6), after which the incidence declined to a similar level to current smokers and
remained stable thereafter (Unadjusted P for trend <0.01). Lung cancers incidence was
negligible in those who never smoked (Figure 4.7), with <1 event per 10,000 PYFU, but was highly
elevated in current smokers. Incidence was highest within the first year of cessation after which
the incidence declined to a similar level to current smokers and remained stable thereafter
(unadjusted P for trend =0.02). Incidence of smoking related cancers (excluding lung) was
highest in the first year after cessation, however incidence declined and thereafter (P for trend
= 0.34, Figure 4.8). Incidence of smoking unrelated cancers was stable for the first 3 years
following cessation, with a slight decline in incidence thereafter (for trend = 0.01, Figure 4.9).
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Figure 4.6 Crude incidence rate (IR) of all cancers by smoking status1 Figure 4.7 Crude incidence rate (IR) of lung cancer by smoking status1
Figure 4.8 Crude incidence rate (IR) of smoking related cancers (excl. lung) by smoking
status1
Figure 4.9 Crude incidence rate (IR) of smoking unrelated cancers by smoking status1
IR: incidence rate, PYFU: person years of follow-up.
1The left hand side of the graph shows the incidence in those who reported to be never smokers, current smokers and those who reported to be previous smokers prior to baseline.
The right hand side shows the crude incidence of cancer with increasing time since cessation in those who quit during active follow-up.
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Table 4.4 Crude incidence rate (IR) and unadjusted incidence rate ratio (IRR) of each cancer group
Smoking status
PYFU All cancers Lung cancers
N IR (95%CI)/1000 PYFU IRR (95%CI) P N IR (95%CI)/1000 PYFU IRR (95%CI) P
Total 309802.67 2183 7.05 ( 6.76, 7.35) 271 0.88 ( 0.78, 0.99)
Never 89818.48 463 5.16 ( 4.71, 5.65) Reference 7 0.08 ( 0.04, 0.16) Reference
Current smoker 31887.46 219 8.06 ( 7.59, 8.56) 1.56 (1.40,1.74) <0.01 163 1.26 ( 1.08, 1.46) 16.10 (7.55,34.30) <.001
previous smoker at baseline 129924.38 1047 6.87 ( 6.02, 7.84) 1.33 (1.13,1.56) <0.01 26 0.82 ( 0.56, 1.20) 10.46 (4.54,24.10) <.001
Ex: < 1 year 15222.8 155 10.18 ( 8.70,11.92) 1.98 (1.65,2.37) <0.01 27 1.77 ( 1.22, 2.59) 22.76 (9.91,52.26) <.001
Ex: 1 - 2 years 10372.76 77 7.42 ( 5.94, 9.28) 1.44 (1.13,1.83) <0.01 11 1.06 ( 0.59, 1.92) 13.61 (5.28,35.10) <.001
Ex: 2 - 3 years 8009.84 61 7.62 ( 5.93, 9.79) 1.48 (1.13,1.93) <0.01 9 1.12 ( 0.59, 2.16) 14.42 (5.37,38.71) <.001
Ex: 3 - 5 years 11581.43 82 7.08 ( 5.70, 8.79) 1.37 (1.09,1.74) 0.01 16 1.38 ( 0.85, 2.26) 17.73 (7.29,43.08) <.001
Ex: >5 years 12985.52 79 6.08 ( 4.88, 7.59) 1.18 (0.93,1.50) 0.17 12 0.92 ( 0.53, 1.63) 11.86 (4.67,30.13) <.001
Smoking status
PYFU Smoking related cancers (excl. lung) Smoking unrelated cancers
N IR (95%CI)/1000 PYFU IRR (95%CI) P N IR (95%CI)/1000 PYFU IRR (95%CI) P
Total 309802.67 577 1.86 ( 1.72, 2.02) 1335 4.31 ( 4.08, 4.55)
Never 89818.48 98 1.09 ( 0.90, 1.33) Reference 358 3.99 ( 3.59, 4.42) Reference
Current smoker 31887.46 273 2.10 ( 1.87, 2.37) 1.93 (1.53,2.43) <0.01 611 4.70 ( 4.34, 5.09) 1.18 (1.04,1.34) 0.01
previous smoker at baseline 129924.38 68 2.13 ( 1.68, 2.71) 1.95 (1.44,2.66) <0.01 125 3.92 ( 3.29, 4.67) 0.98 (0.80,1.21) 0.87
Ex: < 1 year 15222.8 50 3.29 ( 2.49, 4.33) 3.01 (2.14,4.23) <0.01 78 5.12 ( 4.10, 6.40) 1.29 (1.01,1.64) 0.05
Ex: 1 - 2 years 10372.76 20 1.93 ( 1.24, 2.99) 1.77 (1.09,2.86) 0.02 46 4.44 ( 3.32, 5.92) 1.11 (0.82,1.51) 0.5
Ex: 2 - 3 years 8009.84 12 1.50 ( 0.85, 2.64) 1.37 (0.75,2.50) 0.30 40 4.99 ( 3.66, 6.81) 1.25 (0.90,1.74) 0.18
Ex: 3 - 5 years 11581.43 28 2.42 ( 1.67, 3.50) 2.22 (1.46,3.37) <0.01 38 3.28 ( 2.39, 4.51) 0.82 (0.59,1.15) 0.25
Ex: >5 years 12985.52 28 2.16 ( 1.49, 3.12) 1.98 (1.30,3.01) 0.00 39 3.00 ( 2.19, 4.11) 0.75 (0.54,1.05) 0.09
IR: incidence rate, IRR: unadjusted incidence rate ratio, PYFU: person years of follow-up.
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The association between smoking cessation and cancer
The unadjusted IRRs of each cancer outcome for smoking status are shown in Table 4.4. The
adjusted IRRs (aIRR) are shown in Table 4.5. In order to give a visual representation for the
change in incidence with time since cessation, the adjusted associations are also displayed in
Figure 4.10, however, the graphs are on different scales in order to clearly display each
association. Of note, the scale for the aIRR of lung cancer spans from 0 to 32, whereas the scales
do not exceed 4 for all other cancers outcomes. Patterns of association were similar before and
after adjustment.
Figure 4.10 Adjusted incidence rate ratio (aIRR) according to smoking status with never smokers as the reference
category
Models were adjusted for age, calendar year, gender, ethnicity, HIV mode of transmission, body mass
index, current CD4 cell count, current HIV viral load, AIDS defining events (excluding AIDS defining
cancers), Hepatitis C and B coinfection, hypertension, anaemia, diabetes, cardiovascular disease,
combination antiretroviral therapy use, cumulative smoking duration during D:A:D follow-up.
After adjustment (Table 4.5), the incidence of all cancer combined was 1.24 (95%CI: 1.06, 1.45)-
fold higher in current smokers relative to never smokers. A similarly elevated incidence was
observed within one year of cessation relative to non-smokers, which declined with increasing
time since cessation (P for trend=0.03), to a level comparable to non-smokers after 1 - 2 years
of smoking cessation (aIRR: 1.25; 59%CI: 0.97, 1.61).
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Table 4.5 Adjusted incidence rate ratio (aIRR) according to smoking status with never smokers as the reference category
All cancer Lung cancer Smoking related cancers (excl.
lung)
Smoking unrelated cancers
Smoking status aIRR1 (95%CI) P P for
trend1
aIRR1 (95%CI) P P for
trend1
aIRR1 (95%CI) P P for
trend1
aIRR (95%CI) 1 P P for
trend1
Never reference reference reference reference
Current smoker 1.24 (1.06,1.45) 0.01 10.16 (4.46,23.12) <0.01 1.34 (0.97,1.85) 0.07 1.08 (0.89,1.31) 0.44
previous smoker at baseline 1.07 (0.91,1.27) 0.40 7.16 (3.10,16.56) <0.01 1.51 (1.10,2.08) 0.01 0.84 (0.68,1.04) 0.11
Ex: < 1 year 1.64 (1.35,2.00) <0.01 0.03 16.25 (6.86,38.49) <0.01 0.02 2.23 (1.52,3.27) <0.01 0.41 1.18 (0.91,1.52) 0.22 0.23
Ex: 1 - 2 years 1.25 (0.97,1.61) 0.08 10.25 (3.91,26.83) <0.01 1.34 (0.81,2.21) 0.25 1.07 (0.78,1.47) 0.69
Ex: 2 - 3 years 1.29 (0.98,1.70) 0.07 11.13 (4.10,30.20) <0.01 1.02 (0.55,1.89) 0.94 1.23 (0.87,1.72) 0.24
Ex: 3 - 5 years 1.24 (0.97,1.58) 0.08 14.44 (5.85,35.67) <0.01 1.60 (1.03,2.50) 0.04 0.85 (0.60,1.19) 0.35
Ex: >5 years 1.07 (0.84,1.37) 0.59 10.65 (4.11,27.59) <0.01 1.44 (0.93,2.22) 0.10 0.77 (0.55,1.08) 0.13
1 Models were adjusted for age, calendar year, gender, ethnicity, HIV mode of transmission, BMI, current CD4 cell count, current HIV-VL, AIDS defining events (excluding ADC), HCV
coinfection, HBV coinfection, hypertension, anaemia, diabetes, CVD, cART use, cumulative smoking duration during D:A:D follow-up.
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Lung cancer incidence was more than 10-fold higher in current smokers relative to never
smokers (aIRR: 10.16; 95%CI: 4.46, 23.12, Table 4.5). In those who ceased smoking during follow-
up, the incidence was more than 16-fold higher in the first year following cessation, however,
the incidence then quickly returned to approximately 10-fold higher after 1 - 2 years of cessation
and remained stable thereafter. I also looked at the aIRR using current smoking as the reference
category (see Table 4.6) and the incidence of lung cancer was not different to current smokers
after the first year, and even after >5 years (aIRR: 1.05 95%CI: 0.52, 2.10). Although the P for
trend was significant (P=0.03), this was driven by the increase in the first year and there was no
evidence of a decline thereafter.
Table 4.6 Adjusted incidence rate ratio (aIRR) of lung cancer according to smoking status with current smokers as
the reference category
Smoking status aIRR (95%CI) 1 P
Never 0.1(0.04, 0.22) <0.01
Current smoker Reference
previous smoker at baseline 0.71(0.43, 1.15) 0.16
Ex: < 1 year 1.60(1.05, 2.44) 0.03
Ex: 1 - 2 years 1.01(0.53, 1.91) 0.98
Ex: 2 - 3 years 1.10(0.54, 2.21) 0.78
Ex: 3 - 5 years 1.42(0.79, 2.54) 0.24
Ex: >5 years 1.05(0.52, 2.10) 0.89
1 Models were adjusted for age, calendar year, gender, ethnicity, HIV mode of transmission, BMI, current
CD4 cell count, current HIV-VL, AIDS defining events (excluding ADC), HCV coinfection, HBV coinfection,
hypertension, anaemia, diabetes, CVD, cART use, cumulative smoking duration during D:A:D follow-up.
Incidence of smoking related cancers (excluding lung) was highest within the first year of
smoking cessation (aIRR: 2.23 95%CI: 1.52, 3.73, Table 4.5) and returned to a level similar to
never smokers after 1-2 year of smoking cessation (aIRR: 1.34 95%CI: 0.81, 2.21). However it
should be noted that the magnitude of association in this group was similar to that of current
smokers (aIRR: 1.34 95%CI: 0.97, 1.85), and the magnitude was even higher in those who quit
more than 3 years prior. Incidence of smoking unrelated cancers did not vary according to
smoking status (global P=0.13) and there was no change with increasing time since cessation (P
for trend = 0.23).
Smoking cessation and cancer incidence by gender, age, and CD4 cell
count
The association between current smoking status and all cancers combined differed between
genders (P for interaction <0.01), however this was not detectable for individual cancer
outcomes. The association according to gender is shown in Figure 4.11. In females, incidence of
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all cancers was 1.88 (95%CI: 1.40, 2.52)-fold higher in current smokers relative to never smokers,
and remained similarly elevated for 2 years after cessation, after which incidence declined to a
level similar to never smokers. In males, incidence was not elevated in current smokers but was
1.55 (95%CI: 1.21, 2.0)-fold higher in in the first year of smoking cessation and returned to a
level similar to never smokers thereafter (1.05 95%CI: 0.77, 1.44). The association between
smoking status and all cancers combined did not vary according to age, HIV mode of
transmission, or CD4 cell count (all P for interaction > 0.05). There was no significant interactions
between age, HIV mode of transmission, and CD4 cell count and smoking status for lung cancers,
smoking related cancers (excluding lung) and smoking unrelated cancers (all P for interaction>
0.05).
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Figure 4.11 aIRR of lung cancer according to smoking status by gender
aIRR: Adjusted incidence rate ratio.
1 Models were adjusted for Age, calendar year, gender, ethnicity, HIV mode of transmission, body mass index, current CD4 cell count, current HIV-VL, AIDS defining events (excluding
AIDS defining cancers), Hepatitis B and C coinfection, hypertension, anaemia, diabetes, cardiovascular disease, combination antiretroviral therapy use, cumulative smoking duration
during D:A:D follow-up
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Other associations with cancer incidence
The aIRR for each outcome across various risk factors is shown in Table 4.7 to Table 4.10. It
should be noted that these tables display the other associations from the same model used for
the associations with smoking status shown in Table 4.5 and Figure 4.10.
4.3.4.1.1 All cancers combined
After adjustment, incidence of all cancers combined (Table 4.7) increased with older age, and
was lower in females relative to males. Higher incidence was also observed for lower CD4 cell
count, in those with a BMI < 18, current HIV-VL > 1,000 copies/mL, a prior AIDS defining diagnosis
(excluding ADC), a history of diabetes or hypertension, and in those with severe anaemia. Longer
cumulative smoking duration during D:A:D follow-up was also associated with higher cancer risk.
Incidence was lower in those who acquired HIV through heterosexual sex (relative to sex
between men). There was no association with ethnicity, cART use, HBV or HCV coinfection, or a
history of CVD.
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Table 4.7 Adjusted incidence rate ratios (aIRR) for all cancers combined
Factor aIRR1 (95%CI) P Factor aIRR1 (95%CI) P
age (years) Current HIV-VL (copies/mL)
<40 reference ≤50 reference
40 - 49 1.82 (1.59,2.08) <.001 51 - 1,000 1.07 (0.94,1.22) 0.322
≥ 50 3.64 (3.18,4.17) <.001 >1,000 1.66 (1.45,1.90) <.001
Calendar year 0.98 (0.97,1.00) 0.023 Unknown 0.90 (0.48,1.68) 0.734
Female 0.83 (0.72,0.94) 0.005 HCV coinfection
Non-white ethnicity 1.08 (0.98,1.18) 0.128 Positive 0.95 (0.82,1.10) 0.494
HIV mode of transmission Negative reference
Sex between men reference Unknown 0.74 (0.59,0.94) 0.012
IDU 0.94 (0.78,1.12) 0.489 HBV coinfection
Heterosexual 0.77 (0.69,0.87) <.001 Positive/prior 1.00 (0.90,1.12) 0.938
Unknown 0.97 (0.80,1.17) 0.724 Negative reference
BMI (kg/m2) Unknown 1.04 (0.85,1.28) 0.714
<18 1.45 (1.21,1.73) <.001 Hypertension 1.16 (1.06,1.28) 0.002
18 - 26 reference Anaemia
27 - 30 0.77 (0.68,0.88) <.001 severe anaemia 1.87 (1.67,2.10) <.001
>30 0.74 (0.61,0.89) 0.002 mild anaemia/normal reference
unknown 0.85 (0.68,1.06) 0.144 Unknown 1.23 (1.07,1.40) 0.003
Current CD4 cell count (cells/mm3) cART use
<100 4.09 (3.38,4.96) <.001 No 0.92 (0.81,1.05) 0.233
100 - 199 2.23 (1.87,2.66) <.001 Yes reference
200 - 299 1.86 (1.61,2.15) <.001 Unknown 1.15 (0.95,1.39) 0.145
300 - 399 1.62 (1.43,1.84) <.001 AIDS defining event (excl. ADC) 1.15 (1.05,1.27) 0.004
400 - 499 1.37 (1.21,1.56) <.001 Diabetes 1.38 (1.19,1.60) <.001
≥ 500 reference CVD 1.12 (0.95,1.33) 0.188
Unknown 4.26 (1.86,9.75) <.001 Cumulative smoking duration in D:A:D 1.03 (1.01,1.05) <.001
aIRR: adjusted incidence rate ratio, IDU: injecting drug use, BMI: Body mass index, HIV-VL: HIV viral load, HCV: hepatitis C, HBV: hepatitis B, cART: combination
antiretroviral therapy, ADC: AIDS defining cancer, CVD: cardiovascular disease.
1Adjusted for all variables in the table and smoking status
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4.3.4.1.2 Lung cancers
After adjustment, Incidence of lung cancers (Table 4.8) increased markedly with older age and
was higher in those with a BMI < 18. Higher incidence was also observed for lower CD4 cell
count, with elevated incidence in those with CD4 < 300 cells/mm3 relative to CD4 ≥ 500 
cells/mm3. Incidence increased by 7 (95%CI: 3, 12)% with each additional year of cumulative
smoking duration during follow-up in D:A:D. There was no association with gender, ethnicity,
HIV mode of transmission, current HIV-VL, HCV or HBV coinfection, prior AIDS defining events
(excluding ADC), hypertension, diabetes, anaemia, CVD, or cART use.
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Table 4.8 Adjusted incidence rate ratios (aIRR) for lung cancers
Factor aIRR1 (95%CI) P Factor aIRR1 (95%CI) P
age (years) Current HIV-VL (copies/mL)
<40 reference ≤50 reference
40 - 49 9.23 (3.94,21.63) <.001 51 - 1,000 0.96 (0.66,1.40) 0.837
≥ 50 29.35 (12.62,68.24) <.001 >1,000 0.96 (0.61,1.51) 0.861
Calendar year 0.92 (0.88,0.96) <.001 Unknown 0.44 (0.12,1.56) 0.202
Female 1.01 (0.70,1.46) 0.938 HCV coinfection
Non-white ethnicity 1.14 (0.87,1.48) 0.343 Positive 0.86 (0.57,1.31) 0.494
HIV mode of transmission Negative reference
Sex between men reference Unknown 0.38 (0.16,0.88) 0.024
IDU 1.17 (0.69,1.98) 0.567 HBV coinfection
Heterosexual 1.01 (0.72,1.41) 0.953 Positive/prior 1.07 (0.78,1.45) 0.68
Unknown 1.16 (0.69,1.97) 0.571 Negative reference
BMI (kg/m2) Unknown 1.57 (0.89,2.75) 0.117
<18 2.42 (1.61,3.63) <.001 Hypertension 1.14 (0.86,1.50) 0.369
18 - 26 reference Anaemia
27 - 30 0.77 (0.54,1.12) 0.17 severe anaemia 1.26 (0.90,1.78) 0.179
>30 0.57 (0.29,1.11) 0.099 mild anaemia/normal reference
unknown 1.56 (0.91,2.67) 0.103 Unknown 1.23 (0.85,1.77) 0.267
Current CD4 cell count (cells/mm3) cART use
<100 2.60 (1.23,5.49) 0.012 No 1.03 (0.71,1.49) 0.872
100 - 199 2.34 (1.41,3.90) 0.001 Yes reference
200 - 299 2.69 (1.86,3.91) <.001 Unknown 1.27 (0.69,2.35) 0.445
300 - 399 1.92 (1.34,2.75) <.001 AIDS defining event (excl. ADC) 1.26 (0.97,1.64) 0.082
400 - 499 1.69 (1.20,2.39) 0.003 Diabetes 1.29 (0.85,1.95) 0.228
≥ 500 reference CVD 1.24 (0.80,1.90) 0.339
Unknown 10.73 (3.18,36.23) <.001 Cumulative smoking duration in D:A:D 1.07 (1.03,1.12) 0.001
aIRR: adjusted incidence rate ratio, IDU: injecting drug use, BMI: Body mass index, HIV-VL: HIV viral load, HCV: hepatitis C, HBV: hepatitis B, cART: combination
antiretroviral therapy, ADC: AIDS defining cancer, CVD: cardiovascular disease.
1Adjusted for all variables in the table and smoking status
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4.3.4.1.3 Smoking related cancers (excluding lung)
After adjustment, Incidence of smoking related cancers (excluding lung) (Table 4.9) increased
with older age, was higher in those with a BMI < 18, and in those who acquired HIV through IDU
or heterosexual sex (relative to sex between men). Incidence also declined with lower CD4 cell
count, with the highest incidence in those with a CD4 cell count of 100 – 199 cells/mm3.
Incidence was elevated in those who were HCV coinfected, had a history of hypertension,
diabetes, or severe anaemia, or a prior AIDS defining event (excluding ADC). Incidence increased
by 4 (95%CI: 1, 7) % per year for each additional year of cumulative smoking duration. Incidence
was not associated with gender, ethnicity, Current HIV-VL, HBV coinfection, a history of CVD, or
cART use.
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Table 4.9 Adjusted incidence rate ratios (aIRR) for smoking related cancers (excluding lung)
Factor aIRR1 (95%CI) P Factor aIRR1 (95%CI) P
age (years) Current HIV-VL (copies/mL)
<40 reference ≤50 reference
40 - 49 3.63 (2.53,5.21) <.001 51 - 1,000 0.93 (0.72,1.20) 0.577
≥ 50 7.69 (5.36,11.03) <.001 >1,000 1.04 (0.77,1.41) 0.796
Calendar year 0.99 (0.97,1.02) 0.627 Unknown 0.64 (0.18,2.35) 0.505
Female 1.05 (0.84,1.31) 0.662 HCV coinfection
Non-white ethnicity 1.18 (0.99,1.41) 0.071 Positive 1.37 (1.04,1.81) 0.023
HIV mode of transmission Negative reference
Sex between men reference Unknown 0.92 (0.57,1.48) 0.726
IDU 1.65 (1.19,2.31) 0.003 HBV coinfection
Heterosexual 1.26 (1.00,1.59) 0.053 Positive/prior 1.14 (0.93,1.40) 0.212
Unknown 1.36 (0.95,1.96) 0.096 Negative reference
BMI (kg/m2) Unknown 0.78 (0.49,1.24) 0.302
<18 1.52 (1.10,2.09) 0.011 Hypertension 1.44 (1.20,1.73) <.001
18 - 26 reference Anaemia
27 - 30 0.82 (0.65,1.05) 0.113 severe anaemia 2.00 (1.62,2.46) <.001
>30 0.74 (0.51,1.06) 0.101 mild anaemia/normal reference
unknown 0.87 (0.55,1.37) 0.539 Unknown 0.98 (0.73,1.32) 0.898
Current CD4 cell count (cells/mm3) cART use
<100 1.97 (1.22,3.17) 0.005 No 0.80 (0.62,1.04) 0.102
100 - 199 2.22 (1.63,3.03) <.001 Yes reference
200 - 299 1.62 (1.23,2.13) <.001 Unknown 1.04 (0.65,1.66) 0.861
300 - 399 1.40 (1.09,1.80) 0.009 AIDS defining event (excl. ADC) 1.43 (1.20,1.70) <.001
400 - 499 1.01 (0.77,1.31) 0.968 Diabetes 1.61 (1.24,2.07) <.001
≥ 500 reference CVD 1.17 (0.87,1.58) 0.296
Unknown 6.75 (1.55,29.39) 0.011 Cumulative smoking duration in D:A:D 1.04 (1.01,1.07) 0.006
aIRR: adjusted incidence rate ratio, IDU: injecting drug use, BMI: Body mass index, HIV-VL: HIV viral load, HCV: hepatitis C, HBV: hepatitis B, cART: combination
antiretroviral therapy, ADC: AIDS defining cancer, CVD: cardiovascular disease.
1Adjusted for all variables in the table and smoking status
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4.3.4.1.4 Smoking unrelated cancers
After adjustment, Incidence of smoking unrelated cancers (Table 4.10). Incidence was increased
with older age, however the association was much more modest than for lung cancers and
smoking related cancers (excluding lung). Incidence was lower in females, those who acquired
HIV through IDU or heterosexual sex (relative to sex between men), those with a BMI of 27 or
higher, and HCV coinfected people. Incidence increased strongly with lower CD4 cell count, and
higher HIV-VL, and a history of severe anaemia or diabetes. Incidence was not associated with
ethnicity, HBV coinfection, a prior AIDS defining event, a history of hypertension or CVD, cART
use, or cumulative duration of smoking while under follow-up in D:A:D.
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Table 4.10 Adjusted incidence rate ratios (aIRR) for smoking unrelated cancers
Factor aIRR1 (95%CI) P Factor aIRR1 (95%CI) P
age (years) Current HIV-VL (copies/mL)
<40 reference ≤50 reference
40 - 49 1.41 (1.21,1.64) <.001 51 - 1,000 1.19 (1.01,1.42) 0.042
≥ 50 2.48 (2.11,2.90) <.001 >1,000 2.12 (1.79,2.51) <.001
Calendar year 0.99 (0.97,1.01) 0.324 Unknown 1.26 (0.59,2.66) 0.549
Female 0.69 (0.57,0.82) <.001 HCV coinfection
Non-white ethnicity 1.01 (0.89,1.14) 0.864 Positive 0.80 (0.65,0.97) 0.026
HIV mode of transmission Negative reference
Sex between men reference Unknown 0.76 (0.58,1.01) 0.055
IDU 0.66 (0.51,0.85) 0.001 HBV coinfection
Heterosexual 0.63 (0.54,0.73) <.001 Positive/prior 0.92 (0.80,1.07) 0.291
Unknown 0.85 (0.67,1.08) 0.182 Negative reference
BMI (kg/m2) Unknown 1.05 (0.81,1.36) 0.701
<18 1.12 (0.86,1.47) 0.392 Hypertension 1.05 (0.93,1.20) 0.429
18 - 26 reference Anaemia
27 - 30 0.76 (0.65,0.90) 0.001 severe anaemia 2.00 (1.72,2.32) <.001
>30 0.78 (0.61,1.00) 0.047 mild anaemia/normal reference
unknown 0.75 (0.57,1.00) 0.047 Unknown 1.31 (1.11,1.54) 0.001
Current CD4 cell count (cells/mm3) cART use
<100 5.63 (4.50,7.03) <.001 No 0.96 (0.81,1.13) 0.594
100 - 199 2.23 (1.76,2.83) <.001 Yes reference
200 - 299 1.84 (1.52,2.22) <.001 Unknown 1.07 (0.86,1.34) 0.534
300 - 399 1.68 (1.43,1.98) <.001 AIDS defining event (excl. ADC) 1.00 (0.88,1.14) 0.985
400 - 499 1.49 (1.27,1.74) <.001 Diabetes 1.29 (1.05,1.59) 0.015
≥ 500 reference CVD 1.06 (0.83,1.34) 0.652
Unknown 3.39 (1.18,9.73) 0.023 Cumulative smoking duration in D:A:D 1.01 (0.99,1.03) 0.285
aIRR: adjusted incidence rate ratio, IDU: injecting drug use, BMI: Body mass index, HIV-VL: HIV viral load, HCV: hepatitis C, HBV: hepatitis B, cART: combination
antiretroviral therapy, ADC: AIDS defining cancer, CVD: cardiovascular disease.
1Adjusted for all variables in the table and smoking status
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Sensitivity analyses
Results were consistent after removing follow-up with missing smoking status or > 2 years
since last reported smoking status, excluding those with unknown or unspecified cancer type,
and adjusting for baseline calendar year instead of current calendar year.
Discussion
To my knowledge, the results presented in this chapter are the first to show the impact of
smoking cessation on cancer incidence in the HIV+ population, in a large observational study
with a relatively large number of prospectively collected cancers. In this chapter, I have shown
that lung cancer incidence remains highly elevated in HIV+ people at a level similar to current
smokers >5 years after cessation. Lung cancer incidence fell after the first year of cessation,
however, no decline was evident thereafter and incidence remained more than 10-fold higher
than never smokers. In contrast, incidence of other smoking related cancers (excluding lung)
declined after 1 year of smoking cessation, however the magnitude of associations were similar
to current and previous smokers at baseline thereafter (although, not statistically significant
with the exception of 3 – 5 years post quitting,), possibly indicating ongoing elevated risk. As
expected, no association between smoking behaviour and smoking unrelated cancer was shown.
These results support the need for research into and implementation of smoking cessation
efforts in HIV+ people while also highlighting that risk does not vanish after smoking cessation,
warranting ongoing monitoring and awareness of lung cancer.
Impact of cessation on cancer incidence
Lung cancer
Lung cancer incidence remained highly elevated in the first 5 years after cessation, with a peak
in the first year, after which levels remained at a similar level to current smokers. One study in
the US population showed elevated lung cancer mortality in the first 2 years since cessation
which declined thereafter [745]. Most studies in the general population have shown that the
incidence and mortality of lung cancer to be either similar or lower those who recently quit
compared to current smokers, but do not demonstrate a peak [654, 662, 663]. However, it is
difficult to compare as most studies have highly heterogeneous results, longer follow-up time
and use broader categorisation of time since cessation (I.e. < 3 or <5 years rather than < 1 year).
the peak in the first year following cessation observed in my study is likely driven by existing
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disease [654]. This includes people who quit smoking because they feel unwell either because
of their undiagnosed (non-clinical) cancer or because of another condition (such as an AIDS
defining diagnosis or treatment failure), which may lead to cancer diagnosis due to increased
intensity of medical surveillance [727]. It is possible that the increase in cancer incidence in the
first year following cessation may reflect a larger impact of reverse causality in HIV+ people,
possibly due to higher frequency of contact with care and elevated risk of other comorbidities
[746].
The lack of decline in the subsequent years is concerning as it is in contrast to similar studies in
the general population that show a clear decline in lung cancer risk within 5 – 9 years of
cessation, and a 50% reduction in the harms of smoking after 10 years [654, 661]. One USA study
by Sigel et al [747] compared lung cancer incidence in people with AIDS who ceased smoking by
<1 and >1 year prior. In that study, compared to never smokers, lung cancer incidence was 10-
fold higher in those who quit within the last year and declined to 5 in those who quit more than
1 year prior [747]. The reported RR for lung cancer in current smokers by Sigel et al [747] was 5-
fold higher than in never smokers, and was lower than that reported in D:A:D, and with a more
rapid decline in incidence following cessation. However, this study did find a similar peak for
recent quitters. The study by Sigel et al [747] was in people with AIDS, and therefore, the
elevated incidence in the first year and the subsequent decline is probably driven by existing
disease. Furthermore, differences in smoking prevalence and intensity in European countries
and the USA (prevalence: 27.3% and 17.2% respectively) may also explain differences [641, 748].
Research in the HIV-negative population has indicated that the full effects of smoking are not
reflected in national cancer rates until regular smoking has been entrenched in that population
for at least 50 years [622, 654]. Therefore, it is likely that our study underestimates the harms
of smoking and the benefits of cessation, as the HIV+ population is relatively young and the
smoking epidemic in HIV+ people has not yet matured [477, 622, 654]. For example, the benefit
of smoking cessation in the general population is most apparent when the full effects of long-
term smoking are established, such as among men in the United States, United Kingdom, and
Eastern European countries [654]. The long-term effects of smoking will become more apparent
in HIV+ people as they age.
4.4.1.1.1 Mechanisms
The mechanisms for the elevated incidence of lung cancer incidence and persistence of risk in
HIV+ people are largely unknown [727], however several possible explanations exist. It is well
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known that smoking rates are often higher in HIV+ compared to HIV-negative people, and some
studies also indicate that lung cancer may develop with less smoking exposure [728] which could
lead to a more prominent residual effect of long term tobacco use. In addition to this, HIV may
play either a direct or indirect role in lung cancer genesis [294, 706, 707]. HIV infection may
contribute to increased susceptibility of lung cancer through reduced immune surveillance (due
to HIV mediated immune dysfunction), CD8 cell dysfunction and activity, as well as increased
systemic and pulmonary inflammation. Pulmonary infections and COPD are have been
associated with increased inflammation in the lung and higher lung cancer incidence in the
general population [699, 727, 749-753]. HIV+ people are particularly susceptible to pulmonary
infections and COPD which may explain the increased risk [688, 707, 719, 725, 726, 729, 754-
756]. It has also been suggested that HIV infection is associated with antioxidant deficiencies
which increase oxidative stress of the lung and promote carcinogenesis [654, 757]. In addition,
it is possible that HIV viral proteins may have some direct oncogenic activity [758]. Some studies
have noted a higher than expected number of adenocarcinomas in HIV+ people [726].
Adenocarcinomas develop after less exposure to genetic damage than other cancers of the lung
and a link between genomic instability and lung cancer in HIV+ people has been observed [726,
759, 760]. Increased survival of people living with HIV may prolong exposure to genomic
instability which increases risk of adenocarcinoma of the lung [726, 760].
Alternatively, studies have suggested that the elevated lung cancer risk in HIV+ people could
simply reflect more intensive medical evaluations or screening bias in people with HIV,
particularly after an AIDS defining event [617, 727]. Furthermore, It is also possible that the slow
decline in the HIV+ population is due to differences in the intensity and duration of historical
smoking or younger age at smoking initiation in HIV + people compared to HIV-negative people
[725]. In addition, the presence of other lung cancer risk factors, such as use of inhaled illicit
drugs, passive smoking, as well as socio economic factors [492] that may not change, or may
even intensify, with changes in smoking status could even mask benefits of smoking cessation.
Smoking related cancers (excluding lung)
In this chapter, the incidence of smoking related cancers (excluding lung) following smoking
cessation was elevated in recent quitters and returned to a level similar to that of never smokers
after one year. The peak in smoking related cancers (excluding lung) within the first year
following cessation is likely driven by existing disease, which is discussed in section 4.4.1.1.
Although there was statistically little evidence of a difference in incidence of smoking related
cancers (excluding lung) between never smokers and ex smokers after 1 year, the magnitude of
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association in this group is similar to that of current smokers (and even higher in those who quit
more than 3 years prior), which may be evidence of elevated risk. Although the benefits of
cessation are well documented, the harms of smoking cannot be entirely reversed [654]. There
is very little evidence to suggest that smoking cessation can reverse the transformation of cancer
cells, however, cessation can slow the progression of cancer development [654]. In addition, it
has been shown in the general population that younger age, shorter smoking duration, and
lower smoking intensity at time of cessation can result in a cancer risk which approaches that of
never smokers [654].
Smoking unrelated cancers.
The risk of smoking unrelated cancers was similar to that of never smokers regardless of time
since smoking cessation. There was a slight but non-significant decline in incidence over time,
driven by the lower incidence in those who had stopped smoking for more than 3 years. This
could reflect other lifestyle changes, such as improvements to diet and exercise, in people who
choose to stop smoking which further reduce their cancer risk [761, 762].
Smoking prevention and cessation in HIV-positive people
Smoking prevention and cessation are the most effective ways to prevent lung cancers.
Cessation tools, including behavioural interventions and pharmacologic agents (i.e. nicotine
replacement therapy), have been shown to be effective for smoking cessation in HIV+ smokers
[763-767]. The observed declines in smoking related cancers (excluding lung) supports the need
for smoking cessation efforts, however, the remaining long term elevated risk of lung cancer
indicates that smoking prevention in addition to cessation efforts is needed in HIV+ people. In
addition, it is important to keep in mind that the benefits of smoking cessation are not restricted
to cancers, but can have beneficial all smoking related diseases and also lengthen life [477, 647].
This is particularly important in HIV+ people who are known to have higher risk of many diseases
which can be exacerbated by smoking, including CVD, renal complications, bone fractures and
metabolic bone diseases, COPD, pulmonary infections, and pneumonia [420, 682, 711]. Studies
in HIV+ people have shown a lower risk of AIDS defining events, CVD, non-AIDS defining
malignancies, and pneumonia in those who cease smoking [682, 708, 711].
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Associations with other factors
Age
Older age was strongly associated with lung cancer risk, which is repeatedly shown in both the
HIV+ and HIV-negative literature [617, 622, 654, 725]. This could reflect longer exposure to
inflammation which is also associated with aging [707], or prolong exposure to genomic
instability which increases risk of adenocarcinoma of the lung [726, 760]. Alternatively, the
association with age could simply reflect a residual effect of lifetime duration of smoking [622,
654]. I did adjust for cumulative duration of smoking while under follow-up in D:A:D, however
many people will have a history of smoking long before entry into D:A:D. A less strong
association with age was seen for smoking related cancers (excluding lung) and smoking
unrelated cancers. These groups of cancers contains a mix of IRC and infection unrelated cancers
(IURC), many of which are associated with older age (see chapter 3).
Current CD4 cell count and HIV viral load
Lower current CD4 cell count was associated with lung cancer diagnosis, and is consistent with
many published studies [16, 427, 433, 609, 705, 728, 768]. Lower CD4 cell counts may reflect an
indirect role of HIV in lung cancer development, through reduced immune surveillance and
increased susceptibility of pulmonary infections, both of which increase lung cancer risk. A
recent publication demonstrated no association between CD4 and lung cancer incidence after
adjustment for cancer risk factors and history of pneumonia [729]. A similar association was
seen between CD4 cell count and infection related cancers (excluding lung). Neither lung cancer
nor other smoking related cancers (excluding lung) were associated with either current or AUC
of HIV-VL. This has been observed in other studies [638, 705]. It has also been proposed that the
lung may serve as a compartment in which HIV activity may not reflect systemic viral suppression
[707, 758, 769-771]. Smoking unrelated cancer was strongly linked to lower current CD4 cell
counts and higher current HIV-VL, probably driven by the high proportion of IRCs in this group
(primarily NHL and KS). This is explored in depth in for all IRCs in chapter 3 and for NHL and HL
specifically in chapter 5. In addition, I found that the interaction between current CD4 and each
cancer outcome was not significant. I.e. the association between smoking status and each cancer
outcome was similar in those with higher and lower CD4 cell counts.
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Gender
Incidence of lung cancer and smoking related cancers (excluding lung) did not vary by gender.
Elevated incidence of smoking unrelated cancers was linked to male gender, likely driven by NHL
and HL (see chapter 5). There was a difference in the effect of smoking cessation on the
incidence of all cancer according to gender, where the association between current smoking and
cancer risk was stronger and remain elevated for longer after cessation, although this
association was not evident within individual cancer outcomes. This may reflect a difference in
approach to smoking cessation in men and women, where men may be more likely to quit due
to poor health or existing disease as indicated by the elevated incidence within the first year. I
found this result surprising given that prevalence and intensity of smoking tends to be lower in
women [641].
HIV mode of transmission
Incidence of lung cancer did not vary by HIV mode of transmission. However, incidence of
infection related cancers (excluding lung) was higher in those who acquired HIV through routes
other than sex between men. This is probably driven by the higher proportion of HCV coinfected
people in these groups, and the established association between HCV and HBV and liver cancers
[474, 624, 625] (see chapter 3). Furthermore, incidence of smoking unrelated cancers was lower
according to those who acquired their HIV through means other than sex between men, likely
reflecting competing risks of death in this group.
Comorbidities
Those who developed smoking related cancers (excluding lung) were more likely to have a
history of comorbidities, including hypertension, anaemia, AIDS defining events (excluding ADC),
and diabetes. Similarly, smoking unrelated cancers was associated with anaemia and diabetes.
The incidence of lung cancer was not associated with a history of any of the comorbid conditions
investigated. The associations with anaemia are not surprising as anaemia is common in people
diagnosed with many types of cancer, particularly leukaemia and lymphomas [772, 773]. The
link between diabetes and smoking related cancers (excluding lung) and smoking unrelated
cancers is likely in part due to sharing several common lifestyle risk factors, including poor diet,
alcohol use, and obesity [774]. In addition, a meta analysis in the general population found
elevated levels of liver, pancreas, endometrium, colon and rectum, breast, and bladder cancer
in those with diabetes [774], which may also explain the association.
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Strengths of these analyses
The major strengths of the data presented here include the use of the D:A:D database, which
contains data from a large, multi-cohort study spanning 3 continents with relatively large
numbers of prospectively collected cancers and access to individual level patient and clinical
information. All NADCs are centrally validated and require histological evidence of diagnosis,
which minimises the chances of misclassification of cancer events. This is one of the few studies
in HIV+ people with detailed smoking information over a long period of time and on a large scale.
Limitations of these analyses
These analyses have a number of limitations which need to be kept in mind when interpreting
these data. This is an observational study and therefore we cannot establish causality or rule out
the effects of unmeasured or residual confounding. Another significant limitation is that smoking
information in D:A:D is updated at the clinic visit, therefore, exact start and stop dates of
smoking episodes, intensity, and lifetime duration were not available. Furthermore, smoking
information is collected according to physician inquiry and smoking (and possibly restarting of
smoking after quitting) may be underreported, due to social desirability bias, concerns about
the effect on health care, or lack of inquiry by physicians (who for example may assume smoking
has not been restarted). All adjusted analyses included cumulative duration of smoking as
reported in D:A:D and did not impact on the associations presented. However, it is possible that
people may be misclassified as previous smokers who restart smoking between visits, which
would lead to an underestimation of the benefits of smoking cessation [654]. To reduce the
impact of this, the midpoint between clinic visits was used to define smoking behaviours during
follow-up and results were consistent after removing follow-up with missing smoking status or
> 2 years since last reported smoking status. Furthermore, a previous study in D:A:D found a
decline in CVD following cessation to that of never smokers after 3 years [711], which are similar
to results from the general population. This provides some evidence of validity of the smoking
information in D:A:D.
At baseline, the proportion of people on cART was low (Table 4.3). This was due to a number of
participants with no antiretroviral drug information available at baseline (categorised as
unknown). However, this proportion increased over follow-up to approximately 80% as
information became available.
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The interpretation of analyses looking at time since cessation are complex. This is because
previous smokers with a long time since cessation often quit at a younger age or after a shorter
smoking duration than those with shorter times since cessation [654]. Age at cessation and
duration of smoking are strong risk factors for lung cancer and therefore, disentangling the
effects of duration of cessation, age at cessation, and duration of past smoking is not straight
forward. Furthermore, there are several potential confounders which were not collected within
D:A:D (for example: physical activity level, diet, recreational drug use, and socioeconomic
status).
These analyses had a relatively short follow-up period of a median of 10 years (relative to studies
in the HIV-negative population with follow-up of 30 years or longer), and therefore the long-
term benefits of smoking cessation could not be assessed. Short term benefits of smoking
cessation are more difficult to establish than the long term benefits because many people cease
smoking due to pre-existing cancers or other health problems which can inflate estimates of
cancer risk and bias results [477, 654]. Most studies in the HIV-negative population do not
conclusively establish the benefit of cessation on lung cancer risk within the first 5 years of
cessation [654]. In addition, this study does not take into account that various factors are
associated with cessation attempts and success (for example age, income, education) and the
relationship of these factors to cessation attempts may also be different from the relationship
with cessation success [775]. For example, younger people are more likely to attempt cessation
[775], however older people are more likely to achieve long term cessation [654, 776].
Conclusion
In conclusion, incidence of lung cancer incidence in HIV+ people appears to remain more than
10-fold higher several years after cessation, at a similar level to current smokers, and with no
evidence of a decline after the first year. This suggests that the oncogenic potential for smoking
is not reduced for lung cancer in the time frame that we have investigated. This is in contrast
with similar studies in HIV-negative people, which show a consistent decline in lung cancer
incidence with increasing time since cessation. Although incidence of smoking related cancers
(excluding lung) was similar to never smokers after 1 year following cessations, the magnitude
of effect was similar to current smokers and may indicate remaining risk. Deterring uptake of
smoking and smoking cessation efforts should be a priority to reduce the risk of cancer, however,
monitoring and awareness of lung cancer should continue in those who stop smoking. These
results strongly support efforts into smoking cessation and prevention. Studies following HIV+
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people throughout their lifetimes are needed to determine when the benefit of cessation will
be seen.
Publications
This chapter was awarded a young investigator scholarship and presented at CROI 2017 as an
oral presentation slides are in Appendix V. A manuscript has been drafted with the intention to
submit to JAMA.
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5 Differences in virological and immunological risk factors for
non-Hodgkin and Hodgkin lymphoma in the D:A:D study
Introduction
Non-Hodgkin and Hodgkin lymphoma in the general population
Malignant lymphomas are a heterogeneous group of cancers, which vary in terms of clinical and
biological features [607, 777]. In the general population, non-Hodgkin lymphomas (NHL) account
for around 90% of all malignant lymphomas; Hodgkin lymphomas (HL) account for the remaining
10% [607]. HL is distinguishable from NHL due to the unique presence of a small number of
neoplastic cells known as Reed-Sternberg cells (RS) [778-780].
NHL is the 10th most common cancer in the world [781] and is more common in developed
countries, with the highest incidences reported in USA, Australia, and Northern Europe, and
lowest incidences in eastern and South central Asia [607, 782]. NHL incidence has been
increasing worldwide since the 1970s but has slowed in recent years (Figure 5.1) [783]. In 2014
the incidence in the UK was estimated to be 22.9 (men: 27.5, women: 19.1) events per 100,000
people [784]. HL, on the other hand, is less common than NHL in the general population, with
an incidence rate of 3.3 (men: 3.9, women: 2.8) events per 100,000 people in the UK, 2014 [785].
HL incidence has increased in the UK general population since the early 1990s (Figure 5.2), driven
by large increases in those aged over 70 years [785]. Slightly lower rates have been observed for
HL and NHL in Europe [786]. Similar to NHL, HL incidence is higher in more developed countries
[787].
Figure 5.1 Non-Hodgkin lymphoma (C82-C86), European age-standardised incidence rates, UK, 1993-2014 [784].
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Figure 5.2 Hodgkin lymphoma (C81), European age-standardised incidence, UK, 1993-2014 [785].
Risk factors for NHL in the general population have been extensively investigated and include
male gender, older age, high socioeconomic status, immune suppression (such as that caused
by HIV infection, B-cell activating autoimmune disorders, or following an organ transplant),
atopic disorders, family history of NHL, higher body mass index (BMI) when younger,
recreational sun exposure, and skin cancer history [607, 788-794]. Infection with Epstein-Barr
virus (EBV), Hepatitis C (HCV, although results are inconsistent), and T cell lymphoma virus 1
(HTLV1) are also associated with NHL risk. Additional risk factors in women have included oral
contraception use before 1970, hormone therapy use initiated at age ≥50 years, low usual adult 
BMI, previous blood transfusion, and greater lifetime alcohol consumption [607, 788, 789].
Furthermore, certain occupations (including farmers, pesticide applicators, grain millers, wood
and forestry workers, workers in the petroleum, rubber, plastic and synthetic industries and hair
dressers) have been associated with increased risk of NHL attributed to exposure to harmful
substances [607, 789].
Risk factors for HL in the general population include male gender, age, family history of
lymphomas, HIV, and EBV infection. HL has a distinctive bi-modal age distribution, with one peak
at around 30 years (known as the young adult peak) and a second at 50 years [794-798]. Some
studies have indicated that smoking may play an etiological role in HL, particularly EBV positive
HL [799, 800]. In addition, people with NHL also have excess risk of HL (and vice versa), likely
due to somewhat shared aetiology [788, 801].
The strongest and most well established risk factors for both NHL and HL is suppression of the
immune system, as reflected by the elevated incidence of both in HIV-positive (HIV+) people
[607]. Recent estimates indicate that the incidence of NHL and HL remain elevated in HIV+
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people compared to the general population, with NHL incidence estimated to be around 10-fold
higher [436, 445, 802, 803] and HL incidence estimated to be around 11-times higher [15, 438,
470, 797]. This is despite a significant reduction of NHL (with the exception of Burkitt
lymphomas) incidence following the introduction of combination antiretroviral therapy (cART)
in 1996 [15, 16, 20, 21, 438, 439, 441-443, 450, 451, 604]. The basic epidemiology of both NHL
and HL are described in Chapter 1 sections 1.2.2.1 and 1.2.2.4 and are also explored in chapter
3 as a component of infection related cancers (IRCs).
Non-Hodgkin and Hodgkin lymphoma in HIV-positive people
Lymphomas have different clinical characteristics in HIV+ compared with HIV-negative people.
NHL in HIV+ people tend to be more aggressive, have a high proportion of the diffuse large B-
cell subtype, extra-nodal location (meaning outside the lymph nodes and often in the gastro
intestinal tract and central nervous system), and a stronger association with EBV than in HIV-
negative people [607]). NHL can be further grouped into subtypes, including primary brain and
central nervous system (PBCNS) lymphomas, and the systemic lymphomas which are Burkitt,
diffuse large B-cell (DLBC, includes immunoblastic) and other less common subtypes [442, 450,
451]. HL in HIV+ people compared to HIV-negative people tend to also be more aggressive,
presenting with B-cell symptoms, extra-nodal location, with poorer prognosis [471, 797], and
have a higher proportion of RS cells [797]. In addition, nearly all are associated with EBV [471,
797, 804] compared with 30 – 50% of HL in HIV-negative people from the USA and western
Europe [805]. The categories of HIV associated lymphomas are shown in Table 5.1.
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Table 5.1 Immunological and Epstein-Barr virus (EBV) status in AIDS related lymphomas [804].
Lymphoma histology HIVSpecific
Association with
Immunodeficiency
%
in
HIV
% EBV
associated
EBV
latency
Systemic AIDS related NHL
Burkitt lymphomas (BL) Mild 55 55% Type I
Classic BL Mild 30 30% Type I
BL with plasmocitoid Mild 20 50–70% Type I
Atypical BL Mild <5 30–50% Type I
Diffuse Large B-cell
lymphomas
Centroblastic type Mild 20 30–40% Type I
Immunoblastic type Marked 10 90–100% Type III
AIDS Primary central
nervous system Lymphomas Marked <5 100% Type III
Primary effusion
Lymphomas Yes Marked <5 90-100% Type I
Plasmablastic lymphomas
of the oral cavity Yes Not clear <5 50%
Not
clear
Hodgkin Disease Classical Marked 80-100% Type II
EBV: Epstein-Barr virus, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma.
In HIV+ people, the pathogenesis of NHL and HL is thought to be driven by a combination of
latent EBV infection and HIV associated immune suppression and dysfunction [606-608]. The
interaction between HIV infection, immune suppression, and dysfunction and EBV coinfection is
not well characterised, however, it is thought to differ between NHL and HL, as well as by NHL
subtype (Table 5.1) [452, 804].
For example: almost all HL is EBV related in HIV+ people and incidence is higher at lower CD4
cell counts [16, 427, 433, 804]. However, the association between HL and CD4 cell count is not
as strong as that observed for PBCNS or DLBC lymphomas. Both PBCNS and immunoblastic DLBC
lymphomas often occur at very low CD4 cell counts and are almost entirely EBV associated [804].
Furthermore, a lack of EBV-specific CD4 T-cell function has been shown in HIV+ people prior to
PBCNS lymphoma development irrespective of absolute CD4 cell counts [806]. Finally, Burkitt
lymphomas tend to occur at modest CD4 cell counts and approximately half are EBV related
[450, 804, 807].
In the context of HL, some studies have indicated an association with other markers of
immune deficiency in addition to low CD4 cell counts. For example, it has been hypothesised
that an imbalance in the pool of EBV-specific CD4 and/or CD8 cells in peripheral blood may
increase the risk of HL in HIV+ people [586]. It is thought that that EBV surveillance is largely
controlled by CD8 cells, although CD4 cells are likely required for the expansion and long term
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function of EBV-specific CD8 cells [808]. This has also been suggested for NHL [809], specifically
PBCNS lymphomas [806] which is also predominantly EBV related.
A detailed description of the pathogenesis if NHL and HL is given in chapter 6.
Risk factors in HIV-positive people
Several prior studies have indicated that the risk factors for NHL and HL differ [474, 499, 500,
810-814]. A summary of risk factors explored and identified to date are given below.
 Age: Older age has been linked to NHL in HIV+ people [433, 435, 450, 815, 816]. The
association between age and HL is less straight forward, with many studies reporting no
association with age in HIV+ people [433, 586].
 Gender: Many studies have found no difference according to gender for NHL [817] and
HL [586] in HIV+ people. However, differences have been observed according to HIV
mode of HIV transmission (see below).
 Ethnicity: Incidence of NHL has been shown to be lower in non-white people in some
studies [433, 606]. No association with HL has been shown [433].
 Mode of HIV transmission: higher NHL incidence has been reported in those who
acquired HIV through sex between men [433, 435, 606, 815, 817], however, one study
found this in treated people only [435, 817], and another in untreated patients only
[815]. Similarly, higher HL incidence has also been found in men who acquired HIV
through sex between men [586].
 CD4: Many studies have shown the dose response type of association between lower
CD4 cell count and higher NHL, and to a lesser extent, HL incidence [16, 18, 20, 429, 433,
435, 441, 450, 451, 468, 470, 471, 606, 815-818]. For NHL, similar associations have been
found for nadir CD4 cell count [435, 819] and time weighted CD4 cell count, however
not after adjustment for current CD4 cell count [817]. Furthermore, the association
between CD4 cell count and NHL varies by NHL subtype (as mentioned in section 5.1.2
and Table 5.1) [441]. For HL, many studies have shown that incidence peaks at low to
moderate CD4 cell counts, rather than at very low CD4 cell counts [433, 468, 470, 820].
Some studies have found a dramatic decline in CD4 cell counts within 1-2 years prior to
HL diagnosis in HIV+ [468, 586]. There was no evidence of a gradual decline in CD4 cell
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count leading up to diagnosis and similar declines were observed in the CD8 and total
lymphocyte cell count [821]. Therefore, it was suggested that this drop in CD4 cell count
was a consequence of the tumour rather than a step in the tumour development [821].
 Previous Kaposi’s sarcoma (KS) diagnosis and NHL. This association exists for several
NHL subtypes and persists after adjusting for current CD4. The association is likely due
to a combination of immune deficiency (which is a common risk factor for both NHL and
KS), as well as additional immune suppression and chronic B-cell stimulation and
transformation caused by uncontrolled replication of EBV and human herpes virus 8
(HHV8) [435, 500, 822-826]. Although uncommon, HHV8 is also aetiologically linked to
some NHL subtypes [500].
 HIV-VL: Studies have shown an association between current, lagged, and cumulative
HIV-VL and NHL incidence, independent of CD4 cell count and treatment status [16, 18,
433, 435, 451, 606, 816, 819]. Most studies have not shown an association between HL
incidence and HIV-VL [16, 429, 433, 468].
 HIV treatment: When compared directly, the incidence of NHL in HIV+ people on cART
has been estimated to be as low as half that of those not on cART [18, 20, 433, 435, 818].
However some studies showed only a borderline association [450, 815, 827]. A clear
impact of HIV treatment on HL incidence has not been shown, with some studies
showing lower HL incidence [586] particularly with longer duration of time on cART [828,
829] and others showing a higher incidence in treated people [20]. There is very little
evidence of a difference in NHL or HL incidence according to cART regimen [435, 468,
827].
 HCV: An analysis within the COHERE database found an association between HCV (and
hepatitis B [HBV]) and NHL incidence in treated patients, but not untreated patients
[830]. This association has also been identified in two meta analyses [831, 832].
However, many other studies have failed to show an association between HCV and NHL
incidence [433, 818, 833, 834]. One study found an association in men who acquired HIV
through sex between men but no other subgroups [834]. A borderline association
between HCV and HL incidence was identified in one meta-analysis [832].
204
Survival following non-Hodgkin lymphoma and Hodgkin lymphoma
diagnosis in HIV-positive people
HIV+ people in the post cART era have a higher mortality rate following NHL diagnosis than HIV-
negative people [835]. In treated HIV+ people in Europe, the 5 year survival rate for those
diagnosed with systemic lymphomas is estimated to 55% (95%CI: 51–60%), with the highest
mortality within the first year of diagnosis [807]. For PBCNS NHL, the 1 year survival was 54%
(95%CI: 43–65%) and to too few people survived for 5 years or more to estimate the rate.
Although the incidence of HL has not declined since the introduction of cART [19, 21, 430, 467],
Survival of HIV+ people following HL diagnosis has dramatically improved in the cART era due to
greater chemotherapy options and improved responses to cancer treatment [836]. Studies have
shown a similar mortality rate in HIV+ and HIV-negative people after adjustment for age, cancer
stage, and treatment, with a 5 year survival of 83% vs. 89%, respectively [535].
Implications of the START study
Although not specific to lymphomas, the START study (see chapter 1 section 1.1.8.7.1)
demonstrated that immediate cART initiation significantly reduced the risk of IRC, independently
of CD4 cell count and HIV-VL, indicating that IRC risk is mediated through other mechanisms
such as immune activation and reduced immune surveillance, above and beyond the depletion
of CD4 cell counts [141].
Aims
There are many studies which have investigated incidence of NHL and HL since the introduction
of cART and associated risk factors. However, to my knowledge, few previous European studies
have identified NHL and HL risk factors within the same population (with the exception of the
French Hospital Database on HIV [433]). Furthermore, no studies have directly compared the
risk factors for NHL and HL in order to identify and develop the understanding of different
mechanistic pathways which may suggest different preventive approaches for reducing NHL and
HL risk. Therefore this chapter had two aims:
 To identify independent risk factors for NHL and HL within the same population,
focussing on immunological and virological related factors
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 To directly compare and formally test factors that differently affect NHL and HL risk
in order to develop the understanding of different mechanistic pathways, which
may then suggest different preventive approaches for reducing NHL and HL risk.
Methods
This study was conducted within the Data Collection on Adverse events of Anti-HIV Drugs Study
(D:A:D) collaboration using the 16th merger the D:A:D database (included follow-up on 49,709
people). NHL is classified as an AIDS defining cancer (ADC [133]) and such events have been
collected in D:A:D since 1999. Non-AIDS defining cancers (NADC), such as HL, have been
routinely collected and validated since 1 January 2004. The D:A:D study is described in detail in
chapter 2 section 2.1.2.
Outcomes
This study investigated the association between multiple possible risk factors (with a focus on
immunological and virological factors) and two main outcomes: the first diagnosis of NHL during
follow-up and the first diagnosis of HL during follow-up. As a sensitivity analysis, immunological
and virological factors associated with NHL subtypes (Burkitt, PBCNS, and immunoblastic NHL)
were also investigated in the subset of people with NHL subtype reported (33.6%).
Inclusion criteria
People included in D:A:D were followed from their baseline date, defined as the latest of date
of study entry, first reported CD4 cell count, or 1st January 2004, until the earliest of first NHL or
HL diagnosis, last visit plus 6 months, death, or 1st February 2015.
There were 42,102 people in D:A:D with follow-up after 1 January 2004. I excluded a total of 682
people, of whom 509 had a prior NHL (N=408), HL (N=97) diagnosis or both (N=4), 10 had no
recorded gender, and 163 had no CD4 measurement prior to end of follow-up. Those excluded
were slightly older, and a higher proportion were male compared to those included. A flow chart
for the inclusion criteria is shown in Figure 5.3.
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Figure 5.3 Flow chart for inclusion of D:A:D participants in analysis.
Measures of CD4 cell count and HIV viral load
Time updated current and historical measures of CD4 cell count and HIV-VL were considered
and are outlined in Table 5.2. Historical measures of CD4 cell count included: nadir CD4 cell
count, as a measure of the maximum level of immune suppression reached, and duration of time
with CD4 cell count < 200 cells/mm3, as a time varying measure of cumulative exposure to
suppressed CD4 cell counts. Measures looking at time since last CD4<200 cells/mm 3 were also
considered.
The area under the curve (AUC) of HIV-VL was considered as a time varying measure of
accumulated exposure to replicating HIV. The measure refers to the area under each individuals’
HIV-VL curve over time [837]. Formally, it can be interpreted as the total number of copies/mL
of HIV-VL accumulated over time. For example, an AUC of HIV-VL of 10000 is equal to having a
HIV-VL of 10000 copies/mL for 1 year or a HIV-VL of 1000 copies/mL for 10 years. The measure
is calculated using the trapezoidal rule, a mathematical tool used to estimate the area under a
curve (Equation 5.1):
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Equation 5.1 Formula for area under the curve measures.
Where is the date of the current HIV-VL measurement, is the current HIV-VL level, is
the date of the previous HIV-VL measurement, is the date of the previous HIV-VL
measurement. For this chapter, I calculated the AUC for uncontrolled viremia (HIV-VL >50
copies/mm3), meaning that 50 copies/mm3 was subtracted from the HIV-VL measurements
when using the equations. The AUC of HIV-VL was categorised into quintiles for analysis as
detailed in Table 5.2: lowest 20%: lowest quintile (Q1), 21% - 40%: Q2, 41 – 60%: Q3, 61 – 80%:
Q4, highest 20%: highest quintile– (Q5), where those in the lowest quintiles had the lowest
accumulated exposure to HIV viral replication, and highest quintiles had the highest
accumulated exposure to HIV viral replication since the latest of HIV-diagnosis (or entry into
D:A:D).
For some analyses, current HIV-VL and AUC of HIV-VL were log10 transformed and current and
nadir CD4 cell count were log2 transformed, due to the right skewed nature of the data, and
also for interpretive reasons i.e. a one unit increase in log10 current HIV-VL is equivalent to a
10-fold increase, and a one unit increase in log2 CD4 cell count is equivalent to a 2-fold
increase.
Variables included in analyses
Both baseline and time updated variables from the D:A:D database were included in this
analysis, as detailed in Table 5.2. Use of cART was considered as both a current variable (i.e. on
cART and not on cART) and according to duration of time on cART. Duration of time on cART was
used for the main analysis as it was deemed a clinically important factor. Person years of follow-
up (PYFU) were calculated per month of additional follow-up.
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Table 5.2 Summary of baseline and time updated variables considered in analysis.
Variable Time
updated
Levels Definitions and comments
Immunological markers
Current CD4 cell
count (cells/mm3)
Yes Continuous (per 2-fold
higher) and <200, 200 –
349, 350 – 499, ≥500 
cells/mm3, unknown
Nadir CD4 cell
count (cells/ mm3)
Yes Continuous (per 2-fold
higher) and <200, 200 –
349, 350 – 499, ≥500 
cells/mm3, unknown
Lowest recorded CD4 cell count
measurement prior to date
Cumulative time
spent with CD4 cell
count < 200
cells/mm3
Yes Continuous (per year
longer) and Categorised as
0, 0.1 – 2, 2 – 4, ≥ 4 years 
CD4 cell counts <
200 cells/mm3 in
the last 12 months
Yes Yes, no, unknown
Virological markers
Current HIV-VL
(copies/mL)
Yes Continuous (per 10-fold
higher) and <400, ≥ 400 
copies/mL, unknown
Area under the
curve (AUC) of
HIV-VL calculated
from first visit into
D:A:D
Yes Continuous (per 10-fold
higher) and categorised
into quintiles: lowest 20%:
lowest quintile (Q1), 21% -
40%: Q2, 41 – 60%: Q3, 61
– 80%: Q4, highest 20%:
highest quintile– (Q5).
Age (years) Yes Continuous (per 10 years
older) and
categorised into 16 – 29,
30 – 39, 40 – 49, 50 – 59, ≥ 
60 years
Calendar year of
baseline
Continuous (per year) and
categorised by year
(2004/05, 2006/07,
2008/09, 2010/11,
2012/13/14/15)
Years were combined into categories
due to the small amount of follow-up
and events accrued within some
years category.
Calendar year of
follow-up
Yes Continuous (per year) and
Categorised by year (2004,
2005, 2006, 2007, 2008,
2009, 2010, 2011, 2012,
2013, 2014/15
The years 2014 and 2015 were
combined into one category due to
the small amount of follow-up and
events accrued within this category
Ethnicity white, black, other or
unknown
Gender Male, female
HIV mode of
transmission
Sex between men,
heterosexual, IDU, other or
unknown
BMI (kg/m2) Yes Under weight (<18),
normal weight (18 – 25),
Over weight (25 – 30),
obese( 30+)
Classified according to the WHO
standard [597]
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Smoking status Yes Non-smokers, current
smokers, previous
smokers, unknown
Prior ADC
diagnosis
(excluding NHL)
Yes Yes, no Classified according to the 1993 CDC
clinical definition [133]
Prior AIDS defining
event (excluding
ADC)
Yes Yes , no Classified according to the 1993 CDC
clinical definition [133]
Prior
cardiovascular
disease
Yes Yes , no Defined as whether the person ever
had a diagnosis since entry into
D:A:D.
Hypertension Yes Yes, no Defined as ever having systolic BP
>140, diastolic BP >90 mm Hg or
receiving any antihypertensive drugs
or ACE inhibitors since entry into
D:A:D
Diabetes Yes Yes, no Defined as a reported diabetes
diagnosis on a case-report form or
use of anti-diabetic medication
HBV status Yes Positive, prior, negative, or
unknown
Positive HBV status was defined by a
prior positive HBsAG surface antigen
test or presence of detectable HBV
DNA, Prior HBV status was defined by
a prior positive HBsAG surface
antigen test or presence of
detectable HBV DNA, with a negative
latest HBsAG surface antigen test
and/or undetectable HBV DNA.
HCV status Yes Positive, negative, or
unknown
Positive hepatitis-C (HCV) status was
defined as having a prior positive HCV
surface antibody test.
cART use Yes On cART, not on cART defined as being on at least 1
protease inhibitor (PI) or non-
nucleoside reverse transcriptase
inhibitor (NNRTI)
cART regimen Yes PI or NNRTI
Duration of time
on cART (years)
Yes Both continuous (per year
longer) and categorised as
0, 1-2, 2-4, >4 years
Duration of time
on protease
inhibitors (PI)
(years)
Yes Both continuous (per year
longer) and categorised as
0, 1-2, 2-4, >4 years
Duration of time
on Non-nucleoside
reverse
transcriptase
inhibitor (NNRTI)
(years)
Yes Both continuous (per year
longer) and categorised as
0, 1-2, 2-4, >4 years
HIV-VL: HIV viral load, AUC: area under the curve, IDU: injecting drug use, BMI: Body mass index, ADC: AIDS defining
cancer, HBV: Hepatitis B, HCV; Hepatitis C, cART combination antiretroviral therapy.
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Statistical methods
Characteristics at baseline.
Characteristics of people in D:A:D who had a NHL or a HL diagnosed during follow up were
described using numbers and percentages for categorical variables and median with
interquartile range (IQR) for numerical variables at baseline. All bivariate associations were
tested using chi squared tests for categorical variables and Kruskal-Wallis tests for numerical
variables.
Incidence rates of non-Hodgkin and Hodgkin lymphoma
Incidence rates of NHL and HL per 1000 PYFU were calculated according to categories of key
variables of interest. These included calendar year of follow-up, current and nadir CD4 cell count,
duration of time with CD4<200 cells/mm3, current and AUC of HIV-VL, and cumulative time on
treatment.
Identification of independent risk factors for non-Hodgkin and
Hodgkin lymphoma
Separate Cox regression models were used to calculate both unadjusted hazard ratios (HR) and
adjusted HR (aHR) to identify factors associated with NHL and HL, focussing on current and nadir
CD4 cell count duration of time with CD4<200 cells/mm3, and current and AUC of HIV-VL. Models
were adjusted for baseline and time varying factors listed in Table 5.2.
Collinearity and over fitting of the models was a consideration due to the limited number of NHL
and HL events that accrued during follow-up and the high correlation between the various
immunological markers. To take this into account, I selected the single best fitting
immunological marker to include in the models. Spearman’s ρ was used to investigate the 
correlation between immunological factors and virological factors. Due to the high correlation
between current and nadir CD4 cell count, and duration of time spent with CD4 cell count < 200
cells/mm3 (Table 5.3), only one measure was selected to be included in the analysis according
to the smallest Akaike information criterion (AIC) for both NHL and HL. Current and AUC of HIV-
VL were not strongly correlated (Table 5.3) and therefore both were included in the same model.
All other variables included in the model were identified a priori based on expert clinical input,
availability of data, and the published literature.
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Table 5.3 Correlations between immunological and virological variables at baseline1.
Current CD4
(cells/mm3)
Nadir CD4
(cells/mm3)
Time since last CD4 cell
count < 200 cells/mm3
(years)
Duration of time with CD4
<200 cells/mm3 (years)
Current HIV-VL
(copies/mL)
Spearman’s r P Spearman’s ρ P Spearman’s ρ P Spearman’s ρ P Spearman’s ρ P
Nadir CD4 (cells/mm3) 0.60 <0.01 1 _
Time since last CD4 <
200 cells/mm3 (years)
0.82 <0.01 0.18 <0.01 1 _
Duration of time with
CD4 cell count <200
cells/mm3 (years)
-0.38 <0.01 -0.80 <0.01 -0.05 <0.01 1 _
Current HIV-VL
(copies/mL)
-0.25 <0.01 0.20 <0.01 -0.32 <0.01 -0.26 <0.01 1 _
AUC of HIV-VL
(copies/mL – year)
-0.06 <0.01 -0.28 <0.01 -0.07 <0.01 0.31 <0.01 -0.04 <0.01
HIV-VL: HIV viral load, AUC: area under the curve.
1 Baseline was defined as the latest of 1 January 2004, entry into D:A:D, or first CD4 cell count.
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Comparison of factors which distinguished between people at high
risk of non-Hodgkin or Hodgkin lymphoma
The Wei, Lin, and Weissfeld method, based on the marginal Cox model [565], was used to
identify factors that were differently associated with NHL and HL risk. The models were used to
jointly calculate and compare the aHRs for NHL and HL for current and historical measures of
HIV-VL and CD4, adjusting for variables listed above. In order to fit a more parsimonious model
(i.e. reduce the number of parameters) variables not associated with either NHL or HL incidence
were assumed to have a similar association for both NHL and HL. The remaining variables were
allowed to vary according to outcome. It should be noted that the marginal Cox models are
therefore different models to those used to identify independent risk factors (Cox models) with
minor differences in adjustments (fixed and outcome specific variables) which give slightly
different estimates.
The ratio of the aHRs (RHR) was used to identify factors with different risk profiles for NHL and
HL. I refer to these factors as “differential factors”. Variables for which the lower limit of the
95% confidence interval (95%CI) is > 1 indicates a relatively stronger association with NHL than
HL for that factor. Conversely, when the upper limit of the 95%CI < 1 indicates a relatively
stronger association with HL than NHL. Variables for which the 95%CI of the RHR crosses 1
indicates no evidence of a different association between the risk factor and HL and NHL risk.
Subtypes
Risk factors for NHL subtypes were investigated using separate adjusted Cox models only,
however too few events were accrued to perform a direct comparison using marginal Cox
models.
All statistical tests were two sided with a type I error rate of 5%. All statistical analyses were
performed using SAS 9.4 (Statistical Analysis Software, Cary NC, USA).
Results
There were 41,420 people included in the analysis contributing 337,020 PYFU with a median
follow-up of 9.2 (Interquartile range [IQR]: 6.3, 11.1) years per person. A total of 392 people
developed NHL and 149 developed HL during follow-up (Table 5.4).
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Baseline characteristics
Baseline characteristics of the study population, as well as those who developed NHL or HL
during follow-up are shown in Table 5.4. Overall, 17.4% were aged ≥ 50 years at baseline and 
the median age was 40 (IQR: 34, 47) years, 72.9% were of male gender and 43.8% acquired HIV
through sex between men. Almost half of those included (49.9%) were of white ethnicity and
40.9% were of unknown ethnicity. Furthermore, 40.7% were current smokers whereas 27.4%
had never smoked. Approximately two thirds of people had a BMI within the healthy range of
18 – 26 kg/m2, 1 in 5 people had a previous AIDS defining event (excluding ADCs), and 3.4% had
a previous ADC (excluding NHL). HCV and HBV confection occurred in 19.2% and 18.9% of people
respectively. A history of cardiovascular disease, diabetes or hypertension was reported in 2.1%,
2.5% and 14.8% of the study population, respectively. Just over half were on cART (51.8%) at
baseline, with a median cART duration of 1.1 (IQR: 0.0, 4.9) years. The median CD4-cell count
was 431 (IQR: 280, 620) cells/mm3, nadir CD4 cell count was 248 (116, 403) cells/mm3 and
duration of time with CD4 < 200 cells/mm3 was 0.0 (IQR: 0.0, 0.4) years. Just over half had a HIV-
VL ≤ 500 copies/mL and the median AUC of log10 HIV-VL was 4.2 (3.0, 4.9) log10 copies/mL-years.
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Table 5.4 Characteristics at baseline1 of those included in the analysis and of those who developed either a non-Hodgkin (NHL) or Hodgkin (HL) lymphoma during follow-up.
Factors All people (N=41,420) people who developed NHL (n=392) people who developed HL (N=149)
N (%) N (%) N (%)
Age (years)
<30 5,922 (14.3) 22 ( 5.6) 16 (10.7)
30 - 39 14,833 (35.8) 118 (30.1) 44 (29.5)
40 - 49 13,449 (32.5) 142 (36.2) 56 (37.6)
50 - 59 5,170 (12.5) 71 (18.1) 23 (15.4)
   ≥60 2,046 ( 4.9) 39 ( 9.9) 10 ( 6.7)
Gender
Male 30,214 (72.9) 337 (86.0) 126 (84.6)
Female 11,206 (27.1) 55 (14.0) 23 (15.4)
HIV transmission mode
Sex between men 18,124 (43.8) 200 (51.0) 87 (58.4)
IDU 5,926 (14.3) 53 (13.5) 15 (10.1)
Heterosexual 14,800 (35.7) 106 (27.0) 39 (26.2)
Other/Unknown 2,570 ( 6.2) 33 ( 8.4) 8 ( 5.4)
Race
White 20,658 (49.9) 181 (46.2) 70 (47.0)
Black 2,963 ( 7.2) 10 ( 2.6) 6 ( 4.0)
Other 840 ( 2.0) 7 ( 1.8) 3 ( 2.0)
Unknown 16,959 (40.9) 194 (49.5) 70 (47.0)
smoking status
Current 16,859 (40.7) 155 (39.5) 70 (47.0)
Ex 7,332 (17.7) 65 (16.6) 31 (20.8)
Never 11,364 (27.4) 98 (25.0) 28 (18.8)
Unknown 5,865 (14.2) 74 (18.9) 20 (13.4)
BMI (kg/m2)
<18 1,377 ( 3.3) 13 ( 3.3) 4 ( 2.7)
18 - 26 27,709 (66.9) 255 (65.1) 102 (68.5)
27 - 30 5,360 (12.9) 59 (15.1) 15 (10.1)
>30 1,833 ( 4.4) 16 ( 4.1) 10 ( 6.7)
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Factors All people (N=41,420) people who developed NHL (n=392) people who developed HL (N=149)
N (%) N (%) N (%)
Unknown 5,141 (12.4) 49 (12.5) 18 (12.1)
Previous AIDS defining event (excluding ADC) 8,801 (21.2) 85 (21.7) 31 (20.8)
Previous ADC (excluding NHL) 1,419 ( 3.4) 26 ( 6.6) 8 ( 5.4)
On cART 21,436 (51.8) 161 (41.1) 70 (47.0)
HBV
Negative 29,355 (70.9) 271 (69.1) 119 (79.9)
Positive/prior 7831 (18.9) 86 (21.9) 19 (12.8)
Unknown 4,234 (10.2) 35 ( 8.9) 11 ( 7.4)
HCV
Negative 28,168 (68.0) 261 (66.6) 117 (78.5)
Positive 7,947 (19.2) 76 (19.4) 19 (12.8)
Unknown 5,305 (12.8) 55 (14.0) 13 ( 8.7)
Prior cardiovascular disease 857 ( 2.1) 5 ( 1.3) 6 ( 4.0)
Diabetes 1,055 ( 2.5) 12 ( 3.1) 2 ( 1.3)
Prior hypertension 6,121 (14.8) 68 (17.3) 30 (20.1)
Baseline year
2004 - 2005 29,715 (71.7) 290 (74.0) 99 (66.4)
2006 - 2007 6,334 (15.3) 65 (16.6) 29 (19.5)
2008 - 2009 5,327 (12.9) 35 ( 8.9) 21 (14.1)
2010 - 2011 29 ( 0.1) 1 ( 0.3) 0 ( 0.0)
2012 - 2015 15 ( 0.0) 1 ( 0.3) 0 ( 0.0)
HIV-VL (copies/mL)
    ≤500 21,546 (52.0) 113 (28.8) 65 (43.6)
>500 18,337 (44.3) 265 (67.6) 81 (54.4)
Unknown 1,537 ( 3.7) 14 ( 3.6) 3 ( 2.0)
N Median (IQR) N Median (IQR) N Median (IQR)
Age (years) 41420 40 (34,47) 392 43 (38,51) 149 42 (35,49)
CD4 count (cells/mm3) 41420 431 (280,620) 392 342 (189,534) 149 409 (276,575)
Nadir CD4 count (cells/mm3) 41420 248 (116,403) 392 197 (77,368) 149 259 (130,409)
Duration of time CD4 <200 cells/mm3 (years) 37962 0.0 (0.0,0.4) 353 0.0 (0.0,0.6) 137 0.0 (0.0,0.2)
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Factors All people (N=41,420) people who developed NHL (n=392) people who developed HL (N=149)
N Median (IQR) N Median (IQR) N Median (IQR)
HIV viral load (copies/mL) 39883 260 (<50,20400) 378 13419 (80,90951) 146 2615 (<50,34000)
Log10 AUC viral load (copies/mL- years) 36840 4.2 (3.0,4.9) 345 4.5 (3.3,5.2) 135 4.3 (2.4,5.0)
NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, BMI: body mass index, ADC: AIDS defining cancer, cART: combination antiretroviral therapy, HBV: hepatitis
B, HCV: hepatitis C, IQR: interquartile range, HIV-VL: HIV viral load, AUC: area under the curve.
1 Baseline was defined as the latest of 1 January 2004, entry into D:A:D, or first CD4 cell count.
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Crude incidence rates
A total of 392 people developed NHL (crude incidence rate [IR] 1.17/1000 PYFU, 95%CI: 1.06,
1.30) and 149 developed HL (IR 0.44/1000 PYFU 95%CI: 0.38, 0.52) during follow-up.
Calendar time
The crude incidence of NHL and HL by calendar year is shown in Figure 5.4. The crude incidence
of NHL declined over time by 13.3% per year (95%CI: 10.3, 16.2%) from an incidence rate of 1.96
(95%CI: 1.48, 2.58) events/1000 PYFU in 2004 to 0.32 (95%CI: 0.17, 0.2) in 2014/15. Conversely,
crude HL incidence was stable over time (change per year: -2.7%, 95%CI: -7.7, 2.6%), with an
incidence of 0.36 (95%CI: 0.19, 0.66) in 2014/15. An interesting observation is the convergence
of the incidence of NHL and HL over the duration of this study up to 2014/15 where the incidence
of NHL and HL are similar (and in fact, slightly higher for HL).
Figure 5.4 Crude incidence of non-Hodgkin (NHL) and Hodgkin (HL) lymphoma by calendar time.
NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, PYFU: person years of follow-up.
The unadjusted percentage change per year (% change) incidence of NHL and HL per more recent calendar
year is shown in the top right hand corner of the graph.
Immunological markers
The crude incidence of both NHL and HL according to immunological measures is shown in Figure
5.5-Figure 5.7. A rapid decline in crude NHL incidence with increasing CD4 cell count category is
demonstrated in Figure 5.5, which equates to a decline of 16 (95%CI: 14, 19)% per 2-fold increase
in current CD4 cell count. Although less pronounced, a significant decline is also seen for crude
HL incidence of 11 (95%CI: 5, 17)% per 2-fold increase in current CD4 cell count (Figure 5.5). NHL
and HL incidence according to nadir CD4 cell count is shown in Figure 5.6. There is a significant
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decline in crude NHL incidence of 7 (95%CI: 3, 11)% per 2-fold higher nadir CD4 cell count,
however no significant association with crude HL incidence (% change per 2-fold higher: -1,
95%CI: -9, 7%). Figure 5.7 demonstrates an increase in crude NHL incidence with increasing
duration of time with CD4 cell count < 200 cells/mm3, which equates to an increase of 5 (95%CI:
3, 9)% per year longer. No association with crude HL incidence was found (% change per year
longer: 0% 95%CI: -8, 8%).
Virological markers
The crude incidence of both NHL and HL according to virological measures is shown in Figure 5.8
and Figure 5.9. A clear increase in crude NHL incidence is shown for both higher current HIV-VL
category (Figure 5.8: % change per 10-fold higher: 74%, 95%CI: 62, 86%) and AUC of HIV-VL
category (Figure 5.9: % change per 10-fold higher: 81%, 95%CI: 59,106%). Conversely, incidence
of HL was stable across current (% change per 2-fold higher: 5, 95%CI: -10, 22%, Figure 5.8) and
AUC of HIV-VL (% change per 2-fold higher: 4, 95%CI: -12, 23%, Figure 5.9) category.
HIV treatment
Figure 5.10 shows the crude incidence rates of NHL and HL by treatment. Crude NHL and HL
incidence was highest within the first 2 years of starting cART, and both declined with increasing
time on cART, by 11 (95%CI: 9, 13)% and 7 (95%CI: 3, 11)% per year longer on cART respectively
(Figure 5.10). Crude incidence of NHL was highest in the first 2 years on protease inhibitors (PIs)
and declined by 6 (95%CI: 3, 8)% per year longer on PI, however no association between
increasing time on PIs and crude HL incidence was found (% change per year longer -1% 95%CI:-
5, 3%) (Figure 5.11). Crude incidence of both NHL and HL declined by 13% per year (95%CI: 10,
17% and 95%CI: 8, 19% respectively) with increasing time on non-nucleoside reverse
transcriptase inhibitors (NNRTIs) (Figure 5.12).
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Figure 5.5 Crude incidence of non-Hodgkin (NHL) and Hodgkin (HL) lymphoma by current
CD4 cell count.
Figure 5.6 Crude incidence of non-Hodgkin (NHL) and Hodgkin (HL) lymphoma by nadir CD4
cell count.
1 0 HL events unknown status, 2 7 NHL events with unknown status.
Figure 5.7 Crude incidence of non-Hodgkin (NHL) and Hodgkin (HL) lymphoma by duration
of time with CD4<200 cells/mm3.
1 1 HL events unknown status, 2 2 NHL events with unknown status.
Figure 5.8 Crude incidence of non-Hodgkin (NHL) and Hodgkin (HL) lymphoma by current
HIV viral load (HIV-VL).
HL: Hodgkin lymphoma, NHL: non-Hodgkin lymphoma, AUC: area under the curve, HIV-VL: HIV viral load, cART: combination antiretroviral therapy, PI: protease
inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.
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1 2 HL events unknown status, 2 29 NHL events with unknown status.
Figure 5.9 Crude incidence of non-Hodgkin (NHL) and Hodgkin (HL) lymphoma by current
AUC of HIV-VL.
Figure 5.10 Crude incidence of non-Hodgkin (NHL) and Hodgkin (HL) lymphoma by duration
of combination antiretroviral therapy (cART).
Figure 5.11 Crude incidence of non-Hodgkin (NHL) and Hodgkin (HL) lymphoma by duration
of protease inhibitor (PI) use.
Figure 5.12 Crude incidence of non-Hodgkin (NHL) and Hodgkin (HL) lymphoma by duration
of non-nucleoside reverse transcriptase inhibitor (NNRTI) use.
HL: Hodgkin lymphoma, NHL: non-Hodgkin lymphoma, AUC: area under the curve, HIV-VL: HIV viral load, cART: combination antiretroviral therapy, PI: protease
inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.
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Comparison and selection of immunological measures for
multivariate model
The purpose of this section is to demonstrate the process of selecting one immunological marker
to include in the analysis going forward. The aHRs for models containing each immunological
measure modelled individually (not adjusting for other immunological factors) are shown in
Table 5.5 and corresponding AICs in Table 5.6. All measures of immune deficiency were strongly
associated with NHL. The rate of NHL declined with increasing current and nadir CD4, and
increased with longer duration of time with CD4< 200 cells/mm3 (Table 5.5). A lower rate of NHL
was also associated with increasing time since last CD4 cell count < 200 cells/mm3, however this
was almost completely driven by the current CD4 level (Table 5.5). The best fit as given by the
lowest AIC was for current CD4 cell count (AIC: 7779, Table 5.6). Rate of HL declined with
increasing current and nadir CD4 cell count, but was not associated with duration of time with
CD4< 200 cells/mm3 (Table 5.5). Similarly to NHL, a lower rate of HL was also associated with
increasing time since last CD4 cell count < 200 cells/mm3, however this was also almost
completely driven by the current CD4 cell count (Table 5.5). The best fit as given by the lowest
AIC was for current CD4 cell count (AIC: 3064, Table 5.6). Based on these exploratory analyses
and the AIC, the current CD4 cell count was included in analyses of both HL and NHL going
forward.
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Table 5.5 Adjusted Hazard ratios (aHR) and 95% confidence intervals for immunological factors (modelled
separately) associated with non-Hodgkin (NHL) and Hodgkin lymphoma (HL).
NHL HL
Immunological factors (fit separately) aHR1 (95%CI) P aHR1 (95%CI) P
Current CD4 cell count (cells/mm3)
<100 8.08 (5.63,11.61) <.001 4.58 (2.22,9.45) <.001
100 - 199 3.67 (2.49,5.39) <.001 6.36 (3.62,11.20) <.001
200 - 299 2.96 (2.12,4.13) <.001 3.37 (1.99,5.69) <.001
300 - 399 2.43 (1.78,3.33) <.001 1.72 (0.99,2.97) 0.053
400 - 499 1.62 (1.15,2.29) 0.006 2.59 (1.64,4.08) <.001
>=500 reference reference
Nadir CD4 cell count (cells/mm3)
<100 4.17 (2.36,7.35) <.0001 5.03 (1.46,17.30) 0.0105
100 - 199 3.07 (1.74,5.41) 0.0001 5.83 (1.73,19.70) 0.0045
200 - 299 2.34 (1.34,4.09) 0.0028 5.41 (1.62,18.01) 0.0059
300 - 399 1.94 (1.09,3.43) 0.0235 2.47 (0.69,8.80) 0.1631
400 - 499 1.42 (0.74,2.75) 0.2938 2.99 (0.79,11.32) 0.1063
>=500 reference reference
Duration of time with CD4 cell count < 200 cells/mm3
0 reference reference
0.1 - 2 1.37 (1.06,1.76) 0.0146 1.32 (0.91,1.92) 0.1461
2.1 - 4 1.28 (0.82,1.98) 0.2743 0.84 (0.37,1.89) 0.672
>4 1.82 (1.22,2.72) 0.0034 1.37 (0.66,2.86) 0.3961
Unknown 4.06 (1.53,10.75) 0.0048 Not estimated -
Time since last CD4 cell count < 200 cells/mm3
0 reference reference
0.1 - 2 0.48 (0.33,0.70) 0.0001 0.30 (0.15,0.57) 0.0003
2.1 - 4 0.36 (0.21,0.61) 0.0002 0.40 (0.19,0.81) 0.0111
>4 0.38 (0.26,0.57) <.0001 0.20 (0.10,0.39) <.0001
Unknown 0.39 (0.29,0.51) <.0001 0.32 (0.20,0.51) <.0001
aHR: adjusted hazard ratio, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma. 1All models were
adjusted for age, gender, ethnicity, mode of HIV acquisition, smoking status, body mass index, baseline
year, cumulative time on combination antiretroviral therapy, Hepatitis B and C status, prior AIDS defining
cancers (ADC), prior AIDS events (excluding ADC), hypertension, diabetes, cardiovascular disease,
duration of time on treatment, current HIV Viral load and area under the curve of HIV viral load.
Table 5.6 AIC from adjusted models containing each immunological factor separately for non-Hodgkin (NHL) and
Hodgkin lymphoma (HL).
Immunological factor
NHL HL
AIC1 Rank AIC1 Rank
Current CD4 cell count 7779 1 3064 1
Nadir CD4 cell count 7869 2 3096 3
Duration of time with CD4 cell count < 200 cells/mm3 7895 3 3109 4
Time since last CD4 cell count < 200 cells/mm3 (years) 7901 4 3084 2
AIC: Akaike information criterion, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma.
1All models were adjusted for age, gender, ethnicity, mode of HIV acquisition, smoking status, body mass
index, baseline year, cumulative time on combination antiretroviral therapy, Hepatitis B and C status, prior
AIDS defining cancers (ADC), prior AIDS events (excluding ADC), hypertension, diabetes, cardiovascular
disease, duration of time on treatment, current HIV Viral load and area under the curve of HIV viral load.
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Independent risk factors of non-Hodgkin and Hodgkin lymphoma
Both unadjusted and adjusted results of the Cox models to identify risk factors for NHL and HL
are shown in Table 5.7 and Table 5.8 respectively.
Focussing on the adjusted associations with NHL (Table 5.7) a higher rate of NHL was strongly
associated with lower current CD4 cell count category (CD4< 100 vs ≥ 500 cells/mm3 aHR: 8.08
95%CI: 5.63, 11.61), higher current HIV-VL (HIV-VL> 1000 vs <50 copies/mL aHR: 1.97 95%CI:
1.50, 2.59) and higher AUC of HIV-VL (highest vs lowest quintile aHR: 2.91 95%CI: 1.92, 4.41).
Higher rates of NHL were also observed in older people, where those aged over 60 years had a
3.15-fold higher rate (95%CI: 2.17, 4.58) compared to those aged 30-39 years, in men compared
to women (aHR: 0.55 95%CI: 0.40, 0.76), and in those with a prior ADC (excluding NHL) (aHR:
1.49 95%CI: 1.02, 2.19).
The results for HL are shown in Table 5.8. Higher rates of HL were also associated with lower
current CD4 cell count category (CD4< 100 vs ≥ 500 cells/mm3 aHR: 4.58 95%CI: 2.22, 9.45),
however, the highest rate was in those with a low-moderate CD4 cell count (CD4 cell count 100
– 199 vs ≥ 500 cells/mm3 aHR: 6.36 95%CI: 3.62, 11.20), however no association was found for
current or AUC of HIV-VL. Other factors associated with the rate of HL included current smokers,
who had almost a 2-fold higher rate compared to non-smokers (aHR: 1.97 95%CI: 1.23, 3.16).
No association was found for HCV or HBV status with either NHL or HL. The HIV-VL associations
were consistent when considering other markers of CD4 cell count as measures of immune
deficiency.
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Table 5.7 Unadjusted (HR) and adjusted Hazard ratios (aHR) and 95% confidence intervals for factors associated
with non-Hodgkin lymphoma (NHL).
Factors HR (95%CI) P aHR2 (95%CI) P
Age (years)1
<30 0.53 (0.29,0.95) 0.032 0.49 (0.27,0.89) 0.019
30 - 39 reference reference
40 - 49 1.41 (1.08,1.85) 0.013 1.53 (1.16,2.01) 0.003
50 - 59 1.77 (1.30,2.40) <.001 2.02 (1.47,2.78) <.001
≥60 2.56 (1.82,3.62) <.001 3.15 (2.17,4.58) <.001
Female gender 0.44 (0.33,0.59) <.001 0.55 (0.40,0.76) <.001
Race
White reference reference
Other 0.51 (0.31,0.84) 0.009 0.65 (0.39,1.10) 0.109
Unknown 1.22 (1.00,1.50) 0.053 0.99 (0.80,1.24) 0.949
HIV transmission mode
Sex between men reference reference
IDU 0.89 (0.66,1.20) 0.451 0.91 (0.59,1.40) 0.677
Heterosexual 0.67 (0.53,0.84) <.001 0.91 (0.70,1.20) 0.523
Unknown 1.23 (0.85,1.77) 0.279 1.35 (0.92,1.98) 0.125
Smoking1
Current 1.08 (0.83,1.39) 0.58 0.91 (0.69,1.19) 0.48
Ex 1.05 (0.78,1.41) 0.747 0.89 (0.66,1.21) 0.461
Never reference reference
Unknown 1.76 (1.28,2.42) <.001 1.35 (0.96,1.89) 0.08
BMI group1 (kg/m2)
<18 1.70 (1.08,2.68) 0.022 1.42 (0.89,2.26) 0.142
18 - 26 reference reference
37 - 30 1.10 (0.84,1.44) 0.495 1.13 (0.86,1.49) 0.384
>30 0.54 (0.31,0.95) 0.031 0.63 (0.35,1.10) 0.104
Unknown 1.34 (0.93,1.91) 0.113 1.16 (0.80,1.67) 0.437
Current CD4 cell count (cells/mm3) 1
<100 13.25 (9.57,18.35) <.001 8.08 (5.63,11.61) <.001
100 – 199 5.17 (3.58,7.47) <.001 3.67 (2.49,5.39) <.001
200 – 299 3.83 (2.77,5.31) <.001 2.96 (2.12,4.13) <.001
300 – 399 3.00 (2.20,4.10) <.001 2.43 (1.78,3.33) <.001
400 – 499 1.91 (1.36,2.69) <.001 1.62 (1.15,2.29) 0.006
≥500 reference reference
Current HIV-VL1
≤ 50 reference reference
51 - 1,000 1.76 (1.31,2.37) <.001 1.35 (1.00,1.83) 0.051
>1,000 3.19 (2.54,4.01) <.001 1.97 (1.50,2.59) <.001
Unknown 0.70 (0.17,2.83) 0.617 0.65 (0.15,2.81) 0.563
AUC of HIV-VL (Quintiles) 1
1 - Lowest reference reference
2 1.32 (0.83,2.11) 0.237 1.10 (0.69,1.76) 0.685
3 1.84 (1.18,2.86) 0.007 1.47 (0.94,2.30) 0.088
4 2.48 (1.62,3.80) <.001 1.81 (1.17,2.80) 0.007
5 - Highest 4.84 (3.24,7.21) <.001 2.91 (1.92,4.41) <.001
unknown 2.30 (1.37,3.88) 0.002 1.63 (0.93,2.85) 0.088
Previous ADC diagnosis (excl. NHL)1 1.83 (1.26,2.65) 0.002 1.49 (1.02,2.19) 0.041
Factors HR (95%CI) P aHR2 (95%CI) P
Previous AIDS diagnosis (excl. ADC) 1 1.27 (1.02,1.59) 0.03 1.01 (0.79,1.28) 0.967
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HBV status1
Positive/prior 1.19 (0.93,1.52) 0.178 1.10 (0.85,1.41) 0.479
Negative reference reference
Unknown 1.11 (0.75,1.64) 0.598 0.97 (0.62,1.53) 0.906
HCV status1
Positive/prior 1.13 (0.88,1.44) 0.342 1.13 (0.81,1.59) 0.462
Negative reference reference
Unknown 1.24 (0.86,1.80) 0.25 1.20 (0.78,1.84) 0.416
Prior cardiovascular disease1 1.15 (0.67,1.96) 0.616 0.97 (0.55,1.70) 0.917
Diabetes1 1.22 (0.81,1.85) 0.338 1.16 (0.75,1.78) 0.499
Prior hypertension1 0.96 (0.75,1.22) 0.72 0.83 (0.63,1.08) 0.158
NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, HR: hazard ratio, aHR: adjusted hazard
ratio, IDU: injecting drug use, BMI: body mass index, HIV-VL: HIV viral load, AUC: area under the
curve, ADC: AIDS defining cancer, HBV: hepatitis B, HCV: hepatitis C.
1Time updated variables.
2 Models adjusted for all factors in the table as well as for time on cART (results in Table 5.9).
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Table 5.8 Unadjusted (HR) and adjusted Hazard ratios (aHR) and 95% confidence intervals for factors associated
with Hodgkin lymphoma (HL).
Factors HR (95%CI) P aHR2 (95%CI) P
Age (years)1
<30 0.88 (0.41,1.90) 0.742 0.90 (0.41,1.95) 0.781
30 - 39 reference reference
40 - 49 1.20 (0.78,1.85) 0.395 1.25 (0.81,1.93) 0.322
50 - 59 1.42 (0.87,2.31) 0.159 1.37 (0.82,2.28) 0.224
≥60 1.15 (0.60,2.20) 0.68 1.06 (0.53,2.15) 0.865
Female gender 0.50 (0.32,0.77) 0.002 0.73 (0.43,1.25) 0.253
Race
White reference reference
Other 0.70 (0.35,1.41) 0.318 0.98 (0.47,2.04) 0.948
Unknown 1.12 (0.80,1.56) 0.502 0.95 (0.66,1.35) 0.758
HIV transmission mode
Sex between men reference reference
IDU 0.59 (0.34,1.02) 0.058 0.72 (0.32,1.59) 0.413
Heterosexual 0.57 (0.39,0.83) 0.003 0.67 (0.42,1.06) 0.084
Unknown 0.69 (0.33,1.42) 0.314 0.78 (0.37,1.66) 0.525
Smoking1
Current 1.91 (1.22,3.00) 0.005 1.97 (1.23,3.16) 0.005
Ex 1.55 (0.94,2.57) 0.086 1.54 (0.92,2.58) 0.098
Never reference reference
Unknown 1.45 (0.75,2.77) 0.266 1.25 (0.63,2.47) 0.523
BMI group1 (kg/m2)
<18 0.61 (0.19,1.92) 0.398 0.59 (0.18,1.86) 0.366
18 - 26 reference reference
37 - 30 0.83 (0.53,1.32) 0.43 0.89 (0.56,1.42) 0.631
>30 1.03 (0.55,1.92) 0.921 1.28 (0.67,2.43) 0.45
Unknown 0.52 (0.21,1.29) 0.159 0.54 (0.22,1.33) 0.181
Current CD4 cell count (cells/mm3) 1
<100 3.81 (1.90,7.64) <.001 4.58 (2.22,9.45) <.001
100 – 199 5.54 (3.24,9.48) <.001 6.36 (3.62,11.20) <.001
200 – 299 3.07 (1.84,5.11) <.001 3.37 (1.99,5.69) <.001
300 – 399 1.62 (0.94,2.79) 0.081 1.72 (0.99,2.97) 0.053
400 – 499 2.53 (1.61,3.97) <.001 2.59 (1.64,4.08) <.001
≥500 reference reference
Current HIV-VL (copies/mL)1
≤50 reference reference
51 - 1,000 1.35 (0.87,2.08) 0.177 1.08 (0.69,1.69) 0.724
>1,000 0.87 (0.55,1.38) 0.559 0.67 (0.39,1.17) 0.158
Unknown 0.70 (0.10,5.07) 0.727 3.73 (0.22,62.35) 0.36
AUC of HIV-VL (Quintiles) 1
1 - Lowest reference reference
2 0.70 (0.41,1.21) 0.205 0.65 (0.37,1.12) 0.12
3 0.86 (0.51,1.44) 0.556 0.79 (0.47,1.34) 0.379
4 0.76 (0.44,1.30) 0.308 0.65 (0.38,1.14) 0.133
5 - Highest 1.26 (0.78,2.04) 0.349 1.01 (0.61,1.68) 0.965
unknown 0.22 (0.05,0.95) 0.042 0.14 (0.02,1.04) 0.055
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Previous ADC diagnosis (excl. NHL)1 1.36 (0.69,2.66) 0.377 1.10 (0.55,2.18) 0.792
Previous AIDS diagnosis (excl. ADC) 1 1.08 (0.75,1.55) 0.691 0.99 (0.67,1.46) 0.956
HBV status1
Positive/prior 0.75 (0.47,1.19) 0.22 0.75 (0.47,1.20) 0.232
Negative reference reference
Unknown 0.63 (0.28,1.43) 0.265 0.94 (0.40,2.25) 0.897
HCV status1
Positive/prior 0.68 (0.44,1.06) 0.091 0.66 (0.35,1.24) 0.193
Negative reference reference
Unknown 0.30 (0.10,0.95) 0.041 0.33 (0.10,1.10) 0.07
Prior cardiovascular disease1 1.60 (0.78,3.27) 0.196 1.56 (0.73,3.34) 0.251
Diabetes1 0.73 (0.32,1.66) 0.452 0.72 (0.31,1.68) 0.451
Prior hypertension1 1.10 (0.76,1.60) 0.617 1.01 (0.67,1.51) 0.972
NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, HR: hazard ratio, aHR: adjusted hazard
ratio, IDU: injecting drug use, BMI: body mass index, HIV-VL: HIV viral load, AUC: area under the
curve, ADC: AIDS defining cancer, HBV: hepatitis B, HCV: hepatitis C.
1Time updated variables.
2 Models adjusted for all factors in the table as well as for time on cART (results in Table 5.9).
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HIV treatment
The aHR for NHL and HL associated with being on treatment and increasing time on treatment
are shown in Table 5.9. There was no difference in rate of NHL or HL in those on cART vs those
not on cART, however, risk of both NHL (aHR per year longer on cART: 0.92 95%CI: 0.89, 0.95)
and HL (aHR per year longer on cART: 0.92 95%CI: 0.87, 0.97) were reduced with each additional
year on cART. Rate of NHL was significantly lower in those with 2 or more years of PI exposure
compared to those who had never used PIs. The rate of HL did not decline with increasing time
on PIs (aHR per year longer: 0.98 95%CI: 0.93, 1.03). The rate of both NHL and HL were
significantly lower in those with more than 4 years of NNRTI exposure compared to those who
had never used NNRTIs.
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Table 5.9 Adjusted hazard ratios for non-Hodgkin (NHL) and Hodgkin (HL) lymphoma for current use of cART and
duration of time on cART overall and according to regimen.
Cumulative time on treatment
aHR1 (95%CI)
NHL HL
On cART2 1.06 (0.81, 1.37) 1.11 (0.69, 1.81)
cART duration (Years)3
Never on cART Reference Reference
0.1 - 2 1.22(0.87,1.7) 1.31(0.67,2.55)
2.1 - 4 0.72(0.49,1.08) 0.8(0.39,1.68)
>4 0.49(0.34,0.7) 0.61(0.3,1.21)
Per year longer 0.92 (0.89,0.95) 0.92 (0.87,0.97)
On PI vs Not on PI4 1.09 (0.85, 1.39) 1.38 (0.90, 2.13)
PI duration (Years)5
Never on PI Reference Reference
0.1 - 2 1.01(0.77,1.32) 0.87(0.55,1.38)
2.1 - 4 0.62(0.43,0.88) 0.48(0.26,0.91)
>4 0.55(0.41,0.74) 0.75(0.47,1.19)
Per year longer 0.95 (0.92,0.98) 0.98 (0.93,1.03)
On NNRTI vs Not on NNRTI4 1.19 (0.92, 1.53) 0.92 (0.59, 1.43)
NNRTI duration (Years)5
Never on NNRTI Reference Reference
0.1 - 2 1.12(0.87,1.44) 0.96(0.63,1.45)
2.1 - 4 0.87(0.63,1.21) 0.93(0.57,1.51)
>4 0.65(0.46,0.92) 0.42(0.24,0.74)
Per year longer 0.93 (0.89,0.97) 0.86 (0.8,0.92)
NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, aHR: adjusted hazard ratio, cART:
combination antiretroviral therapy, PI: protease inhibitor, NNRTI: non-nucleoside reverse
transcriptase inhibitor.
1All models were adjusted for age, gender, ethnicity, mode of HIV acquisition, smoking status,
body mass index, baseline year, cumulative time on cART, HCV and HBV status, prior AIDS
defining cancers (ADC), prior AIDS events (excluding ADC), hypertension, diabetes,
cardiovascular disease, current CD4 cell count, current HIV-viral load and AUC of HIV-viral load.
Differences in risk factors for non-Hodgkin and Hodgkin
lymphoma
Factors that were associated with either NHL or HL in Table 5.7 and Table 5.8 were considered
as potential differential factors, that is, they were jointly modelled to determine if they were
differently associated with NHL and HL (Figure 5.13). For each factor, the ratio of the aHR for
NHL relative to the aHR for HL was calculated. Current HIV-VL was a differential factor, as
demonstrated by the increase in ratio of the aHRs with higher HIV-VL category. For example, the
ratio of the aHRs (of NHL relative to HL) was 2.52 (95%CI: 1.32, 4.81) and 4.57 (95%CI: 2.20, 9.50)
in those with current HIV-VL 50 – 1000 copies/mL and >1000 copies/mL relative to <50
copies/mL respectively. This indicates a progressively stronger relative association between
current HIV-VL and NHL than for HL, where current HIV-VL >1000 copies/ml was a more than
4.5-fold stronger predictor for NHL compared to HL. A similar result was found for the AUC of
HIV-VL, which was also a differential factor. Current CD4 cell count was not a differential factor
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as the 95%CI of the ratio of the aHRs for each CD4 category relative to CD4 cell count 200 - 299
cells/mm3 contained 1, indicating no evidence that lower CD4 cell count was differently
associated with NHL and HL. Age was a differential risk factor as the ratio of the aHRs of people
aged > 60 relative to those aged 30 – 39 was more than 3 (95%CI: 1.43, 6.55), indicating a
stronger relative association between current HIV-VL and NHL than for HL for people in this older
age group. Finally, smoking status was a differential factor, as the ratio of the aHRs for current
smokers relative to never smokers was 0.49 (95%CI: 0.28, 0.83), indicating a stronger relative
association with HL than NHL in this group. None of the other factors investigated were
differential factors, including gender, HIV transmission mode, or time on cART either overall or
stratified by use of a PI or NNRTI.
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Figure 5.13 Adjusted ratio of the hazard ratios of NHL (NHL HR) and HL (HL HR) for each considered risk factor, and
the ratio of the HR (RHR).
NHL: non Hodgkin lymphoma, HL: Hodgkin lymphoma, HR: adjusted hazard ratios, RHR: ratio of
the HRs, cART: combination antiretroviral therapy, HIV-VL: HIV viral load, AUC: area under the
curve. Model was also adjusted for gender, ethnicity, mode of HIV acquisition, body mass index,
baseline year, hepatitis C and B status, prior AIDS defining cancers (ADC), prior AIDS events
(excluding ADC), cardiovascular disease, diabetes, hypertension. Variables for which the 95%CI
for the ratio of the hazard ratios of NHL to HL cross 1 indicate no evidence of a difference in HRs
for NHL relative to HL. A P value < 0.05 corresponds to a ratio of the HR significantly different to
1, i.e. a significantly different HR for NHL relative to HL (or vice versa).
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Non-Hodgkin lymphoma subtypes
Of the 392 NHL, 42 were Burkitt (10.7%), 25 were PBCNS (6.4%), 65 were immunoblastic (16.6%),
and 260 were unknown (66.3%). Those with known and unknown subtype were similar in age,
gender, mode of transmission, smoking status, comorbidities, immunological and virological
markers and use of cART at diagnosis (all P>0.05). Slightly more people with known subtype
reported being on PIs (known subtype: 46.2% vs unknown subtype: 38.6%, P=0.05), and slightly
fewer had a previous cancer diagnosis (3.1% vs 10.6%, P=0.02). In the 33.7% of people who had
a subtype recorded, associations between immunological and virological risk factors modelled
separately for each subtype are shown in Table 5.10. For example, lower risk of PBCNS NHL was
associated with higher current CD4 cell count (aHR for 2-fold higher: 0.59 95%CI: 0.51, 0.70) and
nadir CD4 cells count (aHR for 2-fold higher: 0.68 95%CI: 0.58, 0.80) and lower AUC of HIV-VL
(aHR for 10-fold higher: 2.21 95%CI: 1.22, 4.00) but not current HIV-VL. Lower risk of
immunoblastic NHL was associated with higher current and nadir CD4 and lower current and
AUC of HIV-VL. Lower Burkitt NHL risk was associated with higher current and AUC of HIV-VL but
not immunological markers. Nadir CD4 cell count was not associated with PBCNS, immunoblastic
or Burkitt lymphoma after additional adjustment for current CD4 cell count.
Table 5.10 Adjusted Hazard ratios (aHR) and 95% confidence intervals for factors associated with non-Hodgkin
lymphoma (NHL) subtypes.
PBCNS (N=25) Immunoblastic (N=65) Burkitt (N=42)
aHR1 (95%CI) P aHR1 (95%CI) P aHR1 (95%CI) P
log2 current CD42 0.59 (0.51,0.70) <0.01 0.75 (0.67,0.85) <0.01 0.88 (0.74,1.05) 0.15
log2 nadir CD42 0.68 (0.58,0.80) <0.01 0.87 (0.77,0.98) 0.02 0.97 (0.82,1.14) 0.68
log10 current HIV-VL3 1.11 (0.80,1.54) 0.54 1.32 (1.08,1.61) 0.01 1.38 (1.08,1.76) 0.01
Log10 of AUC of HIV-VL3 2.21 (1.22,4.00) <0.01 1.60 (1.16,2.21) <0.01 2.14 (1.35,3.38) <0.01
NHL: non-Hodgkin lymphoma, PBCNS: Primary brain and central nervous system, HIV-VL: HIV
viral load, AUC: area under the curve.
1Models were adjusted age, gender, mode of HIV acquisition, race, current smoking status,
cumulative time on combination antiretroviral therapy.
2Models were additionally adjusted for log10 current HIV-VL and Log10 of AUC of HIV-VL in
addition to variables listed in (1).
3Models were additionally adjusted for log2 current CD4 in addition to variables listed in (1).
Discussion
This study is the first to directly compare the risk factors for NHL and HL in order to identify
differences in the underlying pathology of both in HIV+ people. Higher current and accumulated
HIV-VL were stronger risk factors for NHL than HL. Although current CD4 cell count and gender
were strong predictors of both, they were equally associated with risk of NHL and HL.
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Furthermore, these results identified independent risk factors for NHL and HL, which were
consistent with those described in the existing literature. In this study, the crude incidence of
NHL declined steadily over time while HL incidence remained stable, and as a result, incidence
of NHL and HL has been similar in HIV+ people in recent years.
Before discussing the main results of this chapter, it is important to note that most analyses
presented treat NHL as a single entity, however, there is considerable heterogeneity in aetiology
between NHL subtypes [804, 838]. This is somewhat demonstrated in that the risk of NHL
subtypes differed according to immunological and virological factors [804], however, the low
number of NHL with known subtype prevented me from exploring this in depth. This should be
kept in mind when interpreting the results for NHL.
Changes in incidence of non-Hodgkin and Hodgkin lymphoma
over time
The incidence of NHL declined over time by 13% per year while HL incidence remained stable at
around 0.36/1000 PYFU. The NHL decline is consistent with previous studies which have shown
a clear decline for non-Burkitt subtypes (i.e. DLBC and PBCNS NHL) [15, 16, 19-21, 430, 438, 439,
441-443, 451, 467]. The trends over time are not surprising and have been reported before,
however, my study is one of the first to show a convergence of incidence of NHL and HL in HIV+
people in recent years. A convergence in NHL and HL has also been suggested in a German study
in the context of sustained viral suppression and limited immune suppression [839]. This result
demonstrates a shift away from the cancers with a strong link with immune deficiency, and
highlights the need for a better understanding of how generalised immune dysfunction above
and beyond low CD4 cell counts can facilitate lymphoma development.
Immunological and virological factors
This chapter shows that the risk of NHL and HL differs according to current and accumulated
HIV-VL, but not current CD4. It is believed that HIV infection facilitates lymphoma development
by inducing immune suppression [608, 840, 841]. This has a number of consequences including
reduced control of oncogenic viruses (such as EBV) [608, 840, 841]. My results indicate a similar
role of immunodeficiency in both NHL and HL development, however, an important distinction
is the involvement of HIV-VL in NHL but not HL development.
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My findings that NHL is independently associated with both current CD4 and current and
accumulated HIV-VL are consistent with previous research [429, 433, 435, 441, 468, 818] and
indicates that NHL behaves like a typical opportunistic disease. The risk of opportunistic disease
is higher at very low CD4 cell counts, but is also higher in people with uncontrolled HIV
replication regardless of CD4 cell count [842]. This was experimentally shown by the results of
the START trial, which demonstrated that risk of AIDS defining events was not zero among those
on immediate cART indicating that immune damage may occur early in HIV infection and lead
to ongoing immune dysfunction and AIDS defining events [141]. One clinician I spoke to
speculated that he would not be surprised if I observed a biphasic association between CD4 and
NHL incidence, due to the vastly different associations between DLBC and Burkitt lymphomas
and CD4 cell count, however, this was not observed. Subtype information is missing on two
thirds of the NHL events. However, close to two thirds of those with known subtype were PBCNS
or DLBCL NHL, both of which are associated with very low CD4. Therefore, if we assume the
distribution of NHL in the unknown subtypes is similar to that in the known, it is likely these
subtypes are driving the strong association with low CD4 cell count.
The association between NHL and current and cumulative HIV-VL indicate that HIV infection may
contribute to lymphomagenesis of NHL through additional immune dysfunction, not captured
by a supressed CD4 cell count [141, 840]. These may include reduced immune surveillance for
proteins expressed by cells infected with latent EBV, immune activation, cytokine over
production, and CD8-dysfunction leading to depleted response from EBV specific CD8 cytotoxic
cells [606-608, 806, 840, 843-845]. Some studies have found that levels of circulating free light
chains are predictive of NHL in HIV+ people, which supports the involvement of immune
activation [846, 847]. This is further explored in chapter 6, which investigates several markers of
immune activation preceding NHL and HL diagnosis. Recent data have suggested that HIV may
play a more direct role in lymphomagenesis [840, 848], with HIV-derived p17 secreted within
lymphoid tissues, possibly promoting lymphoma development by inducing changes to the
microenvironment [848].
The finding that HL incidence increases with lower current CD4 cell count with highest incidence
in CD4 cell counts ranging from 100 – 199 cells/mm3, but no association with virological
measures is also consistent with previous research [433, 471, 500]. Almost all cases of HL are
associated with EBV in the context of HIV [474, 499, 500, 810-814], and thus, the impact of HIV-
infection on HL development may be primarily driven by a balance between impaired immune
function and loss of control of EBV as well as remaining immune activity to allow for the influx
235
of immune cells to the tumour microenvironment [849]. Low availability of CD4 cells in the
severely immune suppressed may explain the lower HL incidence observed in those with CD4
cell counts < 100 cells/mm3 [470]. The RS cells secrete chemokines and chemokines which
attract activated CD4 cells (and other cells) to their microenvironment which are induced to
proliferate near the tumour cells in order to produce molecules required for RH cell proliferation
and to prevent apoptosis [470, 850, 851]. The cytokine and chemokines secreted contribute to
both the growth of RS cells as well as the maintenance of an environment in which a sufficient
immune response to RH cells cannot be achieved [470, 850, 851]. This clinically manifests as a
decline in CD4 (as well as total lymphocyte and CD8) cell counts, independent of HIV-VL level,
due to influx of CD4 cell counts to the tissue of the HL often within 1-2 years prior to diagnosis
[468, 586]. In addition, it has been suggested that an unbalanced pool of EBV-specific CD4 and
or CD8 cells may increase the risk of HL in HIV+ people [586].
HIV treatment
The link between increasing treatment duration and reduced incidence of NHL and HL is
consistent with the previous literature [18, 20, 433, 435, 818, 828, 829]. Longer duration of PI
and NNRTI based regimens both resulted in a decline in NHL risk. Longer duration of NNRTI use
was associated with lower HL risk, however, the decline in HL risk for longer duration of PI use
was not significant. A previous study from the D:A:D collaboration showed that that use of
NNRTIs was associated with a slight reduction in HL incidence but no association with PIs was
shown, which is consistent with my results. However in my study, there was no evidence that PI
use or NNRTI use were differential factors for NHL or HL risk. The use of measures of cART
duration in the D:A:D study are based on clinical notes of starting, continuing, swapping, and
stopping cART regimens. This does not take into account the actual adherence of the individual
and it is possible that people are misclassified as being on cART when they do not actively take
their treatment.
Smoking status
Current smoking was a differential factor, where those who were current smokers had a higher
risk of HL but not NHL. Previous research in the general population has indicated that smoking
may play an etiological role in HL, specifically, EBV positive HL [799, 800]. This is particularly
relevant as almost all HL in HIV+ people are EBV related, and therefore smoking presents as one
of the few modifiable risk factors for this cancer. A possible biological explanation for this
association is the known negative impacts of smoking on the immune system [852] which could
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amplify the effects of HIV-induced immune deficiency and thus loss of control of latent EBV.
These results provide additional evidence for the importance of smoking cessation strategies in
HIV+ people. The benefits of smoking cessation on cancer incidence in HIV+ people are explored
in chapter 4.
Hepatitis B and C status
This study did not find a significant association between HCV or HBV coinfection and increased
risk of lymphomas. This is in contrast to results from the COHERE study, which found a significant
association between both HCV and HBV and NHL risk in treated patients [830], and two meta
analyses [831, 832]. However, my results are consistent with the bulk of the literature that found
a negative association with HCV [433, 818, 833, 834]. Interestingly, the direction of effect for the
association between HCV and HL was protective, likely due to competing risks of death or higher
rates of loss to follow-up in HCV coinfected people. Furthermore, low number of people on
treatment in the early years of follow-up may further mask a possible association.
Other factors
Risk of NHL and HL differed according to age, where the people aged over 50 years had a
stronger relative association with NHL than HL, which is consistent with previous studies [433,
450, 586, 606, 815, 853]. This may reflect age associated immune activation and inflammation
and further supports the hypothesis that immune dysfunction beyond a low CD4 cell count is
involved in the pathology of NHL [721]. Alternatively, this may also reflect longer exposure to
EBV infection and associated impacts on the immune system (for more detail on HIV and aging
see chapter 1 section 1.2.4) [3, 617]. NHL incidence is strongly associated with age in the general
population [784], and therefore, the association in HIV+ people may just mirror that in the
background population. The higher NHL and HL (although not significant) incidence in men is
interesting. A similar but less marked observation has been made in the general population
[784]. Furthermore, a consistent association between men who acquired HIV through sex
between men and elevated risk for both NHL and HL have been shown in HIV+ people [433, 435,
606, 815, 817]. Some studies have suggested that this difference may reflect differences in
exposures to known environmental risk factors for NHL or higher prevalence of EBV in this
population [606]. After adjustment for gender, no association with mode of HIV transmission
was found in this study. I also attempted to replace gender and mode of transmission with a
gender specific HIV transmission mode variable grouped as follows: sex between men, female
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IDU, and male IDU, female heterosexual, and male heterosexual, other/unknown, which had no
impact on the results.
Strengths of these analyses
The major strengths of this study include the extensive follow-up on over 40,000 people
available within the D:A:D data study. This allowed for the analysis of a relatively large number
of prospectively collected and validated NHL and HL events. The end point review process in
D:A:D (detailed in chapter 2 section 2.1.2.5) minimises the risk of misclassification of lymphomas
as other cancers, as lymphomas can develop in almost any part of the body. Furthermore, the
D:A:D study contains highly detailed individual level data on demographic, HIV, and health
related factors collected over a long follow-up period. In addition, this is one of the only studies
to directly compare NHL and HL risk factors within the same cohort, which further strengthens
my results.
Limitations of these analyses
However, the study has a number of limitations which need to be kept in mind when interpreting
these data. First, there were several known risk factors for NHL and HL that are not collected in
D:A:D and could not be taken into account. For example, environmental exposures, autoimmune
disorders, family history, and EBV coinfection [607, 788, 789]. Second, NHL subtype is only
reported by a subset of cohorts in D:A:D, and as a result it was missing on 66% of people,
however I did compare those with and without subtype information, and they were similar in
terms of demographics, HIV-related and treatment information. In addition, D:A:D does not
collect information on cancer treatment or care following diagnosis and analyses of patient
outcomes following diagnosis are not possible. Furthermore, other markers of immune
suppression (such as CD8 cell counts), markers of immune dysfunction, or EBV viral load are not
collected. Although D:A:D has extensive follow-up, data on CD4 and HIV-VL are only available
since date of entry into D:A:D or HIV-diagnosis. This means that estimated cumulative and
historical measures of HIV-VL and CD4 will underestimate true exposure to replicating HIV-VL
and immune suppression due to unknown levels during their time living with undiagnosed and
untreated HIV as well as time prior to entry into D:A:D.
The D:A:D dataset is a collaboration of 11 cohorts, each of which have differences in terms of
the data collected and data quality. For example, demographic and clinic data is reported
differently to each cohort and this may impact on the quality and consistency of the data.
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However, all contributing cohorts perform random monitoring of at least 10% of study
participants’ clinical records to ensure events are not missed. Finally, this is an observational
study and I cannot rule out the effects of residual, unknown, and unmeasured confounding on
the results and causality of the associations presented cannot be determined.
Conclusions
In conclusion, this chapter investigated and compared the variations in factors associated with
NHL and HL development in HIV+ people. It has demonstrated that although CD4 cell depletion
increased risk of both types of lymphomas, current and accumulated HIV-VL had a stronger
relative association with NHL than HL. This suggests that NHL development is related to both
CD4 cell depletion and added immune dysfunction derived from ongoing HIV replication, which
is consistent with opportunistic disease. This latter factor is not affecting HL risk. In addition,
these results support that HL in HIV+ people is the result of a balance between impaired immune
function and loss of control of EBV as well as remaining immune activity to allow for the influx
of immune cells to the tumour microenvironment. Furthermore, the incidence of NHL and HL
are now similar within HIV+ people. These findings stress the importance of early HIV diagnosis
and treatment, and of ensuring sustained viral suppression.
Publications
A manuscript of this chapter was submitted to the Journal of the National Cancer Institute (JNCI)
in 2017. The results were presented at the HIV drug therapy Glasgow conference in 2016.
Preliminary results from the EuroSIDA study were also presented at CROI 2015. The manuscript
and slides are included in Appendix VI, Appendix VII, and Appendix VIII respectively.
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6 The extent of B-cell activation preceding lymphoma
development in HIV-positive people
Introduction
In the previous chapter (chapter 5), I investigated and compared the involvement of HIV
associated immune suppression and viral replication in the development of non-Hodgkin (NHL)
and Hodgkin (HL) lymphoma in HIV-positive (HIV+) people. In this chapter, I will expand on the
results of chapter 5 by exploring markers of immune activation leading up to the diagnosis of
lymphomas in HIV+ people.
As explored in chapter 3, HIV+ people have particularly elevated risk of infection related cancers
(IRC) [8, 15, 18, 616, 854]. In the setting of HIV infection, the oncogenic virus Epstein-Barr Virus
(EBV) has been associated with almost all cases of HL [474, 499, 500, 810-814] and between 30-
100% of cases of NHL, depending on subtype [474, 499, 500, 855, 856]. As shown in chapter 3,
NHL is the most commonly occurring cancer since 2001, and HL the 4 th most common, and
together they accounted for approximately 40% of all diagnosed cancers in EuroSIDA. Similar
results were found in the Swiss cohort study [430], the French Hospital Database on HIV cohort
[433] and studies from the USA [436].
Pathogenesis of lymphomas in HIV-positive people
Although several processes are thought to contribute to lymphoma development in HIV+
people, the mechanisms driving pathogenesis are poorly understood. One of the main drivers
of B-cell lymphomas is thought to be disruption to the immune system due to untreated HIV
infection [507, 608, 857], characterised by polyclonal B-cell activation,
hypergammaglobulinaemia, immune deficiency, immune dysfunction, impaired immune
surveillance, senescence, and inflammation [475, 505-507, 608, 841, 858, 859]. Another is the
loss of immunoregulatory control of EBV due to HIV mediated immune suppression and
dysfunction which can result in the uncontrolled growth and transformation of EBV infected B-
cells [608, 841]. It should be noted that lymphomas in HIV+ people are heterogeneous across
NHL subtypes and HL in terms of pathology, pathogenic pathways, and cellular derivation [860].
Furthermore, infectious origin of a tumour can only be definitively determined through in situ
hybridisation studies in tumour samples.
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HIV infection and the development of lymphomas
Chronic B-cell activation due to HIV infection is thought to be one of the main mechanisms for
B-cell lymphoma development in HIV+ people [608, 841]. Until recently, HIV was thought to
largely play an indirect role in the development of lymphomas, as HIV infection causes immune
suppression and facilitates the loss of control EBV-positive B-cells [608]. However, a more direct
role for HIV beyond immune suppression is emerging [840, 848]. HIV derived p17 is secreted
within lymphoid tissues, possibly promoting lymphoma development by inducing changes to the
microenvironment of lymphoid tissue [840, 848, 861]. Furthermore, HIV virions themselves
might induce B-cell activation, thus increasing the likelihood of chromosomal translocations and
of oncogene mutations, leading to DNA damage that can result in lymphomas [608, 862]. It has
been shown that accumulation of exposure to HIV replication is predictive of NHL development
in HIV+ people, which further supports this theory [608, 816]. Finally, recent findings indicate
viral cooperation between EBV and HIV in lymphoma development [841, 863]. This is the
mechanism by which coinfection with 2 or more viruses simultaneously have synergistic or
regulatory effects on the tumour microenvironment and promote carcinogenesis [863]. For
example, highly oncogenic latency patterns (see section 6.1.1.2 and Figure 6.1) are observed
during untreated HIV infection due to loss of immune surveillance against EBV [864], however,
studies have indicated a shift towards lymphomas associated with lower latency patterns during
the post combination antiretroviral therapy (cART) era [844]. Loss of T-cell response to EBV may
also play a role, as HIV+ people with EBV-positive lymphomas have been shown to have
compromised CD4 and CD8 T-cell responses to EBV protein EBNA1 [809, 845].
Epstein-Barr virus and the development of lymphomas
EBV is a gamma herpes virus that is estimated to infect >90% of the world’s adult population. It
has been implicated in the development of a wide range of B and T-cell NHL and HL as well as
various cancers including nasopharynx and stomach carcinomas and smooth muscle tumours
[471, 499, 865]. Despite widespread infection, EBV associated cancers are uncommon in people
with preserved immunity [499].
EBV is transmitted through bodily fluids, in particular saliva, and infects the B-cells of the oral
mucosa [499, 866]. Early after primary infection, EBV drives proliferation of various types of
infected B-cells and the pool of infected cells expands [867]. The immune system quickly targets
the proliferating cells for destruction by virus specific cytotoxic T-cells (or killer T-cells), however,
EBV infection is maintained by a reservoir of resting latently infected B-cells [499, 867, 868].
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These latent cells are not cycling, not targeted for immune destruction, and persist indefinitely
[608, 869].
The EBV life cycle includes two states: lytic and latent [499]. New virions are produced during
the lytic cycle [499]. Production of virions cease during latent infection, however, proliferation
continues and the virus spreads through the B-cell compartment following primary infection
[499]. There are three stages of latency (latency I, II and III) which are characterised by the
different patterns of genes and viral proteins expressed (Figure 6.1). These different gene
patterns are also found in tumours and indicate the stage of EBV infection in which they occurred
[499]. EBV viral proteins produced during higher latency patterns are highly immunogenic
(meaning they induce a strong immune response), and as a result, cancers associated with these
latency patterns tend to occur in immune compromised people [499, 870].
Figure 6.1 Major patterns of Epstein-Barr virus latent gene expression in lymphoproliferative disorders [870].
The exact mechanisms of how EBV infection leads to lymphoma genesis is not understood.
However, it is likely that EBV plays both a direct and indirect role in lymphoma genesis [608].
For example, EBV infection can induce B-cell activation either directly through its viral genes
(such as Epstein–Barr nuclear antigen 1 [EBNA-1], which is a viral protein produced during all
stages of latency and present in all B-cell lymphomas) or indirectly by regulating host gene
expression in order to immortalise B-cells [608, 871, 872]. As mentioned in section 6.1.1, HIV+
people with poorly controlled HIV infection and reduced immune function are at higher risk of
lymphoma due to loss of control of EBV-positive B-cells. This is the case for primary brain and
central nervous system (PBCNS) lymphomas which are almost all EBV+ and strongly linked to
immune deficiency [608, 804]. On the other hand, the role that EBV plays in the genesis of other
lymphoma subtypes in the context of HIV, such as Burkitt or diffuse large B-cell (DLBC)
lymphoma, is less clear [608]. For example, Burkitt lymphomas develop in HIV+ people with
relatively preserved CD4 cell counts and around half are EBV-positive. Burkitt lymphoma tends
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to occur as a consequence of errors in Ig gene rearrangement during B-cell hyperproliferation
with hypergamaglobulinaemia, which is a feature of early HIV infection [873-875]. In addition,
Immunoblastic DLBC lymphomas tend to occur at very low CD4 cell counts due to failure to
eradicate EBV latency type III infected lymphocytes [500, 804, 876], whereas centroblastic DLBC
lymphomas are weakly associated with low CD4 cell counts and less than 40% are EBV related
[804]. Finally, EBV latent membrane protein 1 (LMP1) is expressed in almost all HL in HIV+
people, suggesting an etiological role of EBV in these cancer in the context of HIV [477].
Primary brain and central nervous system (PBCNS) lymphomas are almost all EBV+ and strongly
linked to immune deficiency [16, 427, 433, 608, 804]. On the other hand, the role that EBV plays
in the genesis of other lymphoma subtypes in the context of HIV, such as Burkitt or diffuse large
B-cell (DLBC) lymphoma, is less clear [608]. For example, Burkitt lymphomas develop in HIV+
people with relatively preserved CD4 cell counts and around half are EBV-positive. Burkitt
lymphoma tends to occur as a consequence of errors in Ig gene rearrangement during B-cell
hyperproliferation with hypergamaglobulinaemia, which is a feature of early HIV infection [873-
875]. In addition, Immunoblastic DLBC lymphomas tend to occur at very low CD4 cell counts due
to failure to eradicate EBV latency type III infected lymphocytes [500, 804, 876], whereas
centroblastic DLBC lymphomas are weakly associated with low CD4 cell counts and less than
40% are EBV related [804]. Finally, EBV latent membrane protein 1 (LMP1) is expressed in almost
all HL in HIV+ people, suggesting an etiological role of EBV in these cancer in the context of HIV
[477].
The lymphatic system
Lymphomas are cancers of the lymphatic system. The lymphatic system provides protection
against pathogens and also produce immunoregulatory cytokines to coordinate other parts of
the immune system [607, 877, 878]. Components of the lymphatic system run throughout the
whole body, and for this reason, lymphomas can arise in almost any part of the body.
The immune system has two categories of responses: the innate and adaptive immune system
[879]. The Innate response is the first line of defence to infection and occurs rapidly [879]. If the
innate immune system fails to eliminate a pathogen, the adaptive immune system is initiated
[879]. The adaptive immune response involves pathogen specific lymphocytes, which increases
protection against reinfection with the same pathogen [879]. Lymphocytes are created in the
central lymphatic organs (the thymus and bone marrow) and can differentiate into 3 lines: T-
lymphocytes which operate in antibody and cellular immunity, B-lymphocytes which can
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differentiate into plasma cells and secrete antibodies (or immunoglobulins), and natural killer
(NK) cells [816, 878, 879].
B lymphocytes and the production of immunoglobulins
Mature B-lymphocytes primarily remain in peripheral lymphoid organs (the lymph nodes,
tonsils, spleen, thymus, and mucosal and submucosal tissues of the alimentary and respiratory
systems), where they can be activated by specific antigens and induce an immune response
[877, 878]. The lymphocyte receptor repertoire is made up of millions of lymphocytes, each
carrying a different receptor (a surface immunoglobulin molecule) which is specific to a single
antigen (a protein on the surface of pathogens) [879, 880]. If the B-cell surface receptor binds
to the specific antigen then the B-cell will become activated [816, 878-880]. At this point the
cellular structure changes and the B-cell becomes a lymphoblast. The lymphoblast starts to
proliferate (creating around 1000 identical clones) [878, 879]. This process is called “clonal
expansion” and takes around 4-5 days to complete [878, 879]. The clones then differentiate into
plasma cells which are able to secrete immunoglobulins [816, 878, 879].
The production of Immunoglobulins
Immunoglobulins are an essential part of the immune system [816, 878, 879]. Immunoglobulin
molecules are made up 2 identical heavy chains and two identical light chains (Figure 6.2) [881].
There are 5 classes of antibodies: IgA, IgD, IgE, IgG, and IgM and two classes of light chains: κ or 
λ [816, 881]. Either type of light chain may be associated with any of the heavy chains 
[881]. Elevated total serum globulins are thought to reflect hypergammaglobulinaemia and
generalised B-cell activation [882]. Immunoglobulins as markers of B-cell activation are present
years before lymphoma diagnosis [846, 883], making them potentially useful markers of future
lymphoma development which may also provide insight into the aetiology of these cancers
[608]. Furthermore, polyclonal elevation of FLCs (a marker of polyclonal B-cell activation and
indicates the presence of many different immunoglobulin molecules made by many different B-
cells) is a marker of general immune activation and polyclonal hypergammaglobulinamia and
has been linked to malignant disease [884]. Monoclonal elevation of FLCs indicates the presence
of many identical immunoglobulins produced by many clones of a single parent B-cell and is
indicative of several plasma cell proliferative disorders, including monoclonal gammopathy of
undetermined significance (MGUS) and multiple myeloma [885, 886].
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Figure 6.2 A typical immunoglobulin molecule [881].
Immunoglobulin M
IgM is the first class of immunoglobulin to be made by a developing B-cell (although many
subsequently switch to IgG) and is the principal antibody produced during the early stages of a
primary antibody response to infection [878, 881]. IgM accounts for 5-10% of serum
immunoglobulins in adults and has a half-life of 5 days[885]. IgM levels can be detected in the
blood 3–14 days after the first exposure to an antigen and peaks after around 10-14 days. IgM
returns pre immune response levels after several weeks [878, 881]. Subsequent repeated
exposure to an antigen induce a response involving IgG molecules (see Figure 6.3), and the
antibody response is more rapid and for a longer duration. IgM is mainly found in the blood [878,
885].
Figure 6.3 Isotypes of serum antibodies in primary and secondary immunization [878].
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Immunoglobulin D
IgD exists alongside IgM primarily as a surface receptor on early mature B-cell membranes to
help initiate antibody responses by activating B-cell growth [878, 881, 885]. IgD is only secreted
in small amounts (< 1% of serum immunoglobulins) [878].
Immunoglobulin G
IgG is the main immunoglobulin class in the blood and extracellular fluid. It accounts for around
85% of serum immunoglobulins in adults and has the longest half-life of 23 days [879, 885]. IgG
primarily operates in tissues where it acts as an efficient opsonin, meaning it efficiently binds
with surface antigens on pathogens to mark them for elimination [879]. In order for a plasma
cell to produce IgG it must undergo a process called “class switching” which is initiated through
an interaction between activated B-cells and T helper cells [885]. During this process, a region
of the immunoglobulin molecule on the B-cell surface undergoes gene-rearrangement (or
recombination) in order to switch from producing IgM (and IgD) to IgG [885]. There are four
subclasses of IgG (IgG1 – IgG4) [878].
Immunoglobulin A
IgA at mucosal sites is one of the first lines of defence against infection [878]. IgA is the principal
class of immunoglobulin in secretions, including saliva, tears, milk, and respiratory and intestinal
secretions, and is the second most common immunoglobulin in serum (accounting for 5 – 15%
of serum immunoglobulins) [878, 879, 881, 885]. IgA has a half-life of 6 days [885]. IgA primarily
operates on epithelial surfaces and acts as a neutralising antibody [878], however, IgA also acts
as an opsonin (but much less potent than IgG) [879]. The production of IgA by plasma cells
involves the input of T-helper cells [885].
Free light chain kappa and lambda
The heavy and light chains are produced separately within the plasma cells and are then
assembled to form a whole (“intact”) immunoglobulin. During immunoglobulin production, the
B-cells produce more light chains relative to heavy chains, and excess unbound light chains
(known as free light chains, FLCs) enter circulation. Both immunoglobulins and FLCs can be
detected in serum [887, 888]. The relative concentrations of κ to λ (i.e. the FLC-κ/λ ratio) can be 
used as a numerical measure of clonality [886]. During polyclonal B-cell activation and
immunoglobulin production, both FLC-κ and FLC-λ concentrations can be 30 to 40-fold higher 
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[886], however, the FLC-κ/λ ratio remains relatively unchanged [886]. In contrast, monoclonal 
B-cell activation is characterised by the excess production of one FLC type and an abnormal FLC-
κ/λ ratio occurs [886].  
Immunoglobulins and free light chains in HIV-positive people
Hypergammaglobulinaemia occurs early in HIV infection [889]. Ongoing B-cell dysfunction in
HIV+ people is characterised by abnormally low levels of antibodies to specific pathogens and
poor immune responses to vaccines. Paradoxically, total serum levels of IgG are actually
elevated, reflecting a non-specific polyclonal activation of B-cells [858, 859, 882].
Immunoglobulin levels have been implicated as markers of B-cell hypergammaglobulinaemia
and generalised B-cell activation [882]. However, studies linking immunoglobulin levels and
lymphoma development in HIV+ people have had mixed results, with some finding elevated risk
with higher level of IgG [890], and others finding no association (serum globulin) [606, 846, 891].
Studies in the general population have found lower levels of IgM, IgA and IgG prior to lymphoma
[892], and levels declined with more advanced disease [893], speculated to be a consequence
of lymphoma development.
The level of individual FLCs (FLC-κ and FLC-λ), the ratio (FLC-κ/λ), and the sum of FLC-κ and FLC-
λ (FLC-κ+λ) are markers of B-cell activation and hypergammaglobulinaemia [846, 847, 894]. Non-
specific polyclonal B-cell activation has been shown to be strong and sensitive predictor of the
risk of lymphomas in HIV+ people [846, 847, 894]. Polyclonal FLC elevation levels have also been
associated with AIDS [895], HIV severity [896], and are reduced in those on cART [896].
Objectives
HIV associated immune deficiency, B-cell dysfunction, B-cell activation, as well as reactivation of
latent EBV infection all play a role in lymphoma development. This chapter aims to investigate
the relationship between B-cell activation, as demonstrated by increased levels of
immunoglobulins and FLCs, and the subsequent risk of developing lymphomas in HIV+ people.
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Methods
The EuroSIDA study
Analyses for this chapter were conducted within the EuroSIDA cohort and utilised the EuroSIDA
plasma biobank of prospectively stored plasma samples. Both the EuroSIDA study and the
plasma biobank are described in detail in in chapter 2 sections 2.1.1 and 2.1.1.9.
Study design
A 1:2 nested case control study utilising stored plasma samples to investigate the kinetics and
predictive value of several markers of immune activation: FLC-κ, FLC-λ, IgG, IgA, IgM and IgD.  
Inclusion criteria
Those with follow-up after the 1 of January 2001 with no history of a lymphoma diagnosis prior
to this date were eligible for inclusion. Both cases and controls were required to have at least
one plasma sample available for analysis in the plasma biobank (the plasma biobank is explained
in detail in chapter 2 section 2.1.1.9) prior to lymphoma diagnosis (or equivalent in controls).
Date of earliest plasma sample was considered as baseline.
Cases and controls
All eligible people with a primary diagnosis of lymphoma after 1 January 2001 were considered
as cases. For each case, 2 matched controls (where available) were selected using incidence
density sampling (see Figure 6.4). If two controls were not available, 1 control was selected.
Controls were selected from eligible people with prospective follow-up after 1 January 2001
with no history of NHL or HL at the time of diagnosis for each case. Both cases and controls were
HIV+.
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Figure 6.4 Selection of cases and controls using incidence density sampling.
NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma
Matching variables
Cases and controls were matched on region of Europe, gender, date of earliest plasma sample
date (±2 years), date of latest plasma sample date (±2 years), age at earliest plasma sample date
(± 5 years), and CD4 cell count at earliest plasma sample (taken from closest visit) (± 200
cells/mm3). The windows used for matching were selected to allow suitable identification of
controls while ensuring as few cases as possible were excluded from analyses.
An example of the selection of a case control pair is shown in Figure 6.4. For each case of
lymphoma (top person), a similar person who was lymphoma free at the date of diagnosis of the
case (represented by the open circle) was selected. Incidence density sampling means the cases
and controls are matched on follow-up time. In the example, the date of each plasma sample is
represented by a red drop. The date of earliest plasma sample for the case and control had to
be within a 2 year window (represented by the blue region), and the date of the plasma latest
plasma sample for the case and control had to be within a 2 year window (within the blue
region).
Plasma samples and measurement of markers
All available serial plasma samples for cases and controls prior to the date of lymphoma
diagnosis (or matched date in controls) were considered for inclusion. Where more than one
plasma sample was available during the same calendar year, one plasma sample was randomly
selected for inclusion in order to preserve plasma for future analyses.
Serial plasma samples for cases and controls (up to a maximum of 1 per calendar year) were
analysed for FLC-κ, FLC-λ, IgG, IgA, IgM and IgD. All biomarkers were centrally measured by a 
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technician blinded to case control status on frozen stored plasma at the Department of Clinical
Biochemistry at Rigshospitalet. FLC (the κ and λ Freelite® turbidimeteric/nephelometric  
immunoassay, product code: LK016.S and KL018.S), IgG (NK004.S), IgA (NK010.S), IgM (NK012.S),
and IgD (LK013.S) concentrations were measured on plasma in all patients using Immunoassay
from the Binding Site Group Ltd, Birmingham, UK on the SPAPLUS ®. There were initially 73 cases
and 143 controls (3 cases had only 1 suitable control available) selected for analysis with 600
plasma samples for inclusion. However 6 plasma samples were not in the freezer, therefore 594
plasma samples were analysed. This study was performed in collaboration with the Binding Site,
who provided the kits free of charge. Information and contact details for the Binding Site are
available at http://www.bindingsite.com/en.
In this chapter, I considered the relationship between FLC-κ, FLC-λ, the ratio of FLC-κ to FLC-λ 
(FLC-κ/λ), the sum of FLC-κ and λ (FLC-κ+λ), IgG, IgA, IgM and IgD and lymphoma development. 
I also assessed whether monoclonal or polyclonal elevations were associated with lymphoma
development. Many other studies have used the upper limit of the normal to identify high
marker levels (Table 6.1), however, it was decided not to use this approach as these limits have
been validated in the HIV-negative population only. Instead, marker levels were investigated on
the log2 scale, giving an odds ratio which corresponded to a 2-fold higher marker level. However,
I did use the definitions for combined FLC elevations in order to classify monoclonal or polyclonal
elevations (as defined in Table 6.1).
Table 6.1 Marker reference ranges in the general population.
Marker Normal range
FLC-κ 3.3 – 19.4 mg/L [897]
FLC-λ 5.71 – 26.3 mg/L [898]
FLC-κ/λ ratio 0.26–1.65 [897, 898]
FLC-κ+λ 9.01- 45.7 mg/L [897, 898]
Combined FLC
elevations
Monoclonal elevations: FLC-κ>19.4 mg/L or FLC-λ > 26.3 mg/L and FLC-
K/L not between 0.26 – 1.65. [897, 898]
Polyclonal elevations: FLC-κ >19.4 mg/L or FLC-λ > 26.3 mg/L and FLC-
K/L between 0.26 mg/L – 1.65 mg/L. [897, 898]
Normal levels: FLC-κ <19.4 mg/L and FLC-λ <26.3 mg/L. [897, 898] 
IgG 6.103 - 16.16 g/L [899]
IgA 0.845-4.990g/L [900]
IgM 0.35-2.42 g/L [901]
IgD 7.7-132.1 g/mL [902]
FLC: free light chain, Ig: Immunoglobulin
Variables included in analyses
Both baseline and time updated variables from the EuroSIDA database were included in this
analysis, as detailed in Table 6.2. Both current and area under the curve (AUC) of HIV viral load
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(HIV-VL) were used. In Brief, AUC of HIV-VL is a measure of accumulated exposure to replicating
HIV [837]. The calculation and interpretation of AUC HIV-VL is described in detail in chapter 5
section 5.2.3. When referring to time updated variables, the term “current” was used, for
example “current CD4 cell count” refers to time updated CD4 cell count.
Table 6.2 Summary of baseline and time updated variables.
Variable Time
updated
Levels Definitions and comments
Age (years) Yes Continuous (per 10
years older)
Region of
Europe
East, east central,
south, west
central, north
Europe
See chapter 2 section 2.1.1.2
Ethnicity White, non-white
Mode of HIV
transmission
Sex between men,
other transmission
modes
Other transmission modes included
through IDU, heterosexual sex, and other
or unknown
Gender Male, female
Current CD4
cell count
(cells/mm3)
Yes Continuous (per 2–
fold higher)
Within 6 months prior to date of interest
Nadir of CD4
cell count
Yes Continuous (per 2–
fold higher)
Lowest recorded CD4 cell count
measurement prior to date of interest.
Calculated since entry into EuroSIDA
Current HIV-VL
(copies/mL)
Yes Continuous (per
10–fold higher)
and categorised as
≤ 500, > 500 
copies/mL, and
unknown
Within 6 months prior to date of
interest.
Area under the
curve of HIV-VL
(copies/mL –
year)
Yes Continuous (per
10–fold higher)
and categorised as
≤ 50%, > 50%, 
unknown. 50%
represents the
median value
Calculated since entry into EuroSIDA.
Explained in detail in chapter 5 section
5.2.3.
Prior AIDS
defining event
(excluding
NHL)
Yes Yes , no Classified according to the 1993 CDC
clinical definition [133]
Prior non-AIDS
defining event
(excluding HL)
Yes Yes , no Pancreatitis, grade 3 or 4 hepatic
encephalopathy or liver-related death,
non-AIDS defining cancers, myocardial
infarction, stroke, coronary artery bypass
graft, coronary angioplasty, carotid
endarterectomy, and end-stage renal
disease [221]
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Variable Time
updated
Levels Definitions and comments
HBV
coinfection
Yes Positive, negative,
or unknown
Most recent positive HBsAG surface
antigen test or presence of detectable
HBV DNA. Those without a HBV test
were categorised as unknown
HCV
coinfection
Yes Positive, negative,
or unknown
A prior positive HCV surface antibody
test. Those without a HCV test were
categorised as unknown
cART use Yes Yes, no Defined as use of ≥ 3 antiretroviral drugs 
from any class.
Duration of
time on cART
Yes Continuous (per
year longer)
Date of first
plasma sample
Continuous date Date of first plasma sample available for
analysis in the plasma biobank
estimated
glomerular
filtration rate
(eGFR)
(ml/min)
Continuous Cockcroft–Gault
formula[903] standardised for body
surface area [904]
IDU: injecting drug use, HIV-VL: HIV viral load, NHL: non-Hodgkin lymphoma, HL: Hodgkin
lymphoma, cART: combination antiretroviral therapy, HBV: Hepatitis B, HCV: hepatitis C,
Statistical methods
Characteristics of cases and controls at earliest plasma sample and
matching variables
The characteristics of cases and controls were compared using numbers and percentages for
categorical variables and median with interquartile range (IQR) for numerical variables at
baseline. All bivariate associations were tested using univariate conditional logistic regression
due to the matched nature of the data.
Association of each marker with likelihood of lymphoma diagnosis
Unadjusted conditional logistic regression models were used to investigate the association
between the odds of developing lymphoma and each marker using plasma samples that were
collected ≤ 2 and > 2 years prior to lymphoma diagnosis (in cases) or matched date in controls. 
In the case where ≥ 1 plasma sample was available within the same time period, one was 
randomly selected.
Predictive value of each marker for lymphoma diagnosis
The area under the receiver operator curve statistic (c-statistic) was calculated to determine the
predictive value of each marker, where a c-statistic = 0.5 indicates no predictive ability (i.e. the
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marker is no better at determining lymphoma than flipping a coin) and a c-statistic = 1 indicates
perfect predictability [905]. Predictive ability was classified as follows (0.51 – 0.6: Poor, 0.61 –
0.7: Poor-moderate, 0.71 – 0.8: Moderate, 0.81 – 0.9: Good, 0.9 – 1: Excellent). This was
performed for each marker using plasma samples collected ≤ 2 and > 2 years prior to lymphoma 
diagnosis in cases or matched date in controls, as described in section 6.2.8.2.
Kinetics of each marker in the time before lymphoma diagnosis
The percentage change for each marker over calendar time (% change per year) in cases or
matched date in controls in the period prior to diagnosis or matched date in controls was
investigated using mixed models with random slopes and intercepts (accounting for multiple
measurements within each person). Differences in the trajectory of cases and controls were
investigated by testing for an interaction between time until lymphoma diagnosis or matched
date in controls and case and control status. The magnitude of change in marker levels over time
were compared using three different approaches:
1. Unadjusted models
2. Models adjusted for region of Europe, gender, age at first plasma sample and log2 CD4
cell count at first plasma sample (i.e. the matching variables)
3. Models adjusted for region of Europe, gender, current age, current log2 CD4 cell count,
current use of cART, and duration of time on cART
Factors associated with elevated marker levels
Patient factors associated with higher B-cell activation marker levels were assessed using mixed
models (accounting for multiple measurements within each person). In order to minimise bias
due to the nested-case control study design (leading to a non-representative patient population
where 1 in 3 develop lymphomas) this analysis of factors was restricted to controls only. Factors
investigated included current age, gender, region of Europe, current use of cART (defined as ≥ 3 
antiretroviral drugs), current and nadir CD4 cell count, and current and AUC of HIV viral load
(HIV-VL).
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Results
Baseline characteristics
Characteristics of cases (N=73, 52 NHL and 21 HL) and controls (N=143) are shown in Table 6.3.
Overall, there was a median of 2.0 years (IQR: 0.4, 3.1) between first and last plasma sample
(cases: 2.1 years IQR: 0.6, 4.4; controls: 1.8 years IQR: 0.0, 4.3, P=0.72) and in cases there was
1.3 years (IQR: 0.3, 2.9) between last plasma sample and date of lymphoma diagnosis. Cases
differed from controls according to HIV and treatment related factors. Median HIV-VL level was
higher in cases (672 1QR: 80, 10,994 copies/mL) than controls (140 IQR: <50, 848 copies/mL),
and a lower proportion of cases (63.0%) were on cART at baseline compared to controls (78.3%).
The median duration of cART was also shorter in cases (0.9 IQR: 0.0, 2.5 years) than controls (1.7
IQR: 0.4, 3.3 years). In addition, a lower proportion of cases were HCV positive compared to
controls (9.6 vs 27.3%). Cases and controls were well balanced on other non-matched
demographic characteristics. At earliest plasma sample, median levels of FLC-κ, FLC-λ and FLC-
κ+λ were elevated in cases relative to controls, however the median FLC-κ/λ ratio was similar. 
Levels of IgG and IgM were also elevated in cases, however levels of IgA and IgD were similar in
cases and controls.
Characteristics at latest plasma sample
Immunological, HIV, and B-cell related markers at latest plasma sample prior to lymphoma
diagnosis in cases or matched date in controls is shown in Table 6.4. Cases had a higher median
HIV-VL (cases: <200 IQR: <50, 6,560; controls: <50.0 IQR: <50, 600 copies/mL) and a shorter
duration of cART (cases: 2.7 IQR: 0.8, 4.4; controls: 4.2 IQR: 1.7, 6.6 years) relative to controls
at latest plasma sample. There was no difference in levels of any B-cell markers at latest plasma
sample (all P>0.05).
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Table 6.3 Baseline1 characteristics of cases and controls.
Factors Overall (N=216) Cases (N=73) Controls (N=143) p-value
Categorical variables
Male gender2 193 (89.4) 65 (89.0) 128 (89.5) Na
HIV transmission group
Sex between men 114 (52.8) 41 (56.2) 73 (51.0) 0.39
Other 102 (47.2) 32 (43.8) 70 (49.0)
White ethnicity 180 (83.3) 56 (76.7) 124 (86.7) 0.06
Region of Europe2
South 46 (21.3) 16 (21.9) 30 (21.0) Na
West-central 75 (34.7) 25 (34.2) 50 (35.0)
North 72 (33.3) 24 (32.9) 48 (33.6)
East central 21 ( 9.7) 7 ( 9.6) 14 ( 9.8)
East 2 ( 0.9) 1 ( 1.4) 1 ( 0.7)
Prior AIDS event (excluding NHL) 60 (27.8) 23 (31.5) 37 (25.9) 0.33
Prior non-AIDS event (excluding HL) 5 (2.3) 2 (2.7) 3 (1.4) 0.88
HCV
Positive 46 (21.3) 7 (9.6) 39 (27.3) 0.02
Negative 128 (59.3) 50 (68.5) 78 (54.5)
Unknown 42 (19.4) 16 (21.9) 26 (18.2)
HBV
Positive 17 (7.9) 8 (11) 9 (6.3) 0.22
Negative 171 (79.2) 53 (72.6) 118 (82.5)
Unknown 28 (13.0) 12 (16.4) 16 (11.2)
On cART 158 (73.1) 46 (63.0) 112 (78.3) 0.02
Numerical variables N Median (IQR) N Median (IQR) N Median (IQR) p-value
Age (years) 2 216 42.2 (36.9,49.7) 73 42.6 (37.0,50.5) 143 41.8 (36.6,49.3) 0.47
CD4 cell count (cells/mm3) 2 216 317.5 (208.0,477.0) 73 316.0 (180.0,500.0) 143 319.0 (213.0,461.0) 0.063
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First plasma sample date2 216
11DEC1999
(20JUL1998,09OCT2004)
73
15NOV1999
(24JAN1998,16JUL2004)
143
25JAN2000
(28JUL1998,14OCT2004)
0.67
Nadir CD4 cell count (cells/mm3) 216 120 (44,228) 73 179 (55,280) 143 101 (40,200) 0.373
HIV-VL (copies/mL) 206 215 (<50,2100) 68 672 (80,10993.5) 138 140 (<50,848) <.014
Log 10 of AUC of HIV-VL (copies/mL - years ) 206 4.3 (3.6,5.0) 68 4.5 (3.6,5.1) 138 4.2 (3.6,5.0) 0.51
Duration of time on cART (years) 216 1.4 (0.2,3.1) 73 0.9 (0.0,2.5) 143 1.7 (0.4,3.3) <.01
eGFR 53 97.1 (77.2, 104.4) 19 98.6 (61.9, 107.4) 34 95.4 (79.9, 104.1) 0.82
Markers
 FLC—κ (mg/L) 213 32.0 (23.4,50.5) 71 39.9 (28.1,62.1) 142 29.4 (20.8,41.0) <.013
 FLC—λ (mg/L) 214 21.8 (14.5,31.4) 72 27.7 (19.2,45.0) 142 18.6 (13.7,27.2) <.013
 FLC—κ/λ 213 1.6 (1.2,2.0) 71 1.6 (1.2,2.0) 142 1.6 (1.2,2.1) 0.123
 FLC—κ+λ 213 53.4 (39.3,80.8) 71 69.6 (49.6,99.5) 142 48.2 (36.7,67.6) <.013
IgG (g/L) 214 14.3 (11.1,17.8) 72 15.8 (12.5,19.6) 142 13.2 (10.3,16.9) <.013
IgA (g/L) 214 2.2 (1.5,3.6) 72 2.7 (1.5,3.8) 142 2.2 (1.6,3.3) 0.343
IgM (g/L) 214 0.8 (0.5,1.3) 72 1.1 (0.7,1.7) 142 0.8 (0.5,1.1) 0.023
IgD (g/L) 214 28.5 (6.7,58.9) 72 39.2 (9.0,60.3) 142 26.0 (6.7,58.2) 0.123
NHL: non-Hodgkin lymphoma. HL: Hodgkin lymphoma, HCV: hepatitis C, HBV: hepatitis B, cART: combination antiretroviral therapy, HIV-VL: HIV viral load, AUC: area under the curve,
eGFR estimated Glomerular Filtration Rate, IQR: interquartile range, FLC: free light chain, Ig: immunoglobulin.
1 Baseline defined as the date of earliest plasma sample.
2 Matching variable.
3 p-value calculated on the log 2 scale.
4 p-value calculated on the log 10 scale.
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Table 6.4 Marker levels at latest plasma sample.
Overall Cases Controls
p-value
N Median(IQR) N Median(IQR) N Median(IQR)
CD4 (cells/mm3) 1 216 378 (238,541) 73 380 (223,530) 143 373 (255,547) 0.072
Nadir CD4 (cells/mm3) 216 104 (34,211) 73 140 (30,254) 143 95 (36,196) 0.862
HIV-VL (copies/mL) 215 60 (<50,1700) 73 <200 (<50,6560) 142 <50.0 (<50,600) 0.023
Log 10 AUC of HIV-VL (copies/mL - years ) 215 4.6 (3.9,5.3) 73 4.9 (4.0,5.5) 142 4.4 (3.8,5.2) 0.10
Duration of time on cART (years) 216 3.5 (1.3,6.3) 73 2.7 (0.8,4.4) 143 4.2 (1.7,6.6) <.01
B-cell Markers
FLC—κ (mg/L) 213 34.9 (21.3,55.1) 71 36.7 (24.5,57.0) 142 33.1 (20.1,54.8) 0.682
FLC—λ (mg/L) 214 21.8 (13.7,34.3) 72 24.5 (17.2,40.1) 142 21.3 (12.9,31.7) 0.872
FLC—κ/λ 214 1.6 (1.3,2.1) 72 1.6 (1.2,2.0) 142 1.7 (1.3,2.2) 0.812
FLC—κ+λ 214 56.9 (38.3,90.3) 72 63.5 (41.1,92.0) 142 53.9 (35.5,84.9) 0.752
IgG (g/L) 214 13.0 (10.5,17.1) 72 14.4 (11.5,18.2) 142 12.8 (10.1,16.4) 0.182
IgA (g/L) 214 2.3 (1.4,3.4) 72 2.5 (1.3,3.5) 142 2.2 (1.5,3.4) 0.282
IgM (g/L) 214 0.8 (0.5,1.3) 72 0.8 (0.5,1.5) 142 0.8 (0.5,1.2) 0.862
IgD (g/L) 214 21.9 (7.2,59.8) 72 24.5 (10.7,87.1) 142 21.0 (6.7,53.9) 0.287
IQR: interquartile range, HIV-VL: HIV viral load, AUC: area under the curve, FLC: free light chain, Ig: immunoglobulin.
1 Matched at first plasma sample.
2 p-value calculated on the log 2 scale.
3 p-value calculated on the log 10 scale.
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Odds of developing a lymphoma during prospective follow-up
The odds of developing lymphoma for a 2-fold higher marker level both ≤ 2 and > 2 years before 
lymphoma diagnosis or matched date in controls are shown in Figure 6.5. A 2-fold higher level
of FLC-κ (OR: 1.84 95%CI: 1.19, 2.84), FLC-λ (OR: 2.15 95%CI: 1.34, 3.46), IgG (OR: 3.05 95%CI: 
1.41, 6.59), and IgM (OR: 1.46 95%CI: 1.01, 2.11) were predictive of lymphoma development >2
years prior to diagnosis. However, associations were not evident ≤ 2 years prior to diagnosis. No 
association was found for 2-fold higher IgA or IgD (although, the p-value was close to 0.05 for
the association > 2 years prior for IgD) at either time point. FLC-κ+λ (OR: 2.08 95%CI: 1.30, 3.35) 
was predictive > 2 years but not ≤ 2 years prior to diagnosis prior to lymphoma diagnosis. The 
ratio of FLC-κ/λ was not predictive at either > 2 years or ≤ 2 years prior to diagnosis.  
Proportionately high levels of both FLC-κ and FLC-λ (a marker of polyclonal expansion) was 
associated with lymphoma >2 years prior to diagnosis (OR: 4.74 95%CI: 1.71 – 27.56), but not ≤ 
2 years prior (1.62 94%CI: 0.54, 5.05). Having a disproportionately high level of one FLC (a marker
of monoclonal expansion) was not associated at either time point.
Figure 6.5 Odds ratio (OR) of lymphoma associated with a 2-fold increase in B-cell markers, ≤2 and >2 years prior 
to diagnosis.
OR: Odds ratio, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, FLC: free light chain, Ig:
immunoglobulin.
The odds of developing lymphoma for both a 10-fold higher current and AUC of HIV-VL level ≤2 
and > 2 years before lymphomas are shown in Figure 6.6. In those who had HIV-VL measured (N
= 586 samples in 214 people), a 10-fold higher AUC of HIV-VL was associated with a higher risk
of lymphoma in plasma samples ≤ 2 years prior to diagnosis (OR: 1.68, 95%CI: 1.08, 2.62), 
however HIV-VL was predictive >2 years prior (OR: 1.51 95%CI: 1.1, 2.08).
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Figure 6.6 Odds ratio of lymphoma associated with a 2-fold increase in current HIV viral load (HIV-VL) and area
under the curve (AUC) of HIV-VL, ≤ 2 and > 2 years. 
OR: Odds ratio, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, HIV-VL: HIV viral load,
AUC: area under the curve.
Predictive value of B-cell markers
The marker with the best predictability ≥ 2 years prior to lymphoma diagnosis was FLC-λ (Table 
6.5). This marker predicted lymphoma diagnosis with better accuracy than chance alone
(P<0.01), however the c-statistic of 0.67 suggests only poor to moderate classification power.
The following markers also had some predictive power (all P<0.05), however prediction was
poor to moderate at best: FLC-κ+λ (c-statistic = 0.67, poor-moderate prediction), and IgG (c-
statistic: 0.64, poor-moderate). Only FLC-λ (c-statistic: 0.61) predicted lymphoma within 2 years 
of diagnosis, however accuracy was poor. No other markers were predictive (all P>0.05).
Table 6.5 c-statistics for prediction of lymphoma diagnosis for each marker, stratified by < 2 years prior to diagnosis
and ≤ 2 years prior to diagnosis. 
B-cell markers
≥ 2 years <2 years 
c-statistic P1 c-statistic P1
FLC–κ 0.65 (0.56,0.74) 0.29 0.56 (0.45,0.66) 0.29 
FLC–λ 0.67 (0.58,0.76) <.01 0.61 (0.51,0.71) 0.04 
Ratio FLC–κ/λ 0.53 (0.43,0.62) 0.60 0.54 (0.43,0.64) 0.48 
Sum FLC–κ+λ  0.67 (0.58,0.76) <.01 0.58 (0.47,0.68) 0.15 
IgG 0.64 (0.55,0.73) <.01 0.55 (0.45,0.65) 0.32
IgA 0.52 (0.42,0.62) 0.65 0.50 (0.40,0.61) 0.94
IgM 0.59 (0.49,0.69) 0.09 0.52 (0.41,0.63) 0.70
IgD 0.58 (0.49,0.68) 0.10 0.54 (0.44,0.64) 0.43
FLC: free light chain, Ig: immunoglobulin.
1 P compares the c-statistic for each marker to 0.5 (i.e. prediction is no better than chance).
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Trajectories of each B-cell marker prior to diagnosis
The trajectories of each marker in the cases and controls and unadjusted percentage change per
year for each marker in the time leading up to diagnosis or matched date in controls are shown
in Figure 6.7 to Figure 6.16. In unadjusted analysis, the largest difference was observed for IgM,
which was declining in cases by 6.42% (95%CI: 3.12, 9.61) per year, but levels were stable in
controls (%Change per year: 0.40 95%CI:-2.09, 2.95%) (Figure 6.13). The difference in the rates
of change per year between cases and controls was statistically significant (P for interaction <
0.01). Levels of IgG were also declining in cases, but stable in controls (Figure 6.11), which was
a borderline significant difference in the rates of change per year when comparing cases and
controls (P for interaction=0.10). Although levels of FLC-κ were stable in cases but increasing in 
controls (Figure 6.7), the difference in the rates of change per year between cases and controls
were non-significant (P for interaction = 0.20). The ratio of FLC-κ/λ was increasing in cases, but 
stable in controls (Figure 6.9), and conversely, FLC-κ+λ level was increasing in controls but stable 
in cases (Figure 6.10), however the differences in the rates of change per year between cases
and controls were not-significant for either (P for interaction = 0.44 and 0.16, respectively).
Levels of FLC-λ (Figure 6.8), IgA (Figure 6.12), and IgD (Figure 6.14) did not change over time in 
either cases or controls. The trajectories were similar after adjustment for matching variables
(Table 6.6, adjusted model 1). Further adjustment for current CD4 cell count, current age and
HIV treatment variables also produced consistent results (Table 6.6, adjusted model 2).
Trajectories of HIV-VL prior to diagnosis
In those who had a HIV-VL measured (N = 586 samples in 214 people), in unadjusted analysis,
HIV-VL levels were high many years prior to diagnosis (Figure 6.15), and significantly declined in
cases in the time leading up to diagnosis, whereas levels were stable in controls, however this
difference was not significant (P=0.11). The level of current CD4 cell count was stable in both
cases and controls (Figure 6.16). The trajectories for HIV-VL were similar after adjustment for
matching variables (Table 6.6, adjusted model 1) and after further adjustment for current CD4
cell count, current age and HIV treatment variables also produced consistent results (Table 6.6,
adjusted model 2). Trajectories for CD4 attenuated after adjustment for HIV treatment variables,
however the conclusions remained unchanged (Table 6.6, adjusted model 2).
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% change1 cases 0.28 (-2.91,3.55)
% change1 controls 2.90 (0.53,5.31)*
Figure 6.7 Trajectory of FLC-κ prior to lymphoma 
diagnosis in cases and controls.
% change1 cases -1.54 (-4.63,1.66)
% change1 controls 1.74 (-0.58,4.11)
Figure 6.8 Trajectory of FLC-λ prior to lymphoma 
diagnosis in cases and controls.
% change1 cases 2.22 (0.23,4.25)*
% change1 controls 1.26 (-0.17,2.7)
Figure 6.9 Trajectory of FLC-κ/λ prior to lymphoma 
diagnosis in cases and controls.
% change1 cases -0.4 (-3.43,2.73)
% change1 controls 2.38 (0.11,4.68)*
Figure 6.10 Trajectory of FLC-κ+λ prior to lymphoma 
diagnosis in cases and controls.
FLC: free light chain
1 The unadjusted percentage change per year (% change) in each marker per year (i.e. the slope) in the
time leading up to diagnosis is shown at the top of each panel.
* P for change<0.05: This is testing whether there is a significant increase or decline in the markers over
time.
P for interaction: This tests whether the % change per year is different in cases and controls. FLC-κ: 0.2, 
FLC-λ: 0.1, Ratio FLC- κ/λ: 0.44, FLC- κ+λ: 0.16. 
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% change1 cases -2.54 (-4.18,-0.88)*
% change1 controls -0.84 (-2.04,0.38)
Figure 6.11 Trajectory of IgG prior in cases and
controls.
% change1 cases -1.46 (-4.00,1.14)
% change1 controls -1.26 (-3.11,0.61)
Figure 6.12 Trajectory of IgA prior in cases and controls.
% change1 cases -6.42 (-9.61,-3.12)*
% change1 controls 0.40 (-2.09,2.95)
Figure 6.13 Trajectory of IgM in cases and controls.
% change1 cases -1.46 (-5.99,3.29)
% change1 controls -0.76 (-4.09,2.68)
Figure 6.14 Trajectory of IgD in cases and controls.
% change1 cases -20.88 (-33.04,-6.52)*
% change1 controls -6.50 (-16.85,5.13)
Figure 6.15 Trajectory of HIV viral load (HIV-VL) in
cases and controls.
% change1 cases 3.78 (-0.88,8.66)
% change1 controls 3.30 (-0.07,6.77)
Figure 6.16 Trajectory of CD4 cell count in cases and
controls.
Ig: immunoglobulin, HIV-VL: HIV viral load,
1 The unadjusted percentage change per year in each marker per year (i.e. the slope) in the time leading
up to diagnosis is shown at the top of each panel.
* P for change<0.05: This is testing whether there is a significant increase or decline in the markers over
time.
P for interaction: This tests whether the % change per year is different in cases and controls. IgG: 0.10,
IgA: 0.90, IgM<0.01, IgD: 0.81, current HIV-VL: 0.11, current CD4 cell count: 0.87.
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Table 6.6 Percent (%) change per year in FLC-κ and FLC-λ, FLC-κ/λ, FLC-κ+λ, IgG, IgA, IgM, IgD, current HIV viral load and CD4 cell count (unadjusted and adjusted). 
Marker Unadjusted model Adjusted model 12 Adjusted model 23
% change per year
(95%CI) P for interaction
1 % change per year
(95%CI) P for interaction
1 % change per year
(95%CI) P for interaction
1
FLC–κ
Case 0.28 (-2.91,3.55) 0.20 0.4 (-2.78,3.69) 0.21 1.9 (-1.33,5.22) 0.32
Control 2.9 (0.53,5.31) 2.96 (0.58,5.41) 3.82 (1.07,6.63)
FLC–λ
Case -1.54 (-4.63,1.66) 0.10 -1.3 (-4.42,1.94) 0.10 0.78 (-2.54,4.22) 0.12
Control 1.74 (-0.58,4.11) 2.02 (-0.35,4.43) 3.92 (1.07,6.84)
Ratio FLC–κ/λ
Case 2.22 (0.23,4.25) 0.44 2.1 (0.1,4.13) 0.44 1.46 (-0.59,3.53) 0.30
Control 1.26 (-0.17,2.7) 1.14 (-0.31,2.59) 0.18 (-1.47,1.87)
Sum FLC–κ+λ
Case -0.4 (-3.43,2.73) 0.16 -0.18 (-3.23,2.96) 0.16 1.56 (-1.56,4.79) 0.24
Control 2.38 (0.11,4.68) 2.52 (0.25,4.86) 3.78 (1.11,6.5)
IgG
Case -2.54 (-4.18,-0.88) 0.10 -2.5 (-4.13,-0.83) 0.10 -1.06 (-2.71,0.61) 0.07
Control -0.84 (-2.04,0.38) -0.82 (-2.03,0.41) 0.7 (-0.71,2.14)
IgA
Case -1.46 (-4,1.14) 0.90 -1.72 (-4.25,0.89) 0.89 -0.5 (-3.27,2.34) 0.73
Control -1.26 (-3.11,0.61) -1.5 (-3.34,0.39) 0.04 (-2.38,2.51)
IgM
Case -6.42 (-9.61,-3.12) <0.01 -6.72 (-9.91,-3.43) <0.01 -4.26 (-7.5,-0.92) <0.01
Control 0.4 (-2.09,2.95) 0 (-2.5,2.57) 2.34 (-0.62,5.38)
IgD
Case -1.46 (-5.99,3.29) 0.81 -0.78 (-5.35,4.02) 0.79 0.36 (-4.77,5.76) 0.89
Control -0.76 (-4.09,2.68) 0 (-3.39,3.5) . 0.76 (-3.75,5.5)
Current CD4 cell count
Case 3.78 (-0.88,8.66) 0.87 4.18 (-0.51,9.07) 0.85 1.44 (-3.2,6.31)4 0.49
Control 3.3 (-0.07,6.77) 3.62 (0.22,7.13) -0.5 (-4.23,3.37)4
Current HIV-VL
Case -20.88 (-33.04,-6.52) 0.11 -21.88 (-33.81,-7.79) 0.09 -17.06 (-28.96,-3.15) 0.13
Control -6.5 (-16.85,5.13) -6.94 (-17.27,4.67) -4.68 (-15.57,7.61)
FLC: free light chain, Ig: immunoglobulin, HIV-VL: HIV viral load. 1 P for interaction: This tests whether the % change per year is different in cases and controls. 2Adjusted Model 1: Age and CD4 at earliest
plasma sample, region of Europe and gender, 3Adjusted Model 2: Time updated Age, time updated CD4 (with the exception of current CD4 cell count trajectory), region of Europe, gender, currently on
cart, duration of time on cART, 4 Model adjusted for CD4 at earliest plasma sample instead of time updated CD4.
263
Patient factors associated with B-cell marker levels in controls
Adjusted associations between demographic, HIV, and immunological related factors and
marker levels in the control population are shown in Table 6.7 and Table 6.8. For each factor,
the adjusted fold change in marker level is presented. For example, those from southern Europe
had on average a 1.46-fold higher marker level compared to those from west-central Europe
(Table 6.7). The results for FLC-κ, FLC-λ, and IgG are shown in Table 6.7, and for IgA, IgM, and 
IgD in Table 6.8. Higher FLC-κ, FLC-λ, and IgG were all associated with HIV transmission modes 
other than sex between men, lower current CD4 cell count, higher current HIV-VL and not being
on cART (borderline for FLC-λ) (Table 6.7). FLC-κ and FLC-λ levels also increased with older age. 
Higher IgA was associated with lower CD4 cell count and higher AUC of HIV-VL (Table 6.8). Higher
IgM was as associated with higher HIV-VL, not being on cART, and HIV transmission mode other
than sex between men. Higher IgD level was associated with higher AUC of HIV-VL and higher
nadir CD4 cell count (borderline).
Collaboration with the Binding Site
This study was performed in collaboration with the Binding Site. The Binding Site provided the
kits free of charge. As part of an academic collaboration and have not been involved in the
presentation of these data or the decision to publish these data. Contact details for the Binding
Site are below.
The Binding Site Group Ltd
8 Calthorpe Road
Edgbaston
Birmingham
B15 1QT
Tel: 44 (121) 456 9500
Fax: 44 (121) 456 9749
Email: info@bindingsite.co.uk
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Table 6.7 Multivariate analysis of the fold change in FLC-κ, FLC-λ, and IgG associated with patient factors.  
Effect
FLC-κ FLC- λ IgG 
Fold change (95%CI) P Fold change (95%CI) P Fold change (95%CI) P
Age (1 year older) 1.25 (1.13 , 1.38) <.01 1.14 (1.03 , 1.26) 0.01 1.00 (0.94 , 1.05) 0.81
Region
South 1.46 (1.10 , 1.95) 0.01 1.45 (1.08 , 1.95) 0.01 1.31 (1.12 , 1.52) <.01
North 1.20 (0.95 , 1.52) 0.12 1.25 (0.98 , 1.59) 0.07 1.20 (1.06 , 1.37) <.01
East and East central 1.11 (0.77 , 1.59) 0.58 0.99 (0.69 , 1.44) 0.98 1.15 (0.95 , 1.40) 0.13
West-central Reference Reference Reference .
Female Gender 1.03 (0.73 , 1.46) 0.87 0.88 (0.61 , 1.25) 0.47 0.97 (0.81 , 1.17) 0.77
Non-white ethnicity 0.90 (0.65 , 1.23) 0.5 0.92 (0.66 , 1.27) 0.6 1.06 (0.89 , 1.26) 0.46
Non-sex between men HIV transmission mode 1.33 (1.07 , 1.66) 0.01 1.36 (1.09 , 1.70) <.01 1.19 (1.06 , 1.34) <.01
Current CD4 cell count (2-fold higher) 0.91 (0.86 , 0.97) <.01 0.91 (0.86 , 0.96) <.01 0.97 (0.94 , 0.99) 0.04
Nadir of CD4 (2-fold higher) 1.00 (0.95 , 1.06) 0.92 1.01 (0.96 , 1.08) 0.63 0.99 (0.96 , 1.02) 0.14
Current HIV-VL
Missing 1.39 (0.76 , 2.53) 0.29 1.54 (0.88 , 2.68) 0.13 1.15 (0.85 , 1.55) 0.54
low: < 500 0.86 (0.78 , 0.94) <.01 0.86 (0.79 , 0.94) <.01 0.92 (0.88 , 0.96) <.01
high: ≥ 500 Reference Reference Reference
AUC of HIV-VL
Missing 0.81 (0.48 , 1.36) 0.42 0.73 (0.45 , 1.19) 0.21 0.82 (0.63 , 1.07) 0.22
low < 50% 0.91 (0.78 , 1.05) 0.2 0.96 (0.83 , 1.10) 0.53 0.95 (0.88 , 1.02) 0.1
high  ≥ 50% Reference Reference Reference
Not on cART 1.25 (1.07 , 1.47) <.01 1.16 (0.99 , 1.35) 0.06 1.15 (1.06 , 1.25) <.01
FLC: free light chain, Ig: immunoglobulin, HIV-VL: HIV viral load, AUC: area under the curve, cART: antiretroviral therapy.
Models were adjusted for all variables listed in the table.
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Table 6.8 Multivariate analysis of the fold change in IgA, IgM, and IgD associated with patient factors.
Effect
IgA IgM IgD
Fold change (95%CI) P Fold change (95%CI) P Fold change (95%CI) P
Age (1 year older) 1.00 (0.94 , 1.05) 0.89 0.96 (0.87 , 1.06) 0.47 1.06 (0.95 , 1.17) 0.29
Region
South 1.31 (1.12 , 1.52) <.01 0.98 (0.74 , 1.30) 0.91 1.24 (0.92 , 1.67) 0.15
North 1.20 (1.06 , 1.37) <.01 1.16 (0.92 , 1.46) 0.22 1.12 (0.88 , 1.44) 0.35
East and East central 1.15 (0.95 , 1.40) 0.14 1.11 (0.78 , 1.59) 0.55 1.66 (1.15 , 2.41) <.01
West-central Reference Reference Reference
Female Gender 0.97 (0.81 , 1.17) 0.76 0.90 (0.64 , 1.27) 0.55 1.17 (0.81 , 1.67) 0.41
Non-white ethnicity 1.06 (0.89 , 1.26) 0.51 0.74 (0.54 , 1.02) 0.07 0.84 (0.60 , 1.17) 0.3
Non-sex between men HIV transmission mode 1.19 (1.06 , 1.34) <.01 0.87 (0.70 , 1.07) 0.19 1.34 (1.07 , 1.68) 0.01
Current CD4 cell count (2-fold higher) 0.97 (0.94 , 0.99) 0.02 0.92 (0.88 , 0.97) <.01 0.96 (0.90 , 1.02) 0.15
Nadir of CD4 (2-fold higher) 0.99 (0.96 , 1.02) 0.68 0.98 (0.93 , 1.04) 0.53 1.06 (1.00 , 1.13) 0.05
Current HIV-VL
Missing 1.15 (0.85 , 1.55) 0.37 0.99 (0.59 , 1.66) 0.97 1.36 (0.75 , 2.49) 0.31
low: < 500 0.92 (0.88 , 0.96) <.01 1.02 (0.94 , 1.11) 0.63 0.72 (0.66 , 0.80) <.01
high: ≥ 500 Reference Reference Reference
AUC of HIV-VL
Missing 0.82 (0.63 , 1.07) 0.15 0.82 (0.52 , 1.28) 0.38 0.66 (0.39 , 1.11) 0.12
low < 50% 0.95 (0.88 , 1.02) 0.16 0.85 (0.74 , 0.97) 0.02 0.88 (0.76 , 1.02) 0.09
high  ≥ 50% Reference Reference Reference
Not on cART 1.15 (1.06 , 1.25) <.01 0.98 (0.85 , 1.14) 0.83 1.29 (1.09 , 1.52) <.01
Ig: immunoglobulin, HIV-VL: HIV viral load, AUC: area under the curve, cART: antiretroviral therapy.
Models were adjusted for all variables listed in the table.
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Discussion
This study investigated the trajectories of FLC-κ, FLC-λ, IgG, IgA, IgM, and IgD over time prior to 
lymphoma diagnosis. I show that the strength of association diminishes consistently with time
leading up to diagnosis. Levels of FLC-κ, FLC-λ, and IgG were associated with lymphoma 
development in HIV+ people more than 2 years prior to lymphoma development, however,
predictive power for lymphoma development was poor. The markers investigated in this
chapter, therefore, are unlikely to be strong candidates for risk assessment for targeted
interventions for monitoring of high risk patients and early diagnosis.
Levels of markers of B-cell activation in cases and controls
In my study, proportionately higher levels of both FLC-κ and FLC-λ (a marker of polyclonal 
expansion) were associated with lymphoma >2 years prior to diagnosis. Two main studies have
also demonstrated that elevated levels of FLC-κ and FLC-λ are associated with higher likelihood 
of lymphoma development in HIV+ people [846, 847]. The study by Landgren et al (2010) [846]
found that elevated FLC-κ and FLC-λ were associated with NHL 2–5 years prior to diagnosis, 
conversely only FLC-λ was associated 0–2 years prior [846]. However, a later study by the same 
group subsequently found FLC-κ and FLC-λ levels to be similarly predictive of all AIDS defining 
events and not specifically NHL [895]. Results were consistent in the more recent study by Bibas
et al (2012) [847], who found FLC-κ and FLC-λ to be predictive of both NHL and HL independently 
of CD4 cell count and HIV-VL [847]. My finding that FLC-κ and λ are predictive of lymphoma in 
the long term are somewhat concurrent with those of Landgren et al and Bibas et al [846, 847],
however, I did not find an association with FLC-λ closer to diagnosis. Furthermore, my finding 
the polyclonal FLC elevations preceded lymphoma development is also concurrent with both
studies [846, 847].
The results presented in this chapter demonstrate an association between IgG and IgM >2 years
prior to date of lymphoma diagnosis (although the association with IgM was borderline), which
attenuated closer to this date. This was driven by a faster decline in levels in cases while controls
remained stable. This was not identified in study by Landgren et al (2010), which reported no
association between IgG, IgA or IgM and NHL diagnosis (possibly due to lower prevalence of
cART use in that study which may have masked this association) [846]. Studies have found mixed
associations between immunoglobulins and lymphomas in HIV. For example, an Australian study
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found high levels of serum globulin, mainly IgG, were predictive of NHL [890]. However, other
studies found no association between serum globulin, immunoglobulins and NHL [606, 891].
In this study, levels of FLC-κ and λ were higher in cases and controls long before diagnosis, 
however the difference between cases and controls attenuated closer to the matched date. For
FLC-κ and λ, this was driven by an increase in levels in controls while levels in cases remained 
constant. The attenuation in the difference between cases and controls over time is intriguing
and is consistent with previous findings [846, 847, 890]. This result could simply reflect a 2 year
lag period for the increase in B-cell activity to manifest as a clinically detectable lymphoma [847].
However, I hypothesise that the observed trends are probably reflecting the concurrent, but
very different, immune consequences induced by HIV infection and lymphoma development and
disentangling this relationship is not straight forward. HIV associated immunosuppression
causes hypergammaglobulinaemia with elevated serum levels of immunoglobulins, mainly IgG
but also IgA and IgD [858]. Conversely, studies in the general population have found lower levels
of IgM, IgA and IgG prior to lymphoma diagnosis [892], and levels declined with more advanced
disease [892, 893, 906-908], speculated to be driven by the developing lymphoma. Additionally,
transformed B-cells may have compromised immunoglobulin production and levels may not
reflect the immune environment in which the lymphoma initiated [893]. Therefore, it is possible
the decline in marker levels ≤2 years may be a consequence of early undiagnosed lymphoma. A 
similar phenomenon has been reported for undiagnosed HL and declining CD4 cell counts within
1–2 years prior to diagnosis [468, 586].
Current HIV-VL was found to be a strong predictor of lymphoma risk > 2 years prior to diagnosis
however, AUC of HIV-VL was a predictor ≤2 years prior to diagnosis. This indicates that exposure 
to uncontrolled HIV replication in the past and the associated effects on the immune system,
may play a role in lymphomagenesis. This result is independent of CD4 cell count which was a
matching factor. Furthermore, these results are in keeping with the study by Bibas et al (2012),
which found duration of undetectable HIV-VL, but not current CD4 cell count or current VL, to
be associated with lymphoma risk [847]. Additionally, NHL has been repeatedly linked with HIV-
VL in the literature [16, 18, 433, 435, 451, 606, 816, 819], and the results in this chapter add to
the growing body of literature supporting the involvement of HIV-induced immune dysfunction,
above and beyond immune deficiency, in the development of NHL in HIV+ people [816, 840].
In chapter 5, I demonstrated that NHL was associated with both current and AUC of HIV-VL, but
HL was not associated with HIV-VL. In this chapter, I have again demonstrated a link between
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previous HIV-VL level and lymphoma, probably driven by the high proportion of NHL in this
analysis. Furthermore, in this chapter, I have shown that markers of polyclonal rather than
monoclonal B-cell expansion precedes lymphoma diagnosis. This implies that HIV induced B-cell
activation precedes lymphoma development in HIV+ people, rather than or in addition to EBV
induced activation [857]. Furthermore, elevated levels of IgG and IgM many years prior to
diagnosis indicate HIV associated hyperglobulinaemia, which further supports the involvement
of HIV induced B-cell dysfunction. Although not evident in this chapter, HL is almost completely
EBV related in HIV+ people and lymphomagenesis is likely driven by low CD4 cell counts (as
shown in chapter 5) allowing for loss of EBV control and HIV itself does not seem to play a direct
role.
Predictive value of B-cell markers
Although FLC-λ, Sum FLC-κ+λ, and IgG were predictive of lymphoma development ≥ 2 years prior 
to lymphoma development, the predictive power was poor. This is likely reflecting the
complexity of the processes surrounding lymphomagenesis.
Factors associated of markers of B-cell activation
Age
The Higher levels of FLC-κ and FLC-λ were associated with older age, which may reflect the 
increased immune dysfunction and inflammation associated with aging (see chapter 1 section
1.2.4) [909]. This finding adds further evidence to the conclusions in chapter 5, that immune
dysfunction, such as chronic activation and inflammation, which occurs with older age is
involved in the pathology of NHL [721]. This is further supported by recent results that link
polyclonal FLCs to impaired dendritic cell maturation, which could indicate that elevated
polyclonal FLCs may be a marker of innate immune dysfunction and reduced immune
surveillance and immune senescence [909].
Immunological and Virological factors
Elevated levels of FLC-λ, FLC-κ, and IgG were associated with higher current HIV-VL and lower 
current CD4 cell count in controls, which is consistent with other studies [847, 896]. Higher levels
of IgM were correlated with higher current HIV-VL only. The markers were not associated with
historical measures of HIV-VL or CD4, indicating that levels reflect the immediate immune
environment, rather than long term immune dysfunction. When considered in light of the
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discussion in section 6.4.1, these findings may indicate that exposure to uncontrolled HIV-VL is
playing an integral role in lymphoma development [816], and elevated FLCs may be reflecting
HIV specific B-cell dysfunction [857] occurring long before diagnosis. In addition, IgA was also
associated with both higher current CD4 and lower AUC of HIV-VL. IgD was associated with lower
AUC of HIV-VL and borderline associated with higher nadir CD4. However these two markers
were not associated with lymphoma development.
HIV treatment
Levels of FLC-λ, FLC-κ, IgG, and IgM were higher in those not on cART, after adjustment for CD4 
cell count and HIV-VL. This is in line with another study which found that FLCs in HIV+ people
were markers of disease severity and antiretroviral use [896]. Results from the START study have
demonstrated that cART use is associated with lower HIV-VL, higher CD4 and reduced
inflammation [910]. My results may reflect the benefit of cART by reducing the activation and
dysfunction of B-cells HIV+ people. This further supports the findings of the START study
indicating that HIV-treatment improves immune function beyond that of low CD4 cell counts
[141].
Other factors
Several markers varied according to region of Europe, for example, of FLC-λ and FLC-κ were 
higher in southern relative to west central Europe, where as IgM was higher in east or east
central Europe. To my knowledge, there is no reason for this biologically and likely reflects
confounding in the data due to unmeasured or unknown factors. There was no variation by
gender or ethnicity. Levels of FLC-λ, FLC-κ, IgG, and IgM were higher in those who acquired HIV 
through exposure other than sex between men, possibly indicating that immune activation and
dysfunction is higher in these groups. This could reflect increased activation due to higher
prevalence of HCV and HBV in those who inject drugs [911]. HCV infection is associated with
several B-cell disorders, including cryoglobulinaemia and B-cell NHL, and elevated levels of FLC-
κ and an abnormal FLC-ratio have been associated with the severity of B-cell dysfunction in HCV-
positive people [912, 913].
Strengths of these analyses
The major strength of this study is the availability of serial plasma samples collected prior to and
independently of lymphoma diagnosis, as well as the inclusion of a comparatively large number
of lymphomas from contemporary HIV+ individuals. Furthermore, although this is a case control
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study, cases and controls were nested within the EuroSIDA cohort. This design minimised the
risk of some biases common to case-control studies, such as selection and recall bias. Selection
bias is reduced as the cases and controls were drawn from the same population. In addition,
although the number of lymphomas were low, the matching between cases and controls
improved the efficiency of this analysis.
Limitations of these analyses
However, this chapter has a number of limitations which need to be kept in mind when
interpreting from the results. This is an observational study and a comparatively small nested
case-control study. Therefore, there is a risk the associations presented are affected by
confounding and conclusions regarding causality cannot be determined. There are many known
risk factors for lymphomas that are not collected in EuroSIDA and therefore could not be taken
into account. For example, environmental exposures, autoimmune disorders, family history and
EBV coinfection [607, 788, 789]. The original design of this study also involved measuring EBV
DNA in stored plasma samples. A laboratory was identified to perform the analysis, however, no
agreement on the time frame and cost of plasma sample analyses were attained within a timely
manner (further discussed in chapter 8). Therefore, I made the executive decision to progress
the study without the EBV component. Further adjustment for potential confounders was not
possible due to low numbers, although only minor significant imbalances were evident at
baseline. These included a lower proportion of cases on treatment and a lower proportion HCV
positive. The higher HCV prevalence in the control group may result in an underestimation of
the effects. Finally, the use of the matched design reduces risk of confounding of important risk
factors by design, but also increases the complexity of the data, requiring specialist methods for
analysis. Baseline CD4 was included as a matching factor in order to investigate the independent
associations between B-cell activation and lymphoma development, however, it should be kept
in mind that this may result in an underestimate of the association between markers of B-cell
activation and lymphoma development.
In this chapter NHL and HL were combined as the numbers were not sufficient to investigate
them separately. HL and NHL subtypes are a very heterogeneous group of cancers and
considering them together ignores important pathological differences [804, 838]. Bibas et al
(2012) [847] found that the elevated FLCs seems to be more associated with the risk of NHL than
HL, possibly suggesting a different pathological mechanism (although only 16 HL cases were
included). Another previous study investigated whether FLCs and immunoglobulins differed
according to NHL subtypes and found HL had slightly higher levels of IgA and lower levels of IgM,
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but no different in FLCs than NHL subtypes [894]. I repeated my analysis excluding HL cases and
their respective controls and the results were unchanged. For this chapter, associations could
not be investigated by NHL subtype due to insufficient numbers.
Another possible limitation is that FLCs levels may be affected by renal function as FLCs are
excreted and catabolised by the kidneys [888, 914]. Measurements of eGFR were only available
on one third of measurements (175/592, prospective collection of serum creatinine to calculate
eGFR started in 2004). However, in people with eGFR measurements available, there was no
evidence of a difference in eGFR between cases and controls at baseline. It is also possible that
changes in FLCs and immunoglobulins reflect undiagnosed or late diagnosed cancer rather than
preceding cancer development, however, the extended period over which plasma samples were
taken make this unlikely. And finally, the assays used to measure B-cell markers were not
validated in Plasma (validated in serum and whole blood) at the time of this study. Therefore it
is possible that these results are due to lack of sensitivity to the markers levels in the plasma
samples rather than true reflections of circulating levels at the time the plasma samples were
drawn.
Conclusions
In conclusion, FLC-λ, FLC-λ and IgG were higher more than 2 years before lymphoma diagnosis, 
but the difference diminished nearer diagnosis. B-cell dysfunction, as demonstrated by
polyclonal hyperglobulinemia, occurs many years prior to lymphoma development. The
trajectories of FLC-κ and λ IgG, IgA, IgM, and IgD over time prior to lymphoma diagnosis show 
that the strength of association diminishes consistently with time leading up to diagnosis. The
magnitude of the associations was moderate at best, and poorly predicted lymphoma
development. The markers investigated in this chapter are unlikely to be strong candidates for
risk assessment for targeted interventions
Publications
A manuscript for this chapter was accepted for publication in HIV Medicine in 2017. The results
were presented at the HIV drug therapy Glasgow conference in 2016. The manuscript and
presentation are included in Appendix IX and Appendix X respectively.
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7 Testing patterns and predictive value of prostate specific
antigen in a European HIV–positive cohort: does one size fit all?”
Introduction
Prostate cancer in the general population
Prostate cancer (PCa) is the most common solid neoplasm in older European men, with an
incidence of >200 cases per 100,000 men in the general population from north and west-central
Europe [915]. Over 41,700 men are diagnosed with PCa each year in the UK, accounting for
almost 1 in 4 of all cancers in men [916], with an estimated 1 in 8 men developing PCa in their
lifetime [916, 917].
Risk factors for prostate cancer
The causes of PCa in the general population are widely unknown, however, several factors
associated with a higher risk of PCa have been identified.
 Age is thought to be one of the strongest risk factors. Clinical PCa is relatively rare in
men aged <50 years, with approximately 1 in 3 of all diagnosis in men aged over 75 years
[916].
 Family history: Men with a first degree relative diagnosed with PCa also have higher risk
of PCa, and the risk increases with the number of first degree relatives diagnosed [915,
918, 919]. Risk is also increased in men whose mother was diagnosed with breast cancer
[916]. It is estimated that 9% of PCa is truly hereditary [915].
 BRCA1 and BRCA2 mutations: Men with a mutation on the BRCA2 gene have increased
risk of early onset PCa and more aggressive disease [920-922]. Mutations in the BRCA1
may also increase risk of PCa [916, 922].
 Ethnicity: Risk of PCa is 2-fold higher in men of black ethnicity relative to white ethnicity
[916, 917].
 Hormone levels: Previous research suggested that high total testosterone levels may be
associated with higher risk of PCa and more rapid progression [923, 924], however,
recent studies have found no impact [431, 925-928]. Furthermore, no association has
been found in hypergonadal men (a condition with a higher prevalence in HIV-positive
[HIV+] men)[929].
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 Prostatitis: Two meta analyses indicated that prostatitis is associated with PCa
development, however they included studies that were heterogeneous and as well as
case-control studies [916, 930, 931]. Inflammation of the prostate has been found to be
predictive of PCa risk in prospective studies, however this may be driven by an
association with higher PSA levels [932].
 Diabetes: Diabetes has been associated with lower PCa risk. Recent studies have
attributed this to generally lower PSA levels in diabetic men and a lower rate of PCa
diagnosed through PSA testing (i.e. PSA > 4 ng/mL) compared to non-diabetic men [916,
933, 934].
Early detection and diagnosis of prostate cancer
European guidelines on the early detection and management of PCa in the general population
is provided by the European Association of Urology [915]. Men at high risk of PCa are generally
identified though elevated prostate specific antigen (PSA) tests and digital rectal exams (DRE).
A PSA ≥4 ng/mL and/or an abnormal DRE are commonly used as clinical indicators of PCa risk 
[935-937]. A DRE can be used to detect PCas in the peripheral area of the prostate and around
18% of PCas are detected using this method alone (regardless of PSA level) [915, 938]. The
introduction of PSA testing revolutionised PCa diagnosis. PSA level is thought to be a better
predictor of cancer than DRE alone [935, 939] and is the most common reason why PCa is
detected in the United States [935]. Men with an elevated PSA and/or abnormal DRE are then
required to have a biopsy to confirm the presence of PCa [915, 937, 939]. The biopsy involves
taking several small cores of prostate tissue which are then examined by a pathologist [939].
The biopsy results are summarised using the Gleason score which is a measure of PCa grade
(ranging from 2 – 10) based on the mix of cancer cells present [940]. Less aggressive cancers
tend to have lower Gleason scores (2 – 4), while more aggressive PCa tend to have higher
Gleason scores (7 – 10) [940].
Screening for prostate cancer
Screening is often initiated by health authorities with the intention of identifying PCa early to
maximise treatment options, reduce the PCa associated mortality, and to maintain or improve
future quality of life [935, 941]. There are two main approaches to screening: population based
(or mass) screening which is defined as the systematic examination of asymptomatic men at risk
for a disease, and opportunistic (or early detection) screening which involves individual case
finding initiated through communication between patient and physician [935]. Population based
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screening for PCa is currently one of the most controversial topics in the urological literature.
Population based screening is not currently recommended by most urological societies and
associated medical entities, however, recommendations on the appropriate use of screening in
PCa detection and management is conflicting [915, 937, 939, 942-944].
PCa is often asymptomatic while it remains localised to the prostate gland, however, if
diagnosed after the cancer has spread beyond the prostate, treatments are less effective [941].
Therefore, early detection and treatment could be highly beneficial [941]. It has been estimated
that screening for PCa can result in a diagnosis of PCa between five to 13 years earlier (referred
to as the lead time) [945]. There is currently no high level evidence that population based
screening using PSA testing reduces PCA mortality [915, 939, 941, 946, 947]. A Cochrane review
concluded that population based PCa screening leads to a 30% higher rate of diagnosis of PCa
as well as a higher rate of localised and less advanced PCa, however, no overall or PCa specific
survival benefit was found [488, 941, 948]. Furthermore, screening was associated with a high
degree of overdiagnosis, invasive and expensive follow-up tests, and unnecessary treatment in
some men (which can cause more adverse events than the PCa itself) [941]. One large RCT did
report a 20% significant reduction of PCa specific mortality in a pre-specified subgroup of men
aged 55 to 69 years (results were inconclusive in other age groups), but an overdiagnosis rate of
50% in those screened [945, 946, 949, 950]. Overdiagnosis refers to the situation where a man
is diagnosed with a clinically non-significant PCa though PSA testing that would not have been
apparent in the absence of PSA testing. Autopsy studies have shown many men living with
undiagnosed PCa often go on to die from another cause, therefore, overdiagnosis puts men at
risk of unnecessary treatment [945, 951, 952]. The European Randomised study of Screening for
Prostate Cancer Study (ERSPC) have estimated that the number needed to invite for PSA
screening to avoid one prostate cancer death was 781 and the number needed to detect and
treat was 27 [946], which is comparable to some breast cancer trials [953]. The benefits and
harms of screening are summarised in Figure 7.1
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Figure 7.1 Benefits and harms of prostate specific antigen (PSA) screening for prostate cancer (PCa) diagnosis in
men aged 55 or older from the US preventative task force 2017 draft recommendation statement on screening for
prostate cancer [954].
* This includes men who choose surgery or radiation at diagnosis, as well as men who choose to
monitor their cancer initially and later have surgery or radiation when it progresses.
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Survival after prostate cancer diagnosis
The 5 year survival for prostate cancer has been estimated to be 83.4 (83.1 – 83.6)% in Europe
and has increased over time from 76% to 87% between 1999 – 2007 [955]. The high 5 year
survival for PCa in Europe is closely linked to increasing diagnoses of early stage cancers and
longer lead time (the time by which the diagnosis is brought forward due to screening [956])
due to PSA testing [957]. Men with Low grade (Gleason < 6) and low volume PCa have less than
a <6% risk of disease progression within a decade of diagnosis and rate of progression is slow
[957].
Prostate cancer in HIV-positive men
Recent studies have consistently found a protective effect of HIV infection on PCa incidence in
the combination antiretroviral therapy (cART) era [15, 16, 21, 431, 438, 469, 486-488],
independently of PSA screening patterns and risk factors for PCa. Nonetheless, the frequency of
PCa diagnoses in HIV+ men has increased and is expected to continue as the proportion of HIV+
men aged >50 years grow [7, 436, 438, 958]. Furthermore, HIV+ people are estimated to have a
higher 2-fold higher mortality rate following PCa diagnosis than HIV-negative people after
adjustment for various patient factors, including age, cancer stage, and cancer treatment [535].
As PCa becomes more prevalent, urologist, and oncologists will increasingly contribute to HIV
care, with early PCa detection, diagnosis, and treatment likely to become an integral component
of management of HIV+ men [959, 960].
Guidelines on prostate specific antigen testing in HIV-positive
men
There are no clear guidelines on the use of PSA tests and screening for PCa in HIV+ men. The
British HIV association (BHIVA) recommend managing PCa in HIV+ men in a similar fashion to
those HIV-negative, however, detection and diagnosis of PCa is not addressed [961]. The
European AIDS Clinical society (EACS) guidelines are based on those for the general population.
They suggest that screening should be limited to men aged >50 years (unless considered high
risk) and to men with a life expectancy of more than 10 years. Recommended methods of
diagnosis include using a DRE, with or without a PSA test [140, 915]. Furthermore, it is
recommended that a decision to use PSA testing is performed on a per patient basis, where the
decision is between the patient and physician [140, 915]. The lack of clear or consistent
guidelines facilitates variations in screening patterns across clinics and regions.
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Markers associated with prostate cancer
Prostate specific antigen
PSA is a glycoprotein enzyme produced by epithelial cells of the prostate gland. It is elevated in
the presence of PCa, however PSA is organ specific rather than cancer specific, thus it is also
elevated in the presence of other prostate disorders [915]. Level of PSA is a continuous
parameter of PCa risk, meaning that the higher the PSA level, the higher the likelihood of PCa.
Unfortunately this is not useful in the context of clinical practice, and a PSA cut-off of PSA >4
ng/mL is often applied to identify “high risk” men [935, 936]. The sensitivity (true positive rate)
and specificity (true negative rate) of using a cut-off of PSA >4 ng/mL in the general population
has been estimated to be 21% and 90%, respectively, with a positive predictive value of 30%
[935, 942]. Indeed 79% of PCa will exist with PSA <4 ng/mL and can even exist even at very low
levels of PSA (Table 7.1) which may be missed in the screening process [915, 962].
Table 7.1 Prevalence of PCa in relation to low PSA values in the general population in the control arm of the
Prostate Cancer Prevention Trial [962].
PSA level (ng/mL) Prevalence of PCa
(%)
Prevalence of high grade PCa
(Gleason > 7) (%)
0.0 – 0.5 6.6 0.8
0.6 – 1.0 10.1 1.0
1.1 – 2.0 17.0 2.0
2.1 – 3.0 23.9 4.6
3.1 – 4.0 26.9 6.7
PSA: Prostate specific antigen, PCa: prostate cancer.
Serum Total PSA (tPSA) is made up of complexed PSA (cPSA) and free PSA (fPSA) [963]. How the
presence of PCa impacts on the prostate and PSA related processes is shown in Figure 7.2 and
Figure 7.3. In a healthy prostate (Figure 7.2), PROpsa is converted into active PSA in the lumen
region of the prostate. Some of the active PSA diffuses into circulation where it forms cPSA with
protease inhibitors (cPSA consists of three different forms: PSA-ACT, PSA-A2M and PSA-API),
however the majority undergoes proteolysis in the lumen to produce inactive PSA. Inactive PSA
enters circulation as fPSA (inactive and uncomplexed) and is made up of intact PSA and BPSA.
The presence of PCa can cause break down in basal cells, basement membrane and normal
lumen architecture (Figure 7.3). This results in a reduction of inactive PSA production in the
lumen and an increased amounts of active PSA leak into circulation and is converted into cPSA
[964-966]. This effectively increases the concentration of tPSA overall, but also increases ratio
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of cPSA to fPSA present in circulation. Therefore both fPSA and tPSA concentrations increase,
however fPSA increases at a slower rate and the proportion of free PSA declines.
Figure 7.2 Production of various molecular forms of
PSA within the prostate gland for men without PCa
(adapted from [964-966]). PSA-A2M is not easily
measured and is coloured in grey to demonstrate this.
Figure 7.3 Production of various molecular forms of
PSA within the prostate gland for men with PCa
(adapted from [964-966]). PSA-A2M is not easily
measured and is coloured in grey to demonstrate this.
PSA: Prostate specific antigen, PCa: prostate cancer.
Various derivatives of PSA have been suggested in order to improve the predictive power of PSA
alone for PCa detection and these are outlined in Table 7.2.
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Table 7.2 PSA derivatives and alternate measurements.
PSA derivatives Definition Association
fPSA/tPSA ratio
(f/tPSA) [915]
fPSA Divided by tPSA In the presence of PCa, the amount of both tPSA and fPSA in the blood increase, however fPSA
levels increases at a slower rate than tPSA, resulting in a lower ratio of fPSA to tPSA [915, 936, 967,
968]
f/tPSA is often used to differentiate benign prostate hyperplasia from PCa in men with moderately
elevated tPSA 4 – 10 ng/mL and a negative DRE. F/tPSA is not predictive in men with PSA >10
ng/mL [915, 969, 970]
PSA density [915] tPSA divided by prostate volume
(determined by trans-rectal
ultrasound) (TRUS)
The higher the PSA density, the more likely that PCa is clinically significant [971, 972]
PSA velocity
(PSAV) [973, 974].
absolute annual increase in tPSA
(ng/mL/year)
High levels of background noise limit use as a diagnostic marker. Potentially useful as prognostic
markers [975]
PSA doubling time
(PSA-DT) [974,
976].
measures the exponential
increase in tPSA over time
High levels of background noise limit use as a diagnostic marker. Potentially useful as prognostic
markers [975]
Prostate health
index (PHI)
Combines three isotypes of PSA:
pro[-2]PSA, fPSA and tPSA.
PHI = (pro[-2]PSA
/fPSA)*sqrt(tPSA)
Some studies have shown PHI to be a better diagnostic marker than tPSA or fPSA as well as having
improved detectability of clinically significant PCa. [977, 978]
PSA: Prostate specific antigen, PCa: Prostate cancer, tPSA: total PSA, fPSA: free PSA, DRE: digital rectal exam.
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Testosterone
Testosterone is the most important testicular androgen in men [979]. Deficient sex hormone
production, or hypogonadism, is common in HIV+ men (prevalence 12 - 20% in the cART era)
and may be treated with testosterone replacement therapy (TRT) to relieve symptoms [980,
981]. Some studies in the general population have linked elevated testosterone levels to
increased risk of PCa [923, 924], however, recent studies have found no impact [431, 925-927].
Very low testosterone levels have been linked with lower PSA values and therefore may mask
PCa detection through PSA testing [982], however, recent studies have shown that testosterone
replacement therapy does not raise PSA concentration in the long term [983]. In the adult
general population, testosterone levels tend to decline with older age [984].
Sex hormone binding globulin
Sex hormone binding globulin (SHBG) regulates the plasma levels and biological actions of
testosterone within the body [985]. In the adult general population, most circulating
testosterone is bound to SHBG (50-60%) [979]. When SHBG levels are low, this indicates that a
higher proportion of total testosterone will be bioavailable (not bound to SHBG) [985]. SHBG has
been modestly inversely associated with PCa risk as well as the velocity and doubling time [925].
SHBG levels also tend to increase with older age as testosterone levels decline [984].
Aims of this chapter
There is limited data available on variations in PSA testing practices in HIV+ men. Most studies
are US-based, where PSA testing has been widely used since 1980, and may not be generalizable
to European settings [431, 546]. No previous studies have investigated how PSA behaves prior
to PCa diagnosis in HIV+ men and appropriate use of a cut-off in HIV+ men remain largely
unverified. Therefore, these analyses had two aims.
 Aim 1: To perform a cohort analysis to assess variations in PSA testing patterns in
European HIV+ men.
 Aim 2: To perform a nested-case-control study to assess the diagnostic ability of tPSA
and fPSA associated with PCa risk, including changes in marker levels prior to diagnosis.
As PCa is a hormone dependent cancer, plasma levels of testosterone and SHBG were
also measured.
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Methods
Patients and methods
This study was conducted within the EuroSIDA cohort and utilised the EuroSIDA plasma biobank
of prospectively stored plasma samples. Both the EuroSIDA study and the biobank are described
in detail in chapter 2 sections 2.1.1 and 2.1.1.9. The EuroSIDA study has collected the results of
PSA tests performed locally at clinics (i.e. as part of patient care) since 1 January 2008. These
PSA tests will be referred to as reported PSA to distinguish them from centrally measured PSA
on plasma samples as part of the nested-case-control study. This study was done on the D38
version of the EuroSIDA database.
Aim 1: Reported testing for prostate specific antigen in Europe
The first component of this study investigated reported PSA testing rates in a cohort of European
men. Baseline was defined as the later of either first visit, 1 January 2008 or 1 January of the
first year the clinic reported PSA testing in ≥5% of men. Men were followed until the earliest of 
PCa diagnosis, last visit or death. The primary outcome was the incidence rate of reported PSA
testing during follow-up. All PSA tests reported to EuroSIDA during the follow-up period were
included and multiple PSA tests were allowed per person.
Inclusion criteria
Men enrolled in EuroSIDA with prospective follow-up after 1 January 2008 were included. Men
who were aged <16 years, without a CD4 cell count, or HIV viral load (HIV-VL) measured during
follow-up were excluded. Not all clinics use PSA testing as part of routine care or have routinely
reported PSA to EuroSIDA. Therefore, the main analysis was restricted to clinics that reported
PSA testing in ≥5% of attending men per year (N=4,482). Sensitivity analyses investigated how 
the results changed when including all clinics, regardless of PSA testing practices, and centers
that reported PSA testing in ≥10% and ≥25% of men per year. Prospective data collection for all 
cancers diagnosed in EuroSIDA has been in place since 2001. All cancers were classified using
the International Classification of Diseases and Related Health Problems, 10th edition [986].
Men with PCa prior to baseline, metastases of any cancer and recurrences of PCa during follow-
up were excluded. A flow chart for the inclusion criteria is shown in Figure 7.4.
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Figure 7.4 Flow chart for inclusion of EuroSIDA participants in cohort analysis.
PCa: Prostate cancer, PSA: prostate specific antigen.
Variables included in analyses
Both baseline and time updated variables from the EuroSIDA database were included in this
analysis, as detailed in Table 7.3.
Table 7.3 Summary of baseline and time updated variables.
Variable Time
updated
Levels Definitions and comments
Age (years) Yes Categorised into ≤35, 
36 – 40, 41 – 50, ≥ 51 
years
Calendar year Yes Categorised by year
Region of Europe East, east central,
south, west central,
north Europe, and
Argentina
See chapter 2 section 2.1.1.2
Ethnicity White, Non-white and
other (includes Asian,
black and unknown
race)
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Variable Time
updated
Levels Definitions and comments
HIV mode of
transmission
Sex between men,
heterosexual, IDU
other or unknown
BMI (kg/m2) Under weight (<18),
normal weight (18 –
25), Over weight (25 –
30), obese( 30+)
Classified according to the WHO standard
[597]
Smoking status Yes Non-smokers, current
smokers, previous
smokers, unknown
Current CD4 cell
count (cells/mm3)
Yes Categorised into <200,
200 – 349, 350 – 499,
≥500 cells/mm3,
unknown
Within 6 months prior to date of interest
Current HIV-VL
(copies/mL)
Yes Categorised into <400,
≥ 400 copies/mL, 
unknown
Within 6 months prior to date of interest
Prior AIDS
defining cancer
(ADC) diagnosis
Yes Yes , no Classified according to the 1993 CDC
clinical definition [133]
Prior AIDS
defining event
(excluding ADC)
Yes Yes , no Classified according to the 1993 CDC
clinical definition [133]
Prior non-AIDS
defining cancer
(NADC) diagnosis
Yes Yes , no
Prior non-AIDS
defining event
(excluding NADC)
Yes Yes , no Pancreatitis, grade 3 or 4 hepatic
encephalopathy or liver-related death,
myocardial infarction, stroke, coronary
artery bypass graft, coronary angioplasty,
carotid endarterectomy, and end-stage
renal disease [221]
HBV coinfection Yes Positive, negative, or
unknown
Most recent positive HBsAG surface
antigen test or presence of detectable HBV
DNA. Those without a HBV test were
categorised as unknown
HCV coinfection Yes Positive, negative, or
unknown
A prior positive HCV surface antibody test.
Those without a HCV test were categorised
as unknown
Hypertension Yes Yes, no systolic blood pressure >140 mmHG,
diastolic blood pressure >90 mmHg or
receiving any hypertensive drugs
Antiretroviral use Yes Yes, no Antiretroviral regimen containing ≥1 drugs 
from any class
IDU: through injecting drug use, BMI: Body mass index, HIV-VL: HIV viral load, ADC: AIDS defining cancer, NADC: non-
AIDS defining cancer, HBV: Hepatitis B, HCV; Hepatitis C.
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Statistical methods
7.5.2.3.1 Characteristics at baseline
Characteristics of men who had ≥1 reported PSA test recorded were compared to men who had 
no reported PSA test using numbers and percentages for categorical variables and median with
interquartile range (IQR) for numerical variables at baseline. All bivariate associations were
tested using chi squared tests for categorical variables and Kruskal-Wallis tests for numerical
variables.
7.5.2.3.2 Patient factors associated with prostate specific antigen testing
Poisson regression with generalised estimating equations assuming auto-regressive (AR1)
correlation allowing for repeated tests per person were used to investigate the association
between various demographic, HIV, and lifestyle related characteristics and PSA testing. The
AR(1) correlation structure was selected in order to assume that correlation diminished with
increasing time between observations. Variables included in the model were identified a priori
based on expert clinical input, availability of data, and the published literature.
Aim 2: The kinetics of and predictive value of prostate specific
antigen and other biomarkers for prostate cancer
The second component of this project involved designing and analysing a 1:2 nested-case-
control study within the EuroSIDA cohort to assess the kinetics and predictive value of PCa
biomarkers. The methodology used for the design of this study was similar to that described in
chapter 6.
Inclusion criteria
Men with follow-up after the 1 of January 2001 with no history of PCa were eligible for inclusion.
Both cases and controls were required to have at least one sample in the prospective sample
repository (the plasma repository is explained in detail in chapter 2 section 2.1.1.9) available
prior to PCa diagnosis (or equivalent in controls). Date of earliest plasma sample was considered
as baseline.
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Cases and controls
All eligible men with a primary diagnosis of PCa after 1 January 2001 were considered as cases.
For each case, 2 matched controls (where available) were selected using incidence density
sampling (see Figure 7.5). Controls were selected from eligible men with prospective follow-up
after 1 January 2001 with no history of PCa at the date of diagnosis for each case. If two controls
were not available, 1 control was selected. The date of diagnosis of each case and equivalent
date of latest sample in controls will be referred to as the “matched date”.
Matching variables
Cases and controls were matched on region of Europe, date of earliest plasma sample (±2 years),
date of latest plasma sample (±2 years), age at earliest plasma sample (± 5 years), CD4 cell count
at earliest plasma sample (± 200 cells/mm3). The windows used for matching were selected to
allow suitable identification of controls while ensuring as few cases as possible were excluded
from analyses.
An example of the selection of a case-control pair is shown in Figure 7.5. For each case of PCa
(top person), a similar person who was PCa free at the date of diagnosis of the case (represented
by the open circle) was selected. Incidence density sampling means the cases and controls are
matched on follow-up time. In the example, the date of each plasma sample is represented by
a red drop. The date of earliest sample for the case and control had to be within a 2 year window
(represented by the blue region), and the date of the latest sample for the case and control had
to be within a 2 year window (within the blue region).
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Figure 7.5 Selection of cases and controls using incidence density sampling.
PCa: prostate cancer.
Plasma samples and measurement of markers
All available serial plasma samples for cases and controls prior to the matched date were
considered for inclusion. Where more than one plasma sample was available during the same
calendar year, one sample was randomly selected for inclusion in order to preserve plasma
samples for future analysis in other biomarker studies. There were 284 samples selected for
analysis, however 2 were missing, 1 sample ID did not match to the correct patient and 4 were
not in the freezer. This resulted in 277 samples that were analyzed.
Serial plasma samples were analysed for tPSA, fPSA, SHBG, and testosterone. All biomarkers
were centrally measured by a technician blinded to case control status and other information
on frozen stored plasma at the Department of Clinical Biochemistry at Rigshospitalet. tPSA, fPSA,
and testosterone were measured by competitive electrochemiluminescense immunoassays
using Cobas 8000 (Roche Diagnostics, Indianapolis, IN). SHBG was measured by a sandwich
chemiluminescence immunometric assay using Immunulite 2000 (Siemens Healthcare
Diagnostics, Flanders, NJ). Lower limits of detection were 0.03 µg/L for tPSA, 0.02 µg/L for fPSA,
0.42 nmol/L for testosterone, and 2 nmol/L for SHBG.
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I considered the relationship between tPSA, fPSA, testosterone, SHBG and the ratio of fPSA to
tPSA (f/tPSA) and PCa. In men with ≥2 plasma samples available, the doubling time and the 
average percentage change in marker level were calculated for each marker. Doubling time
measures the exponential increase in serum PSA over time, in other words, the time in years it
takes for the PSA level to double (years).
Statistical methods
7.5.3.5.1 Characteristics of cases and controls at earliest sample and matching
variables
The characteristics of cases and controls were compared using numbers and percentages for
categorical variables and median with IQR for numerical variables at baseline. All bivariate
associations were tested using univariate conditional logistic regression due to the matched
nature of the data.
7.5.3.5.2 Kinetics of each marker in the time before matched date
Mixed models with random slopes and intercepts were used to describe kinetics of each marker
in the period prior to the matched date (accounting for multiple measurements within each
person). Differences in the trajectory of each marker in cases and controls were investigated by
testing for an interaction between time since first sample and case control status. Models were
adjusted for age at first sample, and current log2 CD4 cell count and log10 HIV-VL. Models for
fPSA and tPSA were further adjusted for current testosterone and SHBG level.
7.5.3.5.3 Association of each marker with likelihood of PCa
Unadjusted conditional logistic regression models were used to investigate the association
between the odds of PCa and levels of each marker at baseline and latest sample. A log2
transformation was applied to each marker. The average percentage change per year and
doubling time of each marker were also considered.
7.5.3.5.4 Sensitivity and specificity of total PSA for predicting PCa diagnosis
Receiver operator curve (ROC) analyses were used to assessed the predictive performance of
each marker [905]. The area under the ROC curve (c-statistic) can be used to assess which marker
(or combination of markers) best predicts cases and controls [905]. The c-statistic ranges from
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0.5 to 1, where a c-statistic = 0.5 indicates no predictive ability (i.e. the marker is no better at
determining PCa than flipping a coin) and a c-statistic = 1 indicates perfect predictability [905].
This was performed for each marker individually, all four markers combined, f/t PSA ratio, and
the average percentage change per year and doubling time of each marker. The sensitivity and
specificity of the widely used cut-off of tPSA>4 ng/mL was assessed and alternate cut-offs which
jointly optimised sensitivity and specificity were investigated. For the purposes of this study, I
considered sensitivity and specificity to be equally as important. For men with ≥2 samples 
available for analysis, the furthest sample from diagnosis was selected. I also considered age
specific cut-offs for men aged <50 and ≥50 years. 
All statistical tests were two sided with a type I error rate of 5%. All statistical analyses were
performed using SAS 9.3 (Statistical Analysis Software, Cary NC, USA).
Results
Aim 1: Reported testing for prostate specific antigen in Europe
Out of the 110 clinics who provide data to EuroSIDA, 59 clinics reported PSA test results in >5%
of men who attended their clinic annually, resulting in 4,482 men who were included in the
study. Of the 4,482 men who were included, 1,318 (29.4%) of them had ≥1 reported PSA test 
recorded during follow-up. A total of 3,368 PSA reported tests were reported across all men with
a median of 2 (IQR: 1, 3) tests per man.
I compared the 4,482 men included in this analysis who attended a clinic with a PSA testing rate
of 5% or higher annually to those who were excluded but under follow-up after 2008 (N=6,957).
Comparing men who were included to those who were not, a higher proportion were treatment
experienced (87.4 vs 78.7%, respectively), whereas a lower proportion had a CD4 cell count <200
cell/mm3 (6.7 vs 14.8%), HIV-VL >400 copies/mL (15.5 vs 34.9%), were HCV coinfected (13.8 vs
20.6%), or acquired their HIV through IDU (12.5% vs 20.1). A lower proportion of men from
Eastern Europe were included (1.9 vs 11.9%). Age was similar in both groups.
Prostate cancer incidence
There were 14 reported diagnoses of PCa during 14,169 person-years of follow-up (incidence
rate 1.0/1000 PYFU, 95%CI: 0.6, 1.7), and 10/14 PCa events which occurred in men who were
PSA tested, with a median most recent PSA level of 7.9 (IQR: 3.8, 10.4) ng/mL, measured a
median of 7 (IQR: 2, 13) months prior to PCa diagnosis.
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Baseline characteristics
The baseline characteristics of the cohort are shown in Table 7.4. Of the men included in the
analysis, 54% were aged 41 or older, 60% acquired HIV through sex between men, over 90%
were of white ethnicity and over three quarters were from south, west central or northern
Europe. Close to 80% of men has a baseline year of 2008. Over half had a CD4 cell count of 500
cells/mm3 or higher and almost 85% were virally suppressed (HIV-VL≤ 400 copies/mL). 
Approximately 5% had ever had an AIDS defining cancer (ADC) diagnosis and just over one
quarter had a prior AIDS event (other than ADC). Approximately 2% had been diagnosed with a
non-AIDS defining cancer (NADC), and just under 5% had had a non-AIDS defining event (other
than NADC). Just over one quarter had a history of hypertension while 5% were coinfected with
HBV and 14% of HCV. Close to 90% of the men included were antiretroviral experienced. Almost
70% of PSA testing in HIV+ men occurred in those aged under 50, and approximately one third
occurred in men aged under 40 years.
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Table 7.4 Baseline1 characteristics of men attending a clinic where >5% of men have at least one rouptinely reported
prostate specific antigen (PSA) test result per year.
Characteristics Baseline1 N(%)
All patients PSA test2 
Overall 4,482 ( 100) 1,318 ( 100)
Age (years)
    ≤ 35  1,100 (24.5) 218 (16 .5) 
36 – 40 943 (21.0) 216 (16.4)
41 – 50 1,520 (33.9) 478 (36.3)
51 or older 919 (20.5) 406 (30.8)
Region
East central 610 (13.6) 289 (21.9)
East 84 ( 1.9) 13 ( 1.0)
Argentina 262 ( 5.8) 27 ( 2.0)
South 1,389 (31.0) 393 (29.8)
West central 814 (18.2) 284 (21.5)
North 1,323 (29.5) 312 (23.7)
Calendar year of baseline1
2008 3,625 (80.9) 1,187 (90.1)
2009 17 ( 0.4) 8 ( 0.6)
2010 2 ( 0.0) 0 ( 0.0)
2011 82 ( 1.8) 20 ( 1.5)
2012 692 (15.4) 103 ( 7.8)
2013/14 64 ( 1.4) 0 ( 0.0)
Mode of HIV transmission
Sex between men 2,701 (60.3) 860 (65.3)
IDU 561 (12.5) 141 (10.7)
Heterosexual 925 (20.6) 242 (18.4)
Other/missing 295 ( 6.6) 75 ( 5.7)
Non-white ethnicity 348 ( 7.8) 78 ( 5.9)
Smoking status
Never 1,777 (39.6) 520 (39.5)
Current 1,508 (33.6) 422 (32.0)
Former 24 ( 0.5) 9 ( 0.7)
Unknown 1,173 (26.2) 367 (27.8)
prior ADC3 240 ( 5.4) 77 ( 5.8)
prior AIDS event (excluding ADC)3 1,202 (26.8) 413 (31.3)
prior NADC 96 ( 2.1) 36 ( 2.7)
prior Non-AIDS event (excluding NADC) 4 198 ( 4.4) 66 ( 5.0)
Prior Hypertension5 1,207 (26.9) 380 (28.8)
HBV6
Yes 247 ( 5.5) 69 ( 5.2)
No 3,575 (79.8) 1,059 (80.3)
Unknown 660 (14.7) 190 (14.4)
HCV 7
Yes 619 (13.8) 150 (11.4)
No 3,045 (67.9) 889 (67.5)
Unknown 818 (18.3) 279 (21.2)
CD4 cell count cells/mm3
    ≤ 200 300 ( 6.7) 81 ( 6.2) 
200 – 349 760 (17.0) 218 (16.5)
350 – 499 1,077 (24.0) 307 (23.3)
    ≥ 500 2,345 (52.3) 712 (54.0) 
HIV-VL > 400 copies/mL 695 (15.5) 168 (12.7)
Antiretroviral experienced8 3,917 (87.4) 1,205 (91.4)
PSA: prostate specific antigen, IDU: injecting drug use, ADC: AIDS defining cancer, NADC: non-AIDS
defining cancer, HBV: hepatitis B, HCV: hepatitis C, HIV-VL: HIV viral load.
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1 Baseline was defined as the latest of first visit, 01 January 2008, or the 1 of January of the first year in
which the attending clinic reported PSA testing rates >5% per year.
2 Reported PSA testing done in the clinic.
Factors associated with prostate specific antigen testing across
Europe
Unadjusted (IRR) and adjusted incidence rate ratios (aIRR) for reported PSA testing are shown
in Table 7.5. After adjustment, reported PSA testing in Europe was stable over time (aIRR for 1
year later: 1.00; 95%CI: 0.98, 1.02), although lower rates were observed in 2008 relative to 2010
and stabilized thereafter. The rate of reported PSA testing significantly increased with older age,
with the highest rate in those aged 51 or older. Testing was also elevated in men aged 41 – 50
compared to those aged 36 – 40 years. East central Europe had very high rates of reported PSA
testing, more than 7-fold higher than north Europe, and rates were also elevated in south and
west-central Europe. Testing rates were higher in men who acquired their HIV through sex
between men compared to other modes of HIV transmission, and were lower in those with
lower current CD4 cell counts, current smokers relative to never smokers, a history of
hypertension, or HCV coinfection. PSA testing was not associated with current HIV-VL, ethnicity,
prior ADC, NADC, AIDS or non-AIDS events or HBV coinfection.
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Table 7.5 Unadjusted (IRR) and adjusted incidence (aIRR) rate ratios of reported prostate specific antigen (PSA)
testing in EuroSIDA clinics where >5% of men have at least one PSA test result per year.
Characteristics Univariate analysis Multivariate analysis1
IRR (95%CI) P aIRR (95%CI) P
Overall
Age (years)
    ≤35 1.14 (0.82,1.59) 0.438 0.96 (0.73,1.26) 0.76 
36 – 40 reference reference
41 – 50 0.89 (0.68,1.17) 0.402 1.37 (1.10,1.70) <0.01
51 or older 1.39 (1.06,1.82) 0.017 2.37 (1.92,2.94) <0.01
Region
East central 6.25 (5.34,7.32) <.001 7.49 (6.42,8.73) <0.01
East 0.52 (0.29,0.92) 0.025 0.96 (0.56,1.66) 0.89
Argentina 0.48 (0.27,0.83) 0.009 0.74 (0.42,1.30) 0.3
South 1.31 (1.11,1.54) 0.001 1.72 (1.46,2.02) <0.01
West central 1.51 (1.28,1.79) <.001 1.54 (1.31,1.81) <0.01
North reference reference
Calendar year
2008 0.54 (0.46,0.63) <.001 0.67 (0.57,0.79) <0.01
2009 1.12 (1.02,1.23) 0.016 1.11 (1.01,1.22) 0.03
2010 reference reference
2011 0.95 (0.87,1.04) 0.251 0.95 (0.87,1.04) 0.26
2012 0.98 (0.90,1.08) 0.725 0.96 (0.88,1.05) 0.41
2013/14 1.19 (1.07,1.32) 0.001 0.96 (0.86,1.06) 0.42
Mode of HIV transmission
Sex between men reference reference
IDU 0.41 (0.34,0.51) <.001 0.64 (0.49,0.83) <0.01
Heterosexual 0.68 (0.57,0.81) <.001 0.74 (0.64,0.87) <0.01
Other/missing 0.74 (0.55,0.98) 0.038 0.73 (0.55,0.96) 0.03
Non-white ethnicity 0.65 (0.51,0.85) 0.001 1.28 (0.93,1.76) 0.13
Smoking status
Never reference reference
Current 0.71 (0.62,0.82) <.001 0.80 (0.71,0.90) <0.01
Former 0.75 (0.62,0.90) 0.002 0.96 (0.82,1.13) 0.61
Unknown 0.82 (0.58,1.16) 0.262 0.80 (0.60,1.06) 0.12
prior ADC 0.99 (0.78,1.26) 0.939 1.05 (0.84,1.32) 0.66
prior AIDS event (excluding ADC) 0.91 (0.80,1.05) 0.2 1.02 (0.89,1.16) 0.82
prior NADC 1.13 (0.90,1.41) 0.303 1.26 (0.94,1.70) 0.12
prior Non-AIDS event (excluding NADC) 0.95 (0.80,1.14) 0.602 0.84 (0.69,1.03) 0.1
Prior Hypertension 0.92 (0.81,1.04) 0.191 0.89 (0.79,0.99) 0.03
HBV
Yes 1.01 (0.80,1.27) 0.954 1.06 (0.89,1.27) 0.5
No reference reference
Unknown 0.67 (0.49,0.92) 0.013 0.69 (0.52,0.92) 0.01
HCV
No reference reference
Yes 0.55 (0.46,0.65) <.001 0.75 (0.61,0.93) <0.01
Unknown 1.53 (1.24,1.89) <.001 1.12 (0.94,1.33) 0.19
CD4 cell count cells/mm3
    ≤ 200 0.71 (0.55,0.91) 0.006 0.76 (0.61,0.95) 0.015
200 – 349 0.83 (0.71,0.98) 0.026 0.86 (0.75,0.99) 0.03
350 – 499 0.84 (0.75,0.94) 0.003 0.87 (0.79,0.97) 0.011
    ≥ 500 reference reference
HIV-VL > 400 copies/mL 1.17 (0.95,1.44) 0.134 1.11 (0.92,1.33) 0.28
Antiretroviral experienced 0.78 (0.56,1.09) 0.15 0.79 (0.58,1.09) 0.15
PSA: prostate specific antigen, IDU: injecting drug use, ADC: AIDS defining cancer, NADC: non-
AIDS defining cancer, HBV: hepatitis B, HCV: hepatitis C, HIV-VL: HIV viral load.
1 Models adjusted for all variables listed
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Sensitivity analysis: varying inclusion criterion of the proportion of
men tested for prostate specific antigen in each center per year
Sensitivity analyses varying the cut-off for the proportion of men tested in each center per year
to ≥ 0 (i.e. all centers), 5, 10 and 25% are shown in Table 7.6. Only key variables are shown. 
Overall, the main difference in results was an attenuation in the aIRR with an increasingly
restrictive definition. Starting with age, the association between older age and a higher rate of
reported PSA testing attenuates as the inclusion criteria moves from ≥0% to ≥25%, however the 
result was still significant. For calendar year, the lower rate of reported PSA testing observed in
2008 was similar for all sensitivity analyses, however a general increase in reported PSA testing
over time was observed when all centers were included, and when the analysis was restricted
to centers that tested ≥25% of men. The higher rate of reported PSA testing in east central 
Europe remained, regardless of changes in the entry criteria.
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Table 7.6 Sensitivity analyses varying the cut-off inclusion: proportion of men tested for prostate specific antigen (PSA) in each center per year to ≥ 0 (i.e. all centers), 5, 10 and 25%. 
Center screening rate
≥0% (All centers)
Men: 11439
Men with ≥1 PSA test: 1381
Main results: ≥5%
Men: 4482
Men with ≥1 PSA test: 1318
≥10%
Men: 2688
Men with ≥1 PSA test: 1026
≥25%
Men: 973
Men with ≥1 PSA test: 575
Variable aIRR P-value aIRR P-value aIRR P-value aIRR P-value
Age at baseline
    ≤ 35 years 1.01 (0.75,1.36) 0.942 0.96 (0.73,1.26) 0.76 1.13 (0.92,1.40) 0.247 1.03 (0.85,1.23) 0.789
36 – 40 years reference reference reference reference
41 – 50 years 1.52 (1.20,1.92) <.001 1.37 (1.10,1.70) <0.01 1.28 (1.08,1.52) 0.004 1.17 (1.01,1.35) 0.037
51 + years 2.57 (2.03,3.25) <.001 2.37 (1.92,2.94) <0.01 1.97 (1.66,2.34) <.001 1.77 (1.53,2.05) <.001
Calendar year
2008 0.07 (0.06,0.08) <.001 0.67 (0.57,0.79) <0.01 0.64 (0.53,0.78) <.001 0.06 (0.05,0.07) <.001
2009 0.84 (0.76,0.93) <.001 1.11 (1.01,1.22) 0.03 1.07 (0.97,1.18) 0.191 0.91 (0.83,1.01) 0.072
2010 reference reference reference reference
2011 1.11 (1.01,1.21) 0.024 0.95 (0.87,1.04) 0.26 0.91 (0.82,1.01) 0.079 1.07 (0.97,1.17) 0.198
2012 1.20 (1.10,1.32) <.001 0.96 (0.88,1.05) 0.41 0.83 (0.75,0.92) <.001 1.24 (1.13,1.36) <.001
2013/14 1.47 (1.32,1.63) <.001 0.96 (0.86,1.06) 0.42 0.91 (0.81,1.02) 0.104 1.58 (1.43,1.75) <.001
Region
East central 5.95 (5.03,7.03) <.001 7.49 (6.42,8.73) <0.01 4.77 (4.11,5.53) <.001 5.66 (4.89,6.56) <.001
East 0.32 (0.19,0.53) <.001 0.96 (0.56,1.66) 0.89
Argentina 0.78 (0.51,1.20) 0.262 0.74 (0.42,1.30) 0.3
South 2.00 (1.69,2.37) <.001 1.72 (1.46,2.02) <0.01 1.09 (0.91,1.31) 0.33 0.77 (0.63,0.93) 0.008
West-central 1.29 (1.08,1.55) 0.005 1.54 (1.31,1.81) <0.01 1.06 (0.89,1.26) 0.531 0.83 (0.70,0.99) 0.034
North reference reference reference reference
aIRR: adjusted incidence rate ratio, PSA: prostate specific antigen,
Models were further adjusted for mode of HIV transmission, ethnicity, smoking status, AIDS defining cancers (ADC), AIDS defining events (excluding ADC), non-AIDS
defining cancers (NADC), non-AIDS defining events (excluding NADC), hypertension, Hepatitis B, Hepatitis C, CD4 cell count, HIV viral load.
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Aim 2: The kinetics of PSA biomarkers and predictive value of
PSA and other biomarkers
Baseline characteristics and matching variables
Characteristics of cases (N=21) and controls (N=40) are shown in Table 7.7. Cases and controls
were well balanced on both matched and non-matched variables, with a median of 6 years (IQR:
1, 9) between first and last plasma sample. Cases only differed from controls according to nadir
CD4 cell count, which was higher in cases than controls.
Marker levels at earliest and latest sample in cases and controls
Of men with tPSA available at first sample, 53/59 (89.8%) of cases and controls had tPSA ≤4 
ng/mL. Levels of tPSA were elevated in cases relative to controls at earliest sample and even
more so at latest sample (Table 7.8). The average change per year of tPSA was increasing in
cases, but was stable in controls. Doubling time for tPSA was similar for cases and controls. A
similar trend was observed for fPSA. Cases had a lower f/tPSA than controls at baseline and even
more so at latest sample, however no differences in average change per year or doubling time
were detected (both P>0.05). Baseline and latest testosterone and SHBG levels, as well as
doubling time and average change per year were similar for cases and controls.
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Table 7.7 Baseline1 characteristics for cases and controls.
Factors Cases Controls p-value
N (%) N (%)
All 21 ( 100) 40 ( 100) -
Region2
East central 5 (23.8) 10 (25.0) Na
Argentina 1 ( 4.8) 1 ( 2.5)
South 2 ( 9.5) 3 ( 7.5)
North 6 (28.6) 12 (30.0)
west-central 7 (33.3) 14 (35.0)
Mode of HIV transmission
Sex between men 17 (81.0) 30 (75.0) 0.98
IDU 0 ( 0.0) 2 ( 5.0)
Heterosexual 2 ( 9.5) 5 (12.5)
Other/Missing 2 ( 9.5) 3 ( 7.5)
Non-white ethnicity 0 ( 0.0) 4 (10.0) 0.99
Smoking status
Never 6 (28.6) 14 (35.0) 0.48
Current 2 ( 9.5) 1 ( 2.5)
Former 0 (0) 0 (0)
Missing 13 (61.9) 25 (62.5)
prior ADC 21 ( 100) 34 (85.0) 0.99
prior AIDS (excluding ADC) 4 (19.0) 13 (32.5) 0.17
prior NADC 19 (90.5) 40 ( 100) 0.99
prior Non-AIDS event (excluding
NADC) 17 (81.0) 39 (97.5) 0.1
Prior Hypertensive 8 (38.1) 15 (37.5) 0.56
HBV 3 (14.3) 1 ( 2.5) 0.12
HCV 0 ( 0.0) 1 ( 2.5) 1
Antiretroviral experienced 20 (95.2) 38 (95.0) 1
HIV-VL > 400 copies/mL 4 (19.0) 10 (25.0) 0.58
Median (IQR) Median (IQR) Median (IQR)
Age at sample2 51.9 (48.6,56.7) 51.1 (47.3,55.5) 0.18
Earliest sample date2 OCT 1999 (MAR 1999, APR2006)
AUG 2000 (JAN 1998, JUN
2006) 0.909
Latest sample date2 JUL 2008 (DEC 2004, MAR2011)
SEP 2007 (SEP 2004, OCT
2010) 0.524
Time till PCa 6.6 (2.8,10.1) - -
CD4 cell count/mm32 460.0 (260.0,610.0) 426.0 (229.5,595.0) 0.07
Nadir CD4 count/mm3 202.0 ( 144.0,320.0) 143.0(57.0,276.0) 0.05
IQR: interquartile range, ADC: AIDS defining cancer, NADC: non-AIDS defining cancer, HBV:
hepatitis B, HCV: hepatitis C, HIV-VL: HIV viral load, PCa: Prostate cancer.
1 Baseline defined as the date of earliest plasma sample.
2 Matching variables.
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Table 7.8 Marker levels at baseline, latest sample, and changes over time for cases and controls.
Cases Controls1 p-value
Marker level Median (IQR) Median (IQR)
tPSA
Baseline (ng/mL) 2.8 (1.6,4.6) 0.8 (0.5,1.2) <0.01
latest (ng/mL) 6.1 (4.7,9.5) 0.8 (0.5,1.4) 0.04
Doubling time (years) 4.5 (2.8, 5.2) 4.1 (-12.6, 15.7) 0.83
Average change per year (ng/mL/year) 0.76 (0.37,0.86) 0.00 (-0.02,0.39) Not estimated
fPSA
Baseline (ng/mL) 0.4 (0.2,0.8) 0.3 (0.2,0.4) <0.01
Latest (ng/mL) 0.9 (0.6,1.3) 0.2 (0.2,0.4) <0.01
Doubling time (years) 5.59 (3.84,7.2) 13.43 (-7.31,31.05) 0.79
Average change per year (ng/mL/year) 0.07 (0.05,0.1) 0 (0,0.01) 0.01
f/t PSA ratio
Baseline 0.2 (0.1,0.3) 0.3 (0.3,0.4) <0.01
Latest 0.1 (0.1,0.2) 0.3 (0.2,0.5) 0.008
Doubling time (years) -7.07 (-16.49,-3.07) -2.2 (-16.13,18.55) 0.58
Average change per year (/year) 1.72 (0.33,29.48) 0.18 (-0.15,1.09) 0.54
Testosterone (nmol/L)
Baseline (nmol/L) 19.3 (14.5,22.2) 19.7 (15.8,25.9) 0.73
Latest (nmol/L) 17.7 (16.6,21.7) 18.0 (14.0,23.7) 0.917
Doubling time (year) 0.53 (-15.25,29.73) -6.8 (-17.1,23.78) 0.52
Average change per year 0.01 (-0.87,0.49) -0.32 (-1.01,0.3) 1
SHBG (nmol/L)
Baseline (nmol/L) 48.0 (34.0,69.0) 53.5 (34.0,64.0) 0.83
Latest (nmol/L) 54.0 (34.0,63.0) 49.0 (36.0,65.0) 0.83
Doubling time (year) 10.66 (-5.72,31.98) -4.01 (-13.24,12.82) 0.49
Average change per year (nmol/L/year) 0.9 (-2.17,2.48) -0.58 (-3.08,1.59) 0.64
IQR: interquartile range, PSA: prostate specific antigen, tPSA: total PSA, fPSA: free PSA, SHBG:
Sex hormone binding globulin.
1 Marker levels were available on all cases at baseline and latest sample, and 38/41 and 39/41
controls at baseline and latest sample.
Kinetics of each marker in time prior to prostate cancer diagnosis
The trajectories of each marker for cases and controls in the time leading up to the date of
diagnosis or matched date in controls are shown in Figure 7.6 - Figure 7.10. Figure 7.6 shows a
clear increase tPSA level leading up to PCa diagnosis for cases, however levels were stable in
controls and a similar pattern was observed for fPSA (Figure 7.7). Conversely, a clear decline in
f/tPSA in the years prior to diagnosis in cases was demonstrated in cases, but not controls (Figure
7.8). Levels of testosterone and SHBG were similar in cases and controls prior to the matched
date (Figure 7.9 and Figure 7.10).
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The percentage change over time of each marker is summarised in Table 7.9. TPSA and fPSA was
increasing over time in the cases, but not in controls, and this difference was significant (both
p<0.01). For example, level of tPSA and fPSA increased over time in univariate analyses in cases
by 13.7 and 7.9 % per year, respectively, however levels of both were stable in controls. The
difference in change in tPSA and fPSA between cases and controls remained significant after
adjustment (both p<0.01). In unadjusted analyses, the rate of decline in f/tPSA differed in cases
and controls (p=0.04), where f/tPSA declined by 3.5% per year in cases but was stable in controls,
however the difference between the cases and controls was not significant after adjustment
(p=0.11). There was little change over time in testosterone and SHBG, which was similar when
comparing cases and controls both before and after adjustment.
Table 7.9 Average percentage (%) change in markers over time between persons developing prostate cancer (cases)
and those remaining prostate cancer free (controls).
Univariate Multivariate1
% Change per year p-value (slope) p-value 2 % Change per year p-value (slope) p-value 2
tPSA
controls -0.44 (-2.49, 1.65) 0.67 <.01 1.19 (-1.38, 3.82) 0.37 <.01
cases 13.74 (10.29,17.29) <.01 15.47 (10.69,20.46) <.01
fPSA
controls -0.95 (-2.97, 1.10) 0.36 <.01 0.97 (-1.42, 3.42) 0.43 <.01
cases 7.93 ( 4.73,11.21) <.01 11.84 ( 7.62,16.24) <.01
t/fPSA ratio
controls -0.52 (-2.18, 1.16) 0.54 0.04 -0.38 (-2.21, 1.49) 0.69 0.11
cases -3.49 (-5.70,-1.23) <.01 -3.15 (-5.98,-0.23) 0.03
testosterone
controls -3.01 (-4.37,-1.63) <.01 0.09 0.37 (-1.24, 2.00) 0.65 0.96
cases -0.89 (-2.94, 1.21) 0.40 0.29 (-2.18, 2.82) 0.82
SHBG
controls -0.87 (-2.55, 0.83) 0.31 0.11 -2.42 (-3.56,-1.26) <.01 0.58
cases 1.51 (-0.83, 3.91) 0.21 -1.79 (-3.78, 0.25) 0.09
PCa: prostate cancer, PSA: prostate specific antigen, tPSA: total PSA, fPSA: free PSA, SHBG: Sex
hormone binding globulin.
1Adjusted for current age, log2 CD4 cell count, log10 HIV viral load. Models for PSA related
variables were also adjusted for current log2 SHBG and testosterone. Models for testosterone
and SHBG were additionally adjusted for current SHBG and testosterone only.
2 P-value for difference in % change per year in each marker between cases and controls.
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PCa: prostate cancer, PSA: prostate specific antigen, tPSA: total PSA, fPSA: free PSA, SHBG: Sex hormone binding globulin.
Figure 7.6 Scatter plot of tPSA by time till prostate cancer (or last
sample) with superimposed loess curves for cases and controls.
Figure 7.7 Scatter plot of fPSA by time till prostate
cancer (or last sample) with superimposed loess curves
for cases and controls.
Figure 7.8 Scatter plot of f/tPSA by time till prostate cancer (or
last sample) with superimposed loess curves for cases and
controls.
Figure 7.9 Scatter plot of testosterone by time till prostate cancer (or last sample) with
superimposed loess curves for cases and controls.
Figure 7.10 Scatter plot of SHBG by time till prostate cancer (or last sample) with superimposed
loess curves for cases and controls.
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Association between prostate cancer and marker levels
Higher levels of tPSA and fPSA at earliest and latest sample were associated with higher odds of
PCa (Table 7.10), where a 2-fold higher baseline tPSA was associated with almost 5-fold higher
odds of PCa and latest tPSA with an 8-fold higher in odds of PCa. Conversely, a higher f/tPSA
ratio was associated with lower conditional odds of PCa at both first and latest sample. A 1 unit
faster percentage change in tPSA and fPSA over time were associated with higher odds of PCa,
however, no association with the percentage change in the f/tPSA ratio over time was identified.
The time for tPSA level to double (doubling time) was not associated with PCa, nor doubling time
of fPSA or f/tPSA ratio. There was no significant association between odds of PCa and
testosterone and SHBG level at earliest or latest sample, or according to average percentage
change per year or doubling time.
Given the pattern of changes seen in Figure 7.6 - Figure 7.10 and that the levels of tPSA and fPSA
appeared to be significantly elevated in cases relative to controls many years prior to PCa
diagnosis, I investigated how long before PCa the differences in tPSA and fPSA appeared. Both
fPSA and tPSA at 5 years prior to PCa were associated with significantly higher odds of PCa (OR
for 2-fold higher tPSA: 2.92; 95%CI: 1.38, 8.07; P<0.01 and fPSA: 5.46; 95%CI: 1.54, 29.05; P<0.01,
respectively). A similar pattern was seen at 6, 7 and up to 10 years prior to PCa, but the number
of cases and controls with results at these time points were too small to allow formal statistical
analyses.
Predictive ability of markers for prostate diagnosis
C-statistics reflecting the predictive value of each marker are shown in Table 7.11. Looking at
the absolute marker values, the most informative predictor of PCa was tPSA (c-statistic= 0.90),
followed by fPSA (c-statistic= 0.82) and the ratio of fPSA to tPSA (c-statistic= 0.82). Testosterone
(0.51) and SHBG (0.51) did not predict PCa. Combining the four main markers investigated in
this study of tPSA, fPSA, SHBG, and testosterone resulted in a c-statistic of 0.91, which was only
a marginal improvement on tPSA alone. In those who had ≥2 samples available, I also looked at 
the c-statistic associated with average percentage average change per year of tPSA and doubling
time, however this was only based on 16 cases and 32 controls, and the model did not converge,
and therefore these results are not shown. However, for completeness, average percentage
change in tPSA and fPSA per year were highly predictive of PCa (c-statistic = 0.97 and 0.92).
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Percentage change in testosterone and SHBG per year and doubling time of all markers were
poor predictors of PCa.
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Table 7.10 Unadjusted conditional odds ratio of prostate cancer according baseline, latest, average percentage change per year and doubling time.
Variable tPSA fPSA f/tPSA ratio
OR (95%CI) P-value OR (95%CI) P-value OR (95%CI) P-value
Baseline 2-fold higher 4.67 (1.69,12.89) <.01 5.41 (1.68,17.44) <.01 0.31 (0.14,0.67) <.01
Latest 2-fold higher 8.09 (1.11,58.86) 0.04 10.38 (1.94,55.55) <.01 0.08 (0.01,0.4) <.01
Average percentage change per year 1 unit faster 1.18 (1.01,1.37) 0.04 1.09 (1.01,1.17) 0.03 0.94 (0.89,1) 0.06
Doubling time 1 year longer 1.05 (0.96,1.15) 0.27 0.97 (0.93,1.01) 0.09 1 (1,1.01) 0.58
Testosterone SHBG
OR (95%CI) P-value OR (95%CI) P-value
Baseline 2-fold higher 0.83 (0.29,2.35) 0.73 0.91 (0.4,2.08) 0.83
Latest 2-fold higher 1.06 (0.34,3.31) 0.92 1 (0.37,2.68) 0.99
Average percentage change per year 1 unit faster 1.02 (0.98,1.06) 0.31 0.99 (0.95,1.02) 0.45
Doubling time 1 year longer 1 (0.98,1.01) 0.53 1 (0.98,1.02) 0.96
OR: odds ratio, PSA: prostate specific antigen, tPSA: total PSA, fPSA: free PSA, SHBG: Sex hormone binding globulin.
Table 7.11 C-statistics for the prediction of cases and controls.
Marker level c-statistic (95% CI)
Total PSA 0.90 (0.85,0.94)
Free PSA 0.82 (0.77,0.88)
f/t PSA ratio 0.82 (0.76,0.87)
Testosterone 0.51 (0.44,0.59)
SHBG 0.51 (0.430.58)
tPSA + fPSA + testosterone + SHBG 0.91 (0.870.95)
PSA: prostate specific antigen, tPSA: total PSA, fPSA: free PSA, SHBG: Sex hormone binding globulin.
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Sensitivity and specificity of tPSA
The usual cut-off of tPSA >4 ng/mL to identify men who were at risk of a PCa diagnosis had 99%
specificity and 38% sensitivity (Figure 7.11), meaning 99% of men who were PCa free were
correctly identified as “low risk” using a PSA test (I.e. had a PSA ≤4 ng/mL), however only 38% 
with PCa were correctly identified as “high risk” (i.e. had a PSA >4 ng/mL). The specificity and
sensitivity were highest in the year prior to diagnosis (specificity = 100%, sensitivity = 88%, 42
men, 45 samples). The optimal cut-off which maximised both sensitivity and specificity was 1.5
ng/mL overall (specificity=84%, sensitivity=81%) although cut-offs between 1.4 – 1.6 ng/mL
provided >80% sensitivity and specificity. This was similar in those aged <50 years, with an
optimal cut-off 1.4 ng/mL (specificity=94%,sensitivity=86%, in 22 men and 41 samples, with cut-
offs 1.2 – 2.8 ng/mL providing >80% sensitivity and specificity), and ≥50 years with an optimal 
cut-off 1.5 ng/mL (specificity=82%, sensitivity=81%, N=54 men and 236 samples, no other cut-
offs had >80% sensitivity and specificity) at most recent sample.
Figure 7.11 Sensitivity and specificity for tPSA considering varying thresholds from 0.1 – 10.
PSA: prostate specific antigen, tPSA: total PSA.
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Discussion
I have divided the discussion according to the two separate aims of the study.
Aim 1: Reported testing for PSA in Europe
These results show considerable heterogeneity in PSA testing reported by the clinics across
Europe. Testing was concentrated in men aged 41 or older, varied according to region of Europe,
and rates were stable from 2010 onwards but lower previously. Interestingly, although PSA
testing was highest in those aged over 50, almost one in three tests were in men aged ≤40 years, 
a population in which PCa is considered a relatively rare disease [916]. This is in conflict with the
recommendations in the EACS guidelines for use of PSA screening in HIV+ men, which do not
recommend use in men aged 50 or younger [140].
Reported PSA testing varied by region of Europe, partly driven by variable use at the clinic level.
Geographic variations in PSA testing rates also have been reported for the general population
[987]. Reported testing rates were highly variable between clinics, ranging from testing no HIV+
men (0%) to testing all men as part of routine care (100% of men). I contacted clinics with
reported very high or low screening rates to validate the reported testing rates. Furthermore, I
asked the clinics whether there was a reason for the observed rates. Although many clinics
confirmed their reported PSA testing rates to be accurate, many did not offer an explanation.
Very low testing rates were recorded for east Europe, with many clinics testing <5% of men. This
could be driven by a general lack of testing in this region or a lack of reporting. On the other
hand, very high rates were observed for central east Europe, due to a handful of clinics testing
more than 70% of men. Two clinics responded to my email. One physician said he tested all men
as standard care (i.e. 100% of men), however, this was his own practice and did not reflect the
practice of other physicians at his clinic. Another was running a study that involved PSA testing.
Other possible explanations for the regional variations may include poor reporting to EuroSIDA,
varying testing practices between physicians, varying testing practices between clinics, and
targeted testing of men who were older, had PCa risk factors (i.e. a family history), or symptoms
suggestive of PCa. Large variations in the use of PSA testing in HIV+ men in Europe is driven by
lack of clear guidelines on the role of PSA in PCa management [140, 915]. This is reflected in the
large variations seen in this study.
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Reported PSA testing rates were low in 2008, but stable in the later years of this study. PSA
testing was introduced into clinical practice in the late 1980s/early 1990s [988], with rapid
uptake in the general population in both the USA and Europe [987-990]. Major changes to US
guidelines in 2008 (and also 2012) and publication of results from two major trials in 2009 led
to a modest but sustained decline in testing rates in the general population [991, 992], however
some studies still report an increase[990]. It is plausible that the increase in reported PSA testing
in EuroSIDA since 2008 reflects a delay in the uptake of PSA testing, relative to the general
population, due to the relatively recent aging of the HIV+ male population. Alternatively, the
results may reflect a lag in the reporting of PSA test results in EuroSIDA after 2008.
Men who were smokers, acquired HIV through IDU, were HCV coinfected, had a history of
hypertension, and had lower CD4 cell count had a lower rate of reported PSA testing. This could
indicate that PSA testing tends to be less of a priority in sicker patients or those with more
complex needs and where other health issues or patient management is of higher priority. In
addition, reported PSA tests had higher recorded PSA levels than those measured from plasma
samples and most PCa diagnoses in during follow-up were preceded by PSA testing. Taken
together, this suggests that on the whole, PSA testing may be symptom driven rather than a
component of routine care. The rate of PCa was much higher in those who had a previous PSA
test, which may further support that PSA testing is symptom, or alternatively this could reflect
over-diagnosis (and thus over treatment) of clinically insignificant PCa when PSA testing is used
(estimated to be up to 67% in the general population) [993].
The major strengths of this component of this chapter include the use of EuroSIDA, a large
prospective study which collects rich demographic, clinical, and HIV related information on a
heterogeneous group of HIV+ men. Furthermore, clinics have reported PSA tests since 2008, and
to date there is very little published data on the use of PSA testing in clinics in HIV+ men (or HIV-
negative men for that matter). However the limitations need to be taken into account. Firstly,
this is an observational study, which means the results may be influenced by residual and
unmeasured confounding. Reported PSA tests in EuroSIDA are not routinely collected and there
is no way to distinguish between a man where no test was done and a man where a test was
performed but not reported. PSA tests were inconsistently reported across centers and no
information on the prevalence of unreported tests or tests performed outside the cohort were
available. I attempted to limit the impact of this by restricting the analysis to centers with
reported testing rates of >5% per year, however under reporting in some centers is likely,
particularly in early study years. Furthermore, reasons on why reported PSA tests were
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performed by clinicians are unknown and results presented here reflect clinical practice rather
than whether true PSA screening is implemented by clinics. Therefore, the results presented
here may not be generalizable to PSA testing practices in HIV+ men in Europe. Finally, no
information is collected on the diagnostic methods used for PCa identification, stage, or
subsequent treatment or prognosis, therefore the survival benefit of PSA testing could not be
assessed.
Aim 2: The kinetics of PSA biomarkers and predictive value of
PSA and other biomarkers
The strongest predictor of PCa was tPSA in this study with elevations detectable more than 5
years before diagnosis, however, various forms of PSA were predictive. These results show that
the commonly used PSA threshold >4 ng/mL as a marker of high PCa risk in HIV+ men was
substantially less sensitive (38%) than a lower threshold of 1.5 ng/mL or more (81%).
The strongest marker of PCa was tPSA when considering absolute marker levels and t/fPSA only,
which is consistent with the literature [974]. Elevated tPSA levels was found to be detectable
more than 5 years prior to PCa diagnosis, indicating that tPSA has the potential to be a helpful
longer term marker of PCa in HIV+ men. Similar estimates have been shown in the general
population [945, 994]. However, it should be noted that earlier diagnosis is only beneficial if it
results in either improved survival or quality of life. Increased time living with a diagnosis can be
harmful due to unnecessary treatments and increased mental stress including major depression
and anxiety for both the person affected and their families [995, 996]. Testosterone and SHBG
levels were not associated with PCa and did not affect PSA predictability. This finding suggests
that circulating androgens do not influence the risk of PCa and is also consistent with other
studies [431, 925]. I also considered velocities and density of each marker, however this was
only available in 16 cases and 32 controls, and estimates were unreliable.
An interesting observation was that the median tPSA levels measured from plasma samples
were relatively low for the men included in my study. Two American studies reported similar
PSA ranges in HIV+ men to that reported here [997, 998] and previous studies have shown
similar or slightly lower PSA levels in otherwise healthy HIV+ and HIV-negative men in the
absence of PCa[999-1001], but lower latest PSA levels prior to PCa diagnosis in HIV+ men [431].
There are several possible explanations for the lower tPSA levels in my study. It could reflect the
higher prevalence of hypogonadism in HIV+ men (12 - 20%), characterised by reduced androgen
levels [980, 981, 1002]. It is also possible that the lower levels are driven by the comparatively
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younger age at PCa diagnosis since PSA level is known to increase with age [1003]. If this is the
case, the PSA concentration in HIV+ men would expect to approach that of the general
population as they continue to age, and age specific PSA risk ranges may be useful. Finally, there
could be an alternative biological relationship between PCa and PSA in the presence of HIV which
causes PSA levels to be systematically lower in HIV+ men. If this is the case, lower PSA levels
could mask the presence of PCa and delay diagnosis, therefore, HIV specific cut-offs should be
considered.
The commonly used cut-off of tPSA >4 ng/mL to identify men at high risk for PCa was notably
less sensitive than the lower cut-off of tPSA >1.5 ng/mL in HIV + men. However, the sample size
is small and hence this data needs to be validated in larger studies before being applied in clinical
practice. Furthermore, this cut-off was similar for men aged <50 and >50 years, however, I
suspect this is mainly due to the men in the aged over 50 group having a relatively low age (most
aged < 60) and a small numbers. I expect that differences in age specific cut offs will become
apparent as the proportion of HIV+ men aged 50 years or older increase.
Serum tPSA level is measured by a minimally invasive blood test making it an ideal candidate for
a cancer screening tool. However, this study was hypothesis generating, with the aim of
assessing whether PSA concentration has merit as a diagnostic marker in HIV+ men and to
determine whether the commonly used cut-off of >4 ng/mL is appropriate for this population.
For this analysis, I assumed that sensitivity and specificity were equally important. Ideally, a
screening tool with 100% sensitivity and specificity is desired, however in the real world this is
almost never a reality. Prioritising sensitivity leads to tests that correctly identify more PCa cases
while allowing for lower specificity which could lead to overdiagnosis (as is often the case with
PSA testing). On the other hand, prioritising specificity would minimise overdiagnosis but
possibly lead to missed clinical disease due to lowered sensitivity. How to balance these in the
context of PSA testing in HIV+ men is an ongoing controversial issue with no straight forward
answer. In order to properly determine how to properly prioritise sensitivity and specificity, a
cost effectiveness analysis could be a possible route for future research. It is important to
remember that screening tools are to be used as indicators of disease but are not used for
diagnosis alone.
When presenting this work at conferences there has been much interest from clinicians in use
of PSA testing as a screening tool in HIV+ men. This study was not designed or intended to advise
clinical practice on how to use PSA testing as a screening tool or to advise whether population
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based screening is appropriate. The limitations of PSA testing as a screening tool still hold in
HIV+ men and need to be kept in mind. These limitations include that PSA is a continuous marker
of PCa risk where higher PSA level is associated with higher risk and therefore no “ideal” cut-off
exists [915]. Raised PSA levels can be caused by a number of prostate related conditions, such
as chronic prostatitis, and PSA testing alone cannot distinguish between them [1004]. In
addition, PSA levels are influenced by many other facts such as older age, prostate volume, race
[1005], and recent ejaculation[1006]. It is also worthwhile noting that two large RCTs in the
general population found no effect of PSA screening on overall mortality [946, 947]. Taken
together, these limitations have collectively prevented the recommendation of a population
wide PSA based screening program in the general population, and therefore HIV+ men.
The major strengths of this component of this chapter include the large number of prospectively
diagnosed PCa in EuroSIDA, relative to other prospective studies, and access to prospectively
stored plasma samples collected independent of PCa. The frequency of PCa was low from a
statistical point of view, however matching between cases and controls improved the efficiency
of our analysis. Cases and controls were nested within the EuroSIDA cohort. This design
minimised the risk of some biases common to case-control studies, such as selection and recall
bias. Selection bias is reduced as the cases and controls were drawn from the same population
and both information about PCa diagnoses and plasma samples were independently and
prospectively collected. It is unknown if the cases became symptomatic at some point prior to
the date of PCa diagnosis, however, the use of prospectively collected plasma samples to
measure PSA rather than clinically measured PSA prior to PCa diagnosis avoids bias due to
symptom driven PSA testing. However, the study has a number of limitations which need to be
kept in mind when interpreting from the results. This is an observational study and a small
nested case-control study. Therefore, there is a risk the associations presented are affected by
confounding and causality cannot be determined. There are many known risk factors for PCa are
not collected in EuroSIDA and therefore could not be taken into account, for example: family
history [2]. Further adjustment for potential confounders was not possible due to low numbers,
although only minor significant imbalances were evident at baseline. Finally, the use of the
matched design reduces risk of confounding of important risk factors by design, but also
increases the complexity of the data, requiring specialist methods for analysis.
Conclusions
This chapter has demonstrated that there was considerable heterogeneity in PSA testing in
clinics across Europe, and PSA testing was particularly high in older men, as expected.
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Standardisation of PSA testing patterns in European HIV+ men is inhibited by lack of clear
guidelines on the role of PSA in PCa screening and management. Although overall PSA levels
were low, a clinically relevant increase in tPSA and fPSA in the years preceding PCa diagnosis
was observed, and was evident at least 5 years prior to diagnosis. Attention to symptoms of
localised and disseminated PCa even at lower PSA levels is needed, and DRE and rectal
ultrasounds should be performed. The commonly used PSA>4ng/mL to indicate high PCa risk
was not sensitive in our study and use of the lower cut-off of PSA>1.5ng/mL warrants
consideration. Given the limited sample of the study, these potential implications should be
investigated in larger studies.
Publications
A manuscript was published in Antiviral Therapy in 2016 [1007]. Results from this chapter were
presented at the HIV Glasgow drug therapy conference in 2014, the European AIDS clinical
society (EACS) conference in 2015. The manuscript and slides are included in Appendix XI,
Appendix XII, and Appendix XIII, respectively.
310
8 Discussion
Summary of main findings
Effective and durable cART has led to the increased longevity of HIV-positive (HIV+) people [1-
6]. The burden of cancers in the aging HIV+ population raises multiple issues in regard to future
HIV healthcare, including the detection, diagnosis, comanagement, and treatment of cancers
and increased complexity of patient management [504]. The use of cohort studies to understand
the emerging trends of cancers in HIV+ people, to identify and characterise associated factors,
and to describe the underlying mechanisms of cancer genesis are important in order to advise
clinical guidelines, allocate resources, and target interventions to optimally meet the needs of
this population. Therefore, the aims of this thesis were to describe the changing epidemiology
of commonly occurring cancers in HIV+ people and to explore and characterise plasma
biomarkers of common cancers in HIV+ people in order to better understand the mechanisms
leading to cancer development. This thesis focusses on specific cancers or groups of cancers that
are expected to become a major sources of morbidity and mortality as the population ages.
My role in this thesis
I was the lead researcher for each of the pieces of work presented in this thesis, from the study
conception through to publication. I designed and implemented each of the studies, which
involved the conception and development of the research objective, composing and developing
the research proposal for approval by the EuroSIDA steering committee, designing each study,
planning and performing the statistical analysis, interpretation of results, and writing and
publication of the manuscript. I also composed multiple abstracts and delivered presentations
of the work in these chapters at international conferences. A group of clinicians from The Center
of Excellence for Health, Immunity and Infections (CHIP) in Copenhagen provided guidance in
terms of the clinical relevance of research questions, the clinical interpretation of results, and
translation for use in clinical practice. In addition, my supervisor Amanda Mocroft answered
questions and provided guidance in terms of statistical analyses and study design, and also
provided feedback on abstracts, presentations and manuscripts. For the nested case control
studies (chapters 6 and 7), I designed each of the studies, identified the cases and controls, and
selected samples for the nested case controls studies. Furthermore, I also set up an academic
collaboration in order to ensure funding for the measurement of immunoglobulins and free light
chains on plasma samples for the nested case control study in chapter 6. As my thesis focuses
primarily on cancers in HIV+ people, I put together a special interest group composed of
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clinicians and epidemiologists with specialist knowledge of cancers in HIV+ people. They
provided additional guidance on some studies presented here and were involved in discussions
surrounding the selection of markers of B-cell activation prior to non-Hodgkin lymphoma (NHL)
and Hodgkin lymphoma (HL) diagnosis. Throughout my PhD I have been centrally involved in the
EuroSIDA research agenda, an active member of the EuroSIDA steering committee, participated
in regular meetings with colleagues from multidisciplinary back grounds, and also provided
statistical support for other projects within my research area.
Infection related and unrelated cancers, HIV, and the aging
population
HIV+ people are at higher risk of infection related cancers (IRCs), however, increased risk of some
non-infection related cancers (IURCs) have been reported in recent years. This is due to a
combination of aging of the HIV+ population and high prevalence of traditional cancer risk
factors (such as smoking) [8, 14-18, 22, 23, 420, 421, 427, 570]. In chapter 3 I demonstrate the
changing incidence of IRCs and IURCs in HIV+ people in Europe between 2001 and 2012 and also
identify and describe factors that are driving higher risk. This chapter demonstrates that the
demographic and HIV related risk factors that are driving elevated IURC (aging and smoking) and
IRC (immunodeficiency and ongoing viral replication) risk differ markedly. Furthermore, I was
able to demonstrate an expected decline in IRC incidence, likely due to control of HIV related
factors through effective cART, and a rise in IURC incidence, due to aging of the HIV population.
These findings suggest that the burden of cancer is expected to shift towards IURC due to the
non-declining incidence and the increasing proportion of HIV+ people aged over 50 years, as
well as higher prevalence of known cancer risk factors, such as smoking, and low prevalence of
untreated HIV-infection [405, 503]. This highlights the need to consider how to optimise HIV
care for older HIV+ people when planning for the future. In addition, preparing for an increase
in IURC burden allows time to investigate possible strategies for integration of services,
screening and detection strategies, and optimal treatment regimens for the concurrent use of
both cART and chemotherapy. Efforts to minimise the impact of avoidable cancers will
dramatically reduce the strain on the health care system, not just at the HIV clinic but also on
oncological services and potentially free up resources for use elsewhere.
This was the largest study in Europe to investigate the changing incidence of IRCs and IURCs over
time and to investigate associated risk factors. Several other studies had performed similar
analyses at the time of this study, however most were performed within HIV+ people in the USA,
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where the patient demographics and health care structure is considerably different to those in
Europe. Furthermore, many studies had compared incidence in HIV+ people to the background
population or investigated changes in incidence since the introduction of cART, however, few
had considered the impact of individual level risk factors. At the time of this study,
reclassification of cancers into IRC and IURC rather than AIDS defining cancers (ADCs) and non-
AIDS defining cancers (NADCs) was a novel approach.
This chapter was the earliest analyses looking at cancers in HIV+ people that I undertook. I now
have a more in depth understanding of cancers in HIV, including the aetiology, risk factors, and
mechanisms and have a greater appreciation of their heterogeneous nature. If I were to do this
project again, I would try to reduce the scope and focus on a few cancers rather than all IRC and
IURC combined. However, even using a large database such as EuroSIDA (or D:A:D for that
matter), such analyses are limited as cancers are a rare event which take many years to develop
and therefore power is often an issue. I have tried to be more focused in later chapters by
looking at smaller groups of cancers where numbers allow.
This chapter was published in HIV Medicine in 2016 [636] and the manuscript is included in
Appendix III. This chapter was presented at the European AIDS clinical society (EACS) conference
in 2013 and the slides are included in Appendix IV.
Cessation of cigarette smoking and the impact on cancer
incidence in the D:A:D Study
As mentioned in chapter 3, HIV+ people often have elevated rates of smoking, and as a result,
are at risk of various smoking related conditions, including cancers [420, 421]. In addition,
incidence of lung cancer has been shown to be elevated in HIV+ people independently of higher
rates of smoking [725]. Despite the well characterised harms of smoking in HIV+ people, the
clinical benefits of smoking cessation on cancer risk have not, to my knowledge, been reported.
In chapter 4, I estimated the change in incidence of lung, other smoking related cancers, and
smoking unrelated cancers after smoking cessation in HIV+ people from the D:A:D study. This
study demonstrates that the incidence of lung cancers is 10-fold higher in current smokers
relative to never smokers. In those who quit smoking, lung cancer incidence remains at a similar
level to current smokers >5 years after cessation. The incidence of smoking related cancers
(excluding lung) returned to a similar level to never smokers after 1 year of cessation (although
the magnitude of association remained elevated possible reflecting ongoing risk), and smoking
status did not impact on the incidence of smoking unrelated cancers.
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The results of this study have various implications for HIV+ people. Firstly, not only is lung cancer
incidence highly elevated following cessation, there is little evidence of a decline with increasing
time since cessation after the first year. This is in contrast to the general population where a
decline is evident after 5 – 9 years and increases with cessation duration. This implies that the
harms of smoking maybe more severe and take longer to reduce in HIV+ people than the general
population. These results highlight the urgent need for effective smoking cessation efforts in
HIV+ populations as well as efforts into smoking prevention. Furthermore, smoking in the
context of HIV is complex and is intertwined with mental health issues, alcohol, and drug use.
Therefore, programs that focus on smoking alone may not be effective in this population and
methods that address multiple substance use issues and mental health may be beneficial.
The D:A:D collaboration was one of the few HIV+ studies which could address this question due
to the long history of clinically obtained smoking information collected, the large size, and long
follow-up time which allowed for the sufficient acquisition of cancer events (particularly for lung
cancers). No decline in lung cancer incidence was detected following cessation after the first
year, however, the follow-up was relatively short compared to studies in the general population.
These results should therefore not be misinterpreted as a lack of benefit for smoking cessation
on lung cancer risk, rather that the decline in HIV+ people does not manifest within the first 5
years of follow-up. The reason for the lack of reduction in risk could be due to multiple reasons,
including longer and more intense smoking histories in HIV+ people, higher susceptibility to
inflammation in the lung and lung infections, or a more prominent residual effect of long term
tobacco use relative to the HIV-negative population. This should be the focus of future research
efforts.
If I were to repeat this study, the main thing that I would change would be to utilise an
observational study with a much longer follow-up time (i.e. at least 20 years). Unfortunately,
this is not currently possible with the HIV+ cohorts that currently exist. In addition, either
adjustment for or stratification by smoking history (such as smoking duration and intensity)
would further improve this study, however this information was not available in D:A:D.
This chapter was awarded a young investigator scholarship and presented at CROI 2017 as an
oral presentation slides are in Appendix V. A manuscript has been drafted with the intention to
submit to JAMA.
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Differences in virological and immunological risk factors for non-
Hodgkin and Hodgkin lymphoma in the D:A:D study
Despite a clear decline in NHL incidence since the introduction of cART, NHL remains the most
common ADC in HIV+ people (as shown in chapter 3) [430, 437, 441, 443, 451]. On the other
hand HL, incidence has not declined and remains elevated in HIV+ people since the introduction
of cART [8, 14-16, 19, 438, 469]. There are many studies which have investigated incidence of
NHL and HL since the introduction of cART and associated risk factors. However, few previous
studies had identified NHL and HL risk factors within the same population and no studies had
directly compared the risk factors for NHL and HL in order to identify and develop the
understanding of different mechanistic pathways which may suggest different preventive
approaches for reducing NHL and HL risk. In chapter 5 I demonstrate that higher current and
accumulated HIV viral load (HIV-VL) are relatively stronger risk factors for NHL than HL. Although
current CD4 cell count and gender are strong predictors of both, they are similarly associated
with risk of NHL and HL. In addition, I show that current smoking is associated with HL but not
NHL risk. Finally, this is one of the first studies to demonstrate a convergence of the incidence
of NHL and HL in recent years, due to the ongoing decline in the crude incidence of NHL and
unchanging HL incidence.
The results of this chapter suggest different mechanistic pathways for the involvement of HIV in
the development of NHL and HL. My finding that NHL is independently associated with both CD4
and HIV-VL is similar to that observed in opportunistic disease, where risk is higher in people
with uncontrolled HIV replication regardless of CD4 cell count, which has been confirmed in both
observational studies [842] and the START trial [141, 616]. This indicates that ongoing immune
dysfunction (beyond the low CD4 cell count) may play a role. Conversely, the association
between CD4, but not HIV-VL, and HL indicates that the impact of HIV-infection on HL
development may be primarily driven by a balance between impaired immune function and loss
of control of Epstein-Barr virus (EBV) as well as remaining immune activity to allow for the influx
of immune cells to the tumour microenvironment [849]. Furthermore, this study implicates a
link between smoking and HL incidence which further supports the conclusions of chapters 3
and 4 regarding the need for smoking cessation efforts. These findings provide new insights into
the pathogenesis of these lymphomas and call for the characterisation of biological markers of
immune dysfunction before and during the evolution of these cancers to further understand
these processes. This would have implications for other immune impaired populations, other
than HIV+ people, such as transplant recipients. Furthermore, these results stress the
importance of early HIV diagnosis and treatment, and of ensuring sustained viral suppression.
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Initially, this project was performed within EuroSIDA, however due to small numbers of NHL and
HL, it was decided to instead use data from the D:A:D collaboration to improve the number of
outcomes ascertained with the hope of looking at NHL subgroups. Unfortunately, subgroup
information was missing on 66% of NHL in D:A:D which only allowed for very limited analyses by
NHL subtype. The primary results treat NHL as a single entity, however, I am aware there is
considerable heterogeneity in aetiology between NHL subtypes which is not captured by these
results.
A manuscript of this chapter was submitted to the Journal of the National Cancer Institute (JNCI)
in 2017. The results were presented at the HIV drug therapy Glasgow conference in 2016.
Preliminary results from the EuroSIDA study were also presented at CROI 2015. The manuscript
and slides are included in Appendix VI, Appendix VII, and Appendix VIII respectively.
The extent of B-cell activation preceding lymphoma development
in HIV-positive people
The genesis of lymphomas in HIV+ people are thought to be driven by HIV mediate B-cell
dysfunction and infection with EBV, however, how these factors interact to facilitate lymphoma
development is unclear. In chapter 6 I investigate the trajectory of various markers of B-cell
activation in the time leading up to lymphoma diagnosis and explore the associations between
levels of markers of B-cell activation and lymphoma development in HIV+ people. I demonstrate
that various markers of B-cell activation are elevated many years prior to lymphoma diagnosis
in HIV+ people, however, the levels of these markers attenuate with closer time to lymphoma
diagnosis. Levels of HIV-VL were also higher more than 2 years prior to lymphoma diagnosis and
correlated with elevated levels of B-cell activation markers, implying that previous exposure to
HIV-VL may be inducing ongoing B-cell activation and dysfunction which could facilitated
lymphoma development. The predictive ability of these markers to identify people at high risk
of lymphomas is modest at best, and they are unlikely to be candidates for clinic based risk
assessment for lymphomas.
The analyses presented in this chapter took much longer than planned to develop and execute.
There were several reasons for this. Firstly, the kits used to measure the markers of B-cell
activation in the plasma samples were provided by a third party (the Binding Site). This meant
that all proposals, agreed analyses, data ownership, conferences, and manuscripts had to go
through an additional round of discussions, negotiations, and review on top of the usual
EuroSIDA procedures. The original design of this study involved measuring EBV DNA in addition
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to markers of B-cell activation in stored plasma samples. However, this was not feasible due to
laboratory time and cost restraints and I made the executive decision to proceed with the
analysis without the EBV DNA component. Originally, it was not planned to investigate CD4 cell
count and HIV-VL as part of this study. Therefore, it was decided to match on CD4 cell count in
order to control for differences in severity and stage in HIV infection when looking at markers of
B-cell activation. However, this soon became of interest. In hindsight, I would reconsider
whether or not to match on CD4 cell count. Although, it is important to note that replicating HIV
can stimulate B-cell proliferation and antibody production and further controlling for the
contribution from this effect (which is beyond that due to the malignant B-cell replication) would
be of interest.
A manuscript for this chapter was accepted for publication in HIV Medicine in 2017. The results
were presented at the HIV drug therapy Glasgow conference in 2016. The manuscript and
presentation are included in Appendix IX and Appendix X respectively.
Testing patterns and predictive value of prostate specific antigen
in a European HIV–positive cohort: does one size fit all?”
Prostate cancer (PCa) is the most common cancer to occur in older European men and is
emerging as a major contributor to cancer burden in the HIV+ people as they age [7, 436, 438,
958]. It is common practice in the general population to use prostate specific antigen (PSA) ≥4.0 
µg/L as a clinical indicator for men at risk of PCa [935-937], however this has been unverified in
HIV + men and investigation into factors associated with PSA testing in HIV+ men is unknown. In
Chapter 7 I identify factors associated with higher rates of PSA testing in HIV+ men in European
clinics. In addition, I investigate the trajectory of PSA levels prior to PCa diagnosis in HIV+ men
and assess the predictive value of PSA for identifying men at high risk for PCa. Finally, I explore
whether the commonly used cut off of PSA≥4.0 µg/L is appropriate for use in HIV+ men and 
whether lower PSA cut-offs should be considered.
This chapter demonstrates that the use of PSA testing is highly variable in clinics across Europe.
This highlights the need for clear guidelines on the role of PSA in PCa screening and management
which may help to optimise use. In addition, PSA levels were highly predictive of PCa presence
in HIV+ men more than 5 Years prior to PCa diagnosis, however, levels of PSA in HIV+ men were
surprisingly low. This indicates that, while PSA presents as a useful clinical indicator of PCa risk,
using PSA cut-offs intended for the general population may result in underdiagnosis of clinically
significant PCa. When comparing PSA cut-offs to identify men with elevated risk of PCa to
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undergo further testing, it was found that the lower cut-off of 1.5 µg/L dramatically improved
the sensitivity (true positive rate) for PCa with a small reduction in the specificity (true negative
rate). It was unclear in this study whether the lower PSA levels in HIV+ men observed were
possibly driven by the younger age in HIV+ men at diagnosis (due to the younger age of the
population overall), or if PSA operates differently in the presence of HIV-infection. Therefore, a
future avenue of research would be to investigate age-appropriate cut offs as a larger proportion
of HIV+ people live into the older ages. The results presented in chapter 7 were exploratory and
do not sufficiently support use of a lower cut off in clinical practice. However, they do raise the
question of whether a lower PSA cut-off would be beneficial for HIV+ people and this needs to
be independently validated in larger studies before these finding have clinical meaning. It should
be kept in mind that use of PSA testing as a population based screening tool for PCa remains
highly controversial and is not recommended by most urological societies and associated
medical entities [915, 937, 939, 942-944].
The component of this chapter looking at rates of PSA testing across Europe used yearly rates of
PSA testing to identify and reduce the impact of clinics that do not report PSA testing in
EuroSIDA. I suspect that most clinics only tested for PSA after PCa was already symptomatic and
not as part of routine screening and it is likely that handling of those with elevated levels was
highly heterogeneous. If repeating this study with a larger budget, I would have liked to study
PSA as a marker for emerging prostate cancer in a HIV+ cohort with routine screening for PSA
levels and with pre-specified criteria on how to react to an elevated level. In addition, I would
also have liked to measure other forms of PSA that have been shown to be associated with PCa
risk, mainly the isotope Pro[-2]PSA [1008, 1009]. This form is a specific marker of PCa in the
general population, and can be combined with total and free PSA to calculate the prostate health
index (PHI), which some studies have demonstrated to be more predictive of clinically significant
PCa than each measure in isolation [1008, 1009]. In addition, at the time of this study, tests for
urine PSA levels (PCA3) were emerging as markers for PCa which could better differentiate
between PCa and benign prostate disorders than circulating PSA [1010]. Unfortunately, urine
samples were not available in EuroSIDA and this could not be explored.
A manuscript was published in Antiviral Therapy in 2016 [1007]. Results from this chapter were
presented at the HIV Glasgow drug therapy conference in 2014, the European AIDS clinical
society (EACS) conference in 2015. The manuscript and slides are included in Appendix XI,
Appendix XII, and Appendix XIII, respectively.
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Limitations
The specific limitations of each individual analysis has been discussed within each chapter,
however, here I will discuss a selection of broad limitations that are common to several chapters.
Observational studies
The chapters presented in this thesis use data from observational studies. Chapters 3, 6, and 7
utilise data from the EuroSIDA study, which is a large prospective observational cohort study.
Chapters 4 and 5 utilise data from the D:A:D study, which is a collaboration between 11 large
prospective observational cohort studies from Europe, USA, and Australia.
Observational data is very useful in the context of clinical research. In particular, both EuroSIDA
and D:A:D are examples of observational studies which follow a large number of heterogeneous
people (due to liberal inclusion criteria) and accumulate information across a wide range of
demographic, lifestyle, and heath related factors. Furthermore, EuroSIDA periodically recruits
new people to replace those who may have died or are lost to follow-up. A major strength of
both these data sources is the large number of people enrolled and the long period of follow-
up. This increases the power to study the occurrence of rare events (in this case cancers) and
the long term implications of many factors on clinical outcomes.
Use of data from observational studies to answer research questions is extremely useful in
situations where experimental data is not available or not appropriate. In addition, data from
large prospective observational cohorts reflect real world clinical situations. However,
observational studies often have issues with confounding and various types of bias, including
selection and information bias (which are discussed in sections 8.3.1.2 and 8.3.1.3). Lead time
bias refers specifically to screening and is where a patient’s survival time is artificially increased
due to being diagnosed earlier than they otherwise would have. However, this is not relevant
to the results presented here.
Confounding
In many situations, randomised control trials (RCTs) are the gold standard to establish causal
relationships between an exposure and an outcome. RCTs require that participants are allocated
to a regimen at random, and therefore, they control for confounding by design. In observational
319
studies, the researcher does not intervene in the clinical care of participants. This means that
confounding is an issue as allocation to exposure groups is not random, and as a result,
demographic, lifestyle, and health related factors are likely to differ between the groups. The
use of RCTs would not be suitable and not feasible for any of the chapters in this thesis. For
example, studies which investigate the association between smoking and cancer (such as
chapter 4) are one of the few situations where a RCT is not possible. This is because of the ethical
issues of assigning people to a “current smokers” arm, the large sample size, and long follow-up
required to accrue sufficient numbers of cancers (a rare event which take a long time to
develop), and the high cost of running such a study. In this situation observational cohort data
is required.
Methods to account for confounding, such as use of multivariate models and matching of case
control studies, were implemented in the chapters of this thesis. However, I could only attempt
to account for confounders which were known and for which data was available. Both EuroSIDA
and D:A:D collect a wide range of demographic, life style, HIV, laboratory, and health related
variables, however there are many known cancer risk factors not collected in either database
(such as family history). In addition, it is possible that residual confounding remains after
statistical adjustment due to inaccuracies or lack of appropriate detail in the measurement and
reporting of some variables. I cannot rule out that the results presented in this thesis are
affected by confounding due to unknown, unmeasured, or residual confounding variables
[1011].
Selection bias
Selection bias is a broad term used to describe the situation where the people included in a
study are not representative of the population from which they are selected [1012]. This can
arise due to the way people were selected into the study (i.e. non-random selection), refusal to
take part in the study, or high or differential dropout rates. Selection bias becomes an issue
when the selection of people is related to the outcome of interest, and therefore, the
associations explored in the study are different to that in the wider population. For example, it
is known that those enrolled in EuroSIDA are a generally healthy group of HIV+ people compared
to the wider HIV+ population. This is partly because clinics which contribute to EuroSIDA tend
to be larger, high performing clinics which offer above average standards of care. In addition,
recruitment into EuroSIDA requires the individual to be in contact with a participating clinic to
be included. Therefore, the associations presented in this thesis may not be generalizable to the
entire population of HIV+ people across Europe.
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Selection bias is also an issue in case-control studies if the cases and controls are either not
representative of the background population or not drawn from the same population. The risk
of this was minimised in the nested case control studies in chapters 6 and 7 as both the cases
and controls were drawn from the EuroSIDA cohort and the controls were randomly selected.
Information bias
Information bias refers to the situation where information is inaccurately or wrongly recorded
on some patients in measured variables with continuous values, such as differences in PSA, CD4
cell count, or blood pressure. Misclassification refers to a similar error where an individual is
incorrectly allocated to the wrong group. For example, in D:A:D smoking data is only recorded
at the clinic visit and therefore may not accurately reflect the day to day smoking behaviour of
the person. This could lead to misclassification of people who quit smoking but shortly relapse
as previous smokers and bias results.
Recall bias
This is a common bias in case control studies and refers to systematic differences in the ability
of people to accurately recall historical exposures. Nested case control studies were used in
chapters 6 and 7, however the variables of interest were measured in plasma samples and
therefore this was not an issue. Recall bias can also occur in cohort studies. Both EuroSIDA and
D:A:D are based on data that is captured as part of routine clinical care and relies of recall of
history of behaviours at the clinic visit. For example, the ability of the patient to recall recent
smoking and alcohol use as well as to accurately report changes in behaviour (a person may feel
embarrassed if they quit smoking and relapse). Furthermore, in EuroSIDA, each center
completes a follow-up form on each patient every 12 (formerly 6) months and the accuracy of
this data depends on the quality and detail of the clinical notes for each patient. Therefore, it is
possible that clinicians are more likely to record or report certain information in some instances.
Rare events as clinical outcomes
Cancers were the main outcome in each of the chapters presented here. Many cancers are rare
events in HIV+ people, particularly those which occur in the older ages. As a result, the number
of clinical events observed during follow-up were sometimes too low to consider individual
cancer types as separate endpoints and composite endpoints were used. For example, NHL
subtypes were grouped into a single NHL outcome in the analyses in chapter 5, and NHL and HL
were grouped into a single lymphoma outcome in chapter 6. This approach assumes that risk
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factors associated with the composite outcome are the same across the contributing end points,
which is not always the case. In addition, the associations with composite outcomes are more
likely to reflect those of the more common endpoints included and factors associated with rarer
outcomes may be over looked. For example, the associations between B-cell markers and
lymphoma presented in chapter 6 were more in line with what is known of the pathogenesis of
NHL than HL and may not accurately reflect the associations with HL. Similarly, analyses in
chapter 3 used two composite outcomes: IRC and IURC. The risk factors identified are likely
reflecting the high frequency of NHL and Kaposi’s sarcoma (KS) in the IRC group, and lung,
prostate and breast cancers in the IURC group and may not represent the associations present
for less common cancers. Although cancers are rare events, they are fairly easy to ascertain as
a cancer diagnosis leads to further contact with the health system and often admission to
hospital, conversely, benign events are less straight forward to ascertain and typically require
standardised reporting.
Missing data
The EuroSIDA and D:A:D studies were both set up in order to assess HIV alone. As a result,
historical cancer information is often not available. Missing data is a common side effect of using
routine clinical data and is an issue in both the EuroSIDA and D:A:D databases. If the data are
missing at random then missing values will have a negligible impact on the results. However,
some of the missing values may be due to differences in clinical practice, monitoring strategies,
or availability of tests or diagnostic facilities across the centres. For example, missing CD4 cell
counts and HIV-VL values in EuroSIDA are largely due to less frequent monitoring of people in
certain regions, such as eastern Europe. Another example is missing smoking information in
D:A:D. In many cases, smoking information is only recorded in the follow-up form if it is recorded
in the clinic notes, therefore, smoking status will not be updated in patients who are not asked
about smoking during their clinic visit. In addition, differences in when the collection of smoking
status commenced in each individual cohort may contribute. A major limitation of both the
EuroSIDA and D:A:D studies is the high proportion of cancer diagnoses that are missing cancer
subtype information. In D:A:D this is partially due to some cohorts not collecting this
information, however, a large proportion were simply not reported or reported as free text and
not incorporated into the main database. Furthermore, information on cancer treatment and
prognosis was not collected and this limits the ability to investigate the clinical outcomes of HIV+
people following their cancer diagnosis. This will become an increasing area of interest as the
population ages.
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The analysis in chapter 7 looked at PSA testing rates in EuroSIDA. PSA testing is not routinely
reported in EuroSIDA and therefore not all centers consistently provide this data. To account for
this, I only included centers that screened more than 5% of men per year. However, there is no
way to distinguish between a center that does not report PSA and another that does not use
PSA testing as part of routine clinical practice. Therefore, this method likely excludes some
centers that truly have low testing rates, and includes some centers with higher rates but which
provide incomplete data (but still fulfils the inclusion criteria). Another limitation is that there is
no information on why tests were or were not reported, for example, some centers may not
have the facilities to perform PSA testing. This could potentially lead to biased results if the
reported PSA testing rates do not reflect what is actually performed in the clinic.
There are several methods available to deal with missing data, however, no post hoc methods
are equivalent to having a complete dataset. In most analyses presented here, missing data was
dealt with by either including a missing category, using last value carried forward, or using a
complete case approach. For example, in chapter 4, people missing smoking information were
dealt with using last value carried forward. People who never had smoking information available
were excluded. Both these approaches are simple and widely used methods to deal with missing
data. Missing data in predictor variables do not cause bias in analyses of complete cases if the
reasons for the missing data are unrelated to the outcome (i.e. if the data is missing at random)
[1013], however, if this assumption is not true then these methods can lead to biased results
[1013].
EuroSIDA implements several processes to minimise missing data. The number of people lost to
follow-up is reported to each center after each data collection. Centers with high rates of lost to
follow-up are contacted and often a member of staff from the coordinating center will visit the
site to assist with any issues with completing follow-up forms that the site may have. However
loss to follow-up in EuroSIDA is low and is reported as 5% per year [557].
Changes in data collection
The EuroSIDA database has changed over time due to a shift in focus of the research areas
surrounding HIV infection as well as the characteristics of people living with HIV. For example,
NADC have been collected in EuroSIDA since 2001 and in D:A:D since 2004 in response to the
emergence of cancers as a major source of morbidity and mortality in the context of cART.
Therefore, it is possible that any increasing incidence of cancer events over time may actually
reflect changes in data collection and improved ascertainment of events rather than a true
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increase. For example, there has been a steep increase in the number of liver cancers reported
in EuroSIDA over time, which has been in part attributed to improvements in case finding
mechanisms, however, an increase has also been observed in other studies [436, 464]. The
inclusion criteria in EuroSIDA has changed over time, however, this only impacts on people
enrolled in cohort I and cohort X and is unlikely to impact on the results presented here. The
largest change has been the incorporation of cohort X which enrolled hepatitis C (HCV)
coinfected patients. This includes the collection of many HCV specific variables not previously
included. This also led to a restructuring of the follow-up forms to allow a more integrated
collection of HIV and HCV related information. The focus of recruitment has changed over time,
with an increased focus on eastern Europe and women as the study progressed, however, both
gender and region of Europe has been adjusted for in all multivariate analysis. There have been
multiple changes to the follow-up forms over time as various risk factors for not only HIV, but
other important conditions, became apparent.
Availability of resources
Several of the chapters presented here were restricted by the availability of resources. Chapters
6 and 7 involved measuring biological markers in stored plasma samples. This is an expensive
exercise in terms of cost as well as use of a finite biological resource. As a result, the markers I
could feasibly measure were restricted to those performed routinely in laboratories (such as
total PSA) or those subsidised through academic collaboration (such as the measurement of
markers of B-cell activation). In addition, samples were selected in such a way to conserve
biological material.
As already mentioned, the NHL subtype information was missing in a high proportion of people.
At the time of this study, it was not feasible to return to the pathology records and obtain this
information as D:A:D was no longer funded and the resources were not available to perform this
task. However, I do think this exercise is important for future research.
During my PhD, the funding for EuroSIDA also came to an end and, in an effort to conserve
resources, the items collected as part of the core EuroSIDA database were reduced to those
deemed essential and data collection moved from biannual to annual. However, this does not
impact on the analyses presented here as this transition only affected later versions of the data.
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Further research
HIV infection is entering a new era where a substantial proportion of HIV+ people are older and
at risk of various age related comorbidities. Although it is clear that this poses a complex
challenge in terms of integration of healthcare services, healthcare planning, and resource
allocation, this is uncharted territory. It is not yet clear how the HIV epidemic will change in the
context of an aging population and how to best cater to their needs. This will potentially
manifest as a substantial burden on the healthcare system, which may not yet be set up to treat
people with HIV as a chronic with associated health complications. For this reason, it is essential
that research into risk factors for high burden conditions and mechanisms for disease are
continued.
Future steps in HIV and cancer
One possible avenue for future would be to develop the analyses in chapter 5 and investigate
the risk factors for each NHL subtype individually. As mentioned in section 8.3.5, at the time of
this study, it was not feasible to return to the pathology records and obtain subtype information
on those missing this information. Furthermore these results warrant a systematic biological
characterisation of patterns in personal “-omics” data (such as genes, mRNAs, proteins, and
metabolites) in people with and without lymphomas. This would deepen the understanding of
biological differences between NHL subtypes and HL and shed light on the how these cancers
develop. Smoking status was established as a risk factor for HL, which has been suggested in EBV
associated HL in the general population. It would be very interesting to investigate this further
and possibly look at the impacts of cessation on cancer incidence. Another future project that
would be of great interest would be to develop a risk score for NHL and HL, as has been
previously done for cardiovascular and chronic kidney disease in HIV+ people.
Another interesting avenue for future research would be to investigate EBV DNA levels
preceding lymphoma diagnosis in HIV+ people and to correlate this with markers of activation.
Several studies have shown that EBV infection occurs prior to lymphoma diagnosis, [1014-1016],
however none have shown an elevation of EBV replication prior to the development of
lymphomas. This would indicate whether EBV drives lymphoma genesis or acts as a passenger
virus. An extension of this would also be to compare how levels of EBV DNA and markers of B-
cell activation differ across various immune suppressed populations. For example, transplant
recipients have high risk of lymphoma and post transplant lymphoproliferative disorder (PTLD)
and high rates of EBV infection. It has been found that EBV can be reactivated without the
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development of malignant lymphomas (1 in 3 people develop PTLD following EBV reactivation)
in transplant recipients [1017]. If a similar result was found within HIV+ people, this would
warrant the exploration of other factors in addition to EBV that drives the malignant process.
Additionally, investigating the incidence of lung cancer with a longer time since cessation in
studies that follow HIV+ people for long periods of follow up would be a significant contribution
to the literature. Ideally, studies following HIV+ people throughout their lifetimes are needed to
determine when the benefit of cessation will be seen. I speculate that a decline in incidence may
be evident with longer follow-up time. Unfortunately, no additional follow-up in D:A:D will be
accrued as D:A:D funding has ended and the database closed. Furthermore, the epidemiology
and pathology of lung cancers differ according to histology and several studies have suggested
that adenocarcinoma is more prevalent in the HIV+ population. It would be interesting to see if
cessation benefit differs according to subtype and whether cessation benefit differs by previous
AIDS defining events. In addition, a previous study within D:A:D demonstrated an association
between protease inhibitors (PIs) and cancer risk (mainly driven by anal cancers) [577]. PI use
both inhibits and induces various parts of the cytochrome P450 (CYP450) system, which has
been linked with cancer risk. It would be of great interest to investigate this in relation to lung
cancer.
It would also be interesting to investigate age-specific PSA cut offs as a larger proportion of HIV+
people live into the older ages. Furthermore, larger studies to validate a lower cut off for PSA
are needed to inform clinical practice, and a cost effectiveness analysis on the use of PSA testing
for PCa diagnosis could be a possible route for future research.
The RESPOND consortium
A new research platform has been established to answer question about HIV+ people going
forward. RESPOND is a newly formed international cohort consortium of infectious disease to
allow for continued research collaboration between HIV cohorts. RESPOND will consist of a
number of research modules each with a focus on a separate scientific agenda. It is a possibility
that cancers in HIV+ people will be included as a module going forwards and may present as an
appropriate setting to monitor the long term epidemiology of cancers in HIV+ people.
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Concluding remarks.
This thesis had two aims. First, to describe the changing epidemiology of commonly occurring
cancers in HIV+ people, particularly focussing on specific cancers or groups of cancers that are
expected to become a major source of morbidity and mortality as the population ages. Second,
to explore and characterise plasma biomarkers of common cancers in HIV+ people in order to
better understand the mechanisms leading to cancer development. Cancer is now a major area
of research in HIV + people and is gathering a lot of interest. As the HIV+ population age, the
burden of cancers not traditionally associated with HIV are expected to increase and open up a
new set of obstacles and issues for patient treatment and longevity. This thesis provides three
major contributions to the field of HIV. The first is a description of the current distribution of
cancers in HIV+ people in Europe and an indication that IURCs are expected to increase in coming
years, driven by the increasing age of HIV+ population and higher prevalence of traditional
smoking risk cancers, such as smoking. The second is the characterisation of the benefits of
smoking on cancer incidence in HIV+ people. Smoking is a key modifiable risk factor for excess
lung cancer risk, however the benefits of smoking cessation are not evident within the first 5
years of cessation. This suggests that HIV+ people may be at increased risk of smoking harms
and prevention of smoking uptake should be a public health focus. The third is the
characterisation and identification of risk factors which differ between NHL and HL as well as
the suggestion that ongoing HIV replication may be driving lymphoma genesis in some HIV
related lymphomas. Data presented here have also shown that PSA is highly predictive of PCa in
HIV+ men, however, lower cut offs may be useful and need to be validated in larger studies. The
findings from my research have contributed to the understanding of the epidemiology of cancers
in HIV+ people and it is hoped that the results presented in this thesis will provide evidence to
advise patient management guidelines and health care planning as HIV+ people age.
Continued monitoring of HIV+ people will be possible through the newly established RESPOND
consortium. RESPOND will allow for a flexible research agendas as well as data collection
through to the introduction of research modules. This will facilitate more powerful and detailed
analysis on specific clinical events especially as follow-up time accrues.
327
Appendix I. EuroSIDA study group and steering committee
The EuroSIDA Study Group
The multi-centre study group, EuroSIDA (national coordinators in parenthesis).
Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires. Austria: (B Schmied),
Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, Medical University Innsbruck,
Innsbruck. Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM
Mitsura, Gomel State Medical University, Gomel; D Paduto, Regional AIDS Centre, Svetlogorsk.
Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, Brussels; E Florence, Institute
of Tropical Medicine, Antwerp; L Vandekerckhove, University Ziekenhuis Gent, Gent. Bosnia-
Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, Sarajevo. Croatia: (J
Begovac), University Hospital of Infectious Diseases, Zagreb. Czech Republic: (L Machala), D
Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles University Hospital, Plzen. Denmark:
G Kronborg,T Benfield, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein, Rigshospitalet,
Copenhagen; NF Møller, C Pedersen, Odense University Hospital, Odense; L Ostergaard, Skejby
Hospital, Aarhus, L Wiese, Roskilde Hospital, Roskilde; L N Nielsen, Hillerod Hospital, Hillerod.
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond
Siseklinik, Kohtla-Järve. Finland: (M Ristola), I Aho, Helsinki University Central Hospital, Helsinki.
France: (J-P Viard), Hôtel-Dieu, Paris; P-M Girard, Hospital Saint-Antoine, Paris; C Pradier, E
Fontas, Hôpital de l'Archet, Nice; C Duvivier, Hôpital Necker-Enfants Malades, Paris.Germany: (J
Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule Hannover; O Degen,
University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; HJ
Stellbrink, IPM Study Center, Hamburg; C Stefan, JW Goethe University Hospital, Frankfurt; J
Bogner, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität Köln, Cologne. Georgia: (N
Chkhartishvili) Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi. Greece:
(P Gargalianos), G Xylomenos, K Armenis, Athens General Hospital "G Gennimatas"; H
Sambatakou, Ippokration General Hospital, Athens. Hungary: (J Szlávik), Szent Lásló Hospital,
Budapest.Iceland: (M Gottfredsson), Landspitali University Hospital, Reykjavik. Ireland: (F
Mulcahy), St. James's Hospital, Dublin. Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel
Aviv; E Shahar, G Hassoun, Rambam Medical Center, Haifa; H Elinav, M Haouzi, Hadassah
University Hospital, Jerusalem; D Elbirt, ZM Sthoeger, AIDS Center (Neve Or), Jerusalem. Italy:
(A D’Arminio Monforte), Istituto Di Clinica Malattie Infettive e Tropicale, Milan; R Esposito, I
Mazeu, C Mussini, Università Modena, Modena; F Mazzotta, A Gabbuti, Ospedale S Maria
Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; M Zaccarelli, A
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Antinori, R Acinapura, M Plazzi, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome;
A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco,
Milan.Latvia: (B Rozentale), Infectology Centre of Latvia, Riga. Lithuania: (V Uzdaviniene) Vilnius
University Hospital Santariskiu Klinikos, Vilnius; R Matulionyte, Center of Infectious Diseases,
Vilnius University Hospital Santariskiu Klinikos, Vilnius. Luxembourg: (T Staub), R Hemmer,
Centre Hospitalier, Luxembourg. Netherlands: (P Reiss), Academisch Medisch Centrum bij de
Universiteit van Amsterdam, Amsterdam. Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål
Hospital, Oslo. Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; A
Horban, E Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisiak, A Grzeszczuk,
Medical University, Bialystok; M Parczewski, K Maciejewska, B Aksak-Was, Medical Univesity,
Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; T Smiatacz, M
Gensing, Medical University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki
Szpital Specjalistyczny, Lodz; I Mozer-Lisewska, Poznan University of Medical Sciences, Poznan.
Portugal: (L Caldeira), Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon;
F Maltez, Hospital Curry Cabral, Lisbon. Romania: (R Radoi), C Oprea, Spitalul de Boli Infectioase
si Tropicale: Dr. Victor Babes, Bucarest. Russia: (A Panteleev), O Panteleev, St Petersburg AIDS
Centre, St Peterburg; A Yakovlev, Medical Academy Botkin Hospital, St Petersburg; T Trofimora,
Novgorod Centre for AIDS, Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious
Diseases, Kaliningrad; E Kuzovatova, Nizhny Novgorod Scientific and Research Institute of
Epidemiology and Microbiology named after Academician I.N. Blokhina, Nizhny Novogrod; E
Borodulina, E Vdoushkina, Samara State Medical University, Samara. Serbia: (D Jevtovic), The
Institute for Infectious and Tropical Diseases, Belgrade. Slovenia: (J Tomazic), University Clinical
Centre Ljubljana, Ljubljana. Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de Barcelona,
Barcelona; S Moreno, J. M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes,
C Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; P Domingo, M Gutierrez, G
Mateo, MA Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital Universitario de Alava,
Vitoria-Gasteiz. Sweden: (K Falconer), A Thalme, A Sonnerborg, Karolinska University Hospital,
Stockholm; A Blaxhult, Venhälsan-Sodersjukhuset, Stockholm; L Flamholc, Malmö University
Hospital, Malmö.Switzerland: (A Scherrer), R Weber, University Hospital Zurich; M Cavassini,
University Hospital Lausanne; A Calmy, University Hospital Geneva; H Furrer, University Hospital
Bern; M Battegay, University Hospital Basel; P Schmid, Cantonal Hospital St. Gallen.Ukraine: A
Kuznetsova, Kharkov State Medical University, Kharkov; G Kyselyova, Crimean Republican AIDS
centre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS Prevention and Control CTR, Lviv.
United Kingdom: (B Gazzard), St. Stephen's Clinic, Chelsea and Westminster Hospital, London;
AM Johnson, E Simons, S Edwards, Mortimer Market Centre, London; A Phillips, MA Johnson, A
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Mocroft, Royal Free and University College Medical School, London (Royal Free Campus); C
Orkin, Royal London Hospital, London; J Weber, G Scullard, Imperial College School of Medicine
at St. Mary's, London; A Clarke, Royal Sussex County Hospital, Brighton; C Leen, Western General
Hospital, Edinburgh.
The following centers have previously contributed data to EuroSIDA:
Infectious Diseases Hospital, Sofia, Bulgaria; Hôpital de la Croix Rousse, Lyon, France; Hôpital de
la Pitié-Salpétière, Paris, France; Unité INSERM, Bordeaux, France; Hôpital Edouard Herriot,
Lyon, France; Bernhard Nocht Institut für Tropenmedizin, Hamburg, Germany; 1st I.K.A Hospital
of Athens, Athens, Greece; Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy;
Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy; Ospedale Cotugno, III Divisione
Malattie Infettive, Napoli, Italy; Dérer Hospital, Bratislava, Slovakia; Hospital Carlos III,
Departamento de Enfermedades Infecciosas, Madrid, Spain; Kiev Centre for AIDS, Kiev, Ukraine;
Luhansk State Medical University, Luhansk, Ukraine;Odessa Region AIDS Center, Odessa,
Ukraine.
EuroSIDA Steering Committee
Chair: J Rockstroh, Study Co-leads: A Mocroft, O Kirk, Steering Committee: J Gatell, B Gazzard,
A Horban, I Karpov, M Losso, A d’Arminio Monforte, C Pedersen, M Ristola, A Phillips, P Reiss, J
Lundgren, J Rockstroh
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Appendix II. D:A:D Study group and steering committee.
D:A:D Steering Committee: Names marked with *, Chair with ¢
Cohort PIs: W El-Sadr* (CPCRA), G Calvo* (BASS), F Bonnet and F Dabis* (Aquitaine), O Kirk*
and A Mocroft* (EuroSIDA), M Law* (AHOD), A d’Arminio Monforte* (ICONA), L Morfeldt*
(HivBIVUS), C Pradier* (Nice), P Reiss* (ATHENA), R Weber* (SHCS), S De Wit* (Brussels)
Cohort coordinators and data managers: A Lind-Thomsen (coordinator), R Salbøl Brandt,
M Hillebreght, S Zaheri, FWNM Wit (ATHENA), A Scherrer, F Schöni-Affolter, M Rickenbach
(SHCS), A Tavelli, I Fanti (ICONA), O Leleux, J Mourali, F Le Marec, E Boerg (Aquitaine), E Thulin,
A Sundström (HIVBIVUS), G Bartsch, G Thompsen (CPCRA), C Necsoi, M Delforge (Brussels), E
Fontas, C Caissotti, K Dollet (Nice), S Mateu, F Torres (BASS), K Petoumenos, A Blance, R Huang,
R Puhr (AHOD), K Grønborg Laut, D Kristensen (EuroSIDA)
Statisticians: CA Sabin*, AN Phillips*, DA Kamara, CJ Smith, A Mocroft*
D:A:D coordinating office: CI Hatleberg, L Ryom, A Lind-Thomsen, RS Brandt, D Raben, C
Matthews, A Bojesen, AL Grevsen, JD Lundgren*¢
Member of the D:A:D Oversight Committee: B Powderly*, N Shortman*, C Moecklinghoff*,
G Reilly*, X Franquet*
D:A:D working group experts:
Kidney: L Ryom, A Mocroft*, O Kirk *, P Reiss*, C Smit, M Ross, CA Fux, P Morlat, E Fontas,
DA Kamara, CJ Smith, JD Lundgren *¢
Mortality: CJ Smith, L Ryom, CI Hatleberg, AN Phillips*, R Weber*, P Morlat, C Pradier*, P
Reiss*, FWNM Wit, N Friis-Møller, J Kowalska, JD Lundgren*¢
Cancer: CA Sabin*, L Ryom, CI Hatleberg, M Law*, A d'Arminio Monforte*, F Dabis*, F
Bonnet*, P Reiss*, FWNM Wit, CJ Smith, DA Kamara, J Bohlius, M Bower, G Fätkenheuer, A
Grulich, JD Lundgren*¢
External endpoint reviewers: A Sjøl (CVD), P Meidahl (oncology), JS Iversen (nephrology)
The current members of the 11 Cohorts are as follows:
ATHENA (AIDS Therapy Evaluation Project Netherlands):
Central coordination: P. Reiss*, S. Zaheri, M Hillebregt, F.W.N.M. Wit;
CLINICAL CENTRES (¤ denotes site coordinating physician) Academic Medical Centre of the
University of Amsterdam: J.M. Prins¤, T.W. Kuijpers, H.J. Scherpbier, J.T.M. van der Meer,
F.W.N.M. Wit, M.H. Godfried, P. Reiss, T. van der Poll, F.J.B. Nellen, S.E. Geerlings, M. van Vugt,
D. Pajkrt, J.C. Bos, W.J. Wiersinga, M. van der Valk, A. Goorhuis, J.W. Hovius, J. van Eden, A.
Henderiks, A.M.H. van Hes, M. Mutschelknauss, H.E. Nobel, F.J.J. Pijnappel, S. Jurriaans, N.K.T.
Back, H.L. Zaaijer, B. Berkhout, M.T.E. Cornelissen, C.J. Schinkel, X.V. Thomas. Admiraal De
Ruyter Ziekenhuis, Goes: M. van den Berge, A. Stegeman, S. Baas, L. Hage de Looff, D.
Versteeg. Catharina Ziekenhuis, Eindhoven: M.J.H. Pronk¤, H.S.M. Ammerlaan, E.S. de Munnik.
A.R. Jansz, J. Tjhie, M.C.A. Wegdam, B. Deiman, V. Scharnhorst. Emma Kinderziekenhuis: A.
van der Plas, A.M. Weijsenfeld. Erasmus MC, Rotterdam: M.E. van der Ende¤, T.E.M.S. de
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Vries-Sluijs, E.C.M. van Gorp, C.A.M. Schurink, J.L. Nouwen, A. Verbon, B.J.A. Rijnders, H.I. Bax,
M. van der Feltz. N. Bassant, J.E.A. van Beek, M. Vriesde, L.M. van Zonneveld. A. de Oude-
Lubbers, H.J. van den Berg-Cameron, F.B. Bruinsma-Broekman, J. de Groot, M. de Zeeuw- de
Man, C.A.B. Boucher, M.P.G Koopmans, J.J.A van Kampen, S.D. Pas. Erasmus MC–Sophia,
Rotterdam: G.J.A. Driessen, A.M.C. van Rossum, L.C. van der Knaap, E. Visser. Flevoziekenhuis,
Almere: J. Branger¤, A. Rijkeboer-Mes, C.J.H.M. Duijf-van de Ven. HagaZiekenhuis, Den Haag:
E.F. Schippers¤, C. van Nieuwkoop. J.M. van IJperen, J. Geilings. G. van der Hut. P.F.H. Franck.
HIV Focus Centrum (DC Klinieken): A. van Eeden¤. W. Brokking, M. Groot, L.J.M. Elsenburg, M.
Damen, I.S. Kwa. Isala, Zwolle: P.H.P. Groeneveld¤, J.W. Bouwhuis, J.F. van den Berg, A.G.W.
van Hulzen, G.L. van der Bliek, P.C.J. Bor, P. Bloembergen, M.J.H.M. Wolfhagen, G.J.H.M. Ruijs.
Leids Universitair Medisch Centrum, Leiden: , F.P. Kroon¤, M.G.J. de Boer, M.P. Bauer, H.
Jolink, A.M. Vollaard, W. Dorama, N. van Holten, E.C.J. Claas, E. Wessels. Maasstad Ziekenhuis,
Rotterdam: J.G. den Hollander¤, K. Pogany, A. Roukens, M. Kastelijns, J.V. Smit, E. Smit, D.
Struik-Kalkman, C. Tearno, M. Bezemer, T. van Niekerk, O. Pontesilli. Maastricht UMC+,
Maastricht: S.H. Lowe¤, A.M.L. Oude Lashof, D. Posthouwer, R.P. Ackens, J. Schippers, R.
Vergoossen, B. Weijenberg-Maes, I.H.M. van Loo, T.R.A. Havenith. MCH-Bronovo, Den Haag:
E.M.S. Leyten¤, L.B.S. Gelinck, A. van Hartingsveld, C. Meerkerk, G.S. Wildenbeest, J.A.E.M.
Mutsaers, C.L. Jansen. MC Slotervaart, Amsterdam: J.W. Mulder, S.M.E. Vrouenraets, F.N.
Lauw, M.C. van Broekhuizen, H. Paap, D.J. Vlasblom, P.H.M. Smits. MC Zuiderzee, Lelystad: S.
Weijer¤, R. El Moussaoui, A.S. Bosma. Medisch Centrum Leeuwarden, Leeuwarden: M.G.A.van
Vonderen¤, D.P.F. van Houte, L.M. Kampschreur, K. Dijkstra, S. Faber, J Weel. Medisch
Spectrum Twente, Enschede: G.J. Kootstra¤, C.E. Delsing, M. van der Burg-van de Plas, H.
Heins, E. Lucas. Noorwest Ziekenhuisgroep, Alkmaar: W. Kortmann¤, G. van Twillert¤, J.W.T.
Cohen Stuart, B.M.W. Diederen, D. Pronk, F.A. van Truijen-Oud, W. A. van der Reijden, R.
Jansen. OLVG, Amsterdam: K. Brinkman¤, G.E.L. van den Berk, W.L. Blok, P.H.J. Frissen, K.D.
Lettinga W.E.M. Schouten, J. Veenstra, C.J. Brouwer, G.F. Geerders, K. Hoeksema, M.J. Kleene,
I.B. van der Meché, M. Spelbrink, H. Sulman, A.J.M. Toonen, S. Wijnands, M. Damen, D. Kwa, E.
Witte. Radboudumc, Nijmegen: P.P. Koopmans, M. Keuter, A.J.A.M. van der Ven, H.J.M. ter
Hofstede, A.S.M. Dofferhoff, R. van Crevel, M. Albers, M.E.W. Bosch, K.J.T. Grintjes-Huisman,
B.J. Zomer, F.F. Stelma, J. Rahamat-Langendoen,D. Burger. Rijnstate, Arnhem: C. Richter¤, E.H.
Gisolf, R.J. Hassing, G. ter Beest, P.H.M. van Bentum, N. Langebeek, R. Tiemessen, C.M.A.
Swanink. Spaarne Gasthuis, Haarlem: S.F.L. van Lelyveld¤, R. Soetekouw, N. Hulshoff, L.M.M.
van der Prijt, J. van der Swaluw, N. Bermon, W.A. van der Reijden, R. Jansen, B.L. Herpers,
D.Veenendaal. Medisch Centrum Jan van Goyen, Amsterdam: D.W.M. Verhagen, M. van Wijk.
St Elisabeth Ziekenhuis, Tilburg: M.E.E. van Kasteren¤, A.E. Brouwer, B.A.F.M. de Kruijf-van de
Wiel, M. Kuipers, R.M.W.J. Santegoets, B. van der Ven, J.H. Marcelis, A.G.M. Buiting, P.J. Kabel.
Universitair Medisch Centrum Groningen, Groningen: W.F.W. Bierman¤, H. Scholvinck, K.R.
Wilting, Y. Stienstra, H. de Groot-de Jonge, P.A. van der Meulen, D.A. de Weerd, J. Ludwig-
Roukema, H.G.M. Niesters, A. Riezebos-Brilman, C.C. van Leer-Buter, M. Knoester. Universitair
Medisch Centrum Utrecht, Utrecht: A.I.M. Hoepelman¤, T. Mudrikova, P.M. Ellerbroek, J.J.
Oosterheert, J.E. Arends, R.E. Barth, M.W.M. Wassenberg, E.M. Schadd, D.H.M. van Elst-
Laurijssen, E.E.B. van Oers-Hazelzet, S. Vervoort, M. van Berkel, R. Schuurman, F. Verduyn-
Lunel, A.M.J. Wensing. VUmc, Amsterdam: E.J.G. Peters¤, M.A. van Agtmael, M. Bomers, J. de
Vocht, M. Heitmuller, L.M. Laan, A.M. Pettersson, C.M.J.E. Vandenbroucke-Grauls, C.W. Ang.
Wilhelmina Kinderziekenhuis, UMCU, Utrecht: S.P.M. Geelen, T.F.W. Wolfs, L.J. Bont, N.
Nauta. COORDINATING CENTRE P. Reiss, D.O. Bezemer, A.I. van Sighem, C. Smit, F.W.N.M.
Wit., T.S. Boender, S. Zaheri, M. Hillebregt, A. de Jong, D. Bergsma, P. Hoekstra, A. de Lang, S.
Grivell, A. Jansen, M.J. Rademaker, M. Raethke, R. Meijering, S. Schnörr, L. de Groot, M. van
den Akker, Y. Bakker, E. Claessen, A. El Berkaoui, J. Koops, E. Kruijne, C. Lodewijk, L. Munjishvili,
B. Peeck, C. Ree, R. Regtop, Y. Ruijs, T. Rutkens, L. van de Sande, M. Schoorl, A. Timmerman, E.
Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse, T. Woudstra, B. Tuk.
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Aquitaine Cohort (France)
Composition du Conseil scientifique :
Coordination: F. Bonnet, F. Dabis
Scientific committee: M. Dupon, V. Gaborieau, D. Lacoste, D. Malvy, P. Mercié, P. Morlat, D.
Neau, JL. Pellegrin, S. Tchamgoué, E. Lazaro, C. Cazanave, M. Vandenhende, M.O. Vareil, Y.
Gérard, P. Blanco, S. Bouchet, D. Breilh, H. Fleury, I. Pellegrin, G. Chêne, R. Thiébaut, L.
Wittkop, L. Wittkop, O. Leleux, S. Lawson-Ayayi, A. Gimbert, S. Desjardin, L. Lacaze-Buzy, V.
Petrov-Sanchez
Epidemiology and Methodology: F. Bonnet, G. Chêne, F. Dabis, R. Thiébaut, L. Wittkop
Infectious Diseases and Internal Medicine: K. André, N. Bernard, F. Bonnet, O. Caubet, L.
Caunegre, C. Cazanave, I. Chossat, C. Courtault, FA. Dauchy, S. De Witte, D. Dondia, M. Dupon,
P. Duffau, H. Dutronc, S. Farbos, I. Faure, H. Ferrand, V. Gaborieau, Y. Gerard, C. Greib, M.
Hessamfar, Y. Imbert, D. Lacoste , P. Lataste, E. Lazaro, D. Malvy, J. Marie, M. Mechain, P.
Mercié, E.Monlun, P. Morlat, D. Neau, A. Ochoa, JL. Pellegrin, T. Pistone, I. Raymond,MC.
Receveur, P. Rispal, L. Sorin, S. Tchamgoué, C. Valette, MA. Vandenhende, MO. Vareil, JF.
Viallard, H. Wille, G. Wirth.
Immunology: I. Pellegrin, P. Blanco
Virology: H. Fleury, Me. Lafon, P. Trimoulet, P. Bellecave, C. Tumiotto
Pharmacology: S. Bouchet, D. Breilh, F. Haramburu, G. Miremeont-Salamé
Data collection, Project Management and Statistical Analyses: MJ. Blaizeau, M. Decoin, C.
Hannapier, E. Lenaud et A. Pougetoux; S. Delveaux, C. D’Ivernois, F. Diarra B. Uwamaliya-
Nziyumvira, O. Leleux; F. Le Marec, Eloïse Boerg, S. Lawson-Ayayi;
IT department and eCRF development: G. Palmer, V. Conte, V. Sapparrart
AHOD (Australian HIV Observational Database, Australia):
Central coordination: M. Law *, K. Petoumenos, R Puhr, R Huang (Sydney, New
South Wales). Participating physicians (city, state): R. Moore, S. Edwards, J. Hoy,
K. Watson, N. Roth, H Lau (Melbourne, Victoria); M Bloch, D. Baker, A. Carr, D.
Cooper, (Sydney, New South Wales);M O’Sullivan (Gold Coast, Queensland), D.
Nolan, G Guelfi (Perth, Western Australia).
BASS (Spain):
Central coordination: G. Calvo, F. Torres, S. Mateu (Barcelona);
Participating physicians (city): P. Domingo, M.A. Sambeat, J. Gatell, E. Del Cacho, J. Cadafalch,
M. Fuster (Barcelona); C. Codina, G. Sirera, A. Vaqué (Badalona).
The Brussels St Pierre Cohort (Belgium):
Coordination: S. De Wit*, N. Clumeck, M. Delforge, C. Necsoi.
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Participating physicians: N. Clumeck, S. De Wit*, AF Gennotte, M. Gerard, K. Kabeya, D.
Konopnicki, A. Libois, C. Martin, M.C. Payen, P. Semaille, Y. Van Laethem.
CPCRA (USA):
Central coordination: J. Neaton, G. Bartsch, W.M. El-Sadr*, E. Krum, G. Thompson, D.
Wentworth;
Participating physicians (city, state): R. Luskin-Hawk (Chicago, Illinois); E. Telzak (Bronx, New
York); W.M. El-Sadr (Harlem, New York); D.I. Abrams (San Francisco, California); D. Cohn
(Denver, Colorado); N. Markowitz (Detroit, Michigan); R. Arduino (Houston, Texas); D. Mushatt
(New Orleans, Louisiana); G. Friedland (New Haven, Connecticut); G. Perez (Newark, New
Jersey); E. Tedaldi (Philadelphia, Pennsylvania); E. Fisher (Richmond, Virginia); F. Gordin
(Washington, DC); L.R. Crane (Detroit, Michigan); J. Sampson (Portland, Oregon); J. Baxter
(Camden, New Jersey).
EuroSIDA (multinational)
Steering Committee: J Gatell, B Gazzard, A Horban, I Karpov, M Losso, A d’Arminio Monforte, C
Pedersen, M Ristola, A Phillips, P Reiss, J Lundgren, J Rockstroh
Chair: J Rockstroh
Study Co-leads: A Mocroft, O Kirk
Coordinating Centre Staff: O Kirk, L Peters, C Matthews, AH Fischer, A Bojesen, D Raben, D
Kristensen, K Grønborg Laut, JF Larsen, D Podlekareva
Statistical Staff: A Mocroft, A Phillips, A Cozzi-Lepri, L Shepherd, A Schultze, S Amele
The multi-centre study group, EuroSIDA (national coordinators in parenthesis).
Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires.
Austria: (B Schmied), Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, Medical
University Innsbruck, Innsbruck.
Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM Mitsura, Gomel
State Medical University, Gomel; D Paduto, Regional AIDS Centre, Svetlogorsk.
Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, Brussels; E Florence,
Institute of Tropical Medicine, Antwerp; L Vandekerckhove, University Ziekenhuis Gent, Gent.
Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, Sarajevo.
Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb.
Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles
University Hospital, Plzen.
Denmark: G Kronborg,T Benfield, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein,
Rigshospitalet, Copenhagen; NF Møller, C Pedersen, Odense University Hospital, Odense; L
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Ostergaard, Skejby Hospital, Aarhus, L Wiese, Roskilde Hospital, Roskilde; L N Nielsen, Hillerod
Hospital, Hillerod.
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, Nakkusosakond
Siseklinik, Kohtla-Järve.
Finland: (M Ristola), I Aho, Helsinki University Central Hospital, Helsinki.
France: (J-P Viard), Hôtel-Dieu, Paris; P-M Girard, Hospital Saint-Antoine, Paris; C Pradier, E
Fontas, Hôpital de l'Archet, Nice; C Duvivier, Hôpital Necker-Enfants Malades, Paris.
Germany: (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule
Hannover; O Degen, University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit,
Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; C Stefan, JW Goethe University Hospital,
Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität Köln,
Cologne.
Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & Clinical Immunology Research Center,
Tbilisi
Greece: (P Gargalianos), G Xylomenos, K Armenis, Athens General Hospital "G Gennimatas"; H
Sambatakou, Ippokration General Hospital, Athens.
Hungary: (J Szlávik), Szent Lásló Hospital, Budapest.
Iceland: (M Gottfredsson), Landspitali University Hospital, Reykjavik.
Ireland: (F Mulcahy), St. James's Hospital, Dublin.
Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; E Shahar, G Hassoun, Rambam
Medical Center, Haifa; H Elinav, M Haouzi, Hadassah University Hospital, Jerusalem; D Elbirt,
ZM Sthoeger, AIDS Center (Neve Or), Jerusalem.
Italy: (A D’Arminio Monforte), Istituto Di Clinica Malattie Infettive e Tropicale, Milan; R
Esposito, I Mazeu, C Mussini, Università Modena, Modena; F Mazzotta, A Gabbuti, Ospedale S
Maria Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; M
Zaccarelli, A Antinori, R Acinapura, M Plazzi, Istituto Nazionale Malattie Infettive Lazzaro
Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A
Ridolfo, Osp. L. Sacco, Milan.
Latvia: (B Rozentale), Infectology Centre of Latvia, Riga.
Lithuania: (V Uzdaviniene) Vilnius University Hospital Santariskiu Klinikos, Vilnius; R
Matulionyte, Center of Infectious Diseases, Vilnius University Hospital Santariskiu Klinikos,
Vilnius.
Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, Luxembourg.
Netherlands: (P Reiss), Academisch Medisch Centrum bij de Universiteit van Amsterdam,
Amsterdam.
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Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål Hospital, Oslo.
Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; A Horban, E
Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisiak, A Grzeszczuk, Medical
University, Bialystok; M Parczewski, K Maciejewska, B Aksak-Was, Medical Univesity, Szczecin;
M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; T Smiatacz, M Gensing,
Medical University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki Szpital
Specjalistyczny, Lodz; I Mozer-Lisewska, Poznan University of Medical Sciences, Poznan.
Portugal: (L Caldeira), Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz,
Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.
Romania: (R Radoi), C Oprea, Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes,
Bucarest.
Russia: (A Panteleev), O Panteleev, St Petersburg AIDS Centre, St Peterburg; A Yakovlev,
Medical Academy Botkin Hospital, St Petersburg; T Trofimora, Novgorod Centre for AIDS,
Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious Diseases, Kaliningrad; E
Kuzovatova, Nizhny Novgorod Scientific and Research Institute of Epidemiology and
Microbiology named after Academician I.N. Blokhina, Nizhny Novogrod; E Borodulina, E
Vdoushkina, Samara State Medical University, Samara.
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade.
Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.
Spain: (JM Gatell), JM Miró, Hospital Clinic Universitari de Barcelona, Barcelona; S Moreno, J.
M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R Paredes, C Tural, J Puig, I
Bravo, Hospital Germans Trias i Pujol, Badalona; P Domingo, M Gutierrez, G Mateo, MA
Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital Universitario de Alava, Vitoria-
Gasteiz.
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Abstract
Background
Non-Hodgkin (NHL) and Hodgkin lymphomas (HL) are increased in populations with immune
dysfunction including people living with HIV. While independent risk factors for NHL and HL are
known, there is little evidence for to what degree immunological and virological factors
differently affect NHL and HL risk.
Methods
Data from the D:A:D cohort was analysed to identify independent risk factors for NHL and HL
using hazard ratios (HR), focusing on current and cumulative area under the curve [AUC]
measures of immunological and virological status. Variables with different associations with NHL
and HL were identified using marginal cox models.
Results
Among 41,420 people followed for 337,020 person-years, 392 developed NHL (incidence rate
1.7/1000 person-years 95%CI: 1.06, 1.30) and 149 HL (0.44/1000 PYFU 95%CI: 0.38, 0.52). Higher
risk of both NHL and HL was associated with lower current CD4-cell count, whereas higher
current HIV-viral load (HIV-VL) and higher AUC of HIV-VL was associated with NHL only. Both
current and AUC of HIV-VL were factors which had different associations with NHL and HL, where
the hazard ratio for NHL was progressively higher than for HL with increasing HIV-VL category.
Lower current CD4-cell had a strongly but similar association with both NHL and HL.
Conclusion
CD4 depletion increased risk of both types of lymphomas while current and accumulated HIV-
VL was associated with NHL only. This suggests that NHL development is related to both CD4-
cell depletion and added immune dysfunction derived from ongoing HIV replication. This latter
factor was not associated with HL risk.
Introduction
Use of combination antiretroviral treatment (cART) in the people living with HIV (PLWH) has led
to a decline in the incidence of non-Hodgkin lymphoma (with the exception of Burkitt lymphoma
[BL]) but not Hodgkin lymphoma (HL)[1-10]. Recent estimates indicate that the incidence of NHL
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and HL remain elevated in PLWH compared to the general population, with NHL incidence
estimated to be around 10-fold higher [11-13] and HL incidence estimated to be around 11-fold
higher [9, 12].
In PLWH, the pathogenesis of NHL and HL is thought to be driven by a combination of latent
infection with Epstein-Barr virus (EBV) and HIV-associated immune suppression and dysfunction
[14-16]. The interaction between HIV-infection, immune suppression and dysfunction and EBV
co-infection is thought to differ between NHL and HL, as well as between NHL subtypes [17]. For
example, approximately half of BL occur at relatively preserved CD4-cell counts and are not EBV
related [18]. Primary brain lymphomas (PBL) often occur at very low CD4 levels, however, a lack
EBV-specific CD4 T-cell function has been shown in PLWH people prior to PBL development
irrespective of absolute CD4-cell counts [19]. Almost all HL is EBV related in PLWH and although
HL is associated with low CD4 cell counts [8, 18, 20, 21], it is not as strong as for PBL or diffuse
large B-cell lymphomas.
Several prior studies have suggested that the risk factors and strengths of associations differ for
NHL and HL in the context of PLWH [22-29]. For example, older age has been linked to NHL,
however, several studies have reported no association between HL incidence and age in PLWH
[20, 30-34]. Many studies have identified an association between lower current CD4-cell count
and both NHL and HL incidence [5, 20, 31, 35-39]. However both current and cumulative HIV-VL
have been linked with NHL incidence, independently of CD4 [34, 40], an association not usually
reported for HL [37]. The START study demonstrated that immediate cART significantly reduced
the risk of infection-related cancer, independently of CD4 and HIV-VL, suggesting that HIV-
associated cancer risk is mediated through other mechanisms such as immune activation and
reduced immune surveillance, above and beyond the depletion of CD4-cell counts [41].
Although there are many studies investigating incidence of NHL and HL since the introduction of
cART and associated risk factors, to our knowledge no studies have directly compared the risk
factors. Therefore, we aimed to identify independent risk factors of NHL and HL and to identify
factors that differently affect NHL and HL risk in order to develop the understanding of different
mechanistic pathways, which may then suggest different preventive approaches for reducing
NHL and HL risk.
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Methods
The Data Collection on Adverse events of Anti-HIV Drugs Study (D:A:D) is a prospective cohort
collaboration established in 1999; the dataset includes more than 49000 HIV-1-positive people
in Europe, the USA, and Australia. The D:A:D Study has been described in detail previously [42].
Data for routine clinical care, including demographic factors, HIV treatment, laboratory values,
and AIDS-defining events (including NHL[43]) are collected at enrolment and annually
thereafter. Non-AIDS defining cancers, such as HL, have been routinely collected and validated
since 1 January 2004. Detailed information on all Non-AIDS-defining cancers is collected via
designated case report forms, including date of diagnosis, type/location of cancer, stage and
histology/cytology report or other applied diagnostic methods, such as imaging and biochemical
assays, and are supplemented by submitted source documentation supporting the way of
diagnosis. NHL is further characterized by histological type (BL, immunoblastic lymphomas, PBL
and unknown). All events are centrally validated at the D:A:D coordinating center by a medical
doctor, with a proportion of complicated cases selected to be reviewed by an external
oncologist. Events are regularly monitored for accuracy, with random monitoring at
participating sites to ensure complete case ascertainment.
We investigated the association between immunological and virological factors and two main
outcomes: (1) first diagnosis of NHL, and (2) first diagnosis of HL during follow-up. Baseline was
defined as the latest of date of study entry, first reported CD4-cell count, or 1st January 2004,
and people were followed from baseline until the earliest of NHL or HL diagnosis, last visit plus
6 months, death, or 1st February 2015.
We investigated the associations between nadir and current CD4-cell count, and current and
area under the curve (AUC) of HIV-VL and each outcome. The AUC of HIV-VL refers to the area
under each individuals viral load curve [44] and was calculated using all HIV-VL measures since
entry into D:A:D. Formally, it can be interpreted as the total number of copies/mL of HIV-RNA
accumulated over time. For example, an AUC of HIV-VL of 10,000 copies/mL-year is equal to
having a HIV-VL of 10,000 copies/mL for 1 year or a HIV-VL of 1,000 copies/mL for 10 years. Due
to the high correlation between nadir and current CD4, only one measure was included in the
analysis according to the lowest Akaike information criterion (AIC) for both NHL and HL. Current
and AUC of HIV-VL were not strongly correlated and therefore both were included in the same
model.
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Incidence rates per 1,000 person years of follow-up (PYFU) of NHL and HL were calculated
according to calendar year of follow-up. Separate Cox regression models were used to identify
factors associated with NHL and HL, focussing on current and nadir CD4, and current and AUC
of HIV-VL. Models were adjusted for baseline factors (gender, HIV transmission mode, ethnicity,
calendar year of baseline) and current factors (age, body mass index [BMI], smoking status,
hepatitis-B and C coinfection, prior AIDS-defining cancer [excluding NHL], AIDS-defining
diagnosis [excluding cancer], hypertension [diastolic blood pressure >90 mmHg, systolic blood
pressure > 140 mmHg, receiving antihypertensive medication or ACE inhibitors], cardiovascular
disease, diabetes [as validated event or use of anti-diabetic medication], and cumulative time
on cART [defined as being on ≥1 protease inhibitor or non-nucleoside reverse transcriptase 
inhibitor). Immunological and virological risk factors for NHL subtypes were also investigated in
those with NHL subtype reported (33.6%).
The Wei, Lin, and Weissfeld method, based on marginal cox models, [45] was used to identify
factors that differently affected NHL and HL risk. The models were used to jointly calculate and
compare adjusted hazard ratios (aHR) for NHL and HL for all current and historical measures of
HIV-VL and CD4-cell count (separately), adjusting for variables listed previously. In order to fit a
more parsimonious model, variables not associated with either NHL or HL incidence were
assumed to have a similar association for both NHL and HL. The remaining variables were
allowed to vary according to outcome. The marginal cox models differed to those used to
identify independent risk factors (cox models) with minor differences in adjustments (fixed and
outcome specific variables) which give slightly different estimates. The ratio of the adjusted HRs
(RHR) was used to identify factors with different risk profiles for NHL and HL, which we have
termed “differential factors”. Variables for which the 95% confidence interval (95%CI) for the
RHR cross 1 indicates a similar association between the risk factor and both HL and NHL.
All statistical tests were two sided with a type I error rate of 5%. All statistical analyses were
performed using SAS 9.4 (Statistical Analysis Software, Cary NC, USA).
Results
There were 41,420 people included in the analysis contributing 337,020 PYFU with a median
follow-up of 9.2 (Interquartile range [IQR]: 6.3, 1.1) years per person. A total of 392 people
developed NHL (incidence rate [IR] 1.17/1000 PYFU, 95%CI: 1.06,1.30) and 149 developed HL (IR
0.44/1000 PYFU 95%CI: 0.38,0.52) during follow-up.
366
Baseline characteristics
Baseline characteristics of the study population, as well as those who developed NHL or HL
during follow-up are shown in table 1. Overall, 17.4% were aged ≥ 50 years at baseline, 72.9% 
were of male gender and 43.8% acquired their HIV through men who have sex with men. 49.9%
were of white ethnicity and 40.9% had unknown ethnicity. Just over half were on cART (51.8%)
at baseline, with a median cART duration of 1.1(IQR: 0.0,4.9) years. The median CD4-cell count
was 431 (IQR: 280,620) cells/mm3 and the median HIV-VL was 260 (IQR: <50, 20,400) copies/mL.
Crude Incidence rates over time
The crude incidence of NHL and HL by calendar year is shown in figure 1. The crude incidence of
NHL declined by 13.3% per year (95%CI: 10.3,16.2%) from an incidence rate of 1.96 (95%CI:
1.48,2.58) events/1000 PYFU in 2004 to 0.32 (95%CI: 0.17,0.62) in 2014/15. In 2014/15, the
incidence of NHL was similar to HL (HL: 0.36 95%CI: 0.19,0.66), however HL incidence was stable
over time (change per year: -2.7%, 95%CI: -7.7,2.6%).
Independent risk factors for NHL and HL
Current and nadir CD4-cell counts were considered for inclusion in the main analysis. Both
associated with NHL in adjusted analyses, whereas only current CD4 was associated with HL. A
2-fold higher (i.e. doubling of) current CD4 count was associated with a 19% reduced risk of NHL
(95%CI: 15,23%) and a 14% reduced risk of HL (95%CI: 7,21%), whereas a 2-fold higher nadir CD4
count was associated with a 12% reduced risk of NHL (95%CI: 7,17%) but not HL (aHR: 0.96
95%CI: 0.87,1.05). However, current CD4 was the strongest immune marker for both NHL and
HL, and so was the only immunological marker included in multivariate models (provided the
best statistical fit, measured as by the AIC).
Independent risk factors of NHL and HL from a multivariate model are shown in table 2. For
example, a higher rate of NHL was strongly associated with lower current CD4-cell count
category (CD4 <100 VS > 599 cells/mm3 aHR 8.08 95%CI: 5.63,11.61), higher current HIV-VL (HIV-
VL> 1000 VS <50 copies/mL aHR: 1.97 95%CI 1.50,2.59) and higher AUC of HIV-VL (highest vs
lowest quintile aHR: 2.91 95%CI: 1.92,4.41). Higher rates of NHL were also observed in older
people and males. A higher rate of HL was also associated with lower current CD4-cell count
category, however no association was found for current or AUC of HIV-VL. Moreover, current
smokers had almost a 2-fold higher rate of HL compared to non-smokers. No association was
found for HCV or HBV status with either NHL or HL. Rates of both NHL (aHR per year longer on
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cART: 0.92 95%CI: 0.89,0.95) and HL (aHR per year longer on cART: 0.92 95%CI: 0.87,0.97)
reduced for each additional year on cART.
Differences in risk factors for NHL and HL
Factors that were associated with either NHL or HL in table 2 were jointly modelled to identify
factors that were differently associated with NHL and HL (differential factors). Current HIV-VL
was a differential factor, as demonstrated by the increase in ratio of the aHRs with higher HIV-
VL category (figure 2). For example, the RHRs were 2.52 (95%CI: 1.32,4.81) and 4.57 (95%CI:
2.20,9.50) in those with current HIV-VL 50 – 1000 copies/mL and >1000 copies/mL relative to
<50 copies/mL respectively, indicating a progressively stronger association with NHL than for HL
with higher current HIV-VL. A similar result was found for the AUC of HIV-VL, which was also a
differential factor. Current CD4 was not a differential factor as the 95%CI of the ratio of the aHRs
for each CD4 cell coutn category relative to CD4 200 - 299 cells/mm3 contained 1, indicating no
evidence that lower CD4-cell count was differently associated with NHL and HL. Age was a
differential risk factor as the ratio of the aHRs of people aged > 60 relative to those aged 30-39
was more than 3 (95%CI: 1.43,6.55), indicating a relative increase in rates of NHL than for HL for
people in this older age group. Finally, smoking status was a differential factor, as the ratio of
the aHRs for current smokers relative to never smokers was 0.49 (95%CI: 0.28,0.83), indicating
a significantly higher relative increase in risk for HL in this group. None of the other factors
investigated were differential factors, including gender, HIV transmission, or time on cART
overall.
NHL subtypes
Of the 392 NHL, 42 were BL (10.7%), 25 were PBL lymphoma (6.4%), 65 were immunoblastic
(16.6%), and 260 were unknown (66.3%). People with known and unknown NHL subtype had
similar characteristics at diagnosis. Slightly more people with known subtype reported being on
protease inhibitors (known subtype: 46.2% vs unknown subtype: 38.6%, P=0.05), and slightly
less had a previous cancer diagnosis (3.1% vs 10.6%, P=0.02). Associations between
immunological and virological risk factors for each subtype (in those with a subtype recorded)
are shown in table 3. For example, lower risk of PBL was associated with higher current and nadir
CD4-cell count (aHR for 2-fold higher: 0.59 95%CI: 0.51, 0.70 and 0.68 95%CI: 0.58,0.80
respectively) and lower AUC of HIV-VL (aHR for 10-fold higher: 2.21 95%CI: 1.22,4.00), but not
current HIV-VL. Lower immunoblastic NHL risk was associated with higher current and nadir CD4
and lower current and AUC of HIV-VL. Lower BL risk was associated with higher current and AUC
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of HIV-VL but not immunological markers. Nadir CD4-cell count was not associated with PBL,
immunoblastic lymphoma or BL after additional adjustment for current CD4-cell count.
Discussion
This study is the first to attempt to identify differences in the underlying pathology of NHL and
HL in PLWH by directly comparing the immunological and virological risk factors for each and
identifying differences. Higher current and cumulative exposure to HIV-VL were stronger risk
factors for NHL than HL. Although current CD4 was a strong predictor of both, there was no
evidence of a different association between with NHL and HL. In this study, the crude incidence
of NHL declined steadily over time while HL incidence remained stable. The trends over time are
not surprising and have been reported before [1-10], however, our study is one of the first to
show that incidence of NHL and HL is similar in PLWH in recent years. This highlights a shift away
from the cancers with a strong link with immune deficiency and the need for a better
understanding of how generalised immune dysfunction (beyond low CD4-cell counts) can
facilitate lymphoma development.
The risk of NHL and HL differed according to current and accumulated HIV-VL, but not current
CD4-cell count. Our results indicate a similar pathological requirement of immunodeficiency for
both NHL and HL development, however, an important distinction is the involvement of HIV-VL
in NHL but not HL development. This indicates that HIV-infection may contribute to
lymphomagenesis of NHL through additional immune dysfunction not captured by supressed
CD4 [46], possible though reduced immune surveillance for proteins expressed by cells infected
with latent EBV, immune activation, and/or CD8-dysfunction leading to depleted response from
EBV-specific CD8 cytotoxic cells [14-16, 19, 47, 48]. Some studies have found that levels of
circulating free light chains have predictive value of NHL in PLWH, which supports the
involvement of immune activation [49, 50]. In addition, the ratio and percentage of CD8-cells
has been shown to be predictive of HL [30] and may also be predictive of EBV-associated NHL
[19, 51]. Alternatively, HIV may play a more direct role in lymphomagenesis [46, 52], with HIV-
derived p17 secreted within lymphoid tissues, possibly promoting lymphoma development by
inducing changes to the microenvironment [52].
Smoking status had a different association with HL and NHL, where risk of HL was elevated in
current smokers. Previous research in the general population has indicated that smoking may
play an etiological role in HL, particularly EBV-positive HL [53, 54]. Almost all HL in PLWH is EBV
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related, and therefore smoking presents as one of the few modifiable risk factors for this cancer
and emphasises the importance of smoking cessation strategies in PLWH. Age also had a
different association with NHL and HL, where people aged over 50 years had a higher relative
increase in the rate of NHL than for HL, which is consistent with previous studies [14, 20, 30, 32,
33, 55]. This may reflect increases in immune activation and inflammation associated with aging
and further supports the hypothesis that immune dysfunction beyond low CD4 is involved in the
pathology [56]. The lack of association between either HCV or HBV status and NHL or HL is in
contrast to results from the COHERE study, which found a significant association between both
HCV and HBV and NHL risk [57], and two meta analyses [58, 59]. Although other studies have
failed to show a convincing association [20, 60, 61]. This may be in part due to the low number
of people on treatment in the early years of follow-up in our study.
This study has many advantages. The D:A:D study contains follow up on over 40,000 people and
allows for the analysis of a relatively large number of prospectively collected and validated NHL
and HL events. Furthermore, the D:A:D data contains highly detailed demographic, HIV and
health related factors collected over a long follow-up period. However, the limitations need to
be considered. There were several known risk factors for NHL and HL that are not collected in
D:A:D, for example, autoimmune disorders and family history. Furthermore, NHL subtype is only
reported by a subset of cohorts in D:A:D, and as a result it was missing on 66% of people,
however, the characteristics of those with and without subtype information were similar. D:A:D
does not collect additional markers of immune suppression (other CD4-cell count) or
dysfunction, or EBV viral load. And finally, this is an observational study and it is possible that
confounding due to unmeasured or unknown factors remain and the causality of the
associations presented here cannot be determined. It should also be kept in mind that NHL is
treated as a single entity the main analysis, however, there is considerable heterogeneity in
aetiology between NHL subtypes [62].
In conclusion, whereas CD4 depletion similarly increased risk of both types of lymphomas,
current and accumulated HIV-VL was more predictive of NHL than HL. This suggests that NHL
development is related to both CD4-cell depletion and added immune dysfunction derived from
ongoing HIV replication. This latter factor was not associated with HL risk. These findings stress
the importance of early HIV diagnosis and treatment, and of ensuring sustained viral
suppression.
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Tables
Table 1 Baseline characteristics of D:A:D participants included in the analysis
ca All persons(N=41,420)
Persons who
developed NHL
(n=392)
Persons who
developed HL
(N=149)
N (%) N (%) N (%)
Age (years)
<30 5,922 (14.3) 22 ( 5.6) 16 (10.7)
30 - 39 14,833 (35.8) 118 (30.1) 44 (29.5)
40 - 49 13,449 (32.5) 142 (36.2) 56 (37.6)
50 - 59 5,170 (12.5) 71 (18.1) 23 (15.4)
>=60 2,046 ( 4.9) 39 ( 9.9) 10 ( 6.7)
Gender
Male 30,214 (72.9) 337 (86.0) 126 (84.6)
Female 11,206 (27.1) 55 (14.0) 23 (15.4)
HIV-transmission mode
Homosexual 18,124 (43.8) 200 (51.0) 87 (58.4)
IDU 5,926 (14.3) 53 (13.5) 15 (10.1)
Heterosexual 14,800 (35.7) 106 (27.0) 39 (26.2)
Other/Unknown 2,570 ( 6.2) 33 ( 8.4) 8 ( 5.4)
Race
White 20,658 (49.9) 181 (46.2) 70 (47.0)
Black 2,963 ( 7.2) 10 ( 2.6) 6 ( 4.0)
Other 840 ( 2.0) 7 ( 1.8) 3 ( 2.0)
Unknown 16,959 (40.9) 194 (49.5) 70 (47.0)
smoking status
Current 16,859 (40.7) 155 (39.5) 70 (47.0)
Ex 7,332 (17.7) 65 (16.6) 31 (20.8)
Never 11,364 (27.4) 98 (25.0) 28 (18.8)
Unknown 5,865 (14.2) 74 (18.9) 20 (13.4)
BMI group
<18 1,377 ( 3.3) 13 ( 3.3) 4 ( 2.7)
18 - 26 27,709 (66.9) 255 (65.1) 102 (68.5)
27 - 30 5,360 (12.9) 59 (15.1) 15 (10.1)
>30 1,833 ( 4.4) 16 ( 4.1) 10 ( 6.7)
Unknown 5,141 (12.4) 49 (12.5) 18 (12.1)
Previous AIDS defining event 8,801 (21.2) 85 (21.7) 31 (20.8)
Previous AIDS cancer 1,419 ( 3.4) 26 ( 6.6) 8 ( 5.4)
On cART 21,436 (51.8) 161 (41.1) 70 (47.0)
HBV
Negative 29,355 (70.9) 271 (69.1) 119 (79.9)
Positive/prior 7831 (18.9) 86 (21.9) 19 (12.8)
Unknown 4,234 (10.2) 35 ( 8.9) 11 ( 7.4)
HCV
Negative 28,168 (68.0) 261 (66.6) 117 (78.5)
Positive 7,947 (19.2) 76 (19.4) 19 (12.8)
Unknown 5,305 (12.8) 55 (14.0) 13 ( 8.7)
Prior CVD 857 ( 2.1) 5 ( 1.3) 6 ( 4.0)
Diabetes1 1,055 ( 2.5) 12 ( 3.1) 2 ( 1.3)
Hypertension2 6,121 (14.8) 68 (17.3) 30 (20.1)
Baseline year
2004 - 2005 29,715 (71.7) 290 (74.0) 99 (66.4)
2006 - 2007 6,334 (15.3) 65 (16.6) 29 (19.5)
2008 - 2009 5,327 (12.9) 35 ( 8.9) 21 (14.1)
2010 - 2011 29 ( 0.1) 1 ( 0.3) 0 ( 0.0)
374
2012 - 2015 15 ( 0.0) 1 ( 0.3) 0 ( 0.0)
HIV-VL ≤ 500 copies/mL 21,546 (52.0) 113 (28.8) 65 (43.6)
Age (years) 41420 40 (34,47)
39
2 43 (38,51)
14
9 42 (35,49)
CD4 count (cells/mm3) 41420
431
(280,620)
39
2 342 (189,534)
14
9 409 (276,575)
Nadir CD4 count (cells/mm3) 41420
248
(116,403)
39
2 197 (77,368)
14
9 259 (130,409)
Time CD4 <200 cells/mm3
(years)
3796
2 0.0 (0.0,0.4)
35
3 0.0 (0.0,0.6)
13
7 0.0 (0.0,0.2)
HIV viral load (cps/mm3) 39883
260
(<50,20400)
37
8
13419
(80,90951)
14
6
2615
(<50,34000)
Log10 AUC viral load
(copies/mL-year)
3684
0 4.2 (3.0,4.9)
34
5 4.5 (3.3,5.2)
13
5 4.3 (2.4,5.0)
BMI: Body mass index, HBV: Hepatitis B, HCV: Hepatitis C.
1Diabetes defined as a validated event reported on a case-report form or use of anti-diabetic
medication
2Hypertension defined as diastolic blood pressure >90 mm Hg or systolic blood pressure > 140
mm Hg or receiving antihypertensive medication.
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Table 2 adjusted Hazard ratios (aHR) and 95% confidence intervals for factors associated with NHL and HL
NHL HL
Factors aHR2 (95%CI) P aHR2 (95%CI) P
Current CD4 cell count (cells/mm3) 1
<100 8.08 (5.63,11.61) <.001 4.58 (2.22,9.45) <.001
100 – 199 3.67 (2.49,5.39) <.001 6.36 (3.62,11.20) <.001
200 – 299 2.96 (2.12,4.13) <.001 3.37 (1.99,5.69) <.001
300 – 399 2.43 (1.78,3.33) <.001 1.72 (0.99,2.97) 0.053
400 – 499 1.62 (1.15,2.29) 0.006 2.59 (1.64,4.08) <.001
>=500 reference reference
Current HIV-VL1
<= 50 reference reference
51 - 1,000 1.35 (1.00,1.83) 0.051 1.08 (0.69,1.69) 0.724
>1,000 1.97 (1.50,2.59) <.001 0.67 (0.39,1.17) 0.158
Unknown 0.65 (0.15,2.81) 0.563 3.73 (0.22,62.35) 0.36
AUC of HIV-VL (Quintiles) 1
1 - Lowest reference reference
2 1.10 (0.69,1.76) 0.685 0.65 (0.37,1.12) 0.12
3 1.47 (0.94,2.30) 0.088 0.79 (0.47,1.34) 0.379
4 1.81 (1.17,2.80) 0.007 0.65 (0.38,1.14) 0.133
5 - Highest 2.91 (1.92,4.41) <.001 1.01 (0.61,1.68) 0.965
unknown 1.63 (0.93,2.85) 0.088 0.14 (0.02,1.04) 0.055
age (years)1
<30 0.49 (0.27,0.89) 0.019 0.90 (0.41,1.95) 0.781
30 – 39 reference reference
40 – 49 1.53 (1.16,2.01) 0.003 1.25 (0.81,1.93) 0.322
50 – 59 2.02 (1.47,2.78) <.001 1.37 (0.82,2.28) 0.224
≥60 3.15 (2.17,4.58) <.001 1.06 (0.53,2.15) 0.865
Female gender 0.55 (0.40,0.76) <.001 0.73 (0.43,1.25) 0.253
Race
White reference reference
Other 0.65 (0.39,1.10) 0.109 0.98 (0.47,2.04) 0.948
Unknown 0.99 (0.80,1.24) 0.949 0.95 (0.66,1.35) 0.758
HIV transmission mode
Homosexual reference reference
IDU 0.91 (0.59,1.40) 0.677 0.72 (0.32,1.59) 0.413
Heterosexual 0.91 (0.70,1.20) 0.523 0.67 (0.42,1.06) 0.084
Unknown 1.35 (0.92,1.98) 0.125 0.78 (0.37,1.66) 0.525
smoking1
Current 0.91 (0.69,1.19) 0.48 1.97 (1.23,3.16) 0.005
Ex 0.89 (0.66,1.21) 0.461 1.54 (0.92,2.58) 0.098
Never reference reference
Unknown 1.35 (0.96,1.89) 0.08 1.25 (0.63,2.47) 0.523
on cART1 (Years)
Never 1.41 (0.95,2.10) 0.086 1.25 (0.60,2.60) 0.557
0.1 – 2 1.71 (1.23,2.38) 0.001 1.63 (0.97,2.74) 0.064
2.1 – 4 reference reference
>4 0.66 (0.47,0.91) 0.01 0.75 (0.45,1.23) 0.256
Previous ADM diagnosis1 1.49 (1.02,2.19) 0.041 1.10 (0.55,2.18) 0.792
Previous AIDS diagnosis (excl. ADM) 1 1.01 (0.79,1.28) 0.967 0.99 (0.67,1.46) 0.956
Hepatitis B-status1
Positive/prior 1.10 (0.85,1.41) 0.479 0.75 (0.47,1.20) 0.232
Negative reference reference
Unknown 0.97 (0.62,1.53) 0.906 0.94 (0.40,2.25) 0.897
Hepatitis C-status1
Positive/prior 1.13 (0.81,1.59) 0.462 0.66 (0.35,1.24) 0.193
Negative reference reference
376
Unknown 1.20 (0.78,1.84) 0.416 0.33 (0.10,1.10) 0.07
Baseline year
2004 Reference Reference
2005 1.54 (1.1,2.16) 0.012 1.04 (0.53,2.03) 0.921
2006 1.2 (0.85,1.69) 0.301 1.37 (0.78,2.41) 0.279
2007 1.01 (0.65,1.58) 0.957 1.85 (1.02,3.38) 0.044
2008/9 0.92 (0.63,1.33) 0.641 1.69 (1.01,2.83) 0.046
1Time updated variables
2 Models were adjusted for all other covariates in the table and further adjusted for BMI
group, baseline year, prior CVD diagnosis, diabetes.
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Table 3 adjusted Hazard ratios (HR) and 95% confidence intervals for factors associated with NHL subtypes
PBCNS (N=25) Immunoblastic (N=65) Burkitt (N=42)
aHR1 (95%CI) P aHR1 (95%CI) P aHR1 (95%CI) P
log2 current CD42 0.59 (0.51,0.70) <0.01 0.75 (0.67,0.85) <0.01 0.88 (0.74,1.05) 0.15
log2 nadir CD42 0.68 (0.58,0.80) <0.01 0.87 (0.77,0.98) 0.02 0.97 (0.82,1.14) 0.68
log10 current HIV-VL3 1.11 (0.80,1.54) 0.54 1.32 (1.08,1.61) 0.01 1.38 (1.08,1.76) 0.01
Log10 of AUC of HIV-VL3 2.21 (1.22,4.00) <0.01 1.60 (1.16,2.21) <0.01 2.14 (1.35,3.38) <0.01
PBCNS: Primary brain and central nervous system.
1Models were adjusted age, gender, mode of HIV acquisition, race, current smoking status, cumulative time on cART
2Models were additionally adjusted for log10 current HIV-VL and Log10 of AUC of HIV-VL in addition to variables listed in (1)
3Models were additionally adjusted for log2 current CD4 in addition to variables listed in (1)
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Figure 1 Crude incidence of NHL and HL by calendar time.
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Figure 2 Adjusted ratio of the hazard ratios of NHL (NHL HR) and HL (HL HR) for each considered risk factor, and
the ratio of the HR (RHR).
All models were adjusted for age, gender, ethnicity, mode of HIV acquisition, smoking status,
body mass index, baseline year, cumulative time on cART, HCV and HBV status, prior AIDS
defining malignancies (ADM), prior AIDS events (excluding ADM), current CD4, current HIV-
Viral load and AUC of HIV-viral load. Risk factors for which the 95% CI for the Ratio of the
hazard ratios of NHL to HL does not cross 1 (and a corresponding p-value<0.05) indicate that
there is evidence of a different association of the risk factor with HL and NHL.
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Appendix VII. HIV Glasgow Drug therapy 2016 presentation
entitled “5 Differences in virological and immunological risk
factors for non-Hodgkin and Hodgkin lymphoma in the D:A:D
study”
381
382
383
384
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Abstract
Objective
B-cell dysfunction and activation is thought to contribute to lymphoma development in HIV-positive
people, however the mechanisms are not well understood. We investigated levels of several markers of
B-cell dysfunction (free light chain[FLC]-κ, FLC-λ, immunoglobulin[Ig]G, IgA, IgM and IgD) prior to 
lymphoma diagnosis in HIV-positive people.
Design
A nested-matched-case-control study within the EuroSIDA cohort, including 73 HIV-positive people with
lymphoma and 143 HIV-positive lymphoma-free controls.
Methods
Markers of B-cell dysfunction were measured in prospectively stored serial plasma samples before
lymphoma (or selection date in controls). Marker levels ≤2 and >2 years prior to diagnosis were 
investigated.
Results
A 2-fold higher level of FLC-κ(OR: 1.84 95%CI: 1.19, 2.84), FLC-λ (2.15 95%CI: 1.34, 3.46), IgG(3.05 95%CI: 
1.41, 6.59) and IgM(1.46 95%CI: 1.01, 2.11) were associated with increased risk of Lymphoma >2 years
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prior to diagnosis, but not ≤2 years prior. Despite significant associations >2 years prior to diagnosis, 
predictive accuracy of each marker was poor, with FLC-λ emerging as the strongest candidate with a c-
statistic of 0.67 (95%CI: 0.58, 0.76).
Conclusions
FLC-κ, FLC-λ, and IgG levels were higher >2 years before lymphoma diagnosis, suggesting that B-cell 
dysfunction occurs many years prior to lymphoma development. However, the predictive value of each
marker was low and are unlikely candidates for risk assessment for targeted intervention.
Key words
HIV, Free light chains, Immunoglobulins, Lymphoma, B-cell dysfunction, biomarkers
Introduction
HIV-positive (HIV+) persons are known to have higher rates of infection-related malignancies due to
increased immune deficiency [1-4]. Epstein-Barr Virus (EBV) has been associated with almost all cases of
Hodgkins lymphoma (HL) and between 30-100% of non-Hodgkins lymphoma (NHL) occurring in the
setting of HIV infection . Effective combination antiretroviral treatment (cART) has led to a significant
decline in the incidence of all subtypes of NHL (except Burkitt) [5-12]. Despite this, NHL still accounts for
approximately half of all AIDS related malignancies and incidence remains around 10-fold higher in HIV+
compared to HIV-negative (HIV-) people. Conversely, HL incidence has remained stable or even increased
in HIV+ people since the introduction of cART , and is estimated to be 11-fold higher (with estimates
ranging from 5 – 15) than in the HIV-negative.
Despite being common cancers in HIV+ populations, the mechanisms driving pathogenesis of lymphoma
in the HIV+ setting is poorly understood. Untreated HIV infection causes disruption to the immune system,
characterised by hypergammaglobulinaemia, immune deficiency, immune dysfunction, senescence,
chronic immune activation (or T cell activation) and inflammation, several of which are thought to be
drivers in the development B-cell malignancies [4, 13-17]. Increased B–cell activation and proliferation
also leads to increased synthesis of antibodies [18], which consist of 2 light chain immunoglobulins bound
to 2 heavy-chain immunoglobulins (IgG, IgA, IgM, IgD, or IgE). During immunoglobulin production, more
light chains are produced than heavy chains, and excess unbound light chains (known as free light chains,
FLCs) levels enter circulation, where both immunoglobulins and FLCs can be detected in serum [19]. There
are two types FLCs: kappa (FLC-κ) and lambda (FLC-λ) [20], which are markers of non-specific polyclonal 
B-cell activation and hypergammaglobulinemia, both of which have been linked to HIV disease severity
and lymphoma development [19, 21-24].
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While HIV-associated immune deficiency, B-cell dysfunction, B-cell activation, as well as reactivation of
latent EBV infection all play a role in lymphoma development, it is unclear whether HIV-related factors
facilitate B-cell proliferation which promotes EBV expansion or if ongoing EBV replication directly causes
immune activation prior to lymphoma development, or a combination of both. This study aims to
investigate the relationship between B-cell activation, as demonstrated by increased levels of
immunoglobulins and FLCs, and the subsequent risk of lymphoma development in HIV+ people.
Methods
The EuroSIDA study
EuroSIDA is a prospective, observational, open cohort of more than 22,000 HIV-positive people aged over
16 years in 107 centres across 35 European countries, Israel and Argentina recruited since May 1994
(details at www.cphiv.dk). Informed consent was obtained from all patients. Basic demographic, clinical
and laboratory data are collected every six months, including all CD4 counts and HIV-RNA viral load
measured since last follow-up, starting and stopping dates of all antiretroviral drugs, dates of AIDS-
defining diagnoses (using the 1993 CDC clinical definition, including AIDS-defining malignancies [ADM]).
All new non-AIDS-defining diagnoses (including HL) [25] have been collected since 2001. All reported
malignancies were source verified against case notes at the sites by members of the coordinating office
to ensure data accuracy. Loss to follow-up in EuroSIDA is<5% per 100 PYFU and consistent over time [26].
EuroSIDA has an established biobank, where prospective plasma samples have been collected at
approximate 6 monthly intervals. This sample repository currently holds more than 78,000 plasma
samples on 8,300 patients.
Nested case control study
A 1:2 nested case control study was performed within the EuroSIDA cohort utilising stored plasma samples
to investigate the kinetics and predictive value of several markers of immune activation: FLC-κ, FLC-λ, IgG, 
IgA, IgM and IgD. Both cases and controls were selected from HIV-positive people enrolled in EuroSIDA
with prospective follow-up after the 1 January 2001. Eligible people with a primary diagnosis of lymphoma
after 1 January 2001 were considered as cases. For each case, 2 matched controls (where available) were
selected from eligible people with no history of NHL or HL at the time of diagnosis for each case (referred
to as the “selection date” of the matched controls). Both cases and controls were required to have at least
one plasma sample available prior to the diagnosis date (or selection date in controls). Cases and controls
were matched on region of Europe, gender, date of earliest plasma sample (±2years), date of latest plasma
sample (±2years), age at earliest plasma sample (±5 years), and CD4 cell count at earliest plasma sample
(±200 cells/mm3). The windows used for matching were selected to allow suitable identification of
controls while ensuring as few cases as possible were excluded from analyses. All available serial samples
389
for cases and controls prior to the date of lymphoma diagnosis or selection date in controls were
considered for inclusion. Where more than one plasma sample was available during the same calendar
year, one plasma sample was randomly selected. Date of earliest plasma sample was considered as
baseline. We initially selected 73 cases and 143 controls (3 cases had only 1 suitable control available)
with 600 samples for inclusion. However 6 samples were not available and 594 samples were analysed.
Laboratory markers
Serial samples for cases and controls were analysed for FLC-κ, FLC-λ, IgG, IgA, IgM and IgD. All biomarkers 
were centrally measured by a technician blinded to case control status on frozen stored plasma at the
Department of Clinical Biochemistry at Rigshospitalet. FLC (the κ and λ Freelite® 
turbidimeteric/nephelometric immunoassay, product code: LK016.S and KL018.S), IgG (NK004.S), IgA
(NK010.S), IgM (NK012.S), and IgD (LK013.S) concentrations were measured on plasma in all patients using
Immunoassay from Binding Site Group Ltd, Birmingham, UK on the SPAPLUS ®.
Statistical analysis
We considered the relationship between FLC-κ, FLC-λ, the ratio of FLC-κ to FLC-λ (FLC-κ/λ), the sum of 
FLC-κ and λ (FLC-κ+λ), IgG, IgA, IgM and IgD and lymphoma development.  
Unadjusted conditional logistic regression models were used to investigate the association between the
odds of developing lymphoma and a higher level of each marker using samples that were collected ≤2 and 
>2 years prior to lymphoma diagnosis or selection date in controls. In the case where ≥ 1 sample was 
available within the same time period, one was randomly selected. Many other studies have used the
upper limit of the normal to identify high marker levels, however, it was decided not to use this approach
as these limits have been validated in the HIV-negative population only. Instead, marker levels were
investigated on the log2 scale, giving an odds ratio (OR) which corresponding to a 2-fold higher (or a
doubling of) of each marker level. Polyclonal elevations in FLCs refer to proportionately elevated levels of
FLC-κ and FLC-λ, defined as FLC-κ >19.4 mg/L or FLC-λ >26.3 mg/L and FLC-κ/λ between 0.26 mg/L – 1.65 
mg/L. Monoclonal elevations in FLCs were refer to a disproportionately higher level of one FLC, defined
as FLC-κ >19.4 mg/L or FLC-λ >26.3 mg/L and FLC-κ/λ not between 0.26 – 1.65. 
The area under the receiver operator curve statistic (c-statistic) was calculated to determine the predictive
value of each marker. Predictive ability was classified as follows (c-statistic 0.51 – 0.6: Poor; 0.61 – 0.7:
Poor-moderate; 0.71 – 0.8: Moderate, 0.81 – 0.9; Good, 0.9 – 1: Excellent). This was performed for each
marker using plasma samples collected ≤2 and >2 years prior to lymphoma diagnosis or selection date in 
controls.
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The percentage change for each marker over calendar time (% change per year) in the period prior to
diagnosis or selection date in controls was investigated using mixed models with random slopes and
intercepts (accounting for multiple measurements within each person).
Patient factors associated with higher B-cell activation marker levels were assessed using mixed models.
In order to minimise bias due to our nested-case control study design (leading to a non-representative
patient population where 1 in 3 develop a lymphoma), this analysis of factors was restricted to controls
only. Factors investigated included current age, gender, region of Europe, current use of cART (defined as
≥ 3 antiretroviral drugs), current and nadir CD4 cell count, and current and area under the curve (AUC) of 
HIV viral load (HIV-VL). AUC of HIV-VL is a measure of accumulated exposure to replicating HIV [27]. All
statistical tests were two sided with a type I error rate of 5%. All statistical analyses were performed using
SAS 9.4 (Statistical Analysis Software, Cary NC, USA).
Results
Baseline characteristics of cases and controls
Characteristics of cases (N=73, 52 non-Hodgkin lymphoma and 21 Hodgkin lymphoma) and controls
(N=143) are shown in Table 1. There was a median of 2.0 years (IQR 0.4,3.1) between first and last plasma
sample (cases: 2.1 years IQR: 0.6,4.4; controls: 1.8 years IQR: 0.0,4.3, P=0.72) and 1.3 years (IQR: 0.3,2.9)
between last sample and date of lymphoma diagnosis in cases. Cases differed from controls according to
HIV-related factors, including HIV-VL and treatment. Median HIV-VL level was higher in cases than controls
and a lower proportion of cases were on cART at baseline (63.0 vs 78.3%). The duration of cART was also
less in cases (0.9 years IQR: 0.0, 2.5) than controls (1.7 years IQR: 0.4 ,3.3). At earliest sample, median
levels of FLC-κ, FLC-λ and FLC-κ+λ were elevated in cases relative to controls, however the median FLC-
κ/λ ratio was similar. Levels of IgG and IgM were also elevated in cases, however levels of IgA and IgD 
were similar in cases and controls. In addition, a lower proportion of cases were HCV positive compared
to controls (9.6 vs 27.3%). Cases and controls were well balanced on other non-matched demographic
characteristics. There was no difference in levels of any B-cell markers at latest sample (all P>0.05).
Odds ratios (OR) of developing a lymphoma during prospective follow-up
The OR of developing lymphoma for a 2-fold higher marker level both ≤2 and >2 years before lymphoma 
diagnosis or selection date in controls are shown in Figure 1. A 2-fold higher level of FLC-κ (OR: 1.84 95%CI: 
1.19,2.84), FLC-λ (OR:2.15 95%CI: 1.34,3.46), IgG (OR:3.05 95%CI: 1.41,6.59), and IgM (OR:1.46 95%CI: 
1.01,2.11) were predictive of lymphoma development >2 years prior to diagnosis. However, associations
were not evident ≤2 years prior to diagnosis. No association was found for 2-fold higher IgA or IgD 
(although, the p-value was close to 0.05 for the association >2 years prior for IgD) at either time point.
FLC-κ+λ (OR: 2.08 95%CI: 1.30,3.35) was predictive >2 years but not ≤2 years prior to diagnosis prior to 
lymphoma diagnosis. The ratio of FLC-κ/λ was not predictive at either >2 years or ≤2 years prior to 
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diagnosis.  Proportionately high levels of both FLC-κ and FLC-λ was associated with lymphoma >2 years 
prior to diagnosis (OR: 4.74 95%CI: 1.71,27.56), but not ≤2 years prior (1.62 94%CI: 0.54,5.05). Having a 
disproportionately high level of one FLC was not associated at either time point.
 Of the HIV related markers, HIV-VL AUC was associated with a higher risk in sample ≤ 2 years prior to 
diagnosis, however HIV-VL was predictive >2 years prior. In those who had HIV-VL measured, a 10-fold
higher HIV-VL was predictive of lymphoma development >2 years prior to development (OR: 1.51 95%CI:
1.1,2.08), but not ≤2 years prior (OR: 1.31 95%CI: 0.99,1.75). Whereas for a 10–fold higher AUC of HIV-VL, 
there was no association >2 years (OR: 1.25 95%CI: 0.93,1.67), but a 1.68-fold higher odds of lymphoma
≤2 years of diagnosis (95%CI: 1.08,2.62).  
Predictive value of B-cell marker markers
The marker with the best predictability >2 years prior to lymphoma diagnosis was FLC-λ (Table 2). This 
marker predicted lymphoma diagnosis with better accuracy than chance alone (P<0.01), however the c-
statistic of 0.67 suggests only poor-moderate classification power. The following markers also had some
predictive power (all P<0.05), however prediction was poor to moderate at best: FLC-κ+λ (c-statistic= 0.67, 
poor-moderate prediction), and IgG (c-statistic: 0.64, poor-moderate). Only FLC-λ (c-statistic: 0.61) 
predicted lymphoma ≤2 years of diagnosis, however accuracy was poor. No other markers were predictive 
(all P>0.05).
Trajectories of B-cell markers prior to lymphoma diagnosis
The trajectories of each marker in the cases and controls and unadjusted % change per year for each
marker in the time leading up to diagnosis or selection date in controls are shown in Figure 2. In
unadjusted analysis, the largest difference was observed for IgM, which was declining in cases by 6.42%
(95%CI: 3.12, 9.61) per year, but levels were stable in controls (%Change per year: 0.40 95%CI:-2.09,
2.95%). The difference in the rates of change per year between cases and controls was statistically
significant (P for interaction<0.01). Levels of IgG were also declining in cases, but stable in controls, which
was a borderline significant difference in the rates of change per year (P for interaction=0.10). Although
levels of FLC-κ were stable in cases but increasing in controls, the difference in the rates of change per 
year between cases and controls were non-significant (P for interaction = 0.20). The ratio of FLC-κ/λ was 
increasing in cases, but stable in controls, and conversely, FLC-κ+λ level was increasing in controls but 
stable in cases, however the differences in the rates of change per year between cases and controls were
not-significant (P for interaction = 0.44 and 0.16, respectively). Levels of FLC-λ, IgA, and IgD did not change 
over time in either cases or controls. In those who had a HIV-VL measured (N= 586 samples in 214 people),
HIV-VL levels were high many years prior to diagnosis (Figure 2), and significantly declined in cases in the
time leading up to diagnosis, whereas levels were stable in controls, however this difference was not
significant (P=0.11). The level of current CD4 cell count was stable in both cases and controls. The results
were similar after adjustment for matching variables (data not shown). Further adjustment for current
CD4, age and HIV-treatment variables also produced consistent results (data not shown).
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Patient factors associated with higher B-cell activation marker levels in controls
Demographic and HIV-related factors which were associated with B-cell marker levels in the control
population are shown in table 3. For each factor, the adjusted fold change in marker level is presented.
For example, those from southern Europe had on average a 1.46-fold higher marker level compared to
those from west-central Europe. Higher levels FLC-κ, FLC-λ, and IgG were associated with HIV transmission 
modes other than MSM, lower current CD4 cell count, higher current HIV-VL, and not being on cART
(borderline for FLC-λ). FLC-κ and FLC-λ levels also increased with older age. Higher IgA level was associated 
with lower CD4 cell count and higher AUC of HIV-VL. Higher IgM level was associated with higher HIV-VL,
not being on cART, and HIV transmission mode other than MSM. Higher IgD level was associated with
higher AUC of HIV-VL only.
Discussion
This study investigated the trajectories of FLC-κ, FLC-λ, IgG, IgA, IgM, and IgD over time prior to lymphoma 
diagnosis. We show that the strength of association diminishes consistently with time leading up to
diagnosis. Levels of FLC-κ, FLC-λ, and IgG were associated with lymphoma development in HIV+ people >2 
years prior to lymphoma development. However, The magnitude of the associations was moderate, and
poorly predicted lymphoma development. The markers investigated in this study, therefore, are unlikely
to be strong candidates for risk assessment for targeted interventions.
Proportionately higher levels of both FLC-κ and FLC-λ (indicating polyclonal expansion) were associated 
with lymphoma >2 years prior to diagnosis. Two main studies have also demonstrated that elevated levels
of FLC-κ and FLC-λ are associated with a higher likelihood of lymphoma in HIV+ people [23, 24]. The study 
by Landgren et al (2010) [24] found that elevated FLC-κ and FLC-λ were associated with NHL 2–5 years 
prior to diagnosis, conversely only FLC-λ was associated 0–2 years prior [24]. However, a later study by 
the same group subsequently found FLC-κ and FLC-λ levels to be similarly predictive of all AIDS defining 
events and not specifically NHL [22]. Results were consistent in the more recent study by Bibas et al (2012)
, who found FLC-κ and FLC-λ to be predictive of both NHL and HL independently of CD4 cell count and HIV-
VL . Our finding that FLC-κ and λ are predictive of lymphoma in the long term are somewhat concurrent 
with those of Landgren et al and Bibas et al , however, we did not find an association with FLC-λ closer to 
diagnosis. Furthermore, our finding that polyclonal FLC elevations preceded lymphoma development is
also concurrent with both studies [23, 24].
Our results demonstrated an association between IgG and IgM >2 years prior to date of lymphoma
diagnosis (although the association with IgM was borderline), which attenuated closer to this date. This
was driven by a faster decline in levels in cases while controls remained stable. Studies have found mixed
associations between immunoglobulins and lymphoma in HIV. For example, an Australian study found
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high levels of serum globulin, mainly IgG, were predictive of NHL [28]. However, other studies found no
association between serum globulin, immunoglobulins and NHL [24, 29, 30].
The attenuation of associations between markers of B-cell activation and lymphoma ≤2 years of diagnosis 
may simply be reflecting a 2 year lag period for an increase in B-cell activity to manifest as a clinically
detectable lymphoma [23]. However, it is more likely that the observed trends are signifying the
concurrent, but very different, immune consequences induced by HIV infection and lymphoma
development and disentangling this relationship is not straight forward. HIV associatied immune
dysfunction is associated with elevated serum levels of immunoglobulins, mainly IgG but also IgA and IgD
[16]. Conversely, Studies in the general population have found lower levels of IgM, IgA and IgG prior to
lymphoma diagnosis [31], and levels declined with more advanced disease [32], speculated to be driven
by the developing lymphoma. Additionally, transformed B-cells may have compromised immunoglobulin
production and levels may not reflect the immune environment in which the lymphoma initiated [32].
Therefore, it is possible the decline in marker levels ≤2 years may be a consequence of early undiagnosed 
lymphoma. A similar phenomenon has been reported for undiagnosed HL and declining CD4 cell counts
within 1–2 years prior to diagnosis [33, 34].
Current HIV-VL was found to be a strong predictor of lymphoma risk >2 years prior to diagnosis, however,
AUC of HIV-VL was a predictor ≤2 years prior to diagnosis. Our results support the strong  association 
between cumulative HIV-VL and AIDS-related lymphoma identified in previous studies [35]. Furthermore,
elevated levels of FLC-λ, FLC-κ, and IgG were associated with higher current HIV-VL and lower current CD4 
in controls, which is consistent with other studies [23, 36]. This may indicate that a history of uncontrolled
HIV-VL is playing an integral role in lymphoma development , and elevated FLCs are reflecting HIV-specific
B-cells dysfunction [37] occurring long before diagnosis. Furthermore, HIV-specific B-cells dysfunction
may contribute to lymphoma development by facilitating the reactivation of latent EBV, resulting in the
long term stimulation and proliferation of impaired B-cells[38].
The major strength of our study is the availability of serial plasma samples collected prior to and
independently of lymphoma diagnosis, as well as the inclusion of a comparatively large number of
lymphomas from contemporary HIV+ individuals. However, the limitations need to be considered. Firstly,
it is possible that changes in FLCs and immunoglobulins reflect undiagnosed or late diagnosed cancer
rather than preceding cancer development. In this study we grouped NHL and HL together as we did not
have the numbers to investigate them separately. Furthermore, FLCs are excreted from the kidneys and
therefore levels are possibly affected by renal function [39]. Measurements of eGFR were only available
on one third of measurements (175/592, prospective collection of serum creatinine to calculate eGFR
started in 2004), however in people with eGFR measurements available, there was no evidence of a
difference in eGFR between cases and controls at baseline. Cases were less likely to be on treatment than
controls and a lower proportion were HCV-positive. HCV infection is associated with several B-cell
disorders, including cryoglobulinaemia and B-cell NHL, and elevated levels of FLC-κ and an abnormal FLC-
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ratio have been associated with the severity of B-cell dysfunction in HCV-positive people [40, 41].
Therefore, the higher HCV prevalence in the control group may result in an underestimation of the effects.
Further adjustment for potential confounders was not possible, although no other significant imbalances
were evident at baseline. Baseline CD4 was included as a matching factor in order to investigate the
independent associations between B-cell activation and lymphoma development, however, it should be
kept in mind that this may result in an underestimate of the association between markers of B-cell
activation and lymphoma development.
In conclusion, FLC-λ, FLC-λ and IgG were higher >2 years before lymphoma diagnosis, but the difference 
diminished nearer diagnosis. B-cell dysfunction, as demonstrated by polyclonal hyperglobulinemia, occurs
many years prior to lymphoma development. The trajectories of FLC-κ, FLC-λ IgG, IgA, IgM, IgD over time 
prior to lymphoma diagnosis show that the strength of association diminishes consistently with time
leading up to diagnosis. The magnitude of the associations was moderate at best, and poorly predicted
lymphoma development. The markers investigated are unlikely to be strong candidates for risk
assessment for targeted interventions.
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Table 1 Baseline characteristics of cases and controls
Factors Overall (N=216) Cases (N=73) Controls (N=143) p-value
Categorical variables
Male gender1 193 (89.4) 65 (89.0) 128 (89.5) Na
Risk group
Homosexual 114 (52.8) 41 (56.2) 73 (51.0) 0.39
Other 102 (47.2) 32 (43.8) 70 (49.0)
White race 180 (83.3) 56 (76.7) 124 (86.7) 0.06
Region of Europe1
South2 46 (21.3) 16 (21.9) 30 (21.0) Na
West-central 75 (34.7) 25 (34.2) 50 (35.0)
North 72 (33.3) 24 (32.9) 48 (33.6)
East central 21 ( 9.7) 7 ( 9.6) 14 ( 9.8)
East 2 ( 0.9) 1 ( 1.4) 1 ( 0.7)
Prior AIDS event (excluding NHL) [1] 60 (27.8) 23 (31.5) 37 (25.9) 0.33
Prior non-AIDS event (excluding HL) [2] 5 (2.3) 2 (2.7) 3 (1.4) 0.88
Hepatitis C
Positive 46 (21.3) 7 (9.6) 39 (27.3) 0.02
Negative 128 (59.3) 50 (68.5) 78 (54.5)
Unknown 42 (19.4) 16 (21.9) 26 (18.2)
Hepatitis B
Positive 17 (7.9) 8 (11) 9 (6.3) 0.22
Negative 171 (79.2) 53 (72.6) 118 (82.5)
Unknown 28 (13.0) 12 (16.4) 16 (11.2)
On Cart 158 (73.1) 46 (63.0) 112 (78.3) 0.02
Numerical variables N Median(IQR) N Median(IQR) N Median(IQR) p-value
Age (years) 1 216 42.2 (36.9,49.7) 73 42.6 (37.0,50.5) 143 41.8 (36.6,49.3) 0.47
CD4 (cells/mm3) 1 216 317.5 (208.0,477.0) 73 316.0 (180.0,500.0) 143 319.0 (213.0,461.0) 0.06
First sample date1 216 11DEC1999(20JUL1998,09OCT2004) 73
15NOV1999
(24JAN1998,16JUL2004) 143
25JAN2000
(28JUL1998,14OCT2004) 0.67
eGFR 53 97.1 (77.2, 104.4) 19 98.6 (61.9, 107.4) 34 95.4 (79.9, 104.1) 0.82
Nadir CD4 (cells/mm3) 216 120.0 (44.0,228.0) 73 179.0 (55.0,280.0) 143 101.0 (40.0,200.0) 0.37
AUC of CD4 (cells x year/mm3 ) 216 1092 (477.7,1943) 73 860.7 (395.3,1585.9) 143 1181.1 (573.9,2284.5) 0.08
400
HIV Viral-load (copies/mL) 206 215.0 (49.0,2100) 68 671.5 (79.5,10993.5) 138 140.0 (39.0,848.0) <.01
AUC of HIV Viral load (copies x year /Ml ) 206 18269 (3671,11E4) 68 35983.7 (4255.5,130491.8) 138 15212.8 (3442.2,100042.1) 0.51
Duration of time on cART (years) 216 1.4 (0.2,3.1) 73 0.9 (0.0,2.5) 143 1.7 (0.4,3.3) <.01
Marker levels
Baseline FLC-κ (mg/L) 213 32.0 (23.4,50.5) 71 39.9 (28.1,62.1) 142 29.4 (20.8,41.0) <.01
Latest FLC-κ (mg/L) 213 34.9 (21.3,55.1) 71 36.7 (24.5,57.0) 142 33.1 (20.1,54.8) 0.684
Baseline FLC-λ (mg/L) 214 21.8 (14.5,31.4) 72 27.7 (19.2,45.0) 142 18.6 (13.7,27.2) <.01
Latest FLC-λ (mg/L) 214 21.8 (13.7,34.3) 72 24.5 (17.2,40.1) 142 21.3 (12.9,31.7) 0.871
Baseline FLC—κ/λ 213 1.6 (1.2,2.0) 71 1.6 (1.2,2.0) 142 1.6 (1.2,2.1) 0.12
Latest FLC—κ/λ 214 1.6 (1.3,2.1) 72 1.6 (1.2,2.0) 142 1.7 (1.3,2.2) 0.813
Baseline FLC—κ+λ 213 53.4 (39.3,80.8) 71 69.6 (49.6,99.5) 142 48.2 (36.7,67.6) <.01
Latest FLC—κ+λ 214 56.9 (38.3,90.3) 72 63.5 (41.1,92.0) 142 53.9 (35.5,84.9) 0.752
Baseline IgG (g/L) 214 14.3 (11.1,17.8) 72 15.8 (12.5,19.6) 142 13.2 (10.3,16.9) <.01
Latest IgG (g/L) 214 13.0 (10.5,17.1) 72 14.4 (11.5,18.2) 142 12.8 (10.1,16.4) 0.18
Baseline IgA (g/L) 214 2.2 (1.5,3.6) 72 2.7 (1.5,3.8) 142 2.2 (1.6,3.3) 0.34
Latest IgA (g/L) 214 2.3 (1.4,3.4) 72 2.5 (1.3,3.5) 142 2.2 (1.5,3.4) 0.284
Baseline IgM (g/L) 214 0.8 (0.5,1.3) 72 1.1 (0.7,1.7) 142 0.8 (0.5,1.1) 0.02
Latest IgM (g/L) 214 0.8 (0.5,1.3) 72 0.8 (0.5,1.5) 142 0.8 (0.5,1.2) 0.86
Baseline IgD (g/L) 214 28.5 (6.7,58.9) 72 39.2 (9.0,60.3) 142 26.0 (6.7,58.2) 0.12
Latest IgD (g/L) 214 21.9 (7.2,59.8) 72 24.5 (10.7,87.1) 142 21.0 (6.7,53.9) 0.287
eGFR estimated Glomerular Filtration Rate
1Matching variable
2Includes Israel and Argentina
401 Figure 1 Odds ratio (OR) of lymphoma associated with a 2-fold increase in B-cell markers, ≤2 and > 2 years prior to diagnosis. 
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Table 2 c-statistics for prediction of lymphoma diagnosis for each marker, stratified by < 2 years prior
to diagnosis and ≤ 2 years prior to diagnosis. 
B-cell markers
≥ 2 years <2 years 
c-statistic P1 c-statistic P1
FLC-κ 0.65 (0.56,0.74) 0.29 0.56 (0.45,0.66) 0.29 
FLC-λ 0.67 (0.58,0.76) <.01 0.61 (0.51,0.71) 0.04 
Ratio FLC κ/ λ 0.53 (0.43,0.62) 0.60 0.54 (0.43,0.64) 0.48 
Sum FLC- κ + λ 0.67 (0.58,0.76) <.01 0.58 (0.47,0.68) 0.15
IgG 0.64 (0.55,0.73) <.01 0.55 (0.45,0.65) 0.32
igA 0.52 (0.42,0.62) 0.65 0.50 (0.40,0.61) 0.94
igM 0.59 (0.49,0.69) 0.09 0.52 (0.41,0.63) 0.70
igD 0.58 (0.49,0.68) 0.10 0.54 (0.44,0.64) 0.43
1 P compares the c-statistic for each marker to 0.5 (i.e. prediction is no better than chance).
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* P for change<0.05: This is testing whether there is a significant increase or decline in the markers over time. P for interaction: This tests whether the % change per year is
different in cases and controls. FLC-κ: 0.2, FLC-λ: 0.1, Ratio FLC- κ/λ: 0.44, IgG: 0.10, IgA: 0.90, IgM<0.01, IgD: 0.81, Current HIV-VL: 0.11, Current CD4 cell count: 0.87
Figure 2 Trajectories of FLC-κ and FLC-λ, FLC-κ/ λ, IgG, IgA, IgM, IgD, current HIV-VL and CD4 prior to the index date. The unadjusted percentage change per year in each marker 
per year (i.e. the slope) in the time leading up to diagnosis is shown at the top of each panel.
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Table 3 Multivariate analysis of the fold change in marker levels associated with patient factors
Effect levels
Fold change in
P
Fold change in
P
Fold change in
P
Fold change in
P
Fold change in
P
Fold change in
P
FLC-κ (95%CI) FLC- λ (95%CI) IgG (95%CI) IgA (95%CI) IgM (95%CI) IgD (95%CI) 
Age (1 year older) 1.25 (1.13 , 1.38) <.01 1.14 (1.03 , 1.26) 0.01 1.00 (0.94 , 1.05) 0.89 0.96 (0.87 , 1.06) 0.47 1.06 (0.95 , 1.17) 0.29 0.84 (0.70 , 1.02) 0.08
Region
South 1.46 (1.10 , 1.95) 0.01 1.45 (1.08 , 1.95) 0.01 1.31 (1.12 , 1.52) <.01 0.98 (0.74 , 1.30) 0.91 1.24 (0.92 , 1.67) 0.15 1.06 (0.61 , 1.84) 0.85
North 1.20 (0.95 , 1.52) 0.12 1.25 (0.98 , 1.59) 0.07 1.20 (1.06 , 1.37) <.01 1.16 (0.92 , 1.46) 0.22 1.12 (0.88 , 1.44) 0.35 1.01 (0.64 , 1.59) 0.98
East and East central 1.11 (0.77 , 1.59) 0.58 0.99 (0.69 , 1.44) 0.98 1.15 (0.95 , 1.40) 0.14 1.11 (0.78 , 1.59) 0.55 1.66 (1.15 , 2.41) <.01 0.53 (0.26 , 1.07) 0.08
West-central Reference Reference Reference Reference Reference Reference
Female Gender 1.03 (0.73 , 1.46) 0.87 0.88 (0.61 , 1.25) 0.47 0.97 (0.81 , 1.17) 0.76 0.90 (0.64 , 1.27) 0.55 1.17 (0.81 , 1.67) 0.41 1.14 (0.58 , 2.23) 0.71
Non-White ethnicity 0.90 (0.65 , 1.23) 0.5 0.92 (0.66 , 1.27) 0.6 1.06 (0.89 , 1.26) 0.51 0.74 (0.54 , 1.02) 0.07 0.84 (0.60 , 1.17) 0.3 0.87 (0.47 , 1.61) 0.65
Non-MSM transmission mode 1.33 (1.07 , 1.66) 0.01 1.36 (1.09 , 1.70) <.01 1.19 (1.06 , 1.34) <.01 0.87 (0.70 , 1.07) 0.19 1.34 (1.07 , 1.68) 0.01 0.99 (0.65 , 1.50) 0.95
Current CD4 (2-fold higher) 0.91 (0.86 , 0.97) <.01 0.91 (0.86 , 0.96) <.01 0.97 (0.94 , 0.99) 0.02 0.92 (0.88 , 0.97) <.01 0.96 (0.90 , 1.02) 0.15 0.93 (0.85 , 1.02) 0.13
Nadir of CD4 (2-fold higher) 1.00 (0.95 , 1.06) 0.92 1.01 (0.96 , 1.08) 0.63 0.99 (0.96 , 1.02) 0.68 0.98 (0.93 , 1.04) 0.53 1.06 (1.00 , 1.13) 0.05 0.99 (0.88 , 1.10) 0.82
Current HIV-VL
Missing 1.39 (0.76 , 2.53) 0.29 1.54 (0.88 , 2.68) 0.13 1.15 (0.85 , 1.55) 0.37 0.99 (0.59 , 1.66) 0.97 1.36 (0.75 , 2.49) 0.31 1.13 (0.43 , 2.99) 0.8
low: < 500 0.86 (0.78 , 0.94) <.01 0.86 (0.79 , 0.94) <.01 0.92 (0.88 , 0.96) <.01 1.02 (0.94 , 1.11) 0.63 0.72 (0.66 , 0.80) <.01 1.09 (0.94 , 1.27) 0.25
high: ≥500 Reference Reference Reference Reference Reference Reference
AUC of HIV-VL
Missing 0.81 (0.48 , 1.36) 0.42 0.73 (0.45 , 1.19) 0.21 0.82 (0.63 , 1.07) 0.15 0.82 (0.52 , 1.28) 0.38 0.66 (0.39 , 1.11) 0.12 0.67 (0.29 , 1.59) 0.37
low < 50% 0.91 (0.78 , 1.05) 0.2 0.96 (0.83 , 1.10) 0.53 0.95 (0.88 , 1.02) 0.16 0.85 (0.74 , 0.97) 0.02 0.88 (0.76 , 1.02) 0.09 0.75 (0.59 , 0.97) 0.03
high ≥ 50% Reference Reference Reference Reference Reference Reference
Not on cART 1.25 (1.07 , 1.47) <.01 1.16 (0.99 , 1.35) 0.06 1.15 (1.06 , 1.25) <.01 0.98 (0.85 , 1.14) 0.83 1.29 (1.09 , 1.52) <.01 0.98 (0.75 , 1.28) 0.88
Models were adjusted for all variables listed in the table.
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Appendix X. HIV Glasgow Drug Therapy 2016 presentation
entitled “The Extent of B cell activation and dysfunction preceding
lymphoma development?”
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Appendix XI. Published manuscript “Predictive value of prostate
specific antigen in a European HIV-positive cohort: does one size
fit all?”
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Appendix XII. EACS 2015 presentation entitled “Testing patterns
and predictive value of prostate specific antigen in a European
HIV-positive cohort: Does one size fit all?”
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Appendix XIII. Internatinal confrerence on drug therapy in HIV
infection presentation entitled “Predictive value of prostate
specific antigen for prostate cancer: A nested case control study in
EuroSIDA”
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